

# Summary Tables by Market Group, Health Area, Country and Product

**POPULATION SERVICES INTERNATIONAL**  
**CYPs, Cases, and Deaths by Market Group**  
**1/2019 - 2/2019**

	New HIV Infections	STI Deaths	PWID Deaths	TB Deaths	CYP*	Maternal Deaths	Unintended Pregnancies	Malaria Deaths	Diarrhea Deaths	Pneumonia Deaths	Cervical Cancer Death	Sum of All Deaths
Acceleration Market Group	5,288	-	-	434	417,957	594	188,561	122	69	17	-	3,378
Anglophone Africa Market Group	14,942	9	-	1	495,685	495	200,999	13	19	-	1	4,728
Franco/Lusophone Africa Market Gro	1,837	1	-	-	208,135	282	79,317	556	41	-	-	2,620
Latin America & Asia Market Group	809	-	-	349	639,797	351	246,362	1	12	-	-	2,308
Foundation Market Group	115	-	-	238	129,805	157	52,285	5,637	59	36	-	7,118
Social Enterprise	3,488	-	-	-	152,673	181	53,304	-	92	-	-	556
<b>Total</b>	<b>26,479</b>	<b>10</b>	<b>-</b>	<b>1,020</b>	<b>2,044,051</b>	<b>2,060</b>	<b>820,828</b>	<b>6,328</b>	<b>294</b>	<b>53</b>	<b>2</b>	<b>20,709</b>

\* Using USAID CYP conversion factors

**POPULATION SERVICES INTERNATIONAL**  
**Monthly DALY Report by Market Group**  
**Period: 2**  
**Year: 2019**

	DALY 2/2019	YTD DALY 2018	YTD DALY 2019	Percentage Change	Percentage of Category	Annual DALY Target	Percentage of Target Achieved
<b>GRAND TOTAL</b>	<b>1,288,390</b>	<b>3,700,591</b>	<b>2,662,447</b>	<b>(28%)</b>		-	<b>-%</b>
<b>Acceleration Market Group</b>	<b>274,591</b>	<b>579,569</b>	<b>465,547</b>	<b>(20%)</b>	<b>100%</b>	-	<b>-%</b>
Modern Contraception	103,545	208,306	200,161	(4)%	43%	-	0%
HIV & STIs	142,264	335,202	222,596	(34)%	48%	-	0%
Malaria	6,963	19,247	10,197	(47)%	2%	-	0%
Maternal, Newborn, and Child H	3,126	5,382	5,593	4%	1%	-	0%
Non-communicable diseases	6	6	11	93%	0%	-	0%
Nutrition	-	37	-	(100)%	0%	-	0%
Safe Abortion	11,417	-	12,393	0%	3%	-	0%
Tuberculosis	6,182	10,936	12,479	14%	3%	-	0%
WASH	1,087	453	2,116	367%	0%	-	0%
<b>Anglophone Africa Market Group</b>	<b>542,071</b>	<b>1,020,304</b>	<b>979,759</b>	<b>(4%)</b>	<b>100%</b>	-	<b>-%</b>
Modern Contraception	223,876	306,898	381,545	24%	39%	-	0%
HIV & STIs	315,355	688,679	593,647	(14)%	61%	-	0%
Malaria	755	20,993	917	(96)%	0%	-	0%
Maternal, Newborn, and Child H	59	232	122	(48)%	0%	-	0%
Non-communicable diseases	23	51	39	(22)%	0%	-	0%
Safe Abortion	1,492	1,731	2,334	35%	0%	-	0%
Tuberculosis	24	108	33	(70)%	0%	-	0%
WASH	487	1,611	1,123	(30)%	0%	-	0%
<b>Franco/Lusophone Africa Market Group</b>	<b>126,754</b>	<b>252,015</b>	<b>282,827</b>	<b>12%</b>	<b>100%</b>	-	<b>-%</b>
Modern Contraception	79,563	136,604	161,042	18%	57%	-	0%
HIV & STIs	22,681	61,760	74,483	21%	26%	-	0%
Malaria	21,386	48,280	41,860	(13)%	15%	-	0%
Maternal, Newborn, and Child H	1,218	1,246	2,114	70%	1%	-	0%
Non-communicable diseases	-	1	-	(86)%	0%	-	0%
Nutrition	-	-	-	0%	0%	-	0%
Safe Abortion	1,219	1,608	2,105	31%	1%	-	0%
WASH	687	2,516	1,222	(51)%	0%	-	0%
<b>Latin America &amp; Asia Market Group</b>	<b>92,803</b>	<b>210,835</b>	<b>210,758</b>	<b>-%</b>	<b>100%</b>	-	<b>-%</b>
Modern Contraception	61,216	148,621	145,405	(2)%	69%	-	0%
HIV & STIs	17,745	35,630	35,389	(1)%	17%	-	0%
Malaria	23	2,063	50	(98)%	0%	-	0%
Maternal, Newborn, and Child H	834	233	1,045	349%	0%	-	0%
Non-communicable diseases	-	-	-	0%	0%	-	0%
Safe Abortion	3,592	8,812	10,318	17%	5%	-	0%
Tuberculosis	9,386	15,452	18,534	20%	9%	-	0%
WASH	7	25	17	(32)%	0%	-	0%
<b>Foundation Market Group</b>	<b>170,271</b>	<b>1,428,361</b>	<b>547,233</b>	<b>(62%)</b>	<b>100%</b>	-	<b>-%</b>
Modern Contraception	53,710	77,139	87,031	13%	16%	-	0%
HIV & STIs	1,529	3,332	5,140	54%	1%	-	0%
Malaria	106,698	1,284,747	427,822	(67)%	78%	-	0%
Maternal, Newborn, and Child H	5,985	42,290	10,759	(75)%	2%	-	0%
Non-communicable diseases	2	9	2	(76)%	0%	-	0%
Nutrition	1,483	-	1,483	0%	0%	-	0%
Safe Abortion	644	1,373	1,029	(25)%	0%	-	0%
Tuberculosis	-	17,244	13,352	(23)%	2%	-	0%
WASH	221	2,228	614	(72)%	0%	-	0%
<b>Social Enterprise</b>	<b>81,900</b>	<b>207,745</b>	<b>176,323</b>	<b>(15%)</b>	<b>100%</b>	-	<b>-%</b>

**POPULATION SERVICES INTERNATIONAL**  
**Monthly DALY Report by Market Group**  
**Period: 2**  
**Year: 2019**

	DALY 2/2019	YTD DALY 2018	YTD DALY 2019	Percentage Change	Percentage of Category	Annual DALY Target	Percentage of Target Achieved
Modern Contraception	6,817	39,010	26,261	(33)%	15%	-	0%
HIV & STIs	63,457	155,499	133,834	(14)%	76%	-	0%
Maternal, Newborn, and Child H	6,226	1,698	7,986	370%	5%	-	0%
Nutrition	20	53	37	(31)%	0%	-	0%
Safe Abortion	5,380	11,485	8,205	(29)%	5%	-	0%
Other	-	-	-	0%	0%	-	0%
<b>Inactive</b>	<b>-</b>	<b>1,762</b>	<b>0</b>	<b>(100)%</b>	<b>-%</b>	<b>-</b>	<b>-%</b>
Modern Contraception	-	1,520	-	(100)%	0%	-	0%
HIV & STIs	-	242	-	(100)%	0%	-	0%

**POPULATION SERVICES INTERNATIONAL**  
**Monthly DALY Report by Health Area**  
**Period: 2**  
**Year: 2019**

	DALY 2/2019	YTD DALY 2018	YTD DALY 2019	Percentage Change	Percentage of Category	Annual DALY Target	Percentage of Target Achieved
<b>GRAND TOTAL</b>	<b>1,288,390</b>	<b>3,700,591</b>	<b>2,662,447</b>	<b>(28)%</b>		-	-%
<b>Modern Contraception</b>	<b>528,727</b>	<b>918,099</b>	<b>1,001,444</b>	<b>9%</b>	<b>100%</b>	-	<b>0 %</b>
Acceleration Market Group	103,545	208,306	200,161	(4)%	20 %	-	0%
Anglophone Africa Market Group	223,876	306,898	381,545	24%	38 %	-	0%
Franco/Lusophone Africa Market Group	79,563	136,604	161,042	18%	16 %	-	0%
Latin America & Asia Market Group	61,216	148,621	145,405	(2)%	15 %	-	0%
Foundation Market Group	53,710	77,139	87,031	13%	9 %	-	0%
Social Enterprise	6,817	39,010	26,261	(33)%	3 %	-	0%
Inactive	-	1,520	-	(100)%	0 %	-	0%
<b>HIV &amp; STIs</b>	<b>563,032</b>	<b>1,280,344</b>	<b>1,065,090</b>	<b>(17)%</b>	<b>100%</b>	-	<b>0 %</b>
Acceleration Market Group	142,264	335,202	222,596	(34)%	21 %	-	0%
Anglophone Africa Market Group	315,355	688,679	593,647	(14)%	56 %	-	0%
Franco/Lusophone Africa Market Group	22,681	61,760	74,483	21%	7 %	-	0%
Latin America & Asia Market Group	17,745	35,630	35,389	(1)%	3 %	-	0%
Foundation Market Group	1,529	3,332	5,140	54%	0 %	-	0%
Social Enterprise	63,457	155,499	133,834	(14)%	13 %	-	0%
Inactive	-	242	-	(100)%	0 %	-	0%
<b>Malaria</b>	<b>135,824</b>	<b>1,375,330</b>	<b>480,847</b>	<b>(65)%</b>	<b>100%</b>	-	<b>0 %</b>
Acceleration Market Group	6,963	19,247	10,197	(47)%	2 %	-	0%
Anglophone Africa Market Group	755	20,993	917	(96)%	0 %	-	0%
Franco/Lusophone Africa Market Group	21,386	48,280	41,860	(13)%	9 %	-	0%
Latin America & Asia Market Group	23	2,063	50	(98)%	0 %	-	0%
Foundation Market Group	106,698	1,284,747	427,822	(67)%	89 %	-	0%
<b>Maternal, Newborn, and Child Health</b>	<b>17,448</b>	<b>51,080</b>	<b>27,619</b>	<b>(46)%</b>	<b>100%</b>	-	<b>0 %</b>
Acceleration Market Group	3,126	5,382	5,593	4%	20 %	-	0%
Anglophone Africa Market Group	59	232	122	(48)%	0 %	-	0%
Franco/Lusophone Africa Market Group	1,218	1,246	2,114	70%	8 %	-	0%
Latin America & Asia Market Group	834	233	1,045	349%	4 %	-	0%
Foundation Market Group	5,985	42,290	10,759	(75)%	39 %	-	0%
Social Enterprise	6,226	1,698	7,986	370%	29 %	-	0%
<b>Non-communicable diseases</b>	<b>30</b>	<b>66</b>	<b>53</b>	<b>(20)%</b>	<b>100%</b>	-	<b>0 %</b>
Acceleration Market Group	6	6	11	93%	22 %	-	0%
Anglophone Africa Market Group	23	51	39	(22)%	74 %	-	0%
Franco/Lusophone Africa Market Group	-	1	-	(86)%	0 %	-	0%
Latin America & Asia Market Group	-	-	-	0%	0 %	-	0%
Foundation Market Group	2	9	2	(76)%	4 %	-	0%
<b>Nutrition</b>	<b>1,503</b>	<b>91</b>	<b>1,520</b>	<b>1,577%</b>	<b>100%</b>	-	<b>0 %</b>
Acceleration Market Group	-	37	-	(100)%	0 %	-	0%
Franco/Lusophone Africa Market Group	-	-	-	0%	0 %	-	0%
Foundation Market Group	1,483	-	1,483	0%	98 %	-	0%
Social Enterprise	20	53	37	(31)%	2 %	-	0%
<b>Safe Abortion</b>	<b>23,744</b>	<b>25,009</b>	<b>36,384</b>	<b>45%</b>	<b>100%</b>	-	<b>0 %</b>
Acceleration Market Group	11,417	-	12,393	0%	34 %	-	0%
Anglophone Africa Market Group	1,492	1,731	2,334	35%	6 %	-	0%
Franco/Lusophone Africa Market Group	1,219	1,608	2,105	31%	6 %	-	0%
Latin America & Asia Market Group	3,592	8,812	10,318	17%	28 %	-	0%
Foundation Market Group	644	1,373	1,029	(25)%	3 %	-	0%
Social Enterprise	5,380	11,485	8,205	(29)%	23 %	-	0%
<b>Tuberculosis</b>	<b>15,592</b>	<b>43,739</b>	<b>44,398</b>	<b>2%</b>	<b>100%</b>	-	<b>0 %</b>

POPULATION SERVICES INTERNATIONAL

Monthly DALY Report by Health Area

Period: 2

Year: 2019

	DALY 2/2019	YTD DALY 2018	YTD DALY 2019	Percentage Change	Percentage of Category	Annual DALY Target	Percentage of Target Achieved
Acceleration Market Group	6,182	10,936	12,479	14%	28 %	-	0%
Anglophone Africa Market Group	24	108	33	(70)%	0 %	-	0%
Latin America & Asia Market Group	9,386	15,452	18,534	20%	42 %	-	0%
Foundation Market Group	-	17,244	13,352	(23)%	30 %	-	0%
<b>WASH</b>	<b>2,490</b>	<b>6,832</b>	<b>5,092</b>	<b>(25)%</b>	<b>100%</b>	<b>-</b>	<b>0 %</b>
Acceleration Market Group	1,087	453	2,116	367%	42 %	-	0%
Anglophone Africa Market Group	487	1,611	1,123	(30)%	22 %	-	0%
Franco/Lusophone Africa Market Group	687	2,516	1,222	(51)%	24 %	-	0%
Latin America & Asia Market Group	7	25	17	(32)%	0 %	-	0%
Foundation Market Group	221	2,228	614	(72)%	12 %	-	0%
<b>Other</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>0%</b>	<b>0%</b>	<b>-</b>	<b>0 %</b>
Social Enterprise	-	-	-	0%	0 %	-	0%

POPULATION SERVICES INTERNATIONAL

Monthly DALY Report by Country

Period: 2

Year: 2019

	DALY 2/2019	YTD DALY 2018	YTD DALY 2019	Percentage Change	Percentage of Category	Annual DALY Target	Percentage of Target Achieved
<b>GRAND TOTAL</b>	<b>1,288,390</b>	<b>3,700,591</b>	<b>2,662,447</b>	<b>(28%)</b>		-	<b>-%</b>
<b>Acceleration Market Group</b>	<b>274,591</b>	<b>579,569</b>	<b>465,547</b>	<b>(20%)</b>	<b>100%</b>	-	<b>-%</b>
<b>India</b>	<b>17,295</b>	<b>52,727</b>	<b>39,059</b>	<b>(26)%</b>	<b>8%</b>	-	<b>-%</b>
Modern Contraception	16,566	52,719	37,693	(29)%	8%	-	0 %
WASH	729	8	1,366	16,109%	0%	-	0 %
<b>Kenya</b>	<b>137,349</b>	<b>204,395</b>	<b>236,732</b>	<b>16 %</b>	<b>51%</b>	-	<b>-%</b>
Modern Contraception	39,909	65,660	68,468	4%	15%	-	0 %
HIV & STIs	92,492	130,890	157,741	21%	34%	-	0 %
Malaria	2,066	3,584	5,251	47%	1%	-	0 %
Maternal, Newborn, and Child Health	2,520	3,812	4,514	18%	1%	-	0 %
Non-communicable diseases	5	6	8	35%	0%	-	0 %
Tuberculosis	-	-	-	0%	0%	-	0 %
WASH	358	444	750	69%	0%	-	0 %
<b>Myanmar</b>	<b>24,645</b>	<b>43,575</b>	<b>37,987</b>	<b>(13)%</b>	<b>8%</b>	-	<b>-%</b>
Modern Contraception	7,539	6,117	9,510	55%	2%	-	0 %
HIV & STIs	5,419	9,251	9,970	8%	2%	-	0 %
Malaria	4,897	15,663	4,946	(68)%	1%	-	0 %
Maternal, Newborn, and Child Health	606	1,570	1,079	(31)%	0%	-	0 %
Non-communicable diseases	1	-	3	0%	0%	-	0 %
Nutrition	-	37	-	(100)%	0%	-	0 %
Tuberculosis	6,182	10,936	12,479	14%	3%	-	0 %
WASH	-	-	-	(100)%	0%	-	0 %
<b>Nigeria</b>	<b>493</b>	<b>9,460</b>	<b>6,776</b>	<b>(28)%</b>	<b>1%</b>	-	<b>-%</b>
Modern Contraception	493	1,160	6,776	484%	1%	-	0 %
HIV & STIs	-	8,300	-	(100)%	0%	-	0 %
<b>PSI Nigeria</b>	<b>50,456</b>	<b>74,014</b>	<b>90,107</b>	<b>22 %</b>	<b>19%</b>	-	<b>-%</b>
Modern Contraception	39,039	74,014	77,714	5%	17%	-	0 %
Safe Abortion	11,417	-	12,393	0%	3%	-	0 %
<b>South Africa</b>	<b>44,353</b>	<b>195,397</b>	<b>54,886</b>	<b>(72)%</b>	<b>12%</b>	-	<b>-%</b>
Modern Contraception	-	8,636	-	(100)%	0%	-	0 %
HIV & STIs	44,353	186,762	54,886	(71)%	12%	-	0 %
<b>Anglophone Africa Market Group</b>	<b>542,071</b>	<b>1,020,304</b>	<b>979,759</b>	<b>(4)%</b>	<b>100%</b>	-	<b>-%</b>
<b>Ethiopia</b>	<b>37,882</b>	<b>88,226</b>	<b>38,503</b>	<b>(56)%</b>	<b>4%</b>	-	<b>-%</b>
Modern Contraception	12,774	30,175	12,774	(58)%	1%	-	0 %
HIV & STIs	24,924	57,762	25,116	(57)%	3%	-	0 %
Tuberculosis	-	-	-	0%	0%	-	0 %
WASH	184	290	613	112%	0%	-	0 %
<b>Ghana</b>	<b>2,288</b>	<b>7,494</b>	<b>6,966</b>	<b>(7)%</b>	<b>1%</b>	-	<b>-%</b>
Modern Contraception	2,279	7,489	6,956	(7)%	1%	-	0 %
WASH	9	4	10	127%	0%	-	0 %
<b>Lesotho</b>	<b>4,132</b>	<b>32,455</b>	<b>7,563</b>	<b>(77)%</b>	<b>1%</b>	-	<b>-%</b>
Modern Contraception	490	2,844	901	(68)%	0%	-	0 %
HIV & STIs	3,617	29,529	6,630	(78)%	1%	-	0 %
Non-communicable diseases	-	-	-	0%	0%	-	0 %
Tuberculosis	24	81	33	(60)%	0%	-	0 %
<b>Malawi</b>	<b>97,530</b>	<b>220,422</b>	<b>139,585</b>	<b>(37)%</b>	<b>14%</b>	-	<b>-%</b>

POPULATION SERVICES INTERNATIONAL  
 Monthly DALY Report by Country  
 Period: 2  
 Year: 2019

	DALY 2/2019	YTD DALY 2018	YTD DALY 2019	Percentage Change	Percentage of Category	Annual DALY Target	Percentage of Target Achieved
Modern Contraception	37,911	87,964	61,457	(30)%	6%	-	0 %
HIV & STIs	59,391	131,859	77,718	(41)%	8%	-	0 %
Malaria	178	424	339	(20)%	0%	-	0 %
Non-communicable diseases	-	-	-	0%	0%	-	0 %
WASH	50	174	71	(59)%	0%	-	0 %
<b>PSI Uganda</b>	<b>116,713</b>	-	<b>187,393</b>	<b>- %</b>	<b>19%</b>	-	<b>-%</b>
Modern Contraception	111,935	-	181,598	0%	19%	-	0 %
HIV & STIs	3,459	-	3,709	0%	0%	-	0 %
Maternal, Newborn, and Child Health	59	-	122	0%	0%	-	0 %
Non-communicable diseases	-	-	2	0%	0%	-	0 %
Safe Abortion	1,225	-	1,928	0%	0%	-	0 %
WASH	35	-	35	0%	0%	-	0 %
<b>Rwanda</b>	<b>14,511</b>	<b>28,650</b>	<b>59,672</b>	<b>108 %</b>	<b>6%</b>	-	<b>-%</b>
Modern Contraception	5,179	8,352	16,641	99%	2%	-	0 %
HIV & STIs	9,288	20,154	42,987	113%	4%	-	0 %
WASH	44	144	44	(69)%	0%	-	0 %
<b>Swaziland</b>	<b>33,799</b>	<b>142,884</b>	<b>116,238</b>	<b>(19)%</b>	<b>12%</b>	-	<b>-%</b>
Modern Contraception	2,025	9,359	7,517	(20)%	1%	-	0 %
HIV & STIs	31,774	133,526	108,721	(19)%	11%	-	0 %
Non-communicable diseases	-	-	-	0%	0%	-	0 %
Tuberculosis	-	-	-	0%	0%	-	0 %
<b>Tanzania</b>	<b>30,098</b>	<b>83,240</b>	<b>53,278</b>	<b>(36)%</b>	<b>5%</b>	-	<b>-%</b>
Modern Contraception	29,215	61,095	52,194	(15)%	5%	-	0 %
HIV & STIs	10	10	46	367%	0%	-	0 %
Malaria	577	20,569	577	(97)%	0%	-	0 %
Non-communicable diseases	-	-	-	0%	0%	-	0 %
Safe Abortion	267	1,439	406	(72)%	0%	-	0 %
WASH	28	126	55	(57)%	0%	-	0 %
<b>Uganda</b>	<b>2,475</b>	<b>68,782</b>	<b>5,604</b>	<b>(92)%</b>	<b>1%</b>	-	<b>-%</b>
Modern Contraception	-	65,842	45	(100)%	0%	-	0 %
HIV & STIs	2,475	2,395	5,558	132%	1%	-	0 %
Maternal, Newborn, and Child Health	-	232	-	(100)%	0%	-	0 %
Non-communicable diseases	-	20	-	(100)%	0%	-	0 %
Safe Abortion	-	292	-	(100)%	0%	-	0 %
WASH	-	-	-	(100)%	0%	-	0 %
<b>Zambia</b>	<b>42,692</b>	<b>44,575</b>	<b>87,811</b>	<b>97 %</b>	<b>9%</b>	-	<b>-%</b>
Modern Contraception	14,722	22,337	28,406	27%	3%	-	0 %
HIV & STIs	27,832	21,365	59,110	177%	6%	-	0 %
WASH	137	873	295	(66)%	0%	-	0 %
<b>Zimbabwe</b>	<b>159,952</b>	<b>303,577</b>	<b>277,144</b>	<b>(9)%</b>	<b>28%</b>	-	<b>-%</b>
Modern Contraception	7,346	11,441	13,056	14%	1%	-	0 %
HIV & STIs	152,584	292,079	264,051	(10)%	27%	-	0 %
Non-communicable diseases	22	31	38	24%	0%	-	0 %
Tuberculosis	-	26	-	(100)%	0%	-	0 %
<b>Franco/Lusophone Africa Market Group</b>	<b>126,754</b>	<b>252,015</b>	<b>282,827</b>	<b>12%</b>	<b>100%</b>	-	<b>-%</b>
<b>Angola</b>	<b>27,520</b>	<b>47,035</b>	<b>45,790</b>	<b>(3)%</b>	<b>16%</b>	-	<b>-%</b>
Modern Contraception	10,038	10,601	11,967	13%	4%	-	0 %



POPULATION SERVICES INTERNATIONAL

Monthly DALY Report by Country

Period: 2

Year: 2019

	DALY 2/2019	YTD DALY 2018	YTD DALY 2019	Percentage Change	Percentage of Category	Annual DALY Target	Percentage of Target Achieved
HIV & STIs	1,309	2,055	1,963	(4)%	1%	-	0 %
Malaria	15,908	34,187	31,475	(8)%	11%	-	0 %
Safe Abortion	63	22	150	585%	0%	-	0 %
WASH	203	171	235	38%	0%	-	0 %
<b>Benin</b>	<b>7,586</b>	<b>13,899</b>	<b>10,994</b>	<b>(21)%</b>	<b>4%</b>	-	<b>-%</b>
Modern Contraception	5,185	11,078	7,238	(35)%	3%	-	0 %
HIV & STIs	1,223	1,767	1,815	3%	1%	-	0 %
Malaria	-	9	-	(100)%	0%	-	0 %
Maternal, Newborn, and Child Health	806	982	1,429	45%	1%	-	0 %
Non-communicable diseases	-	1	-	(86)%	0%	-	0 %
Safe Abortion	67	-	145	0%	0%	-	0 %
WASH	305	61	367	499%	0%	-	0 %
<b>Burundi</b>	<b>13,828</b>	<b>19,145</b>	<b>30,350</b>	<b>59 %</b>	<b>11%</b>	-	<b>-%</b>
Modern Contraception	4,099	3,745	9,357	150%	3%	-	0 %
HIV & STIs	4,432	2,304	10,866	372%	4%	-	0 %
Malaria	5,273	13,075	10,069	(23)%	4%	-	0 %
Safe Abortion	24	21	57	167%	0%	-	0 %
<b>Cameroon</b>	<b>43,376</b>	<b>89,028</b>	<b>93,231</b>	<b>5 %</b>	<b>33%</b>	-	<b>-%</b>
Modern Contraception	28,316	61,866	60,015	(3)%	21%	-	0 %
HIV & STIs	14,053	24,978	31,397	26%	11%	-	0 %
Malaria	148	901	260	(71)%	0%	-	0 %
Maternal, Newborn, and Child Health	412	264	685	160%	0%	-	0 %
Nutrition	-	-	-	0%	0%	-	0 %
Safe Abortion	431	1,019	852	(16)%	0%	-	0 %
WASH	15	-	22	9,683%	0%	-	0 %
<b>Cote d'Ivoire</b>	<b>5,032</b>	<b>1,547</b>	<b>10,589</b>	<b>584 %</b>	<b>4%</b>	-	<b>-%</b>
Modern Contraception	4,936	1,115	10,442	837%	4%	-	0 %
HIV & STIs	-	382	-	(100)%	0%	-	0 %
WASH	95	50	148	192%	0%	-	0 %
<b>Mozambique</b>	<b>18,398</b>	<b>66,747</b>	<b>71,847</b>	<b>8 %</b>	<b>25%</b>	-	<b>-%</b>
Modern Contraception	18,398	34,773	45,530	31%	16%	-	0 %
HIV & STIs	-	29,649	25,968	(12)%	9%	-	0 %
Malaria	-	95	-	(100)%	0%	-	0 %
WASH	-	2,230	349	(84)%	0%	-	0 %
<b>Niger</b>	<b>4,728</b>	<b>7,826</b>	<b>10,110</b>	<b>29 %</b>	<b>4%</b>	-	<b>-%</b>
Modern Contraception	4,573	7,758	9,762	26%	3%	-	0 %
HIV & STIs	122	24	245	914%	0%	-	0 %
Safe Abortion	33	43	103	138%	0%	-	0 %
<b>PSI Benin</b>	<b>2,159</b>	<b>4,893</b>	<b>3,206</b>	<b>(34)%</b>	<b>1%</b>	-	<b>-%</b>
Modern Contraception	1,558	4,391	2,408	(45)%	1%	-	0 %
Safe Abortion	601	502	798	59%	0%	-	0 %
<b>Senegal</b>	<b>4,127</b>	<b>1,894</b>	<b>6,711</b>	<b>254 %</b>	<b>2%</b>	-	<b>-%</b>
Modern Contraception	2,460	1,277	4,324	239%	2%	-	0 %
HIV & STIs	1,541	602	2,229	270%	1%	-	0 %
Malaria	57	13	57	347%	0%	-	0 %
Nutrition	-	-	-	0%	0%	-	0 %
WASH	69	3	101	3,485%	0%	-	0 %

POPULATION SERVICES INTERNATIONAL

Monthly DALY Report by Country

Period: 2

Year: 2019

	DALY 2/2019	YTD DALY 2018	YTD DALY 2019	Percentage Change	Percentage of Category	Annual DALY Target	Percentage of Target Achieved
<b>Latin America &amp; Asia Market Group</b>	<b>92,803</b>	<b>210,835</b>	<b>210,758</b>	<b>-%</b>	<b>100%</b>	<b>-</b>	<b>-%</b>
<b>Cambodia</b>	<b>21,154</b>	<b>39,192</b>	<b>39,419</b>	<b>1 %</b>	<b>19%</b>	<b>-</b>	<b>-%</b>
Modern Contraception	9,437	21,004	17,835	(15)%	8%	-	0 %
HIV & STIs	8,229	13,138	15,319	17%	7%	-	0 %
Malaria	2	307	2	(99)%	0%	-	0 %
Maternal, Newborn, and Child Health	834	231	1,045	352%	0%	-	0 %
Safe Abortion	2,652	4,512	5,218	16%	2%	-	0 %
<b>Costa Rica</b>	<b>232</b>	<b>347</b>	<b>377</b>	<b>9 %</b>	<b>-%</b>	<b>-</b>	<b>-%</b>
Modern Contraception	29	44	48	9%	0%	-	0 %
HIV & STIs	202	303	329	9%	0%	-	0 %
<b>Dominican Republic</b>	<b>2,951</b>	<b>3,115</b>	<b>4,200</b>	<b>35 %</b>	<b>2%</b>	<b>-</b>	<b>-%</b>
Modern Contraception	883	886	1,257	42%	1%	-	0 %
HIV & STIs	2,068	2,229	2,944	32%	1%	-	0 %
<b>El Salvador</b>	<b>504</b>	<b>1,034</b>	<b>925</b>	<b>(10)%</b>	<b>-%</b>	<b>-</b>	<b>-%</b>
Modern Contraception	122	321	228	(29)%	0%	-	0 %
HIV & STIs	382	709	697	(2)%	0%	-	0 %
Maternal, Newborn, and Child Health	-	2	-	(100)%	0%	-	0 %
Non-communicable diseases	-	-	-	0%	0%	-	0 %
Safe Abortion	-	2	-	(100)%	0%	-	0 %
<b>El Salvador SA</b>	<b>287</b>	<b>253</b>	<b>304</b>	<b>20 %</b>	<b>-%</b>	<b>-</b>	<b>-%</b>
Modern Contraception	277	246	292	19%	0%	-	0 %
HIV & STIs	8	6	8	33%	0%	-	0 %
Safe Abortion	2	-	3	3,833%	0%	-	0 %
<b>Guatemala</b>	<b>1,878</b>	<b>14,643</b>	<b>4,232</b>	<b>(71)%</b>	<b>2%</b>	<b>-</b>	<b>-%</b>
Modern Contraception	828	12,098	1,844	(85)%	1%	-	0 %
HIV & STIs	1,050	2,505	2,388	(5)%	1%	-	0 %
Safe Abortion	-	40	-	(100)%	0%	-	0 %
<b>Guatemala SA</b>	<b>501</b>	<b>2,017</b>	<b>3,539</b>	<b>76 %</b>	<b>2%</b>	<b>-</b>	<b>-%</b>
Modern Contraception	455	1,986	3,467	75%	2%	-	0 %
HIV & STIs	7	23	7	(69)%	0%	-	0 %
Safe Abortion	39	8	65	716%	0%	-	0 %
<b>Honduras</b>	<b>1,895</b>	<b>3,093</b>	<b>4,100</b>	<b>33 %</b>	<b>2%</b>	<b>-</b>	<b>-%</b>
Modern Contraception	299	425	637	50%	0%	-	0 %
HIV & STIs	1,596	2,669	3,463	30%	2%	-	0 %
<b>Kazakhstan</b>	<b>59</b>	<b>62</b>	<b>109</b>	<b>77 %</b>	<b>-%</b>	<b>-</b>	<b>-%</b>
Modern Contraception	-	3	-	(100)%	0%	-	0 %
HIV & STIs	59	59	109	87%	0%	-	0 %
Tuberculosis	-	-	-	0%	0%	-	0 %
<b>Kyrgyzstan</b>	<b>50</b>	<b>133</b>	<b>91</b>	<b>(32)%</b>	<b>-%</b>	<b>-</b>	<b>-%</b>
Modern Contraception	-	12	-	(100)%	0%	-	0 %
HIV & STIs	50	121	91	(25)%	0%	-	0 %
Tuberculosis	-	-	-	0%	0%	-	0 %
<b>Laos</b>	<b>1,715</b>	<b>5,065</b>	<b>5,035</b>	<b>(1)%</b>	<b>2%</b>	<b>-</b>	<b>-%</b>
Modern Contraception	1,450	3,994	3,928	(2)%	2%	-	0 %
HIV & STIs	88	897	793	(12)%	0%	-	0 %
Malaria	21	39	48	22%	0%	-	0 %
Safe Abortion	143	114	253	121%	0%	-	0 %

**POPULATION SERVICES INTERNATIONAL**  
**Monthly DALY Report by Country**  
**Period: 2**  
**Year: 2019**

	DALY 2/2019	YTD DALY 2018	YTD DALY 2019	Percentage Change	Percentage of Category	Annual DALY Target	Percentage of Target Achieved
Tuberculosis	13	20	13	(34)%	0%	-	0 %
<b>Nepal</b>	<b>163</b>	<b>8,216</b>	<b>1,683</b>	<b>(80)%</b>	<b>1%</b>	-	<b>-%</b>
Modern Contraception	160	5,401	175	(97)%	0%	-	0 %
HIV & STIs	-	-	-	0%	0%	-	0 %
Safe Abortion	3	2,815	1,508	(46)%	1%	-	0 %
<b>Nicaragua</b>	<b>1,645</b>	<b>3,228</b>	<b>2,534</b>	<b>(22)%</b>	<b>1%</b>	-	<b>-%</b>
Modern Contraception	1,037	1,996	1,365	(32)%	1%	-	0 %
HIV & STIs	600	1,230	1,155	(6)%	1%	-	0 %
Safe Abortion	9	2	14	559%	0%	-	0 %
<b>Pakistan</b>	<b>51,218</b>	<b>105,301</b>	<b>124,261</b>	<b>18 %</b>	<b>59%</b>	-	<b>-%</b>
Modern Contraception	38,627	82,136	97,386	19%	46%	-	0 %
HIV & STIs	2,473	6,414	5,098	(21)%	2%	-	0 %
Safe Abortion	745	1,319	3,256	147%	2%	-	0 %
Tuberculosis	9,373	15,432	18,521	20%	9%	-	0 %
<b>Panama</b>	<b>351</b>	<b>1,323</b>	<b>1,184</b>	<b>(10)%</b>	<b>1%</b>	-	<b>-%</b>
Modern Contraception	80	312	278	(11)%	0%	-	0 %
HIV & STIs	271	1,011	906	(10)%	0%	-	0 %
<b>Papua New Guinea</b>	<b>-</b>	<b>2,015</b>	<b>2</b>	<b>(100)%</b>	<b>-%</b>	-	<b>-%</b>
Modern Contraception	-	157	-	(100)%	0%	-	0 %
HIV & STIs	-	143	-	(100)%	0%	-	0 %
Malaria	-	1,714	-	(100)%	0%	-	0 %
Maternal, Newborn, and Child Health	-	-	-	0%	0%	-	0 %
WASH	-	-	2	6,213%	0%	-	0 %
<b>PSI Pakistan</b>	<b>7,659</b>	<b>17,591</b>	<b>16,897</b>	<b>(4)%</b>	<b>8%</b>	-	<b>-%</b>
Modern Contraception	7,520	17,565	16,633	(5)%	8%	-	0 %
HIV & STIs	139	26	264	923%	0%	-	0 %
<b>Tajikistan</b>	<b>119</b>	<b>1,167</b>	<b>243</b>	<b>(79)%</b>	<b>-%</b>	-	<b>-%</b>
Modern Contraception	4	11	9	(23)%	0%	-	0 %
HIV & STIs	114	1,156	234	(80)%	0%	-	0 %
Tuberculosis	-	-	-	0%	0%	-	0 %
<b>Viet Nam</b>	<b>424</b>	<b>3,042</b>	<b>1,621</b>	<b>(47)%</b>	<b>1%</b>	-	<b>-%</b>
Modern Contraception	7	22	22	0%	0%	-	0 %
HIV & STIs	410	2,993	1,584	(47)%	1%	-	0 %
Malaria	-	2	-	(88)%	0%	-	0 %
Non-communicable diseases	-	-	-	0%	0%	-	0 %
Tuberculosis	-	-	-	0%	0%	-	0 %
WASH	7	25	14	(41)%	0%	-	0 %
<b>Foundation Market Group</b>	<b>170,271</b>	<b>1,428,361</b>	<b>547,233</b>	<b>(62)%</b>	<b>100%</b>	-	<b>-%</b>
<b>Haiti</b>	<b>38</b>	<b>19,474</b>	<b>18,279</b>	<b>(6)%</b>	<b>3%</b>	-	<b>-%</b>
Modern Contraception	26	2,014	2,297	14%	0%	-	0 %
HIV & STIs	-	-	2,615	0%	0%	-	0 %
Malaria	-	215	3	(99)%	0%	-	0 %
Maternal, Newborn, and Child Health	12	-	12	0%	0%	-	0 %
Non-communicable diseases	-	-	-	0%	0%	-	0 %
Tuberculosis	-	17,244	13,352	(23)%	2%	-	0 %
<b>Liberia</b>	<b>307</b>	<b>1,641</b>	<b>1,083</b>	<b>(34)%</b>	<b>-%</b>	-	<b>-%</b>

POPULATION SERVICES INTERNATIONAL

Monthly DALY Report by Country

Period: 2

Year: 2019

	DALY 2/2019	YTD DALY 2018	YTD DALY 2019	Percentage Change	Percentage of Category	Annual DALY Target	Percentage of Target Achieved
Modern Contraception	138	752	493	(34)%	0%	-	0 %
HIV & STIs	158	858	563	(34)%	0%	-	0 %
WASH	11	31	27	(12)%	0%	-	0 %
<b>Madagascar</b>	<b>87,008</b>	<b>55,361</b>	<b>148,900</b>	<b>169 %</b>	<b>27%</b>	-	<b>-%</b>
Modern Contraception	24,615	32,088	39,819	24%	7%	-	0 %
HIV & STIs	1,354	2,474	1,937	(22)%	0%	-	0 %
Malaria	60,254	11,890	106,050	792%	19%	-	0 %
Maternal, Newborn, and Child Health	7	6,743	27	(100)%	0%	-	0 %
Non-communicable diseases	2	2	2	0%	0%	-	0 %
Nutrition	-	-	-	0%	0%	-	0 %
Safe Abortion	644	248	678	174%	0%	-	0 %
WASH	132	1,915	388	(80)%	0%	-	0 %
<b>Mali</b>	<b>28,688</b>	<b>1,253,858</b>	<b>319,581</b>	<b>(75)%</b>	<b>58%</b>	-	<b>-%</b>
Modern Contraception	28,688	42,132	43,985	4%	8%	-	0 %
Malaria	-	1,210,594	275,244	(77)%	50%	-	0 %
Non-communicable diseases	-	7	-	(100)%	0%	-	0 %
Safe Abortion	-	1,125	351	(69)%	0%	-	0 %
WASH	-	-	1	0%	0%	-	0 %
<b>Somaliland</b>	<b>7,857</b>	<b>7,339</b>	<b>13,014</b>	<b>77 %</b>	<b>2%</b>	-	<b>-%</b>
Modern Contraception	244	152	438	188%	0%	-	0 %
HIV & STIs	17	-	25	0%	0%	-	0 %
Malaria	69	-	150	0%	0%	-	0 %
Maternal, Newborn, and Child Health	5,966	6,906	10,720	55%	2%	-	0 %
Nutrition	1,483	-	1,483	0%	0%	-	0 %
WASH	78	282	198	(30)%	0%	-	0 %
<b>South Sudan</b>	<b>46,375</b>	<b>90,688</b>	<b>46,375</b>	<b>(49)%</b>	<b>8%</b>	-	<b>-%</b>
Malaria	46,375	62,047	46,375	(25)%	8%	-	0 %
Maternal, Newborn, and Child Health	-	28,641	-	(100)%	0%	-	0 %
<b>Social Enterprise</b>	<b>81,900</b>	<b>207,745</b>	<b>176,323</b>	<b>(15)%</b>	<b>100%</b>	-	<b>-%</b>
<b>India LLC</b>	<b>18,122</b>	<b>70,795</b>	<b>44,766</b>	<b>(37)%</b>	<b>25%</b>	-	<b>-%</b>
Modern Contraception	2,457	29,640	17,263	(42)%	10%	-	0 %
HIV & STIs	4,060	27,973	11,312	(60)%	6%	-	0 %
Maternal, Newborn, and Child Health	6,226	1,698	7,986	370%	5%	-	0 %
Safe Abortion	5,380	11,485	8,205	(29)%	5%	-	0 %
Other	-	-	-	0%	0%	-	0 %
<b>Paraguay</b>	<b>1,980</b>	<b>2,994</b>	<b>3,680</b>	<b>23 %</b>	<b>2%</b>	-	<b>-%</b>
Modern Contraception	557	1,071	1,180	10%	1%	-	0 %
HIV & STIs	1,403	1,870	2,463	32%	1%	-	0 %
Nutrition	20	53	37	(31)%	0%	-	0 %
<b>PSI South Africa</b>	<b>61,798</b>	<b>133,956</b>	<b>127,877</b>	<b>(5)%</b>	<b>73%</b>	-	<b>-%</b>
Modern Contraception	3,804	8,299	7,817	(6)%	4%	-	0 %
HIV & STIs	57,994	125,656	120,060	(4)%	68%	-	0 %
<b>Inactive</b>	<b>-</b>	<b>1,762</b>	<b>-</b>	<b>(100)%</b>	<b>-%</b>	-	<b>-%</b>
<b>Guinea</b>	<b>-</b>	<b>1,762</b>	<b>-</b>	<b>(100)%</b>	<b>-%</b>	-	<b>-%</b>
Modern Contraception	-	1,520	-	(100)%	0%	-	0 %
HIV & STIs	-	242	-	(100)%	0%	-	0 %

**POPULATION SERVICES INTERNATIONAL**  
**Monthly DALY Report by Country**  
**Period: 2**  
**Year: 2019**

DALY 2/2019	YTD DALY 2018	YTD DALY 2019	Percentage Change	Percentage of Category	Annual DALY Target	Percentage of Target Achieved
----------------	------------------	------------------	----------------------	---------------------------	--------------------------	-------------------------------------

**POPULATION SERVICES INTERNATIONAL**  
**Monthly Distribution by Product**  
**Period: 2**  
**Year: 2019**

	DISTRIBUTION 2/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	YTD USERS REACHED 2019 <sup>(a)</sup>	YTD CYP 2019	YTD DALY 2019
<b>Acute Malnutrition Screening_CU5</b>	-	206,481	389	-	324	20%	619,573	621,339	389	-	-
Franco/Lusophone Africa Market Group	-	-	-	-	324	(100)%	518	1,895	-	-	-
Foundation Market Group	-	206,481	389	-	-	-%	619,055	619,444	389	-	-
<b>Antiretroviral Treatment</b>	-	-	-	-	-	-%	-	18,119	-	-	-
Acceleration Market Group	-	-	-	-	-	-%	-	18,119	-	-	-
<b>Antiretroviral Treatment (Currently Enrolled)</b>	29,324	29,748	58,683	-	42,754	37%	535,855	1,066,880	4,890	-	11,049
Acceleration Market Group	13,657	13,624	27,179	-	23,487	16%	152,003	255,663	2,265	-	5,405
Anglophone Africa Market Group	12,727	13,240	25,661	-	18,012	42%	148,026	292,920	2,138	-	4,542
Franco/Lusophone Africa Market Group	2,940	2,884	5,843	-	1,255	366%	19,016	31,489	487	-	1,101
Latin America & Asia Market Group	-	-	-	-	-	-%	233	233	-	-	-
Foundation Market Group	-	-	-	-	-	-%	216,577	486,575	-	-	-
<b>Antiretroviral Treatment (Newly Enrolled)</b>	789	816	1,491	-	1,597	(7)%	15,865	44,454	1,491	-	-
Acceleration Market Group	326	283	599	-	523	15%	3,434	10,185	599	-	-
Anglophone Africa Market Group	436	396	824	-	944	(13)%	6,634	23,689	824	-	-
Franco/Lusophone Africa Market Group	27	50	68	-	130	(48)%	1,807	2,289	68	-	-
Latin America & Asia Market Group	-	-	-	-	-	-%	92	92	-	-	-
Foundation Market Group	-	87	-	-	-	-%	3,898	8,199	-	-	-
<b>Antiretroviral Treatment (Tablet)</b>	-	-	-	-	-	-%	-	97,980	-	-	-
Acceleration Market Group	-	-	-	-	-	-%	-	97,980	-	-	-
<b>ARV Prophylaxis 28 wks (Mother and Baby)</b>	-	-	-	-	-	-%	-	382	-	-	-
Acceleration Market Group	-	-	-	-	-	-%	-	382	-	-	-
<b>ARV Prophylaxis 28 wks (Mother Only)</b>	-	-	-	-	-	-%	-	359	-	-	-
Acceleration Market Group	-	-	-	-	-	-%	-	359	-	-	-
<b>Basic Care Package</b>	-	-	-	-	-	-%	1	176,452,482	-	-	-
Acceleration Market Group	-	-	-	-	-	-%	-	1,064,698	-	-	-
Anglophone Africa Market Group	-	-	-	-	-	-%	1	174,969,459	-	-	-
Franco/Lusophone Africa Market Group	-	-	-	-	-	-%	-	418,325	-	-	-

<sup>(a)</sup>The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

**POPULATION SERVICES INTERNATIONAL**  
**Monthly Distribution by Product**  
**Period: 2**  
**Year: 2019**

	DISTRIBUTION 2/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	YTD USERS REACHED 2019 <sup>(a)</sup>	YTD CYP 2019	YTD DALY 2019
<b>CD4 Tests Provided to HIV+ Clients</b>	-	-	-	-	666	(100)%	666	16,834	-	-	-
Acceleration Market Group	-	-	-	-	-	-%	-	4,995	-	-	-
Anglophone Africa Market Group	-	-	-	-	544	(100)%	544	9,416	-	-	-
Franco/Lusophone Africa Market Group	-	-	-	-	122	(100)%	122	1,919	-	-	-
Latin America & Asia Market Group	-	-	-	-	-	-%	-	504	-	-	-
<b>Cervical Cancer-HPV DNA and Cryotherapy</b>	-	-	-	-	3	(100)%	3	3	-	-	-
Anglophone Africa Market Group	-	-	-	-	3	(100)%	3	3	-	-	-
<b>Cervical Cancer-HPV DNA and Refer to any Treatment</b>	-	-	-	-	-	-%	-	11	-	-	-
Anglophone Africa Market Group	-	-	-	-	-	-%	-	11	-	-	-
<b>Cervical Cancer-HPV DNA and Refer to Conization</b>	-	-	-	-	-	-%	-	9	-	-	-
Anglophone Africa Market Group	-	-	-	-	-	-%	-	9	-	-	-
<b>Cervical Cancer-Pap and Cryotherapy</b>	-	-	-	-	-	-%	4	39	-	-	-
Latin America & Asia Market Group	-	-	-	-	-	-%	-	25	-	-	-
Foundation Market Group	-	-	-	-	-	-%	4	4	-	-	-
Inactive	-	-	-	-	-	-%	-	10	-	-	-
<b>Cervical Cancer-Pap and Refer to any Treatment</b>	-	-	-	-	-	-%	-	2	-	-	-
Anglophone Africa Market Group	-	-	-	-	-	-%	-	2	-	-	-
<b>Cervical Cancer-Pap and Refer to Conization</b>	-	-	-	-	-	-%	-	9	-	-	-
Anglophone Africa Market Group	-	-	-	-	-	-%	-	9	-	-	-
<b>Cervical Cancer-Pap Smear Screening</b>	11	32	106	-	-	-%	92	7,463	106	-	-
Acceleration Market Group	-	-	-	-	-	-%	-	6,497	-	-	-
Anglophone Africa Market Group	-	-	-	-	-	-%	-	291	-	-	-
Latin America & Asia Market Group	11	32	106	-	-	-%	92	586	106	-	-
Inactive	-	-	-	-	-	-%	-	89	-	-	-
<b>Cervical Cancer-VIA and Conization</b>	19	17	30	-	8	275%	126	334	30	-	11
Anglophone Africa Market Group	19	17	30	-	8	275%	126	334	30	-	11
<b>Cervical Cancer-VIA and Cryotherapy</b>	69	74	130	-	182	(29)%	1,162	21,569	130	-	40

<sup>(a)</sup>The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

**POPULATION SERVICES INTERNATIONAL**  
**Monthly Distribution by Product**  
**Period: 2**  
**Year: 2019**

	DISTRIBUTION 2/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	YTD USERS REACHED 2019 <sup>(a)</sup>	YTD CYP 2019	YTD DALY 2019
Acceleration Market Group	24	24	49	-	26	88%	286	11,295	49	-	11
Anglophone Africa Market Group	39	38	74	-	121	(39)%	639	8,523	74	-	26
Franco/Lusophone Africa Market Group	1	2	1	-	7	(86)%	48	375	1	-	-
Latin America & Asia Market Group	-	-	-	-	-	-%	-	8	-	-	-
Foundation Market Group	5	10	6	-	28	(79)%	189	1,348	6	-	2
Inactive	-	-	-	-	-	-%	-	20	-	-	-
<b>Cervical Cancer-VIA and Refer to any Treatment</b>	<b>8</b>	<b>1</b>	<b>9</b>	<b>-</b>	<b>4</b>	<b>125%</b>	<b>25</b>	<b>447</b>	<b>9</b>	<b>-</b>	<b>2</b>
Acceleration Market Group	-	-	-	-	-	-%	-	127	-	-	-
Anglophone Africa Market Group	8	1	9	-	4	125%	25	320	9	-	2
<b>Cervical Cancer-VIA and Refer to Conization</b>	<b>4</b>	<b>9</b>	<b>6</b>	<b>-</b>	<b>-</b>	<b>-%</b>	<b>102</b>	<b>2,066</b>	<b>6</b>	<b>-</b>	<b>1</b>
Acceleration Market Group	-	1	-	-	-	-%	4	4	-	-	-
Anglophone Africa Market Group	4	8	6	-	-	-%	98	2,062	6	-	1
<b>Cervical Cancer-VIA and Refer to Cryotherapy</b>	<b>-</b>	<b>10</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-%</b>	<b>39</b>	<b>2,084</b>	<b>-</b>	<b>-</b>	<b>-</b>
Acceleration Market Group	-	10	-	-	-	-%	29	913	-	-	-
Anglophone Africa Market Group	-	-	-	-	-	-%	10	625	-	-	-
Franco/Lusophone Africa Market Group	-	-	-	-	-	-%	-	10	-	-	-
Foundation Market Group	-	-	-	-	-	-%	-	536	-	-	-
<b>Cervical Cancer-VIA/VILI Screening</b>	<b>8,670</b>	<b>11,143</b>	<b>15,468</b>	<b>-</b>	<b>25,560</b>	<b>(39)%</b>	<b>194,523</b>	<b>1,056,172</b>	<b>15,468</b>	<b>-</b>	<b>-</b>
Acceleration Market Group	3,286	2,824	6,039	-	2,649	128%	34,714	470,471	6,039	-	-
Anglophone Africa Market Group	4,145	3,510	6,798	-	15,973	(57)%	95,922	347,884	6,798	-	-
Franco/Lusophone Africa Market Group	1,173	4,094	2,528	-	4,673	(46)%	50,592	163,357	2,528	-	-
Latin America & Asia Market Group	-	-	-	-	-	-%	-	387	-	-	-
Foundation Market Group	66	714	103	-	2,265	(95)%	13,295	73,803	103	-	-
Inactive	-	-	-	-	-	-%	-	270	-	-	-
<b>Chlorhexidine</b>	<b>443</b>	<b>1,060</b>	<b>773</b>	<b>-</b>	<b>61,381</b>	<b>(99)%</b>	<b>130,742</b>	<b>618,688</b>	<b>696</b>	<b>-</b>	<b>54</b>
Acceleration Market Group	-	-	-	-	-	-%	-	148,406	-	-	-
Anglophone Africa Market Group	443	1,060	773	-	431	79%	23,622	37,438	696	-	54

<sup>(a)</sup>The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.



**POPULATION SERVICES INTERNATIONAL**  
**Monthly Distribution by Product**  
**Period: 2**  
**Year: 2019**

	DISTRIBUTION 2/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	YTD USERS REACHED 2019 <sup>(a)</sup>	YTD CYP 2019	YTD DALY 2019
Foundation Market Group	-	-	-	-	60,950	(100)%	107,120	432,844	-	-	-
<b>Clean Delivery Kit</b>	-	-	-	-	1,277	(100)%	3,449	1,708,471	-	-	-
Acceleration Market Group	-	-	-	-	-	-%	-	346,994	-	-	-
Anglophone Africa Market Group	-	-	-	-	1,277	(100)%	3,449	470,003	-	-	-
Latin America & Asia Market Group	-	-	-	-	-	-%	-	710,114	-	-	-
Foundation Market Group	-	-	-	-	-	-%	-	180,586	-	-	-
Inactive	-	-	-	-	-	-%	-	774	-	-	-
<b>Condom</b>	29,053,367	50,476,715	62,509,869	-	72,192,891	(13)%	504,429,167	21,509,519,937	468,824	468,824	641,632
Acceleration Market Group	3,415,904	3,059,436	6,351,757	-	5,788,992	10%	38,017,548	9,760,150,108	47,638	47,638	148,856
Anglophone Africa Market Group	3,554,416	5,929,273	8,805,352	-	9,033,061	(3)%	65,266,786	3,155,714,035	66,040	66,040	173,830
Franco/Lusophone Africa Market Group	3,442,340	4,829,622	8,416,546	-	6,877,003	22%	51,015,576	1,637,685,208	63,124	63,124	105,594
Latin America & Asia Market Group	13,244,266	18,494,727	26,441,144	-	29,170,753	(9)%	187,072,729	3,862,598,918	198,309	198,309	63,399
Foundation Market Group	98,136	242,392	263,016	-	269,532	(2)%	3,347,338	952,760,249	1,973	1,973	2,144
Social Enterprise	5,298,305	17,921,264	12,232,054	-	21,053,550	(42)%	159,709,190	724,750,929	91,740	91,740	147,811
USA	-	-	-	-	-	-%	-	16,254,508	-	-	-
Inactive	-	-	-	-	-	-%	-	1,399,605,982	-	-	-
<b>Condom Provided</b>	-	-	-	-	-	-%	-	18,930,351	-	-	-
Acceleration Market Group	-	-	-	-	-	-%	-	50,644	-	-	-
Anglophone Africa Market Group	-	-	-	-	-	-%	-	17,527,104	-	-	-
Franco/Lusophone Africa Market Group	-	-	-	-	-	-%	-	673,774	-	-	-
Latin America & Asia Market Group	-	-	-	-	-	-%	-	651,148	-	-	-
Foundation Market Group	-	-	-	-	-	-%	-	27,681	-	-	-
<b>Counseling &amp; Tx for Moderate Acute MalnutritionCU5</b>	1,169	5,178	1,962	-	-	-%	20,332	177,449	1,962	-	-
Franco/Lusophone Africa Market Group	-	-	-	-	-	-%	-	8	-	-	-
Foundation Market Group	1,169	5,178	1,962	-	-	-%	20,332	177,441	1,962	-	-
<b>Deworming Tablets</b>	-	-	-	-	-	-%	-	1,095,308	-	-	-
Anglophone Africa Market Group	-	-	-	-	-	-%	-	1,095,308	-	-	-

<sup>(a)</sup>The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

**POPULATION SERVICES INTERNATIONAL**  
**Monthly Distribution by Product**  
**Period: 2**  
**Year: 2019**

	DISTRIBUTION 2/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	YTD USERS REACHED 2019 <sup>(a)</sup>	YTD CYP 2019	YTD DALY 2019
<b>Diarrhea Treatment Kit</b>	49,129	41,838	87,477	-	83,035	5%	666,448	19,824,950	78,729	-	6,039
Acceleration Market Group	-	-	-	-	-	-%	-	6,854,139	-	-	-
Anglophone Africa Market Group	-	-	-	-	-	-%	-	24,379	-	-	-
Franco/Lusophone Africa Market Group	18,249	16,838	31,297	-	20,937	49%	431,332	4,164,426	28,167	-	1,791
Latin America & Asia Market Group	10,580	1,717	14,940	-	11,750	27%	57,190	963,616	13,446	-	294
Foundation Market Group	20,300	23,284	41,240	-	50,348	(18)%	177,926	5,071,444	37,116	-	3,955
Inactive	-	-	-	-	-	-%	-	2,746,946	-	-	-
<b>Diarrhea Treatment Kit Provided</b>	2,007	1,726	3,853	-	3,504	10%	20,038	72,784	3,853	-	128
Acceleration Market Group	2,007	1,726	3,853	-	3,098	24%	18,226	58,110	3,853	-	128
Franco/Lusophone Africa Market Group	-	-	-	-	-	-%	-	2,400	-	-	-
Foundation Market Group	-	-	-	-	406	(100)%	1,812	12,274	-	-	-
<b>Early Infant Male Circumcision</b>	-	-	-	-	-	-%	-	4,886	-	-	-
Anglophone Africa Market Group	-	-	-	-	-	-%	-	4,886	-	-	-
<b>Emergency Contraception</b>	286,215	348,838	566,704	-	446,443	27%	3,049,904	45,155,865	25,502	25,502	4,693
Acceleration Market Group	(1,387)	-	(1,387)	-	(126)	-%	(121)	16,364,954	(62)	(62)	(8)
Anglophone Africa Market Group	2,873	13,120	8,305	-	9,400	(12)%	180,947	1,656,062	374	374	121
Franco/Lusophone Africa Market Group	7,609	5,955	14,615	-	54,289	(73)%	135,874	690,921	658	658	389
Latin America & Asia Market Group	250,851	268,421	436,526	-	314,521	39%	2,139,235	21,498,312	19,644	19,644	3,404
Foundation Market Group	(29)	14,945	44,847	-	15,252	194%	40,018	165,378	2,018	2,018	549
Social Enterprise	26,298	46,397	63,798	-	53,107	20%	553,951	3,129,901	2,871	2,871	237
Inactive	-	-	-	-	-	-%	-	1,650,337	-	-	-
<b>Emergency Contraception Provided</b>	4,393	4,005	8,638	-	3,999	116%	29,591	73,587	432	432	105
Acceleration Market Group	1,583	670	1,823	-	274	565%	4,173	7,424	91	91	18
Anglophone Africa Market Group	338	302	656	-	678	(3)%	6,887	8,762	33	33	16
Franco/Lusophone Africa Market Group	371	422	739	-	226	227%	2,877	5,226	37	37	23
Latin America & Asia Market Group	2,072	2,596	5,387	-	2,773	94%	15,372	50,160	269	269	47
Foundation Market Group	29	15	33	-	48	(31)%	282	2,014	2	2	1

<sup>(a)</sup>The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

**POPULATION SERVICES INTERNATIONAL**  
**Monthly Distribution by Product**  
**Period: 2**  
**Year: 2019**

	DISTRIBUTION 2/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	YTD USERS REACHED 2019 <sup>(a)</sup>	YTD CYP 2019	YTD DALY 2019
Inactive	-	-	-	-	-	-%	-	1	-	-	-
<b>Expanded Clean Delivery Kit</b>	-	-	-	-	-	-%	13,160	25,000	-	-	-
Anglophone Africa Market Group	-	-	-	-	-	-%	13,160	25,000	-	-	-
<b>Expanded Clean Delivery Kit (+CHX)</b>	193	925	464	-	694	(33)%	14,531	15,612	418	-	68
Anglophone Africa Market Group	193	925	464	-	694	(33)%	14,531	15,612	418	-	68
<b>Family Planning Counseling</b>	-	-	-	-	-	-%	-	42,190	-	-	-
Anglophone Africa Market Group	-	-	-	-	-	-%	-	15,882	-	-	-
Franco/Lusophone Africa Market Group	-	-	-	-	-	-%	-	21,833	-	-	-
Latin America & Asia Market Group	-	-	-	-	-	-%	-	3,787	-	-	-
Foundation Market Group	-	-	-	-	-	-%	-	688	-	-	-
<b>Fecal Sludge Management (Households)</b>	137	277	274	-	91	201%	2,071	3,927	1,334	-	-
Acceleration Market Group	101	106	210	-	43	388%	697	2,489	1,008	-	-
Franco/Lusophone Africa Market Group	36	171	64	-	48	33%	1,374	1,438	326	-	-
<b>Fecal Sludge Management (Liters)</b>	1,273,000	1,059,000	2,282,000	-	655,000	248%	9,121,000	18,549,200	-	-	195
Acceleration Market Group	505,000	531,667	1,050,000	-	137,000	666%	4,011,000	12,207,200	-	-	65
Franco/Lusophone Africa Market Group	768,000	527,333	1,232,000	-	518,000	138%	5,110,000	6,342,000	-	-	131
<b>Female Condom</b>	158,231	397,102	662,626	-	226,828	192%	1,709,647	86,825,490	4,970	4,970	7,755
Acceleration Market Group	11,275	11,527	23,460	-	10,658	120%	79,641	10,419,053	176	176	126
Anglophone Africa Market Group	14,396	20,225	44,376	-	91,001	(51)%	469,229	48,614,203	333	333	1,280
Franco/Lusophone Africa Market Group	132,560	365,350	594,790	-	125,149	375%	1,160,677	12,347,435	4,461	4,461	6,348
Latin America & Asia Market Group	-	-	-	-	20	(100)%	100	654,680	-	-	-
Foundation Market Group	-	-	-	-	-	-%	-	9,300,709	-	-	-
Social Enterprise	-	-	-	-	-	-%	-	985,104	-	-	-
USA	-	-	-	-	-	-%	-	6,249	-	-	-
Inactive	-	-	-	-	-	-%	-	4,498,057	-	-	-
<b>Female Condom Provided</b>	-	-	-	-	-	-%	-	112,394	-	-	-
Anglophone Africa Market Group	-	-	-	-	-	-%	-	87,306	-	-	-

<sup>(a)</sup>The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

**POPULATION SERVICES INTERNATIONAL**  
**Monthly Distribution by Product**  
**Period: 2**  
**Year: 2019**

	DISTRIBUTION 2/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	YTD USERS REACHED 2019 <sup>(a)</sup>	YTD CYP 2019	YTD DALY 2019
Franco/Lusophone Africa Market Group	-	-	-	-	-	-%	-	22,060	-	-	-
Latin America & Asia Market Group	-	-	-	-	-	-%	-	1	-	-	-
Foundation Market Group	-	-	-	-	-	-%	-	3,027	-	-	-
<b>Fever Cases Attended</b>	<b>58,189</b>	<b>72,833</b>	<b>88,133</b>	<b>-</b>	<b>103,037</b>	<b>(14)%</b>	<b>916,338</b>	<b>6,234,368</b>	<b>88,133</b>	<b>-</b>	<b>-</b>
Acceleration Market Group	39,382	58,899	54,654	-	48,557	13%	697,782	2,512,801	54,654	-	-
Franco/Lusophone Africa Market Group	-	-	-	-	-	-%	14,143	26,907	-	-	-
Latin America & Asia Market Group	4,648	5,767	10,030	-	38,203	(74)%	118,263	289,955	10,030	-	-
Foundation Market Group	14,159	8,167	23,449	-	16,277	44%	86,150	3,404,705	23,449	-	-
<b>Fever Cases Tested with Microscopy</b>	<b>4,379</b>	<b>2,009</b>	<b>4,381</b>	<b>-</b>	<b>10,057</b>	<b>(56)%</b>	<b>56,797</b>	<b>443,869</b>	<b>4,381</b>	<b>-</b>	<b>-</b>
Acceleration Market Group	-	-	-	-	-	-%	-	7,474	-	-	-
Foundation Market Group	4,379	2,009	4,381	-	10,057	(56)%	56,797	436,395	4,381	-	-
<b>Fever Cases Tested with RDTs</b>	<b>80,403</b>	<b>84,075</b>	<b>110,210</b>	<b>-</b>	<b>132,226</b>	<b>(17)%</b>	<b>1,120,815</b>	<b>6,656,106</b>	<b>110,210</b>	<b>-</b>	<b>-</b>
Acceleration Market Group	39,382	58,899	54,654	-	48,557	13%	697,782	2,504,973	54,654	-	-
Franco/Lusophone Africa Market Group	-	-	-	-	-	-%	14,143	42,041	-	-	-
Latin America & Asia Market Group	5,869	8,110	13,496	-	38,200	(65)%	134,061	309,183	13,496	-	-
Foundation Market Group	35,152	17,066	42,060	-	45,469	(7)%	274,829	3,799,909	42,060	-	-
<b>Free Condom</b>	<b>7,852,409</b>	<b>13,437,802</b>	<b>11,201,139</b>	<b>-</b>	<b>21,644,034</b>	<b>(48)%</b>	<b>180,808,636</b>	<b>2,634,288,977</b>	<b>84,009</b>	<b>84,009</b>	<b>240,822</b>
Acceleration Market Group	891,360	7,150,240	1,049,760	-	7,261,200	(86)%	68,170,320	1,487,007,658	7,873	7,873	31,179
Anglophone Africa Market Group	6,688,529	4,690,665	8,599,417	-	13,163,026	(35)%	77,319,731	738,546,068	64,496	64,496	202,478
Franco/Lusophone Africa Market Group	30,600	35,719	31,100	-	141,648	(78)%	3,201,731	70,021,293	233	233	193
Latin America & Asia Market Group	90,000	453,037	564,000	-	397,244	42%	3,430,359	58,454,565	4,230	4,230	1,116
Foundation Market Group	151,920	1,108,141	956,862	-	336,600	184%	28,342,179	161,508,114	7,176	7,176	5,855
USA	-	-	-	-	-	-%	-	53,600	-	-	-
Inactive	-	-	-	-	344,316	(100)%	344,316	118,697,679	-	-	-
<b>Free Female Condom</b>	<b>10,160</b>	<b>304,190</b>	<b>16,160</b>	<b>-</b>	<b>105,169</b>	<b>(85)%</b>	<b>1,803,686</b>	<b>17,668,344</b>	<b>121</b>	<b>121</b>	<b>380</b>
Acceleration Market Group	-	260,300	-	-	57,600	(100)%	1,108,500	6,567,761	-	-	-
Anglophone Africa Market Group	10,160	35,974	16,160	-	27,234	(41)%	623,007	6,105,023	121	121	380

<sup>(a)</sup>The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

**POPULATION SERVICES INTERNATIONAL**  
**Monthly Distribution by Product**  
**Period: 2**  
**Year: 2019**

	DISTRIBUTION 2/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	YTD USERS REACHED 2019 <sup>(a)</sup>	YTD CYP 2019	YTD DALY 2019
Franco/Lusophone Africa Market Group	-	7,916	-	-	2,900	(100)%	49,536	1,054,694	-	-	-
Latin America & Asia Market Group	-	-	-	-	16,245	(100)%	21,200	353,774	-	-	-
Foundation Market Group	-	-	-	-	-	-%	253	3,329,424	-	-	-
Inactive	-	-	-	-	1,190	(100)%	1,190	257,668	-	-	-
<b>HAART (Mother and Baby)</b>	-	-	-	-	-	-%	-	256	-	-	-
Acceleration Market Group	-	-	-	-	-	-%	-	256	-	-	-
<b>HAART (Mother Only)</b>	-	-	-	-	-	-%	-	239	-	-	-
Acceleration Market Group	-	-	-	-	-	-%	-	239	-	-	-
<b>HIV Self-Testing Kit</b>	30,960	634,137	108,580	-	67,428	61%	2,354,376	2,832,503	97,722	-	-
Acceleration Market Group	11,038	456,623	23,486	-	-	-%	1,357,422	1,380,908	21,137	-	-
Anglophone Africa Market Group	19,922	177,514	85,094	-	67,428	26%	996,954	1,451,595	76,585	-	-
<b>HIV Testing Services</b>	71,707	95,522	159,782	-	787,225	(80)%	2,232,177	23,479,320	159,782	-	6,896
Acceleration Market Group	33,068	32,018	64,509	-	684,293	(91)%	1,091,132	7,090,545	64,509	-	2,555
Anglophone Africa Market Group	24,706	25,255	49,969	-	66,313	(25)%	541,424	10,498,067	49,969	-	4,109
Franco/Lusophone Africa Market Group	5,618	7,984	15,243	-	22,288	(32)%	106,415	3,015,815	15,243	-	127
Latin America & Asia Market Group	5,011	4,897	10,254	-	13,491	(24)%	98,169	382,035	10,254	-	22
Foundation Market Group	3,304	25,368	19,807	-	840	2,258%	395,037	1,718,408	19,807	-	83
Inactive	-	-	-	-	-	-%	-	774,450	-	-	-
<b>Hypertension Diagnosis</b>	2,686	1,303	4,415	-	20,484	(78)%	84,148	170,224	4,415	-	-
Acceleration Market Group	731	517	1,417	-	12,854	(89)%	57,768	112,420	1,417	-	-
Anglophone Africa Market Group	25	21	56	-	61	(8)%	278	2,425	56	-	-
Latin America & Asia Market Group	1,930	765	2,942	-	7,569	(61)%	26,102	55,379	2,942	-	-
<b>Hypertension Screening</b>	57,147	52,525	107,666	-	141,531	(24)%	737,910	1,620,052	107,666	-	-
Acceleration Market Group	8,361	7,841	16,839	-	29,511	(43)%	176,640	415,078	16,839	-	-
Anglophone Africa Market Group	14,333	13,191	26,093	-	24,280	7%	147,793	524,546	26,093	-	-
Latin America & Asia Market Group	34,453	31,493	64,734	-	87,740	(26)%	413,477	680,428	64,734	-	-
<b>Hypertension_C Controlled Condition</b>	3,076	2,407	5,150	-	14,910	(65)%	74,033	141,006	2,060	-	-

<sup>(a)</sup>The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

**POPULATION SERVICES INTERNATIONAL**  
**Monthly Distribution by Product**  
**Period: 2**  
**Year: 2019**

	DISTRIBUTION 2/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	YTD USERS REACHED 2019 <sup>(a)</sup>	YTD CYP 2019	YTD DALY 2019
Acceleration Market Group	480	332	883	-	9,196	(90)%	43,499	86,029	353	-	-
Anglophone Africa Market Group	7	4	12	-	21	(43)%	91	169	5	-	-
Latin America & Asia Market Group	2,589	2,071	4,255	-	5,693	(25)%	30,443	54,808	1,702	-	-
<b>Implant 3</b>	<b>14,412</b>	<b>77</b>	<b>15,747</b>	<b>-</b>	<b>(1,378)</b>	<b>-%</b>	<b>24,695</b>	<b>1,023,645</b>	<b>14,172</b>	<b>35,431</b>	<b>30,913</b>
Acceleration Market Group	677	446	1,402	-	(112)	-%	1,528	819,948	1,262	3,155	2,436
Anglophone Africa Market Group	6,222	2,787	6,865	-	(5,587)	-%	6,088	139,460	6,179	15,446	15,997
Franco/Lusophone Africa Market Group	2,796	(3,436)	1,081	-	3,564	(70)%	7,323	24,605	973	2,432	2,268
Latin America & Asia Market Group	926	(25)	944	-	141	570%	1,681	24,788	850	2,124	327
Foundation Market Group	3,791	304	5,455	-	616	786%	8,075	17,109	4,910	12,274	9,885
Inactive	-	-	-	-	-	-%	-	(2,265)	-	-	-
<b>Implant 3 Insertion</b>	<b>26,724</b>	<b>27,932</b>	<b>51,058</b>	<b>-</b>	<b>38,508</b>	<b>33%</b>	<b>334,633</b>	<b>994,782</b>	<b>51,058</b>	<b>127,645</b>	<b>112,321</b>
Acceleration Market Group	412	1,915	1,488	-	695	114%	8,884	13,983	1,488	3,720	2,325
Anglophone Africa Market Group	20,598	13,287	35,396	-	31,726	12%	240,316	745,903	35,396	88,490	83,555
Franco/Lusophone Africa Market Group	1,413	7,511	6,927	-	1,120	518%	24,546	53,630	6,927	17,318	16,184
Latin America & Asia Market Group	952	800	2,114	-	1,515	40%	12,809	36,366	2,114	5,285	1,264
Foundation Market Group	3,349	4,419	5,133	-	3,452	49%	48,078	140,193	5,133	12,833	8,994
Inactive	-	-	-	-	-	-%	-	4,707	-	-	-
<b>Implant 4</b>	<b>(1)</b>	<b>(799)</b>	<b>(28)</b>	<b>-</b>	<b>(3)</b>	<b>-%</b>	<b>(3,897)</b>	<b>20,754</b>	<b>(25)</b>	<b>(81)</b>	<b>(72)</b>
Anglophone Africa Market Group	(1)	(798)	(28)	-	-	-%	(3,883)	7,720	(25)	(81)	(72)
Franco/Lusophone Africa Market Group	-	-	-	-	-	-%	-	6,200	-	-	-
Latin America & Asia Market Group	-	-	-	-	-	-%	-	(700)	-	-	-
Foundation Market Group	-	(1)	-	-	(3)	-%	(14)	7,534	-	-	-
<b>Implant 4 Insertion</b>	<b>1</b>	<b>1,717</b>	<b>31</b>	<b>-</b>	<b>291</b>	<b>(89)%</b>	<b>34,188</b>	<b>44,404</b>	<b>31</b>	<b>99</b>	<b>86</b>
Acceleration Market Group	-	-	-	-	288	(100)%	288	288	-	-	-
Anglophone Africa Market Group	1	1,714	28	-	-	-%	33,884	35,512	28	90	80
Franco/Lusophone Africa Market Group	-	1	3	-	-	-%	2	734	3	10	6
Latin America & Asia Market Group	-	-	-	-	-	-%	-	5,342	-	-	-

<sup>(a)</sup>The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

**POPULATION SERVICES INTERNATIONAL**  
**Monthly Distribution by Product**  
**Period: 2**  
**Year: 2019**

	DISTRIBUTION 2/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	YTD USERS REACHED 2019 <sup>(a)</sup>	YTD CYP 2019	YTD DALY 2019
Foundation Market Group	-	1	-	-	3	(100)%	14	2,528	-	-	-
<b>Implant 5</b>	6,678	11,910	3,756	-	7,987	(53)%	73,825	748,480	3,380	12,846	23,037
Acceleration Market Group	(1,842)	(1,006)	(3,485)	-	(1,244)	-%	2,423	271,513	(3,137)	(11,919)	(8,580)
Anglophone Africa Market Group	3,933	9,754	3,910	-	(2,780)	-%	17,510	184,705	3,519	13,372	15,666
Franco/Lusophone Africa Market Group	385	1,910	(321)	-	(15)	-%	27,720	121,404	(289)	(1,098)	(867)
Latin America & Asia Market Group	(291)	(11)	(840)	-	12,116	(107)%	20,838	84,713	(756)	(2,873)	(631)
Foundation Market Group	4,493	1,264	4,492	-	(90)	-%	5,334	74,510	4,043	15,363	17,449
Inactive	-	-	-	-	-	-%	-	11,635	-	-	-
<b>Implant 5 Insertion</b>	25,221	31,624	56,468	-	41,795	35%	373,214	2,043,429	56,468	214,578	190,699
Acceleration Market Group	7,758	8,731	15,904	-	7,861	102%	82,547	450,540	15,904	60,435	52,612
Anglophone Africa Market Group	12,754	11,756	27,794	-	20,258	37%	154,215	800,528	27,794	105,617	96,077
Franco/Lusophone Africa Market Group	4,181	6,212	9,106	-	7,413	23%	76,301	311,378	9,106	34,603	33,181
Latin America & Asia Market Group	521	1,789	1,977	-	1,953	1%	21,679	89,757	1,977	7,513	1,570
Foundation Market Group	7	3,135	1,687	-	4,310	(61)%	38,472	327,628	1,687	6,411	7,259
Inactive	-	-	-	-	-	-%	-	63,598	-	-	-
<b>Infant Fortified Food</b>	-	-	-	-	-	-%	-	91,859	-	-	-
Latin America & Asia Market Group	-	-	-	-	-	-%	-	91,859	-	-	-
<b>Injectable 1</b>	17,336	13,578	30,430	-	15,234	100%	130,168	3,689,888	2,107	2,107	490
Acceleration Market Group	-	-	-	-	-	-%	-	1,546,164	-	-	-
Latin America & Asia Market Group	17,336	13,578	30,430	-	15,234	100%	130,168	2,143,715	2,107	2,107	490
Inactive	-	-	-	-	-	-%	-	9	-	-	-
<b>Injectable 1 Provided</b>	4,341	4,889	10,336	-	15,425	(33)%	89,057	237,963	795	795	179
Acceleration Market Group	-	14	5	-	-	-%	37	42	-	-	-
Anglophone Africa Market Group	3	7	10	-	78	(87)%	537	1,777	1	1	-
Latin America & Asia Market Group	4,338	4,868	10,321	-	15,347	(33)%	88,483	236,144	794	794	178
<b>Injectable 2</b>	3,741	20,749	24,987	-	63,848	(61)%	188,630	23,312,943	3,748	3,748	869
Acceleration Market Group	-	-	-	-	-	-%	-	15,907,000	-	-	-

<sup>(a)</sup>The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

**POPULATION SERVICES INTERNATIONAL**  
**Monthly Distribution by Product**  
**Period: 2**  
**Year: 2019**

	DISTRIBUTION 2/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	YTD USERS REACHED 2019 <sup>(a)</sup>	YTD CYP 2019	YTD DALY 2019
Franco/Lusophone Africa Market Group	(31)	3,347	195	-	7,145	(97)%	54,602	294,539	29	29	16
Latin America & Asia Market Group	3,772	17,402	24,792	-	56,703	(56)%	134,028	7,111,400	3,719	3,719	854
Inactive	-	-	-	-	-	-%	-	4	-	-	-
<b>Injectable 2 Provided</b>	<b>2,646</b>	<b>7,405</b>	<b>10,321</b>	<b>-</b>	<b>18,382</b>	<b>(44)%</b>	<b>102,606</b>	<b>237,221</b>	<b>1,720</b>	<b>1,720</b>	<b>874</b>
Acceleration Market Group	-	2,250	876	-	-	-%	5,875	6,751	146	146	123
Anglophone Africa Market Group	1,546	1,883	3,587	-	3,598	-%	22,699	37,934	598	598	443
Franco/Lusophone Africa Market Group	888	1,358	2,356	-	2,230	6%	15,848	41,106	393	393	211
Latin America & Asia Market Group	212	1,914	3,502	-	12,554	(72)%	58,184	151,429	584	584	97
Inactive	-	-	-	-	-	-%	-	1	-	-	-
<b>Injectable 3-IM</b>	<b>262,044</b>	<b>286,683</b>	<b>364,351</b>	<b>-</b>	<b>437,545</b>	<b>(17)%</b>	<b>5,050,702</b>	<b>92,308,536</b>	<b>81,979</b>	<b>81,979</b>	<b>33,309</b>
Acceleration Market Group	61,995	27,499	49,340	-	107,212	(54)%	493,679	32,091,301	11,102	11,102	2,560
Anglophone Africa Market Group	28,561	53,318	46,281	-	66,961	(31)%	1,797,775	14,131,279	10,413	10,413	6,993
Franco/Lusophone Africa Market Group	20,943	54,015	7,248	-	15,918	(54)%	272,940	1,251,888	1,631	1,631	1,150
Latin America & Asia Market Group	43,553	45,725	59,629	-	115,994	(49)%	687,092	11,807,988	13,417	13,417	2,655
Foundation Market Group	104,688	95,491	194,568	-	119,652	63%	1,669,487	29,341,104	43,778	43,778	19,678
Social Enterprise	2,304	10,635	7,285	-	11,808	(38)%	129,729	206,095	1,639	1,639	274
Inactive	-	-	-	-	-	-%	-	3,478,881	-	-	-
<b>Injectable 3-IM Provided</b>	<b>95,573</b>	<b>142,595</b>	<b>238,984</b>	<b>-</b>	<b>260,787</b>	<b>(8)%</b>	<b>1,573,348</b>	<b>3,377,375</b>	<b>59,746</b>	<b>59,746</b>	<b>29,837</b>
Acceleration Market Group	19,907	17,155	33,443	-	27,519	22%	175,770	404,497	8,361	8,361	3,822
Anglophone Africa Market Group	34,112	36,487	68,615	-	46,505	48%	342,639	777,363	17,154	17,154	11,364
Franco/Lusophone Africa Market Group	14,048	35,300	51,561	-	37,967	36%	272,082	679,795	12,890	12,890	9,841
Latin America & Asia Market Group	23,371	48,097	78,699	-	140,634	(44)%	705,711	1,236,706	19,675	19,675	3,895
Foundation Market Group	4,135	5,556	6,666	-	8,162	(18)%	77,146	279,014	1,667	1,667	915
<b>Injectable 3-SC</b>	<b>30,374</b>	<b>39,429</b>	<b>47,310</b>	<b>-</b>	<b>67,615</b>	<b>(30)%</b>	<b>786,595</b>	<b>1,886,649</b>	<b>10,645</b>	<b>10,645</b>	<b>5,781</b>
Acceleration Market Group	3,134	67	3,334	-	-	-%	-	3,334	750	750	94
Anglophone Africa Market Group	6,180	8,249	12,630	-	-	-%	224,675	237,305	2,842	2,842	2,115
Franco/Lusophone Africa Market Group	6,530	4,107	10,055	-	470	2,039%	26,328	38,998	2,262	2,262	1,431

<sup>(a)</sup>The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.



**POPULATION SERVICES INTERNATIONAL**  
**Monthly Distribution by Product**  
**Period: 2**  
**Year: 2019**

	DISTRIBUTION 2/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	YTD USERS REACHED 2019 <sup>(a)</sup>	YTD CYP 2019	YTD DALY 2019
Foundation Market Group	14,530	27,007	21,291	-	67,145	(68)%	535,592	1,607,012	4,790	4,790	2,141
<b>Injectable 3-SC Provided</b>	<b>3,970</b>	<b>3,571</b>	<b>8,780</b>	<b>-</b>	<b>-</b>	<b>-%</b>	<b>5,904</b>	<b>14,684</b>	<b>2,195</b>	<b>2,195</b>	<b>1,808</b>
Acceleration Market Group	-	296	887	-	-	-%	-	887	222	222	187
Franco/Lusophone Africa Market Group	3,926	3,211	7,830	-	-	-%	5,729	13,559	1,958	1,958	1,616
Foundation Market Group	44	65	63	-	-	-%	175	238	16	16	6
<b>IPTp2</b>	<b>946</b>	<b>921</b>	<b>1,691</b>	<b>-</b>	<b>594</b>	<b>185%</b>	<b>85,804</b>	<b>346,142</b>	<b>1,691</b>	<b>-</b>	<b>119</b>
Acceleration Market Group	547	418	938	-	573	64%	3,893	15,235	938	-	35
Anglophone Africa Market Group	-	-	-	-	-	-%	-	44,748	-	-	-
Franco/Lusophone Africa Market Group	-	-	-	-	-	-%	-	54	-	-	-
Foundation Market Group	399	503	753	-	21	3,486%	81,911	286,105	753	-	84
<b>Iron Folic Acid Tablet</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-%</b>	<b>-</b>	<b>48,283,018</b>	<b>-</b>	<b>-</b>	<b>-</b>
Acceleration Market Group	-	-	-	-	-	-%	-	48,283,018	-	-	-
<b>ITN</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-%</b>	<b>-</b>	<b>19,397,605</b>	<b>-</b>	<b>-</b>	<b>-</b>
Acceleration Market Group	-	-	-	-	-	-%	-	5,306,807	-	-	-
Anglophone Africa Market Group	-	-	-	-	-	-%	-	12,077,111	-	-	-
Franco/Lusophone Africa Market Group	-	-	-	-	-	-%	-	1,983,399	-	-	-
Inactive	-	-	-	-	-	-%	-	30,288	-	-	-
<b>IUD 10</b>	<b>5,498</b>	<b>23,017</b>	<b>2,519</b>	<b>-</b>	<b>14,462</b>	<b>(83)%</b>	<b>237,366</b>	<b>2,889,472</b>	<b>2,267</b>	<b>10,429</b>	<b>13,281</b>
Acceleration Market Group	(487)	203	(1,164)	-	(900)	-%	1,452	1,449,862	(1,048)	(4,819)	(4,087)
Anglophone Africa Market Group	1,743	10,089	(115)	-	(15,056)	-%	68,242	328,333	(104)	(476)	1,390
Franco/Lusophone Africa Market Group	2,351	(403)	2,727	-	4,008	(32)%	29,804	210,072	2,454	11,290	9,663
Latin America & Asia Market Group	907	834	93	-	26,179	(100)%	64,790	638,408	84	385	1,297
Foundation Market Group	984	656	943	-	231	308%	7,568	80,946	849	3,904	4,987
Social Enterprise	-	11,637	35	-	-	-%	65,510	65,545	32	145	31
Inactive	-	-	-	-	-	-%	-	116,306	-	-	-
<b>IUD 10 Insertion</b>	<b>29,022</b>	<b>34,342</b>	<b>57,204</b>	<b>-</b>	<b>70,841</b>	<b>(19)%</b>	<b>572,847</b>	<b>3,264,442</b>	<b>57,204</b>	<b>263,138</b>	<b>188,619</b>
Acceleration Market Group	7,166	7,309	14,196	-	13,178	8%	90,084	639,567	14,196	65,302	65,263

<sup>(a)</sup>The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

**POPULATION SERVICES INTERNATIONAL**  
**Monthly Distribution by Product**  
**Period: 2**  
**Year: 2019**

	DISTRIBUTION 2/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	YTD USERS REACHED 2019 <sup>(a)</sup>	YTD CYP 2019	YTD DALY 2019
Anglophone Africa Market Group	9,072	7,168	16,649	-	28,965	(43)%	220,262	1,216,287	16,649	76,585	66,596
Franco/Lusophone Africa Market Group	2,003	7,333	6,709	-	8,541	(21)%	73,738	266,512	6,709	30,861	27,806
Latin America & Asia Market Group	9,282	9,706	16,887	-	15,538	9%	148,352	776,041	16,887	77,680	19,191
Foundation Market Group	1,499	2,826	2,763	-	4,619	(40)%	40,411	351,786	2,763	12,710	9,764
Inactive	-	-	-	-	-	-%	-	14,249	-	-	-
<b>IUD 3</b>	<b>(125)</b>	<b>42</b>	<b>(250)</b>	<b>-</b>	<b>1,053</b>	<b>(124)%</b>	<b>6,953</b>	<b>6,703</b>	<b>(225)</b>	<b>(563)</b>	<b>(120)</b>
Social Enterprise	(125)	42	(250)	-	1,053	(124)%	6,953	6,703	(225)	(563)	(120)
<b>IUD 5</b>	<b>4,881</b>	<b>19,697</b>	<b>36,253</b>	<b>-</b>	<b>13,745</b>	<b>164%</b>	<b>101,798</b>	<b>4,421,344</b>	<b>32,628</b>	<b>107,671</b>	<b>30,794</b>
Acceleration Market Group	(5,004)	(107)	(5,115)	-	(132)	-%	(296)	1,130,638	(4,604)	(15,192)	(3,407)
Anglophone Africa Market Group	(15)	(7)	(25)	-	(88)	-%	(263)	14,530	(23)	(74)	(75)
Latin America & Asia Market Group	9,439	11,730	25,281	-	(2,255)	-%	22,736	3,076,003	22,753	75,085	23,427
Social Enterprise	461	8,080	16,112	-	16,220	(1)%	79,621	196,447	14,501	47,853	10,848
Inactive	-	-	-	-	-	-%	-	3,726	-	-	-
<b>IUD 5 Insertion</b>	<b>15,674</b>	<b>14,762</b>	<b>49,976</b>	<b>-</b>	<b>30,893</b>	<b>62%</b>	<b>115,881</b>	<b>1,206,262</b>	<b>49,976</b>	<b>164,921</b>	<b>48,473</b>
Acceleration Market Group	5,004	5,386	11,374	-	9,148	24%	51,661	192,224	11,374	37,534	8,468
Anglophone Africa Market Group	26	42	80	-	88	(9)%	345	28,902	80	264	182
Franco/Lusophone Africa Market Group	-	-	-	-	-	-%	-	45	-	-	-
Latin America & Asia Market Group	10,608	9,291	38,466	-	21,657	78%	63,576	984,736	38,466	126,938	39,635
Foundation Market Group	36	43	56	-	-	-%	299	355	56	185	188
<b>IUS 3</b>	<b>12</b>	<b>7</b>	<b>24</b>	<b>-</b>	<b>-</b>	<b>-%</b>	<b>98</b>	<b>122</b>	<b>22</b>	<b>54</b>	<b>31</b>
Foundation Market Group	12	7	24	-	-	-%	98	122	22	54	31
<b>IUS 3 Insertion</b>	<b>52</b>	<b>13</b>	<b>58</b>	<b>-</b>	<b>-</b>	<b>-%</b>	<b>135</b>	<b>193</b>	<b>58</b>	<b>145</b>	<b>83</b>
Foundation Market Group	52	13	58	-	-	-%	135	193	58	145	83
<b>IUS 5</b>	<b>(9)</b>	<b>78</b>	<b>236</b>	<b>-</b>	<b>(11)</b>	<b>-%</b>	<b>926</b>	<b>2,116</b>	<b>212</b>	<b>701</b>	<b>133</b>
Anglophone Africa Market Group	(18)	(7)	(28)	-	(11)	-%	926	1,852	(25)	(83)	(45)
Foundation Market Group	-	-	-	-	-	-%	-	-	-	-	-
Social Enterprise	9	85	264	-	-	-%	-	264	238	784	178

<sup>(a)</sup>The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

**POPULATION SERVICES INTERNATIONAL**  
**Monthly Distribution by Product**  
**Period: 2**  
**Year: 2019**

	DISTRIBUTION 2/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	YTD USERS REACHED 2019 <sup>(a)</sup>	YTD CYP 2019	YTD DALY 2019
<b>IUS 5 Insertion</b>	229	157	402	-	193	108%	1,516	2,911	402	1,327	1,354
Acceleration Market Group	130	92	232	-	59	293%	775	1,633	232	766	880
Anglophone Africa Market Group	99	64	167	-	134	25%	739	1,272	167	551	472
Latin America & Asia Market Group	-	1	3	-	-	-%	2	6	3	10	2
Foundation Market Group	-	-	-	-	-	-%	-	-	-	-	-
<b>LifeStraw</b>	-	-	-	-	-	-%	-	15,965	-	-	-
Anglophone Africa Market Group	-	-	-	-	-	-%	-	15,320	-	-	-
Franco/Lusophone Africa Market Group	-	-	-	-	-	-%	-	645	-	-	-
<b>LLIN</b>	410,533	6,401,965	1,580,504	-	1,624,881	(3)%	31,104,885	360,215,903	2,560,416	-	344,101
Acceleration Market Group	3,956	125,792	39,765	-	71,182	(44)%	2,332,163	63,991,201	64,419	-	1,311
Anglophone Africa Market Group	14,333	236,476	16,912	-	416,205	(96)%	4,545,198	56,701,314	27,397	-	917
Franco/Lusophone Africa Market Group	134,944	362,695	248,932	-	137,234	81%	4,602,963	52,725,433	403,270	-	29,802
Latin America & Asia Market Group	-	-	-	-	-	-%	-	5,197,868	-	-	-
Foundation Market Group	257,300	5,677,003	1,274,895	-	1,000,260	27%	19,624,561	177,538,968	2,065,330	-	312,071
Inactive	-	-	-	-	-	-%	-	4,061,119	-	-	-
<b>LLIN (Hammock net)</b>	-	138	400	-	15	2,567%	1,259	1,704	360	-	-
Latin America & Asia Market Group	-	138	400	-	15	2,567%	1,259	1,704	360	-	-
<b>Lubricant</b>	507,806	733,770	1,874,339	-	887,372	111%	5,621,900	79,656,213	-	-	-
Acceleration Market Group	7,210	7,837	15,975	-	6,060	164%	51,861	13,568,264	-	-	-
Anglophone Africa Market Group	289,745	173,690	436,586	-	292,976	49%	2,574,286	9,179,768	-	-	-
Franco/Lusophone Africa Market Group	385	4,761	855	-	8,032	(89)%	45,024	1,522,874	-	-	-
Latin America & Asia Market Group	174,634	95,980	306,471	-	225,148	36%	1,423,274	36,997,561	-	-	-
Foundation Market Group	33,864	448,850	1,110,864	-	87,550	1,169%	1,223,813	3,356,892	-	-	-
Social Enterprise	1,968	2,652	3,588	-	1,908	88%	37,944	589,844	-	-	-
USA	-	-	-	-	-	-%	-	7,400	-	-	-
Inactive	-	-	-	-	265,698	(100)%	265,698	14,433,610	-	-	-
<b>Malaria PPT (ACT)</b>	359,942	322,007	508,816	-	862,089	(41)%	7,543,851	135,641,408	457,934	-	132,547

<sup>(a)</sup>The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

**POPULATION SERVICES INTERNATIONAL**  
**Monthly Distribution by Product**  
**Period: 2**  
**Year: 2019**

	DISTRIBUTION 2/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	YTD USERS REACHED 2019 <sup>(a)</sup>	YTD CYP 2019	YTD DALY 2019
Acceleration Market Group	34,689	852	34,896	-	110,766	(68)%	256,333	63,753,182	31,406	-	4,896
Anglophone Africa Market Group	-	-	-	-	-	-%	-	10,387,257	-	-	-
Franco/Lusophone Africa Market Group	18,960	12,857	43,412	-	123,036	(65)%	297,014	1,746,220	39,071	-	12,059
Latin America & Asia Market Group	(56)	(58)	(70)	-	2,855	(102)%	147	2,839,660	(63)	-	(8)
Foundation Market Group	306,349	308,355	430,578	-	625,432	(31)%	6,990,357	56,915,089	387,520	-	115,601
<b>Malaria PPT (Non-ACT)</b>	<b>(147)</b>	<b>(257)</b>	<b>(195)</b>	<b>-</b>	<b>(145)</b>	<b>-%</b>	<b>(2,041)</b>	<b>13,894,093</b>	<b>(176)</b>	<b>-</b>	<b>(27)</b>
Acceleration Market Group	(147)	(229)	(195)	-	(145)	-%	(1,900)	5,113,319	(176)	-	(27)
Latin America & Asia Market Group	-	(28)	-	-	-	-%	(141)	(141)	-	-	-
Foundation Market Group	-	-	-	-	-	-%	-	8,780,915	-	-	-
<b>Malaria RDK</b>	<b>180,400</b>	<b>1,487,188</b>	<b>222,200</b>	<b>-</b>	<b>248,344</b>	<b>(11)%</b>	<b>12,180,985</b>	<b>59,670,163</b>	<b>199,980</b>	<b>-</b>	<b>-</b>
Acceleration Market Group	41,025	46,067	70,035	-	63,650	10%	743,410	12,906,502	63,032	-	-
Anglophone Africa Market Group	-	-	-	-	-	-%	-	263,260	-	-	-
Franco/Lusophone Africa Market Group	15,025	21,020	24,575	-	-	-%	177,919	1,122,134	22,118	-	-
Latin America & Asia Market Group	2,100	1,870	5,340	-	131,394	(96)%	305,189	7,060,236	4,806	-	-
Foundation Market Group	122,250	1,418,231	122,250	-	53,300	129%	10,954,467	38,318,031	110,025	-	-
<b>Male Circumcision (HIV-Positive)</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-%</b>	<b>-</b>	<b>10,836</b>	<b>-</b>	<b>-</b>	<b>-</b>
Acceleration Market Group	-	-	-	-	-	-%	-	6,118	-	-	-
Anglophone Africa Market Group	-	-	-	-	-	-%	-	4,718	-	-	-
<b>Male Vasodilator</b>	<b>74,900</b>	<b>33,333</b>	<b>174,900</b>	<b>-</b>	<b>-</b>	<b>-%</b>	<b>-</b>	<b>174,900</b>	<b>1,312</b>	<b>-</b>	<b>-</b>
Social Enterprise	74,900	33,333	174,900	-	-	-%	-	174,900	1,312	-	-
<b>Manual Vacuum Aspiration for PAC</b>	<b>7,700</b>	<b>8,612</b>	<b>23,215</b>	<b>-</b>	<b>10,769</b>	<b>116%</b>	<b>70,499</b>	<b>182,441</b>	<b>23,215</b>	<b>-</b>	<b>2,753</b>
Acceleration Market Group	1,576	443	1,576	-	-	-%	19,176	26,048	1,576	-	1,262
Anglophone Africa Market Group	492	565	1,104	-	100	1,004%	7,531	11,625	1,104	-	181
Franco/Lusophone Africa Market Group	181	352	410	-	185	122%	2,579	4,793	410	-	147
Latin America & Asia Market Group	5,234	6,809	19,711	-	9,645	104%	34,966	125,675	19,711	-	991
Foundation Market Group	217	443	414	-	839	(51)%	6,247	14,300	414	-	172
<b>Manual Vacuum Aspiration for SA</b>	<b>120</b>	<b>145</b>	<b>237</b>	<b>-</b>	<b>38</b>	<b>524%</b>	<b>1,224</b>	<b>1,461</b>	<b>237</b>	<b>-</b>	<b>88</b>

<sup>(a)</sup>The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

**POPULATION SERVICES INTERNATIONAL**  
**Monthly Distribution by Product**  
**Period: 2**  
**Year: 2019**

	DISTRIBUTION 2/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	YTD USERS REACHED 2019 <sup>(a)</sup>	YTD CYP 2019	YTD DALY 2019
Acceleration Market Group	-	-	-	-	-	-%	-	-	-	-	-
Anglophone Africa Market Group	76	39	143	-	26	450%	411	554	143	-	52
Franco/Lusophone Africa Market Group	36	83	86	-	12	617%	562	648	86	-	34
Latin America & Asia Market Group	8	23	8	-	-	-%	251	259	8	-	1
Foundation Market Group	-	-	-	-	-	-%	-	-	-	-	-
<b>Medical Abortion</b>	<b>91,604</b>	<b>152,272</b>	<b>166,768</b>	<b>-</b>	<b>202,139</b>	<b>(17)%</b>	<b>1,610,639</b>	<b>5,594,308</b>	<b>150,091</b>	<b>-</b>	<b>15,334</b>
Acceleration Market Group	-	-	-	-	-	-%	-	1,497,044	-	-	-
Anglophone Africa Market Group	548	318	854	-	478	79%	13,999	25,864	769	-	269
Franco/Lusophone Africa Market Group	460	143	675	-	(43)	-%	172	682	608	-	248
Latin America & Asia Market Group	32,715	40,589	76,958	-	78,134	(2)%	457,334	2,328,367	69,262	-	6,612
Social Enterprise	57,881	111,223	88,281	-	123,570	(29)%	1,139,134	1,742,351	79,453	-	8,205
<b>Medical Abortion (Misoprostol) Provided</b>	<b>189</b>	<b>123</b>	<b>336</b>	<b>-</b>	<b>36</b>	<b>833%</b>	<b>840</b>	<b>1,176</b>	<b>336</b>	<b>-</b>	<b>110</b>
Anglophone Africa Market Group	109	75	225	-	34	562%	531	756	225	-	70
Franco/Lusophone Africa Market Group	80	48	111	-	2	5,450%	309	420	111	-	40
<b>Medical Abortion Provided</b>	<b>937</b>	<b>838</b>	<b>1,364</b>	<b>-</b>	<b>1,780</b>	<b>(23)%</b>	<b>12,902</b>	<b>23,047</b>	<b>1,364</b>	<b>-</b>	<b>162</b>
Anglophone Africa Market Group	75	44	140	-	175	(20)%	747	1,508	140	-	49
Franco/Lusophone Africa Market Group	-	-	-	-	51	(100)%	51	241	-	-	-
Latin America & Asia Market Group	862	794	1,224	-	1,554	(21)%	12,104	21,298	1,224	-	113
<b>Micronutrient Powder</b>	<b>77,730</b>	<b>531,164</b>	<b>78,120</b>	<b>-</b>	<b>561,112</b>	<b>(86)%</b>	<b>8,746,552</b>	<b>48,621,152</b>	<b>193</b>	<b>-</b>	<b>-</b>
Acceleration Market Group	-	528,193	-	-	-	-%	2,000,000	9,499,690	-	-	-
Franco/Lusophone Africa Market Group	77,730	2,971	78,120	-	550,612	(86)%	948,572	8,048,732	193	-	-
Latin America & Asia Market Group	-	-	-	-	-	-%	-	9,502,912	-	-	-
Foundation Market Group	-	-	-	-	10,500	(100)%	5,797,980	20,562,598	-	-	-
Inactive	-	-	-	-	-	-%	-	1,007,220	-	-	-
<b>Misoprostol for PAC Provided</b>	<b>10,255</b>	<b>7,969</b>	<b>19,275</b>	<b>-</b>	<b>2,649</b>	<b>628%</b>	<b>86,914</b>	<b>125,013</b>	<b>19,275</b>	<b>-</b>	<b>3,303</b>
Acceleration Market Group	1,578	418	1,578	-	-	-%	14,855	16,433	1,578	-	1,496
Anglophone Africa Market Group	281	308	701	-	135	419%	3,631	5,537	701	-	155

<sup>(a)</sup>The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

**POPULATION SERVICES INTERNATIONAL**  
**Monthly Distribution by Product**  
**Period: 2**  
**Year: 2019**

	DISTRIBUTION 2/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	YTD USERS REACHED 2019 <sup>(a)</sup>	YTD CYP 2019	YTD DALY 2019
Franco/Lusophone Africa Market Group	88	314	316	-	169	87%	2,304	3,696	316	-	160
Latin America & Asia Market Group	7,544	6,030	15,470	-	663	2,233%	53,383	72,577	15,470	-	923
Foundation Market Group	764	899	1,210	-	1,682	(28)%	12,741	26,770	1,210	-	570
<b>Misoprostol for PPH</b>	<b>1,000</b>	<b>4,167</b>	<b>2,500</b>	<b>-</b>	<b>7,800</b>	<b>(68)%</b>	<b>30,800</b>	<b>6,319,438</b>	<b>750</b>	<b>-</b>	<b>16</b>
Acceleration Market Group	-	-	-	-	-	-%	-	395,225	-	-	-
Anglophone Africa Market Group	-	-	-	-	-	-%	-	5,442,839	-	-	-
Franco/Lusophone Africa Market Group	-	-	-	-	-	-%	-	100,000	-	-	-
Latin America & Asia Market Group	-	-	-	-	-	-%	-	184,166	-	-	-
Foundation Market Group	1,000	4,167	2,500	-	7,800	(68)%	30,800	197,208	750	-	16
<b>Misoprostol for Safe Abortion</b>	<b>404,265</b>	<b>676,373</b>	<b>839,441</b>	<b>-</b>	<b>518,193</b>	<b>62%</b>	<b>6,085,267</b>	<b>18,268,895</b>	<b>44,071</b>	<b>-</b>	<b>14,634</b>
Acceleration Market Group	196,428	195,213	218,558	-	-	-%	2,321,200	4,524,608	11,474	-	9,635
Anglophone Africa Market Group	81,748	131,372	113,556	-	201,772	(44)%	1,655,420	9,153,532	5,962	-	1,557
Franco/Lusophone Africa Market Group	47,937	87,596	76,943	-	76,185	1%	745,045	2,047,837	4,040	-	1,477
Latin America & Asia Market Group	61,708	247,913	414,184	-	242,300	71%	1,282,555	2,462,911	21,745	-	1,678
Foundation Market Group	16,444	14,279	16,200	-	(2,064)	-%	81,047	80,007	850	-	288
<b>Multivitamin</b>	<b>119,430</b>	<b>156,330</b>	<b>215,610</b>	<b>-</b>	<b>378,740</b>	<b>(43)%</b>	<b>2,424,220</b>	<b>98,570,529</b>	<b>1,078</b>	<b>-</b>	<b>37</b>
Acceleration Market Group	-	-	-	-	67,730	(100)%	450,010	3,531,010	-	-	-
Anglophone Africa Market Group	-	-	-	-	-	-%	-	12,270,645	-	-	-
Latin America & Asia Market Group	-	-	-	-	-	-%	-	11,484,305	-	-	-
Social Enterprise	119,430	156,330	215,610	-	311,010	(31)%	1,974,210	37,225,170	1,078	-	37
Inactive	-	-	-	-	-	-%	-	34,059,399	-	-	-
<b>Naloxone</b>	<b>-</b>	<b>23</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-%</b>	<b>2,570</b>	<b>68,251</b>	<b>-</b>	<b>-</b>	<b>-</b>
Latin America & Asia Market Group	-	23	-	-	-	-%	2,570	32,457	-	-	-
Inactive	-	-	-	-	-	-%	-	35,794	-	-	-
<b>Needle &amp; Syringe</b>	<b>58,200</b>	<b>572,733</b>	<b>225,000</b>	<b>-</b>	<b>502,100</b>	<b>(55)%</b>	<b>5,815,215</b>	<b>32,590,758</b>	<b>785</b>	<b>-</b>	<b>1,583</b>
Acceleration Market Group	-	-	-	-	-	-%	-	2,501,888	-	-	-
Latin America & Asia Market Group	58,200	572,733	225,000	-	502,100	(55)%	5,815,215	26,005,358	785	-	1,583

<sup>(a)</sup>The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

**POPULATION SERVICES INTERNATIONAL**  
**Monthly Distribution by Product**  
**Period: 2**  
**Year: 2019**

	DISTRIBUTION 2/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	YTD USERS REACHED 2019 <sup>(a)</sup>	YTD CYP 2019	YTD DALY 2019
Inactive	-	-	-	-	-	-%	-	4,083,512	-	-	-
<b>Neonates Receiving Essential Care</b>	-	-	-	-	-	-%	-	174	-	-	-
Franco/Lusophone Africa Market Group	-	-	-	-	-	-%	-	174	-	-	-
<b>NVP</b>	-	-	-	-	-	-%	-	11,442	-	-	-
Anglophone Africa Market Group	-	-	-	-	-	-%	-	235	-	-	-
Franco/Lusophone Africa Market Group	-	-	-	-	-	-%	-	11,057	-	-	-
Foundation Market Group	-	-	-	-	-	-%	-	150	-	-	-
<b>OCs</b>	1,977,651	2,130,439	3,301,096	-	3,572,872	(8)%	26,777,114	638,957,633	198,066	198,066	63,940
Acceleration Market Group	941,482	736,755	1,319,500	-	1,255,759	5%	9,492,397	313,832,776	79,170	79,170	24,334
Anglophone Africa Market Group	126,585	203,370	317,797	-	375,888	(15)%	2,600,283	80,272,850	19,068	19,068	8,767
Franco/Lusophone Africa Market Group	277,976	56,030	350,199	-	86,883	303%	1,347,096	25,171,092	21,012	21,012	15,713
Latin America & Asia Market Group	542,268	587,822	1,103,646	-	1,181,711	(7)%	6,484,744	100,556,317	66,219	66,219	12,220
Foundation Market Group	34,459	103,672	73,238	-	251,450	(71)%	2,094,239	70,811,888	4,394	4,394	2,072
Social Enterprise	54,881	442,790	136,716	-	421,181	(68)%	4,758,355	16,220,116	8,203	8,203	835
Inactive	-	-	-	-	-	-%	-	32,092,594	-	-	-
<b>OCs Provided</b>	183,240	198,970	358,053	-	155,914	130%	1,778,915	4,727,367	23,870	23,870	9,848
Acceleration Market Group	19,357	11,765	23,073	-	14,080	64%	151,894	268,182	1,538	1,538	482
Anglophone Africa Market Group	35,602	35,915	64,927	-	41,344	57%	321,499	1,449,673	4,328	4,328	2,500
Franco/Lusophone Africa Market Group	27,439	37,205	60,044	-	50,594	19%	367,827	1,018,526	4,003	4,003	3,469
Latin America & Asia Market Group	99,915	113,013	208,574	-	47,768	337%	921,067	1,840,633	13,905	13,905	3,341
Foundation Market Group	927	1,071	1,435	-	2,128	(33)%	16,628	150,349	96	96	57
Inactive	-	-	-	-	-	-%	-	4	-	-	-
<b>ORS</b>	400,179	255,807	519,211	-	201,348	158%	3,408,447	440,954,770	233,645	-	9,829
Acceleration Market Group	23,125	39,403	41,145	-	59,889	(31)%	514,198	326,004,746	18,515	-	1,079
Anglophone Africa Market Group	-	-	-	-	-	-%	-	21,149,275	-	-	-
Franco/Lusophone Africa Market Group	-	-	-	-	-	-%	-	32,783,783	-	-	-
Latin America & Asia Market Group	66,225	171,084	79,477	-	-	-%	500,000	4,356,458	35,765	-	751

<sup>(a)</sup>The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

**POPULATION SERVICES INTERNATIONAL**  
**Monthly Distribution by Product**  
**Period: 2**  
**Year: 2019**

	DISTRIBUTION 2/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	YTD USERS REACHED 2019 <sup>(a)</sup>	YTD CYP 2019	YTD DALY 2019
Foundation Market Group	560	3	570	-	56,859	(99)%	1,249,743	16,028,251	257	-	13
Social Enterprise	310,269	45,317	398,019	-	84,600	370%	1,144,506	1,868,953	179,109	-	7,986
Inactive	-	-	-	-	-	-%	-	38,763,304	-	-	-
<b>ORS Provided</b>	<b>2,651</b>	<b>1,847</b>	<b>5,203</b>	<b>-</b>	<b>381</b>	<b>1,266%</b>	<b>15,726</b>	<b>86,165</b>	<b>5,203</b>	<b>-</b>	<b>244</b>
Acceleration Market Group	424	252	758	-	381	99%	2,217	8,145	758	-	12
Foundation Market Group	2,227	1,595	4,445	-	-	-%	13,509	78,020	4,445	-	232
<b>Pneumonia PPT</b>	<b>-</b>	<b>353</b>	<b>-</b>	<b>-</b>	<b>41,354</b>	<b>(100)%</b>	<b>768,635</b>	<b>7,124,658</b>	<b>-</b>	<b>-</b>	<b>-</b>
Acceleration Market Group	-	-	-	-	-	-%	-	1,414,256	-	-	-
Anglophone Africa Market Group	-	-	-	-	-	-%	-	987,367	-	-	-
Franco/Lusophone Africa Market Group	-	(28)	-	-	-	-%	30,316	474,924	-	-	-
Latin America & Asia Market Group	-	-	-	-	-	-%	-	119,990	-	-	-
Foundation Market Group	-	381	-	-	41,354	(100)%	738,319	4,128,121	-	-	-
<b>Pneumonia PPT Provided</b>	<b>3,246</b>	<b>2,105</b>	<b>5,654</b>	<b>-</b>	<b>2,973</b>	<b>90%</b>	<b>31,754</b>	<b>161,326</b>	<b>5,654</b>	<b>-</b>	<b>4,533</b>
Acceleration Market Group	1,681	1,187	2,965	-	2,973	-%	20,179	61,038	2,965	-	1,426
Franco/Lusophone Africa Market Group	-	-	-	-	-	-%	-	2,500	-	-	-
Foundation Market Group	1,565	918	2,689	-	-	-%	11,575	97,788	2,689	-	3,107
<b>Positive RDTs</b>	<b>3,014</b>	<b>2,174</b>	<b>4,390</b>	<b>-</b>	<b>11,100</b>	<b>(60)%</b>	<b>52,281</b>	<b>2,310,730</b>	<b>4,390</b>	<b>-</b>	<b>-</b>
Acceleration Market Group	335	746	525	-	859	(39)%	9,712	39,762	525	-	-
Franco/Lusophone Africa Market Group	-	-	-	-	-	-%	13,716	40,358	-	-	-
Latin America & Asia Market Group	266	324	611	-	6,471	(91)%	11,799	39,184	611	-	-
Foundation Market Group	2,413	1,104	3,254	-	3,770	(14)%	17,054	2,191,426	3,254	-	-
<b>Positive RDTs Given First Line Treatment</b>	<b>578</b>	<b>974</b>	<b>1,023</b>	<b>-</b>	<b>6,916</b>	<b>(85)%</b>	<b>32,687</b>	<b>2,146,078</b>	<b>1,023</b>	<b>-</b>	<b>-</b>
Acceleration Market Group	328	711	500	-	818	(39)%	8,937	35,102	500	-	-
Franco/Lusophone Africa Market Group	-	-	-	-	-	-%	13,647	39,926	-	-	-
Latin America & Asia Market Group	250	263	523	-	6,098	(91)%	10,103	36,071	523	-	-
Foundation Market Group	-	-	-	-	-	-%	-	2,034,979	-	-	-
<b>Pregnancy Test</b>	<b>34,970</b>	<b>80,792</b>	<b>58,716</b>	<b>-</b>	<b>-</b>	<b>-%</b>	<b>575,675</b>	<b>1,564,840</b>	<b>-</b>	<b>-</b>	<b>-</b>

<sup>(a)</sup>The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.



**POPULATION SERVICES INTERNATIONAL**  
**Monthly Distribution by Product**  
**Period: 2**  
**Year: 2019**

	DISTRIBUTION 2/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	YTD USERS REACHED 2019 <sup>(a)</sup>	YTD CYP 2019	YTD DALY 2019
Acceleration Market Group	-	-	-	-	-	-%	-	575,317	-	-	-
Latin America & Asia Market Group	-	-	-	-	-	-%	-	222,334	-	-	-
Social Enterprise	34,970	80,792	58,716	-	-	-%	575,675	634,391	-	-	-
Inactive	-	-	-	-	-	-%	-	132,798	-	-	-
<b>PrEP</b>	<b>3,521</b>	<b>3,479</b>	<b>7,097</b>	<b>-</b>	<b>3,443</b>	<b>106%</b>	<b>34,437</b>	<b>44,650</b>	<b>591</b>	<b>-</b>	<b>235</b>
Anglophone Africa Market Group	3,521	3,479	7,097	-	3,443	106%	34,437	44,650	591	-	235
<b>PUR</b>	<b>6,419,240</b>	<b>2,554,634</b>	<b>9,928,130</b>	<b>-</b>	<b>6,753,778</b>	<b>47%</b>	<b>62,440,224</b>	<b>641,457,457</b>	<b>81,601</b>	<b>-</b>	<b>228</b>
Acceleration Market Group	3,354,240	1,520,403	6,063,130	-	4,690,413	29%	28,508,349	202,617,227	49,834	-	123
Anglophone Africa Market Group	3,065,000	1,034,230	3,865,000	-	2,063,365	87%	33,931,875	329,747,542	31,767	-	105
Franco/Lusophone Africa Market Group	-	-	-	-	-	-%	-	239,541	-	-	-
Latin America & Asia Market Group	-	-	-	-	-	-%	-	62,675,382	-	-	-
Foundation Market Group	-	-	-	-	-	-%	-	45,927,973	-	-	-
Inactive	-	-	-	-	-	-%	-	249,792	-	-	-
<b>QAACts Provided after Confirmatory Diagnosis</b>	<b>12,047</b>	<b>11,570</b>	<b>24,574</b>	<b>-</b>	<b>14,015</b>	<b>75%</b>	<b>127,263</b>	<b>2,231,067</b>	<b>24,574</b>	<b>-</b>	<b>4,070</b>
Acceleration Market Group	11,772	10,917	23,955	-	7,912	203%	101,767	144,500	23,955	-	3,945
Franco/Lusophone Africa Market Group	-	-	-	-	-	-%	13,647	13,647	-	-	-
Latin America & Asia Market Group	166	176	324	-	6,103	(95)%	9,977	35,774	324	-	58
Foundation Market Group	109	477	295	-	-	-%	1,872	2,037,146	295	-	66
<b>Referral to Advanced Cervical Cancer Treatment</b>	<b>3</b>	<b>4</b>	<b>10</b>	<b>-</b>	<b>4</b>	<b>150%</b>	<b>17</b>	<b>427</b>	<b>10</b>	<b>-</b>	<b>-</b>
Anglophone Africa Market Group	3	4	10	-	4	150%	17	427	10	-	-
<b>Referral to CD4/Clinical Staging</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-%</b>	<b>-</b>	<b>34,138</b>	<b>-</b>	<b>-</b>	<b>-</b>
Acceleration Market Group	-	-	-	-	-	-%	-	3,364	-	-	-
Anglophone Africa Market Group	-	-	-	-	-	-%	-	30,613	-	-	-
Franco/Lusophone Africa Market Group	-	-	-	-	-	-%	-	18	-	-	-
Latin America & Asia Market Group	-	-	-	-	-	-%	-	143	-	-	-
<b>Referral to Clinical Staging</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-%</b>	<b>-</b>	<b>18,909</b>	<b>-</b>	<b>-</b>	<b>-</b>
Acceleration Market Group	-	-	-	-	-	-%	-	3,364	-	-	-

<sup>(a)</sup>The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

**POPULATION SERVICES INTERNATIONAL**  
**Monthly Distribution by Product**  
**Period: 2**  
**Year: 2019**

	DISTRIBUTION 2/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	YTD USERS REACHED 2019 <sup>(a)</sup>	YTD CYP 2019	YTD DALY 2019
Anglophone Africa Market Group	-	-	-	-	-	-%	-	15,545	-	-	-
<b>Referral to Diabetes Management (gestational)</b>	-	14	-	-	26	(100)%	67	67	-	-	-
Anglophone Africa Market Group	-	14	-	-	26	(100)%	67	67	-	-	-
<b>Referral to Diabetes Management (non-gestational)</b>	-	-	-	-	-	-%	-	1	-	-	-
Anglophone Africa Market Group	-	-	-	-	-	-%	-	1	-	-	-
<b>Referral to Early Infant Male Circumcision</b>	-	-	-	-	-	-%	-	94	-	-	-
Anglophone Africa Market Group	-	-	-	-	-	-%	-	94	-	-	-
<b>Referral to Emergency Contraception</b>	-	-	-	-	-	-%	32	250	-	-	-
Anglophone Africa Market Group	-	-	-	-	-	-%	1	143	-	-	-
Latin America & Asia Market Group	-	-	-	-	-	-%	31	107	-	-	-
<b>Referral to HIV Testing Services</b>	2,614	8,934	5,355	-	4	133,775%	24,729	315,815	5,355	-	166
Acceleration Market Group	-	-	-	-	-	-%	-	25,875	-	-	-
Anglophone Africa Market Group	2,611	8,933	5,352	-	4	133,700%	24,714	203,613	5,352	-	166
Franco/Lusophone Africa Market Group	-	-	-	-	-	-%	-	17,256	-	-	-
Latin America & Asia Market Group	3	1	3	-	-	-%	10	35,554	3	-	-
Foundation Market Group	-	-	-	-	-	-%	5	33,366	-	-	-
Inactive	-	-	-	-	-	-%	-	151	-	-	-
<b>Referral to Hypertension Management</b>	37	38	43	-	37	16%	567	1,173	43	-	-
Anglophone Africa Market Group	37	38	43	-	37	16%	567	1,173	43	-	-
<b>Referral to Implant 3 Insertion</b>	146	540	311	-	2	15,450%	1,457	17,882	311	389	53
Acceleration Market Group	-	-	-	-	-	-%	-	996	-	-	-
Anglophone Africa Market Group	-	-	-	-	2	(100)%	2	7,955	-	-	-
Franco/Lusophone Africa Market Group	-	-	-	-	-	-%	-	1	-	-	-
Latin America & Asia Market Group	146	540	311	-	-	-%	1,455	4,078	311	389	53
Foundation Market Group	-	-	-	-	-	-%	-	1,674	-	-	-
Inactive	-	-	-	-	-	-%	-	3,178	-	-	-
<b>Referral to Implant 5 Insertion</b>	46	30	77	-	31	148%	223	19,806	77	146	33

<sup>(a)</sup>The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

**POPULATION SERVICES INTERNATIONAL**  
**Monthly Distribution by Product**  
**Period: 2**  
**Year: 2019**

	DISTRIBUTION 2/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	YTD USERS REACHED 2019 <sup>(a)</sup>	YTD CYP 2019	YTD DALY 2019
Acceleration Market Group	-	-	-	-	-	-%	-	584	-	-	-
Anglophone Africa Market Group	-	-	-	-	2	(100)%	2	3,596	-	-	-
Franco/Lusophone Africa Market Group	-	-	-	-	-	-%	-	4,681	-	-	-
Latin America & Asia Market Group	46	30	77	-	29	166%	221	1,339	77	146	33
Foundation Market Group	-	-	-	-	-	-%	-	9,606	-	-	-
<b>Referral to Implant Insertion (duration unknown)</b>	-	-	-	-	-	-%	-	89	-	-	-
Anglophone Africa Market Group	-	-	-	-	-	-%	-	89	-	-	-
<b>Referral to Injectable (duration unknown)</b>	-	-	-	-	-	-%	-	773	-	-	-
Anglophone Africa Market Group	-	-	-	-	-	-%	-	110	-	-	-
Latin America & Asia Market Group	-	-	-	-	-	-%	-	663	-	-	-
<b>Referral to Injectable 1</b>	1	3	1	-	12	(92)%	47	412	1	-	-
Anglophone Africa Market Group	-	-	-	-	12	(100)%	36	400	-	-	-
Latin America & Asia Market Group	1	3	1	-	-	-%	11	12	1	-	-
<b>Referral to Injectable 2</b>	-	-	-	-	-	-%	-	56	-	-	-
Anglophone Africa Market Group	-	-	-	-	-	-%	-	56	-	-	-
<b>Referral to Injectable 3</b>	73	37	105	-	103	2%	471	23,578	105	13	2
Anglophone Africa Market Group	-	-	-	-	63	(100)%	75	6,947	-	-	-
Franco/Lusophone Africa Market Group	-	-	-	-	-	-%	-	8,596	-	-	-
Latin America & Asia Market Group	73	37	105	-	40	163%	396	8,035	105	13	2
<b>Referral to IUD 10 Insertion</b>	168	96	297	-	122	143%	734	133,560	297	683	121
Acceleration Market Group	-	-	-	-	-	-%	-	8,256	-	-	-
Anglophone Africa Market Group	-	-	-	-	4	(100)%	5	24,172	-	-	-
Franco/Lusophone Africa Market Group	-	-	-	-	-	-%	-	6,239	-	-	-
Latin America & Asia Market Group	168	96	297	-	118	152%	729	73,487	297	683	121
Foundation Market Group	-	-	-	-	-	-%	-	20,969	-	-	-
Inactive	-	-	-	-	-	-%	-	437	-	-	-
<b>Referral to IUD 5 Insertion</b>	-	-	-	-	-	-%	-	498	-	-	-

<sup>(a)</sup>The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

**POPULATION SERVICES INTERNATIONAL**  
**Monthly Distribution by Product**  
**Period: 2**  
**Year: 2019**

	DISTRIBUTION 2/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	YTD USERS REACHED 2019 <sup>(a)</sup>	YTD CYP 2019	YTD DALY 2019
Acceleration Market Group	-	-	-	-	-	-%	-	440	-	-	-
Anglophone Africa Market Group	-	-	-	-	-	-%	-	58	-	-	-
<b>Referral to IUD Insertion (duration unknown)</b>	-	-	-	-	-	-%	-	16	-	-	-
Anglophone Africa Market Group	-	-	-	-	-	-%	-	16	-	-	-
<b>Referral to IUS 3 Insertion</b>	-	-	-	-	-	-%	-	26	-	-	-
Anglophone Africa Market Group	-	-	-	-	-	-%	-	26	-	-	-
<b>Referral to Linkage to HIV Care</b>	4,413	5,560	9,355	-	4,175	124%	26,986	62,420	9,355	-	7,240
Anglophone Africa Market Group	4,186	5,335	8,934	-	3,636	146%	24,186	55,578	8,934	-	6,885
Franco/Lusophone Africa Market Group	-	-	-	-	-	-%	-	281	-	-	-
Latin America & Asia Market Group	227	225	421	-	539	(22)%	2,800	6,553	421	-	356
Inactive	-	-	-	-	-	-%	-	8	-	-	-
<b>Referral to Manual Vacuum Aspiration - PAC</b>	-	-	-	-	-	-%	-	46	-	-	-
Latin America & Asia Market Group	-	-	-	-	-	-%	-	46	-	-	-
<b>Referral to Medication Abortion</b>	-	-	-	-	-	-%	-	24	-	-	-
Latin America & Asia Market Group	-	-	-	-	-	-%	-	24	-	-	-
<b>Referral to OCs</b>	58	47	83	-	87	(5)%	484	10,183	83	3	1
Anglophone Africa Market Group	-	-	-	-	57	(100)%	93	3,305	-	-	-
Franco/Lusophone Africa Market Group	-	-	-	-	-	-%	-	1,392	-	-	-
Latin America & Asia Market Group	58	47	83	-	30	177%	391	5,486	83	3	1
<b>Referral to Opioid Treatment</b>	2	11	10	-	39	(74)%	135	482	10	-	-
Latin America & Asia Market Group	2	11	10	-	39	(74)%	135	482	10	-	-
<b>Referral to PAC Service (unknown)</b>	-	-	-	-	-	-%	-	488	-	-	-
Latin America & Asia Market Group	-	-	-	-	-	-%	-	488	-	-	-
<b>Referral to Pre-Exposure Prophylaxis (PrEP)</b>	-	-	-	-	-	-%	20	250	-	-	-
Anglophone Africa Market Group	-	-	-	-	-	-%	20	250	-	-	-
<b>Referral to STI Diagnosis (lab confirmed)</b>	-	-	-	-	-	-%	-	332	-	-	-
Anglophone Africa Market Group	-	-	-	-	-	-%	-	332	-	-	-

<sup>(a)</sup>The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

**POPULATION SERVICES INTERNATIONAL**  
**Monthly Distribution by Product**  
**Period: 2**  
**Year: 2019**

	DISTRIBUTION 2/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	YTD USERS REACHED 2019 <sup>(a)</sup>	YTD CYP 2019	YTD DALY 2019
<b>Referral to STI Screening (syndromic)</b>	-	-	-	-	7	(100)%	7	14,419	-	-	-
Anglophone Africa Market Group	-	-	-	-	7	(100)%	7	14,419	-	-	-
<b>Referral to STI Treatment (unknown)</b>	-	-	-	-	16	(100)%	119	9,012	-	-	-
Acceleration Market Group	-	-	-	-	-	-%	-	1,690	-	-	-
Anglophone Africa Market Group	-	-	-	-	16	(100)%	119	4,864	-	-	-
Franco/Lusophone Africa Market Group	-	-	-	-	-	-%	-	128	-	-	-
Latin America & Asia Market Group	-	-	-	-	-	-%	-	2,330	-	-	-
<b>Referral to TB Diagnosis</b>	-	-	-	-	11	(100)%	11	30,963	-	-	-
Acceleration Market Group	-	-	-	-	-	-%	-	3,898	-	-	-
Anglophone Africa Market Group	-	-	-	-	11	(100)%	11	16,052	-	-	-
Latin America & Asia Market Group	-	-	-	-	-	-%	-	11,013	-	-	-
<b>Referral to TB DOTS (completion confirmed)</b>	107	130	165	-	57	189%	1,364	3,691	165	-	415
Acceleration Market Group	72	130	130	-	-	-%	1,214	2,976	130	-	403
Anglophone Africa Market Group	-	-	-	-	-	-%	2	19	-	-	-
Latin America & Asia Market Group	35	-	35	-	57	(39)%	148	691	35	-	12
Inactive	-	-	-	-	-	-%	-	5	-	-	-
<b>Referral to TB DOTS (completion unknown)</b>	70	206	137	-	44	211%	1,692	9,825	137	-	372
Acceleration Market Group	66	206	133	-	-	-%	1,575	5,189	133	-	371
Anglophone Africa Market Group	-	-	-	-	43	(100)%	74	4,388	-	-	-
Latin America & Asia Market Group	4	-	4	-	1	300%	43	248	4	-	1
<b>Referral to TB Screening</b>	-	-	-	-	329	(100)%	329	115,621	-	-	-
Acceleration Market Group	-	-	-	-	-	-%	-	85,548	-	-	-
Anglophone Africa Market Group	-	-	-	-	308	(100)%	308	29,857	-	-	-
Latin America & Asia Market Group	-	-	-	-	21	(100)%	21	216	-	-	-
<b>Referral to Treatment for Cervicitis</b>	-	-	-	-	29	(100)%	47	119	-	-	-
Anglophone Africa Market Group	-	-	-	-	29	(100)%	47	119	-	-	-
<b>Referral to Treatment for Genital Herpes</b>	-	-	-	-	-	-%	3	12	-	-	-

<sup>(a)</sup>The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

**POPULATION SERVICES INTERNATIONAL**  
**Monthly Distribution by Product**  
**Period: 2**  
**Year: 2019**

	DISTRIBUTION 2/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	YTD USERS REACHED 2019 <sup>(a)</sup>	YTD CYP 2019	YTD DALY 2019
Anglophone Africa Market Group	-	-	-	-	-	-%	3	12	-	-	-
<b>Referral to Treatment for Inguinal Bubo</b>	-	-	-	-	-	-%	2	136	-	-	-
Anglophone Africa Market Group	-	-	-	-	-	-%	2	136	-	-	-
<b>Referral to Treatment for Lower Abdominal Pain</b>	-	-	-	-	-	-%	1	137	-	-	-
Anglophone Africa Market Group	-	-	-	-	-	-%	1	137	-	-	-
<b>Referral to Treatment for Urethral Discharge (Men)</b>	-	-	-	-	1	(100)%	53	2,659	-	-	-
Anglophone Africa Market Group	-	-	-	-	1	(100)%	53	2,659	-	-	-
<b>Referral to Treatment for Vaginitis</b>	-	-	-	-	-	-%	-	7,247	-	-	-
Anglophone Africa Market Group	-	-	-	-	-	-%	-	7,247	-	-	-
<b>Referral to Tubal Ligation</b>	-	-	-	-	-	-%	2	67	-	-	-
Anglophone Africa Market Group	-	-	-	-	-	-%	2	6	-	-	-
Latin America & Asia Market Group	-	-	-	-	-	-%	-	61	-	-	-
<b>Referral to Tx for Nonherpetic Genital Ulcer</b>	1	-	1	-	3	(67)%	25	1,100	1	-	-
Anglophone Africa Market Group	1	-	1	-	3	(67)%	25	1,100	1	-	-
<b>Referral to Tx for Urethral Discharge (Women)</b>	2	1	4	-	18	(78)%	48	2,474	4	-	-
Anglophone Africa Market Group	2	1	4	-	18	(78)%	48	2,474	4	-	-
<b>Referral to Vasectomy</b>	1	-	1	-	-	-%	-	3	1	5	1
Anglophone Africa Market Group	-	-	-	-	-	-%	-	2	-	-	-
Latin America & Asia Market Group	1	-	1	-	-	-%	-	1	1	5	1
<b>Referral to Voluntary Medical Male Circumcision</b>	-	-	-	-	79	(100)%	139	20,727	-	-	-
Acceleration Market Group	-	-	-	-	-	-%	-	3,382	-	-	-
Anglophone Africa Market Group	-	-	-	-	79	(100)%	139	17,345	-	-	-
<b>Retreatment</b>	-	-	-	-	-	-%	-	46,984,114	-	-	-
Acceleration Market Group	-	-	-	-	-	-%	-	8,050,379	-	-	-
Anglophone Africa Market Group	-	-	-	-	-	-%	-	35,287,804	-	-	-
Franco/Lusophone Africa Market Group	-	-	-	-	-	-%	-	1,094,479	-	-	-
Latin America & Asia Market Group	-	-	-	-	-	-%	-	1,275,789	-	-	-

<sup>(a)</sup>The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

**POPULATION SERVICES INTERNATIONAL**  
**Monthly Distribution by Product**  
**Period: 2**  
**Year: 2019**

	DISTRIBUTION 2/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	YTD USERS REACHED 2019 <sup>(a)</sup>	YTD CYP 2019	YTD DALY 2019
Foundation Market Group	-	-	-	-	-	-%	-	1,009,438	-	-	-
Inactive	-	-	-	-	-	-%	-	266,225	-	-	-
<b>Retreatment IconMaxx</b>	-	-	-	-	-	-%	-	4,873,846	-	-	-
Anglophone Africa Market Group	-	-	-	-	-	-%	-	2,297,300	-	-	-
Latin America & Asia Market Group	-	-	-	-	-	-%	-	2,576,546	-	-	-
<b>Retreatment KO123</b>	-	-	-	-	-	-%	-	9,124,110	-	-	-
Acceleration Market Group	-	-	-	-	-	-%	-	1,106,836	-	-	-
Anglophone Africa Market Group	-	-	-	-	-	-%	-	8,013,192	-	-	-
Franco/Lusophone Africa Market Group	-	-	-	-	-	-%	-	4,082	-	-	-
<b>Retreatment KO123 net</b>	-	-	-	-	-	-%	-	10,259,477	-	-	-
Acceleration Market Group	-	-	-	-	-	-%	-	2,151,532	-	-	-
Anglophone Africa Market Group	-	-	-	-	-	-%	-	8,107,945	-	-	-
<b>Safe Injection Kit</b>	-	-	-	-	-	-%	-	5	-	-	-
Latin America & Asia Market Group	-	-	-	-	-	-%	-	5	-	-	-
<b>Safe Water Solution</b>	266,140	406,506	765,510	-	1,817,177	(58)%	5,579,483	164,107,775	624,884	-	2,042
Acceleration Market Group	132,288	105,064	297,324	-	171,504	73%	1,114,276	33,286,968	244,376	-	603
Anglophone Africa Market Group	101,092	154,755	287,578	-	642,966	(55)%	2,248,493	82,640,050	198,922	-	701
Franco/Lusophone Africa Market Group	-	90,000	81,360	-	518,413	(84)%	870,831	12,810,481	66,871	-	349
Latin America & Asia Market Group	-	-	-	-	-	-%	-	2,259,684	-	-	-
Foundation Market Group	32,760	56,687	99,248	-	484,294	(80)%	1,345,883	28,511,599	114,715	-	389
Inactive	-	-	-	-	-	-%	-	4,598,993	-	-	-
<b>SD NVP w/o Baby ARV Prophylaxis</b>	-	-	-	-	-	-%	-	271	-	-	-
Acceleration Market Group	-	-	-	-	-	-%	-	271	-	-	-
<b>SD NVP with Baby ARV Prophylaxis</b>	-	-	-	-	-	-%	-	235	-	-	-
Acceleration Market Group	-	-	-	-	-	-%	-	235	-	-	-
<b>SDM (Cycle Beads)</b>	(21)	31	(30)	-	409	(107)%	6,654	627,575	(27)	(41)	(24)
Acceleration Market Group	-	-	-	-	-	-%	-	201,447	-	-	-

<sup>(a)</sup>The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

**POPULATION SERVICES INTERNATIONAL**  
**Monthly Distribution by Product**  
**Period: 2**  
**Year: 2019**

	DISTRIBUTION 2/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	YTD USERS REACHED 2019 <sup>(a)</sup>	YTD CYP 2019	YTD DALY 2019
Anglophone Africa Market Group	-	-	-	-	-	-%	-	8,591	-	-	-
Franco/Lusophone Africa Market Group	13	48	9	-	44	(80)%	1,533	48,038	8	12	9
Latin America & Asia Market Group	-	-	-	-	-	-%	-	2,494	-	-	-
Foundation Market Group	(34)	(17)	(39)	-	365	(111)%	5,121	351,247	(35)	(53)	(34)
Inactive	-	-	-	-	-	-%	-	15,758	-	-	-
<b>SDM (Cycle Beads) Provided</b>	<b>62</b>	<b>34</b>	<b>73</b>	<b>-</b>	<b>62</b>	<b>18%</b>	<b>609</b>	<b>12,738</b>	<b>73</b>	<b>110</b>	<b>90</b>
Acceleration Market Group	20	1	20	-	-	-%	3	23	20	30	36
Anglophone Africa Market Group	-	-	-	-	-	-%	-	10	-	-	-
Franco/Lusophone Africa Market Group	7	10	11	-	5	120%	96	408	11	17	13
Latin America & Asia Market Group	1	-	1	-	1	-%	7	127	1	2	-
Foundation Market Group	34	23	41	-	56	(27)%	503	12,170	41	62	41
<b>Seasonal Malaria Chemoprevention</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>1,665,225</b>	<b>(100)%</b>	<b>2,009,973</b>	<b>4,420,982</b>	<b>-</b>	<b>-</b>	<b>-</b>
Franco/Lusophone Africa Market Group	-	-	-	-	-	-%	344,748	344,748	-	-	-
Foundation Market Group	-	-	-	-	1,665,225	(100)%	1,665,225	4,076,234	-	-	-
<b>Skilled Birth Attendance</b>	<b>3,464</b>	<b>4,077</b>	<b>6,035</b>	<b>-</b>	<b>2,719</b>	<b>122%</b>	<b>45,970</b>	<b>161,801</b>	<b>6,035</b>	<b>-</b>	<b>6,457</b>
Acceleration Market Group	1,967	1,678	3,541	-	2,719	30%	20,115	65,710	3,541	-	2,943
Anglophone Africa Market Group	-	-	-	-	-	-%	-	50,567	-	-	-
Franco/Lusophone Africa Market Group	140	147	255	-	-	-%	9,160	26,590	255	-	323
Foundation Market Group	1,357	2,252	2,239	-	-	-%	16,695	18,934	2,239	-	3,190
<b>STI Kit</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-%</b>	<b>-</b>	<b>691,263</b>	<b>-</b>	<b>-</b>	<b>-</b>
Acceleration Market Group	-	-	-	-	-	-%	-	240,890	-	-	-
Anglophone Africa Market Group	-	-	-	-	-	-%	-	438,695	-	-	-
Franco/Lusophone Africa Market Group	-	-	-	-	-	-%	-	329	-	-	-
Latin America & Asia Market Group	-	-	-	-	-	-%	-	9,882	-	-	-
Inactive	-	-	-	-	-	-%	-	1,467	-	-	-
<b>STI Kit (Non-Ulcerative)</b>	<b>2,067</b>	<b>633</b>	<b>2,067</b>	<b>-</b>	<b>-</b>	<b>-%</b>	<b>6,655</b>	<b>4,020,235</b>	<b>1,860</b>	<b>-</b>	<b>135</b>
Acceleration Market Group	-	-	-	-	-	-%	-	742,374	-	-	-

<sup>(a)</sup>The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.



**POPULATION SERVICES INTERNATIONAL**  
**Monthly Distribution by Product**  
**Period: 2**  
**Year: 2019**

	DISTRIBUTION 2/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	YTD USERS REACHED 2019 <sup>(a)</sup>	YTD CYP 2019	YTD DALY 2019
Anglophone Africa Market Group	2,067	633	2,067	-	-	-%	6,655	868,068	1,860	-	135
Franco/Lusophone Africa Market Group	-	-	-	-	-	-%	-	7,704	-	-	-
Latin America & Asia Market Group	-	-	-	-	-	-%	-	348,335	-	-	-
Foundation Market Group	-	-	-	-	-	-%	-	2,053,754	-	-	-
<b>STI Kit (Ulcerative)</b>	<b>1,115</b>	<b>-</b>	<b>1,115</b>	<b>-</b>	<b>-</b>	<b>-%</b>	<b>-</b>	<b>1,855,269</b>	<b>1,004</b>	<b>-</b>	<b>214</b>
Acceleration Market Group	-	-	-	-	-	-%	-	60,473	-	-	-
Anglophone Africa Market Group	1,115	-	1,115	-	-	-%	-	73,807	1,004	-	214
Franco/Lusophone Africa Market Group	-	-	-	-	-	-%	-	480	-	-	-
Foundation Market Group	-	-	-	-	-	-%	-	1,720,509	-	-	-
<b>STI Screening</b>	<b>17,101</b>	<b>11,185</b>	<b>33,809</b>	<b>-</b>	<b>22,291</b>	<b>52%</b>	<b>254,307</b>	<b>1,320,197</b>	<b>33,809</b>	<b>-</b>	<b>-</b>
Acceleration Market Group	2,157	1,985	3,926	-	4,722	(17)%	27,221	77,842	3,926	-	-
Anglophone Africa Market Group	13,024	6,799	26,777	-	14,285	87%	75,388	589,693	26,777	-	-
Franco/Lusophone Africa Market Group	866	884	1,726	-	1,289	34%	8,747	32,712	1,726	-	-
Latin America & Asia Market Group	12	2	19	-	39	(51)%	99	4,009	19	-	-
Foundation Market Group	1,042	1,515	1,361	-	1,956	(30)%	142,852	615,443	1,361	-	-
Inactive	-	-	-	-	-	-%	-	498	-	-	-
<b>TB Diagnosis</b>	<b>3,026</b>	<b>4,417</b>	<b>8,598</b>	<b>-</b>	<b>10,009</b>	<b>(14)%</b>	<b>62,691</b>	<b>232,455</b>	<b>8,598</b>	<b>-</b>	<b>-</b>
Acceleration Market Group	888	1,132	1,275	-	1,287	(1)%	14,315	88,670	1,275	-	-
Anglophone Africa Market Group	21	15	35	-	56	(38)%	283	1,512	35	-	-
Latin America & Asia Market Group	2,117	2,213	4,116	-	4,810	(14)%	29,853	89,752	4,116	-	-
Foundation Market Group	-	1,057	3,172	-	3,856	(18)%	18,240	42,302	3,172	-	-
Inactive	-	-	-	-	-	-%	-	10,219	-	-	-
<b>TB DOTs</b>	<b>2,982</b>	<b>4,416</b>	<b>9,839</b>	<b>-</b>	<b>10,185</b>	<b>(3)%</b>	<b>61,338</b>	<b>394,405</b>	<b>9,839</b>	<b>-</b>	<b>43,610</b>
Acceleration Market Group	931	1,005	1,887	-	1,763	7%	12,891	223,748	1,887	-	11,705
Anglophone Africa Market Group	3	2	4	-	12	(67)%	35	105	4	-	33
Latin America & Asia Market Group	2,048	2,109	4,047	-	3,372	20%	26,012	117,854	4,047	-	18,521
Foundation Market Group	-	1,300	3,901	-	5,038	(23)%	22,400	46,935	3,901	-	13,352

<sup>(a)</sup>The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

**POPULATION SERVICES INTERNATIONAL**  
**Monthly Distribution by Product**  
**Period: 2**  
**Year: 2019**

	DISTRIBUTION 2/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	YTD USERS REACHED 2019 <sup>(a)</sup>	YTD CYP 2019	YTD DALY 2019
Inactive	-	-	-	-	-	-%	-	5,763	-	-	-
<b>TB Screening</b>	40,537	38,688	86,258	-	77,451	11%	478,931	2,266,538	86,258	-	-
Acceleration Market Group	12,733	12,017	21,553	-	7,650	182%	103,950	501,952	21,553	-	-
Anglophone Africa Market Group	23,023	16,817	40,423	-	39,595	2%	225,880	1,491,448	40,423	-	-
Latin America & Asia Market Group	4,781	4,876	9,349	-	13,980	(33)%	72,433	150,865	9,349	-	-
Foundation Market Group	-	4,978	14,933	-	16,226	(8)%	76,668	115,134	14,933	-	-
Inactive	-	-	-	-	-	-%	-	7,139	-	-	-
<b>Toilets Constructed</b>	-	-	-	-	-	-%	-	16,479	-	-	-
Acceleration Market Group	-	-	-	-	-	-%	-	12,802	-	-	-
Franco/Lusophone Africa Market Group	-	-	-	-	-	-%	-	5	-	-	-
Foundation Market Group	-	-	-	-	-	-%	-	3,672	-	-	-
<b>Toilets Sold</b>	7,927	8,777	14,341	-	710	1,919%	64,462	282,852	70,552	-	1,754
Acceleration Market Group	6,089	6,753	11,363	-	-	-%	50,363	257,607	54,542	-	1,302
Anglophone Africa Market Group	917	939	1,468	-	-	-%	5,651	7,118	6,688	-	258
Franco/Lusophone Africa Market Group	722	597	1,094	-	15	7,110%	4,017	5,111	7,565	-	179
Latin America & Asia Market Group	199	483	410	-	695	(41)%	4,405	6,713	1,722	-	14
Foundation Market Group	-	4	6	-	-	-%	27	6,303	34	-	1
<b>Treatment for Cervicitis</b>	12	17	42	-	5	740%	101	461	42	-	1
Anglophone Africa Market Group	4	11	16	-	5	220%	73	379	16	-	1
Franco/Lusophone Africa Market Group	1	2	6	-	-	-%	-	19	6	-	-
Latin America & Asia Market Group	7	4	20	-	-	-%	28	63	20	-	-
<b>Treatment for Genital Herpes</b>	129	9	131	-	8	1,538%	70	302	131	-	3
Anglophone Africa Market Group	5	1	6	-	7	(14)%	28	105	6	-	-
Franco/Lusophone Africa Market Group	124	8	124	-	1	12,300%	42	188	124	-	3
Latin America & Asia Market Group	-	-	1	-	-	-%	-	9	1	-	-
<b>Treatment for Inguinal Bubo</b>	3	11	12	-	9	33%	89	232	12	-	-
Anglophone Africa Market Group	-	-	-	-	-	-%	3	17	-	-	-

<sup>(a)</sup>The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

**POPULATION SERVICES INTERNATIONAL**  
**Monthly Distribution by Product**  
**Period: 2**  
**Year: 2019**

	DISTRIBUTION 2/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	YTD USERS REACHED 2019 <sup>(a)</sup>	YTD CYP 2019	YTD DALY 2019
Franco/Lusophone Africa Market Group	-	5	6	-	4	50%	33	73	6	-	-
Foundation Market Group	3	5	6	-	5	20%	53	142	6	-	-
<b>Treatment for Lower Abdominal Pain</b>	<b>118</b>	<b>169</b>	<b>263</b>	<b>-</b>	<b>205</b>	<b>28%</b>	<b>1,571</b>	<b>3,640</b>	<b>263</b>	<b>-</b>	<b>-</b>
Anglophone Africa Market Group	8	5	22	-	16	38%	78	235	22	-	-
Franco/Lusophone Africa Market Group	66	98	174	-	84	107%	693	1,241	174	-	-
Latin America & Asia Market Group	-	-	1	-	-	-%	-	1	1	-	-
Foundation Market Group	44	65	66	-	105	(37)%	800	2,163	66	-	-
<b>Treatment for Nonherpetic Genital Ulcer</b>	<b>150</b>	<b>242</b>	<b>374</b>	<b>-</b>	<b>382</b>	<b>(2)%</b>	<b>6,745</b>	<b>16,901</b>	<b>374</b>	<b>-</b>	<b>63</b>
Anglophone Africa Market Group	50	37	95	-	73	30%	546	1,241	95	-	33
Franco/Lusophone Africa Market Group	23	138	167	-	136	23%	1,027	1,956	167	-	18
Latin America & Asia Market Group	-	-	-	-	-	-%	-	2	-	-	-
Foundation Market Group	77	66	112	-	173	(35)%	5,172	13,702	112	-	13
<b>Treatment for Pre-Eclampsia (with MgSO4)</b>	<b>26</b>	<b>46</b>	<b>43</b>	<b>-</b>	<b>14</b>	<b>207%</b>	<b>392</b>	<b>556</b>	<b>43</b>	<b>-</b>	<b>136</b>
Acceleration Market Group	3	3	5	-	14	(64)%	49	175	5	-	4
Foundation Market Group	23	44	38	-	-	-%	343	381	38	-	132
<b>Treatment for Severe Acute Malnutrition</b>	<b>389</b>	<b>1,713</b>	<b>389</b>	<b>-</b>	<b>-</b>	<b>-%</b>	<b>12,893</b>	<b>54,932</b>	<b>389</b>	<b>-</b>	<b>1,483</b>
Franco/Lusophone Africa Market Group	-	-	-	-	-	-%	-	4	-	-	-
Foundation Market Group	389	1,713	389	-	-	-%	12,893	54,928	389	-	1,483
<b>Treatment for Urethral Discharge (Men)</b>	<b>713</b>	<b>553</b>	<b>1,073</b>	<b>-</b>	<b>1,128</b>	<b>(5)%</b>	<b>7,519</b>	<b>18,148</b>	<b>2,146</b>	<b>-</b>	<b>18</b>
Anglophone Africa Market Group	47	19	77	-	39	97%	292	979	154	-	9
Franco/Lusophone Africa Market Group	246	189	433	-	236	83%	1,631	3,389	866	-	5
Foundation Market Group	420	345	563	-	853	(34)%	5,596	13,780	1,126	-	3
<b>Treatment for Urethral Discharge (Women)</b>	<b>402</b>	<b>345</b>	<b>824</b>	<b>-</b>	<b>394</b>	<b>109%</b>	<b>2,577</b>	<b>5,895</b>	<b>824</b>	<b>-</b>	<b>33</b>
Anglophone Africa Market Group	53	42	90	-	96	(6)%	507	1,613	90	-	17
Franco/Lusophone Africa Market Group	349	299	734	-	298	146%	2,054	4,259	734	-	17
Latin America & Asia Market Group	-	-	-	-	-	-%	1	8	-	-	-
Foundation Market Group	-	5	-	-	-	-%	15	15	-	-	-

<sup>(a)</sup>The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

**POPULATION SERVICES INTERNATIONAL**  
**Monthly Distribution by Product**  
**Period: 2**  
**Year: 2019**

	DISTRIBUTION 2/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	YTD USERS REACHED 2019 <sup>(a)</sup>	YTD CYP 2019	YTD DALY 2019
<b>Treatment for Vaginitis</b>	436	319	653	-	899	(27)%	5,511	14,933	653	-	26
Anglophone Africa Market Group	73	23	131	-	102	28%	506	2,343	131	-	22
Franco/Lusophone Africa Market Group	-	-	-	-	1	(100)%	2	7	-	-	-
Latin America & Asia Market Group	5	16	54	-	-	-%	25	82	54	-	-
Foundation Market Group	358	280	468	-	796	(41)%	4,978	12,501	468	-	4
<b>Tubal Ligation</b>	5,279	5,440	10,707	-	16,246	(34)%	67,507	382,263	10,707	135,102	41,303
Acceleration Market Group	4,621	4,314	9,344	-	13,082	(29)%	38,957	91,559	9,344	121,472	32,465
Anglophone Africa Market Group	655	735	1,018	-	1,807	(44)%	16,391	36,832	1,018	10,180	8,013
Franco/Lusophone Africa Market Group	-	68	-	-	-	-%	204	204	-	-	-
Latin America & Asia Market Group	2	321	344	-	1,353	(75)%	11,913	253,551	344	3,440	821
Foundation Market Group	1	3	1	-	4	(75)%	42	117	1	10	5
<b>Type 2 Diabetes Diagnosis</b>	-	-	-	-	-	-%	4	1,435	-	-	-
Anglophone Africa Market Group	-	-	-	-	-	-%	3	1,434	-	-	-
Latin America & Asia Market Group	-	-	-	-	-	-%	1	1	-	-	-
<b>Type 2 Diabetes Screening</b>	370	426	525	-	1,379	(62)%	6,712	17,118	525	-	-
Anglophone Africa Market Group	370	426	525	-	1,379	(62)%	6,711	17,115	525	-	-
Latin America & Asia Market Group	-	-	-	-	-	-%	1	3	-	-	-
<b>Type 2 Diabetes_Controlled Condition</b>	-	1	1	-	1	-%	6	13	-	-	-
Anglophone Africa Market Group	-	-	-	-	1	(100)%	6	12	-	-	-
Latin America & Asia Market Group	-	-	1	-	-	-%	-	1	-	-	-
<b>Vaginal Wash</b>	1,920	-	1,920	-	-	-%	-	1,920	-	-	-
Social Enterprise	1,920	-	1,920	-	-	-%	-	1,920	-	-	-
<b>Vasectomy</b>	26	63	46	-	151	(70)%	709	5,047	46	568	151
Acceleration Market Group	26	11	36	-	99	(64)%	287	3,992	36	468	126
Anglophone Africa Market Group	-	-	-	-	-	-%	-	40	-	-	-
Franco/Lusophone Africa Market Group	-	35	-	-	-	-%	104	104	-	-	-
Latin America & Asia Market Group	-	17	10	-	52	(81)%	318	911	10	100	24

<sup>(a)</sup>The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

**POPULATION SERVICES INTERNATIONAL**  
**Monthly Distribution by Product**  
**Period: 2**  
**Year: 2019**

	DISTRIBUTION 2/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	YTD USERS REACHED 2019 <sup>(a)</sup>	YTD CYP 2019	YTD DALY 2019
<b>Vivax Treatment after Confirmatory Diagnosis</b>	147	273	204	-	257	(21)%	3,400	9,575	204	-	37
Acceleration Market Group	147	244	204	-	257	(21)%	3,244	9,410	204	-	37
Latin America & Asia Market Group	-	28	-	-	-	-%	156	165	-	-	-
<b>Voluntary Medical Male Circumcision</b>	27,651	21,295	45,063	-	53,513	(16)%	424,870	2,537,832	45,063	-	315,177
Acceleration Market Group	6,256	2,937	7,740	-	6,478	19%	78,885	315,515	7,740	-	54,486
Anglophone Africa Market Group	21,395	18,358	37,323	-	47,035	(21)%	345,985	2,161,052	37,323	-	260,691
Franco/Lusophone Africa Market Group	-	-	-	-	-	-%	-	61,265	-	-	-
<b>Water Treatment Tablets</b>	5,310,760	2,713,660	7,001,880	-	5,142,642	36%	38,726,042	825,790,196	115,099	-	873
Acceleration Market Group	542,160	22,377	594,000	-	38,880	1,428%	501,290	6,534,367	9,764	-	24
Anglophone Africa Market Group	507,100	513,967	919,400	-	1,876,042	(51)%	6,957,142	359,103,910	15,113	-	59
Franco/Lusophone Africa Market Group	3,728,300	1,166,430	4,314,620	-	1,618,320	167%	20,217,570	168,560,520	70,925	-	564
Latin America & Asia Market Group	-	22,833	50,500	-	800	6,213%	91,160	10,803,483	830	-	2
Foundation Market Group	533,200	988,053	1,123,360	-	1,608,600	(30)%	10,958,880	280,787,916	18,466	-	224
<b>Woman Condom</b>	480	4,048	480	-	8,496	(94)%	97,728	140,040	4	4	10
Anglophone Africa Market Group	480	4,048	480	-	8,496	(94)%	97,728	140,040	4	4	10
<b>Zika Prevention Kit</b>	-	4	-	-	105	(100)%	725	114,581	-	-	-
Latin America & Asia Market Group	-	4	-	-	105	(100)%	725	114,581	-	-	-
<b>Zinc</b>	42	60	42	-	17,770	(100)%	512,836	7,209,441	38	-	-
Acceleration Market Group	-	-	-	-	-	-%	-	953,402	-	-	-
Anglophone Africa Market Group	-	-	-	-	-	-%	-	1,034,758	-	-	-
Franco/Lusophone Africa Market Group	-	-	-	-	-	-%	-	669,429	-	-	-
Latin America & Asia Market Group	2	-	2	-	-	-%	-	481,251	2	-	-
Foundation Market Group	40	60	40	-	17,770	(100)%	512,836	4,070,601	36	-	-
<b>Zinc Provided</b>	2,181	1,578	4,376	-	-	-%	11,834	49,285	4,376	-	115
Foundation Market Group	2,181	1,578	4,376	-	-	-%	11,834	49,285	4,376	-	115

<sup>(a)</sup>The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

# Acceleration Market Group

**POPULATION SERVICES INTERNATIONAL**  
**CYPs, Cases, and Deaths by Country**  
**1/2019 - 2/2019**

	New HIV Infections	STI Deaths	PWID Deaths	TB Deaths	CYP*	Maternal Deaths	Unintended Pregnancies	Malaria Deaths	Diarrhea Deaths	Pneumonia Deaths	Cervical Cancer Death	Sum of All Deaths
Acceleration Market Group	5,288	-	-	434	417,957	594	188,561	122	69	17	-	3,378
India	-	-	-	-	144,524	38	82,139	-	44	-	-	500
Kenya	3,612	-	-	-	121,598	140	44,568	64	13	17	-	981
Myanmar	227	-	-	434	74,776	18	26,626	58	12	-	-	621
Nigeria	-	-	-	-	6,120	14	2,820	-	-	-	-	85
PSI Nigeria	-	-	-	-	70,939	383	32,407	-	-	-	-	1,191
South Africa	1,448	-	-	-	-	-	-	-	-	-	-	-

\* Using USAID CYP conversion factors

POPULATION SERVICES INTERNATIONAL  
 Monthly Distribution by Market Group and Product  
 Period: 2  
 Year: 2019

	DISTRIBUTION 2/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE SALES	YTD USERS REACHED <sup>(a)</sup> 2019	YTD CYP 2019	YTD DALY 2019
<b>Acceleration Market Group</b>										<b>417,957</b>	<b>465,547</b>
Antiretroviral Treatment (Currently Enrolled)	13,657	13,624	27,179	-	23,487	16%	152,003	255,663	2,265	-	5,405
Antiretroviral Treatment (Newly Enrolled)	326	283	599	-	523	15%	3,434	10,185	599	-	-
Cervical Cancer-VIA and Cryotherapy	24	24	49	-	26	88%	286	4,322	49	-	11
Cervical Cancer-VIA and Refer to Conization	-	1	-	-	-	-%	4	4	-	-	-
Cervical Cancer-VIA and Refer to Cryotherapy	-	10	-	-	-	-%	29	48	-	-	-
Cervical Cancer-VIA/VILI Screening	3,286	2,824	6,039	-	2,649	128%	34,714	293,768	6,039	-	-
Condom	3,415,904	3,059,436	6,351,757	-	5,788,992	10%	38,017,548	981,855,805	47,638	47,638	148,856
Diarrhea Treatment Kit Provided	2,007	1,726	3,853	-	3,098	24%	18,226	58,110	3,853	-	128
Emergency Contraception	(1,387)	-	(1,387)	-	-	-%	5	176,482	(62)	(62)	(8)
Emergency Contraception Provided	1,583	670	1,823	-	274	565%	4,173	7,424	91	91	18
Fecal Sludge Management (Households)	101	106	210	-	43	388%	697	2,489	1,008	-	-
Fecal Sludge Management (Liters)	505,000	531,667	1,050,000	-	137,000	666%	4,011,000	12,207,200	-	-	65
Female Condom	11,275	11,527	23,460	-	10,658	120%	79,641	1,493,926	176	176	126
Fever Cases Attended	39,382	58,899	54,654	-	48,557	13%	697,782	2,485,822	54,654	-	-
Fever Cases Tested with RDTs	39,382	58,899	54,654	-	48,557	13%	697,782	2,485,822	54,654	-	-
Free Condom	891,360	7,150,240	1,049,760	-	7,261,200	(86)%	68,170,320	1,176,206,957	7,873	7,873	31,179
Free Female Condom	-	260,300	-	-	57,600	(100)%	1,108,500	5,030,600	-	-	-
HIV Self-Testing Kit	11,038	456,623	23,486	-	-	-%	1,357,422	1,380,908	21,137	-	-
HIV Testing Services	33,068	32,018	64,509	-	684,293	(91)%	1,091,132	6,122,472	64,509	-	2,555
Hypertension Diagnosis	731	517	1,417	-	12,854	(89)%	57,768	75,226	1,417	-	-
Hypertension Screening	8,361	7,841	16,839	-	29,511	(43)%	176,640	227,993	16,839	-	-

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.



POPULATION SERVICES INTERNATIONAL  
Monthly Distribution by Market Group and Product  
Period: 2  
Year: 2019

	DISTRIBUTION 2/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE SALES	YTD USERS REACHED <sup>(a)</sup> 2019	YTD CYP 2019	YTD DALY 2019
Hypertension_Controlled Condition	480	332	883	-	9,196	(90)%	43,499	56,692	353	-	-
Implant 3	677	446	1,402	-	(112)	-%	1,528	820,078	1,262	3,155	2,436
Implant 3 Insertion	412	1,915	1,488	-	695	114%	8,884	13,853	1,488	3,720	2,325
Implant 4 Insertion	-	-	-	-	288	(100)%	288	288	-	-	-
Implant 5	(1,842)	(1,006)	(3,485)	-	(1,244)	-%	2,423	50,505	(3,137)	(11,919)	(8,580)
Implant 5 Insertion	7,758	8,731	15,904	-	7,861	102%	82,547	430,605	15,904	60,435	52,612
Injectable 1 Provided	-	14	5	-	-	-%	37	42	-	-	-
Injectable 2 Provided	-	2,250	876	-	-	-%	5,875	6,751	146	146	123
Injectable 3-IM	61,995	27,499	49,340	-	107,212	(54)%	493,679	15,501,901	11,102	11,102	2,560
Injectable 3-IM Provided	19,907	17,155	33,443	-	27,519	22%	175,770	404,497	8,361	8,361	3,822
Injectable 3-SC	3,134	67	3,334	-	-	-%	-	3,334	750	750	94
Injectable 3-SC Provided	-	296	887	-	-	-%	-	887	222	222	187
IPTp2	547	418	938	-	573	64%	3,893	15,235	938	-	35
IUD 10	(487)	203	(1,164)	-	(900)	-%	1,452	12,950	(1,048)	(4,819)	(4,087)
IUD 10 Insertion	7,166	7,309	14,196	-	13,178	8%	90,084	543,724	14,196	65,302	65,263
IUD 5	(5,004)	(107)	(5,115)	-	(132)	-%	(296)	132,113	(4,604)	(15,192)	(3,407)
IUD 5 Insertion	5,004	5,386	11,374	-	9,148	24%	51,661	189,303	11,374	37,534	8,468
IUS 5 Insertion	130	92	232	-	59	293%	775	1,633	232	766	880
LLIN	3,956	125,792	39,765	-	71,182	(44)%	2,332,163	4,494,487	64,419	-	1,311
Lubricant	7,210	7,837	15,975	-	6,060	164%	51,861	5,248,661	-	-	-
Malaria PPT (ACT)	34,689	852	34,896	-	110,766	(68)%	256,333	3,223,792	31,406	-	4,896

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

**POPULATION SERVICES INTERNATIONAL**  
**Monthly Distribution by Market Group and Product**  
**Period: 2**  
**Year: 2019**

	DISTRIBUTION 2/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE SALES	YTD USERS REACHED <sup>(a)</sup> 2019	YTD CYP 2019	YTD DALY 2019
Malaria PPT (Non-ACT)	(147)	(229)	(195)	-	(145)	-%	(1,900)	104,131	(176)	-	(27)
Malaria RDK	41,025	46,067	70,035	-	63,650	10%	743,410	4,802,009	63,032	-	-
Manual Vacuum Aspiration for PAC	1,576	443	1,576	-	-	-%	19,176	20,752	1,576	-	1,262
Micronutrient Powder	-	528,193	-	-	-	-%	2,000,000	9,499,690	-	-	-
Misoprostol for PAC Provided	1,578	418	1,578	-	-	-%	14,855	16,433	1,578	-	1,496
Misoprostol for Safe Abortion	196,428	195,213	218,558	-	-	-%	2,321,200	2,539,758	11,474	-	9,635
Multivitamin	-	-	-	-	67,730	(100)%	450,010	883,520	-	-	-
OCs	941,482	736,755	1,319,500	-	1,255,759	5%	9,492,397	67,119,855	79,170	79,170	24,334
OCs Provided	19,357	11,765	23,073	-	14,080	64%	151,894	268,182	1,538	1,538	482
ORS	23,125	39,403	41,145	-	59,889	(31)%	514,198	1,271,999	18,515	-	1,079
ORS Provided	424	252	758	-	381	99%	2,217	8,145	758	-	12
Pneumonia PPT Provided	1,681	1,187	2,965	-	2,973	-%	20,179	61,038	2,965	-	1,426
Positive RDTs	335	746	525	-	859	(39)%	9,712	35,996	525	-	-
Positive RDTs Given First Line Treatment	328	711	500	-	818	(39)%	8,937	31,503	500	-	-
PUR	3,354,240	1,520,403	6,063,130	-	4,690,413	29%	28,508,349	186,843,056	49,834	-	123
QAACs Provided after Confirmatory Diagnosis	11,772	10,917	23,955	-	7,912	203%	101,767	144,500	23,955	-	3,945
Referral to TB DOTS (completion confirmed)	72	130	130	-	-	-%	1,214	1,637	130	-	403
Referral to TB DOTS (completion unknown)	66	206	133	-	-	-%	1,575	1,708	133	-	371
Safe Water Solution	132,288	105,064	297,324	-	171,504	73%	1,114,276	21,771,224	244,376	-	603
SDM (Cycle Beads) Provided	20	1	20	-	-	-%	3	23	20	30	36
Skilled Birth Attendance	1,967	1,678	3,541	-	2,719	30%	20,115	65,710	3,541	-	2,943

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

**POPULATION SERVICES INTERNATIONAL**  
**Monthly Distribution by Market Group and Product**  
**Period: 2**  
**Year: 2019**

	DISTRIBUTION 2/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE SALES	YTD USERS REACHED <sup>(a)</sup> 2019	YTD CYP 2019	YTD DALY 2019
STI Screening	2,157	1,985	3,926	-	4,722	(17)%	27,221	64,435	3,926	-	-
TB Diagnosis	888	1,132	1,275	-	1,287	(1)%	14,315	60,879	1,275	-	-
TB DOTS	931	1,005	1,887	-	1,763	7%	12,891	219,338	1,887	-	11,705
TB Screening	12,733	12,017	21,553	-	7,650	182%	103,950	393,760	21,553	-	-
Toilets Sold	6,089	6,753	11,363	-	-	-%	50,363	61,726	54,542	-	1,302
Treatment for Pre-Eclampsia (with MgSO4)	3	3	5	-	14	(64)%	49	175	5	-	4
Tubal Ligation	4,621	4,314	9,344	-	13,082	(29)%	38,957	91,547	9,344	121,472	32,465
Vasectomy	26	11	36	-	99	(64)%	287	3,991	36	468	126
Vivax Treatment after Confirmatory Diagnosis	147	244	204	-	257	(21)%	3,244	9,410	204	-	37
Voluntary Medical Male Circumcision	6,256	2,937	7,740	-	6,478	19%	78,885	159,967	7,740	-	54,486
Water Treatment Tablets	542,160	22,377	594,000	-	38,880	1,428%	501,290	6,531,200	9,764	-	24

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

Period: 2

Year: 2019

	DISTRIBUTION 2/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
<b>Acceleration Market Group</b>											<b>417,957</b>	<b>465,547</b>
<b>India</b>											<b>144,524</b>	<b>39,059</b>
Emergency Contraception	(1,387)	-	(1,387)	-	-		0%	-	(1,387)	(62)	(62)	(8)
(b)PSI Emergency Contraception Distributed Provided	(1,387)	-	(1,387)	-	-		-%	-	(1,387)	(62)	(62)	(8)
Emergency Contraception Provided	1,387	438	1,387	-	19		7200%	2,574	3,961	69	69	9
Non-PSI Emergency Contraception Provided	-	438	-	-	19		(100)%	2,574	2,574	-	-	-
PSI Emergency Contraception Provided	1,387	-	1,387	-	-		-%	-	1,387	69	69	9
Fecal Sludge Management (Households)	101	106	210	-	43		388%	697	2,489	1,008	-	-
Fecal Sludge Management (Households)	101	106	210	-	43		388%	697	2,489	1,008	-	-
Fecal Sludge Management (Liters)	505,000	531,667	1,050,000	-	137,000		666%	4,011,000	12,207,200	-	-	65
Fecal Sludge Management (Liters)	505,000	531,667	1,050,000	-	137,000		666%	4,011,000	12,207,200	-	-	65
Injectable 3-IM	(8,038)	-	(8,038)	-	-		0%	-	(8,038)	(1,809)	(1,809)	(303)
(b)PSI Injectable 3 IM Distributed Provided	(8,038)	-	(8,038)	-	-		-%	-	(8,038)	(1,809)	(1,809)	(303)
Injectable 3-IM Provided	8,038	1,874	8,038	-	3,648		120%	16,479	59,467	2,010	2,010	336
Non-PSI Injectable 3 IM Provided	-	1,874	-	-	3,648		(100)%	16,479	51,429	-	-	-
PSI Injectable 3 IM Provided	8,038	-	8,038	-	-		-%	-	8,038	2,010	2,010	336
IUD 10 Insertion	-	-	-	-	41		(100)%	41	2,526	-	-	-
Non-PSI IUD 10 Inserted	-	-	-	-	41		(100)%	41	2,526	-	-	-
IUD 5	(4,894)	-	(4,894)	-	-		0%	-	(8,300)	(4,405)	(14,535)	(3,295)
(b)PSI IUD 5 Distributed Inserted	(4,894)	-	(4,894)	-	-		-%	-	(8,300)	(4,405)	(14,535)	(3,295)
IUD 5 Insertion	4,894	5,135	11,153	-	8,838		26%	49,622	130,346	11,153	36,805	8,344
Non-PSI IUD 5 Inserted	-	5,135	6,259	-	8,838		(29)%	49,622	122,046	6,259	20,655	4,683
PSI IUD 5 Inserted	4,894	-	4,894	-	-		-%	-	8,300	4,894	16,150	3,661
OCs	(15,937)	-	(15,937)	-	-		0%	-	(15,937)	(956)	(956)	(169)
(b)PSI OCs Distributed Provided	(15,937)	-	(15,937)	-	-		-%	-	(15,937)	(956)	(956)	(169)

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

**Period: 2**

**Year: 2019**

	DISTRIBUTION 2/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
OCs Provided	15,937	6,244	15,937	-	9,710		64%	100,521	180,594	1,062	1,062	188
Non-PSI OCs Provided	-	6,244	-	-	9,710		(100)%	100,521	164,657	-	-	-
PSI OCs Provided	15,937	-	15,937	-	-		-%	-	15,937	1,062	1,062	188
Toilets Sold	6,089	6,753	11,363	-	-		0%	50,363	61,726	54,542	-	1,302
Toilets Sold	6,089	6,753	11,363	-	-		-%	50,363	61,726	54,542	-	1,302
Tubal Ligation	4,621	4,314	9,344	-	13,082		(29)%	38,957	91,547	9,344	121,472	32,465
Tubal Ligation	4,621	4,314	9,344	-	13,082		(29)%	38,957	91,547	9,344	121,472	32,465
Vasectomy	26	11	36	-	99		(64)%	287	3,991	36	468	126
Vasectomy	26	11	36	-	99		(64)%	287	3,991	36	468	126
<b>Kenya</b>											121,598	236,732
Antiretroviral Treatment (Currently Enrolled)	7,654	7,741	15,329	-	13,545		13%	85,622	129,781	1,277	-	3,335
Antiretroviral Treatment (Currently Enrolled)	7,654	7,741	15,329	-	13,545		13%	85,622	129,781	1,277	-	3,335
Antiretroviral Treatment (Newly Enrolled)	112	102	215	-	182		18%	1,227	3,635	215	-	-
Antiretroviral Treatment (Newly Enrolled)	112	102	215	-	182		18%	1,227	3,635	215	-	-
Cervical Cancer-VIA and Cryotherapy	20	15	35	-	26		35%	227	3,351	35	-	8
Cervical Cancer-VIA and Cryotherapy	20	15	35	-	26	7/13	35%	227	3,351	35	-	8
Cervical Cancer-VIA and Refer to Conization	-	1	-	-	-		0%	4	4	-	-	-
Cervical Cancer-VIA and Refer to Conization	-	1	-	-	-		-%	4	4	-	-	-
Cervical Cancer-VIA and Refer to Cryotherapy	-	10	-	-	-		0%	29	48	-	-	-
Cervical Cancer-VIA and Refer to Cryotherapy	-	10	-	-	-	12/14	-%	29	48	-	-	-
Cervical Cancer-VIA/VILI Screening	3,039	2,490	5,591	-	2,642		112%	31,803	285,965	5,591	-	-
Cervical Cancer-VIA/VILI Screening	3,039	2,490	5,591	-	2,642		112%	31,803	285,965	5,591	-	-
Condom	2,504,736	2,062,960	4,708,080	-	4,213,852		12%	25,124,074	567,511,397	35,311	35,311	139,837
Trust	2,065,824	1,600,440	3,777,264	-	3,288,456	10/93	15%	19,627,309	506,005,512	28,329	28,329	112,190
Trust Ribbed	-	56,328	29,448	-	86,760	5/14	(66)%	701,493	3,722,311	221	221	875

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

**Period: 2**

**Year: 2019**

	DISTRIBUTION 2/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
Trust Scented	-	72	216	-	54,576	5/14	(100)%	60,552	3,301,903	2	2	6
Trust Studded	438,912	406,120	901,152	-	784,060	1/08	15%	4,734,720	54,481,671	6,759	6,759	26,766
Diarrhea Treatment Kit Provided	2,007	1,726	3,853	-	3,098		24%	18,226	58,110	3,853	-	128
Non-PSI Diarrhea Treatment Kit Provided	2,007	1,726	3,853	-	3,098		24%	18,226	58,110	3,853	-	128
Emergency Contraception	-	-	-	-	(126)		0%	(126)	(1,554)	-	-	-
(b)PSI Emergency Contraception Distributed Provided	-	-	-	-	(126)		-%	(126)	(1,554)	-	-	-
Emergency Contraception Provided	196	218	431	-	231		87%	1,539	3,398	22	22	9
Non-PSI Emergency Contraception Provided	196	218	431	-	105		310%	1,413	1,844	22	22	9
PSI Emergency Contraception Provided	-	-	-	-	126		(100)%	126	1,554	-	-	-
Free Condom	891,360	1,848,240	1,049,760	-	576,000		82%	28,851,120	91,547,197	7,873	7,873	31,179
Free Male Condom - NASCOP	891,360	1,848,240	1,049,760	-	576,000	5/11	82%	28,851,120	91,547,197	7,873	7,873	31,179
HIV Self-Testing Kit	11,038	23,057	11,038	-	-		0%	69,171	80,209	9,934	-	-
INSTI HIVST (Blood based)	-	13,333	-	-	-		-%	40,000	40,000	-	-	-
INSTI-ORAQUICK HIVST BUNDLE	-	333	-	-	-		-%	1,000	1,000	-	-	-
ORAQUICK HIV Self-Testing Kit (Saliva based)	11,038	9,390	11,038	-	-		-%	28,171	39,209	9,934	-	-
HIV Testing Services	24,422	25,098	48,427	-	30,650		58%	212,997	1,235,989	48,427	-	2,023
VCT Individual (HIV-Negative)	24,044	24,692	47,666	-	30,167	9/11	58%	209,785	1,200,886	47,666	-	1,991
VCT Individual (HIV-Positive)	378	406	761	-	483	9/11	58%	3,212	35,103	761	-	32
Implant 3	500	333	1,500	-	-		0%	1	808,493	1,350	3,375	2,473
Implanon	500	333	1,500	-	-	3/14	-%	1	808,493	1,350	3,375	2,473
Implant 5	(1,847)	(1,006)	(3,490)	-	(1,244)		0%	2,423	50,393	(3,141)	(11,936)	(8,583)
Jadelle	-	947	-	-	-	1/09	-%	23,710	184,928	-	-	-
(b)PSI Implant 5 Distributed Inserted	(1,847)	(1,953)	(3,490)	-	(1,244)		-%	(21,287)	(134,535)	(3,141)	(11,936)	(8,583)
Implant 5 Insertion	5,160	5,474	10,043	-	3,896		158%	50,514	301,842	10,043	38,163	27,443

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

**Period: 2**

**Year: 2019**

	DISTRIBUTION 2/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
Non-PSI Implant 5 Inserted	3,313	3,521	6,553	-	2,652		147%	29,227	167,307	6,553	24,901	17,906
PSI Implant 5 Inserted	1,847	1,953	3,490	-	1,244		181%	21,287	134,535	3,490	13,262	9,537
Injectable 3-IM	26,174	(1,186)	13,372	-	72,891		(82)%	117,204	5,730,566	3,009	3,009	1,624
Femiplan Injectable	38,016	11,952	38,016	-	96,336	3/00	(61)%	267,954	6,066,294	8,554	8,554	4,617
(b)PSI Injectable 3 IM Distributed Provided	(11,842)	(13,138)	(24,644)	-	(23,445)		-%	(150,750)	(335,728)	(5,545)	(5,545)	(2,993)
Injectable 3-IM Provided	11,842	13,138	24,644	-	23,445		5%	150,750	335,728	6,161	6,161	3,325
PSI Injectable 3 IM Provided	11,842	13,138	24,644	-	23,445		5%	150,750	335,728	6,161	6,161	3,325
IPTp2	547	418	938	-	573		64%	3,893	15,235	938	-	35
IPTp2	547	418	938	-	573		64%	3,893	15,235	938	-	35
IUD 10	(790)	(1)	(1,522)	-	(900)		0%	605	8,505	(1,370)	(6,301)	(4,324)
CU 380A (Copper T)	-	787	-	-	-	3/09	-%	10,551	99,224	-	-	-
(b)PSI IUD 10 Distributed Inserted	(790)	(788)	(1,522)	-	(900)		-%	(9,946)	(90,719)	(1,370)	(6,301)	(4,324)
IUD 10 Insertion	1,580	1,607	2,972	-	1,736		71%	17,347	182,226	2,972	13,671	9,381
Non-PSI IUD 10 Inserted	790	819	1,450	-	836		73%	7,401	91,507	1,450	6,670	4,577
PSI IUD 10 Inserted	790	788	1,522	-	900		69%	9,946	90,719	1,522	7,001	4,804
LLIN	3,956	125,792	39,765	-	71,182		(44)%	2,332,163	4,494,487	64,419	-	1,311
Supanet Conical	855	1,088	1,790	-	3,968	10/16	(55)%	8,447	17,418	2,900	-	59
Supanet Rectangular	801	628	1,673	-	2,931	10/16	(43)%	13,913	20,296	2,710	-	55
Supanet XtraPower BL PNET USAID	2,300	124,075	36,302	-	64,283	3/14	(44)%	2,309,803	4,456,773	58,809	-	1,197
OCs	316,957	280,528	530,784	-	801,198		(34)%	3,635,514	39,177,557	31,847	31,847	18,134
Famipill	5,472	46,464	8,064	-	-	5/18	-%	140,628	148,692	484	484	276
Femi Girl Oral Pills	-	-	-	-	105,480	11/16	(100)%	162,192	171,936	-	-	-
Femiplan Pill	313,920	237,120	527,760	-	699,840	3/00	(25)%	3,376,158	38,934,512	31,666	31,666	18,031
(b)PSI OCs Distributed Provided	(2,435)	(3,056)	(5,040)	-	(4,122)		-%	(43,464)	(77,583)	(302)	(302)	(172)

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

**Period: 2**

**Year: 2019**

	DISTRIBUTION 2/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
OCs Provided	2,945	3,538	6,047	-	4,122		47%	44,411	79,537	403	403	230
Non-PSI OCs Provided	510	481	1,007	-	-		-%	947	1,954	67	67	38
PSI OCs Provided	2,435	3,056	5,040	-	4,122		22%	43,464	77,583	336	336	191
ORS Provided	424	252	758	-	381		99%	2,217	8,145	758	-	12
Non-PSI ORS Provided	424	252	758	-	381		99%	2,217	8,145	758	-	12
Pneumonia PPT Provided	1,681	1,187	2,965	-	2,973		0%	20,179	61,038	2,965	-	1,426
Non-PSI Pneumonia PPT Provided	1,681	1,187	2,965	-	2,973		-%	20,179	61,038	2,965	-	1,426
PUR	3,354,240	1,520,403	6,063,130	-	4,676,640		30%	27,875,040	170,985,266	49,834	-	123
PuR	3,354,240	1,520,403	6,063,130	-	4,676,640	2/06	30%	27,875,040	170,985,266	49,834	-	123
QAACTs Provided after Confirmatory Diagnosis	11,638	10,513	23,733	-	7,384		221%	96,981	124,639	23,733	-	3,904
Non-PSI QAACTs Provided after Confirmed Diagnosis	11,638	10,513	23,733	-	7,384		221%	96,981	124,639	23,733	-	3,904
Safe Water Solution	132,288	105,064	297,324	-	171,504		73%	1,114,276	21,771,224	244,376	-	603
WaterGuard	132,288	105,064	297,324	-	171,504	5/03	73%	1,114,276	21,771,224	244,376	-	603
Skilled Birth Attendance	1,967	1,678	3,541	-	2,719		30%	20,115	65,710	3,541	-	2,943
Skilled Birth Attendance	1,967	1,678	3,541	-	2,719		30%	20,115	65,710	3,541	-	2,943
TB Diagnosis	64	34	110	-	-		0%	56	781	110	-	-
TB Diagnosis	64	34	110	-	-		-%	56	781	110	-	-
TB Screening	6,547	4,365	13,303	-	-		0%	6,339	93,681	13,303	-	-
TB Screening	6,547	4,365	13,303	-	-		-%	6,339	93,681	13,303	-	-
Treatment for Pre-Eclampsia (with MgSO4)	3	3	5	-	14		(64)%	49	175	5	-	4
Treatment for Pre-Eclampsia (with MgSO4)	3	3	5	-	14		(64)%	49	175	5	-	4
Voluntary Medical Male Circumcision	-	7	22	-	-		0%	-	22	22	-	122
Voluntary Medical Male Circumcision	-	7	22	-	-		-%	-	22	22	-	122
Water Treatment Tablets	542,160	22,377	594,000	-	38,880		1428%	501,290	6,531,200	9,764	-	24
Aquatab	542,160	22,377	594,000	-	38,880	3/09	1,428%	501,290	6,531,200	9,764	-	24

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.



**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

Period: 2

Year: 2019

	DISTRIBUTION 2/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
<b>Myanmar</b>											<b>74,776</b>	<b>37,987</b>
Antiretroviral Treatment (Currently Enrolled)	6,003	5,883	11,850	-	9,942		19%	66,381	125,882	987	-	2,070
Antiretroviral Treatment (Currently Enrolled)	6,003	5,883	11,850	-	9,942		19%	66,381	125,882	987	-	2,070
Antiretroviral Treatment (Newly Enrolled)	214	180	384	-	341		13%	2,207	6,550	384	-	-
Antiretroviral Treatment (Newly Enrolled)	214	180	384	-	341		13%	2,207	6,550	384	-	-
Cervical Cancer-VIA and Cryotherapy	4	9	14	-	-		0%	59	971	14	-	3
Cervical Cancer-VIA and Cryotherapy	4	9	14	-	-	11/12	-%	59	971	14	-	3
Cervical Cancer-VIA/VILI Screening	247	333	448	-	7		6300%	2,911	7,803	448	-	-
Cervical Cancer-VIA/VILI Screening	247	333	448	-	7		6,300%	2,911	7,803	448	-	-
Condom	911,168	996,476	1,643,677	-	1,575,140		4%	12,893,474	414,344,408	12,328	12,328	9,019
Aphaw	34,400	261,213	34,700	-	293,280	7/96	(88)%	2,515,280	191,300,379	260	260	190
Aphaw - Natural Touch	2,388	1,464	2,646	-	204,015	8/12	(99)%	1,039,098	14,780,319	20	20	15
Aphaw Flavors	546,540	254,764	607,080	-	682,859	10/01	(11)%	5,926,276	177,427,771	4,553	4,553	3,331
Aphaw Studded	1,920	161,285	362,211	-	175,530	7/12	106%	1,050,858	18,810,756	2,717	2,717	1,987
Generic Male Condom	325,200	312,133	635,600	-	201,000	1/08	216%	2,270,400	6,794,529	4,767	4,767	3,488
OK Condom	720	5,616	1,440	-	18,456	5/03	(92)%	91,562	5,230,654	11	11	8
Emergency Contraception	-	-	-	-	-		0%	5	177,869	-	-	-
OK EC	-	-	-	-	-	8/07	-%	5	177,869	-	-	-
Female Condom	11,275	11,527	23,460	-	10,658		120%	79,641	1,493,926	176	176	126
Generic Female Condom	11,275	11,527	23,460	-	10,658	5/08	120%	79,641	1,493,926	176	176	126
Fever Cases Attended	39,382	58,899	54,654	-	48,557		13%	697,782	2,485,822	54,654	-	-
Fever Cases Attended	39,382	58,899	54,654	-	48,557		13%	697,782	2,485,822	54,654	-	-
Fever Cases Tested with RDTs	39,382	58,899	54,654	-	48,557		13%	697,782	2,485,822	54,654	-	-
Fever Cases Tested with RDTs	39,382	58,899	54,654	-	48,557		13%	697,782	2,485,822	54,654	-	-
HIV Testing Services	4,592	4,212	8,721	-	8,035		9%	48,784	403,515	8,721	-	10

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**  
**Monthly Distribution by Country**  
**Period: 2**  
**Year: 2019**

	DISTRIBUTION 2/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
VCT Individual (HIV-Negative)	4,345	4,002	8,273	-	7,461	12/09	11%	45,712	375,230	8,273	-	10
VCT Individual (HIV-Positive)	247	210	448	-	574	12/09	(22)%	3,072	28,285	448	-	1
Hypertension Diagnosis	731	517	1,417	-	12,854		(89)%	57,768	75,226	1,417	-	-
Hypertension Diagnosis	731	517	1,417	-	12,854		(89)%	57,768	75,226	1,417	-	-
Hypertension Screening	8,361	7,841	16,839	-	29,511		(43)%	176,640	227,993	16,839	-	-
Hypertension Screening	8,361	7,841	16,839	-	29,511		(43)%	176,640	227,993	16,839	-	-
Hypertension_Controlled Condition	480	332	883	-	9,196		(90)%	43,499	56,692	353	-	-
Hypertension_Controlled Condition	480	332	883	-	9,196		(90)%	43,499	56,692	353	-	-
Implant 3	177	113	(98)	-	(112)		0%	1,527	11,585	(88)	(221)	(37)
Implanon NXT	589	543	698	-	583	12/15	20%	6,278	20,613	628	1,571	267
(b)PSI Implant 3 Distributed Inserted	(412)	(430)	(796)	-	(695)		-%	(4,751)	(9,028)	(716)	(1,791)	(305)
Implant 3 Insertion	412	430	796	-	695		15%	4,751	9,028	796	1,990	338
PSI Implant 3 Inserted	412	430	796	-	695		15%	4,751	9,028	796	1,990	338
Implant 5	5	-	5	-	-		0%	-	112	5	17	3
Jadelle	5	-	5	-	-	5/16	-%	-	112	5	17	3
Injectable 3-IM	43,859	28,685	44,006	-	34,321		28%	376,475	9,779,373	9,901	9,901	1,238
OK-3 Injection	43,859	28,685	44,006	-	34,321	9/01	28%	376,475	9,779,373	9,901	9,901	1,238
Injectable 3-SC	3,134	67	3,334	-	-		0%	-	3,334	750	750	94
Sayana Press	3,134	67	3,334	-	-		-%	-	3,334	750	750	94
IUD 10	303	204	358	-	-		0%	847	4,445	322	1,482	237
OK IUD (Copper T Cu 380A)	303	204	358	-	-	10/14	-%	847	4,445	322	1,482	237
IUD 5	(110)	(107)	(221)	-	(132)		0%	(296)	140,413	(199)	(656)	(112)
OK IUD	-	-	-	-	175	5/03	(100)%	1,206	198,833	-	-	-
(b)PSI IUD 5 Distributed Inserted	(110)	(107)	(221)	-	(307)		-%	(1,502)	(58,420)	(199)	(656)	(112)
IUD 5 Insertion	110	107	221	-	307		(28)%	1,502	58,420	221	729	124

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

Period: 2

Year: 2019

	DISTRIBUTION 2/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
PSI IUD 5 Inserted	110	107	221	-	307		(28)%	1,502	58,420	221	729	124
Lubricant	7,210	7,837	15,975	-	6,060		164%	51,861	5,248,661	-	-	-
Aphaw Gel - Sachet	-	-	-	-	-	10/06	-%	250	4,428,308	-	-	-
Aphaw Gel - Tube 20 cc	-	7,837	8,765	-	6,060	10/06	45%	51,611	690,445	-	-	-
Aphaw Gel - Tube 20 cc - Flavors	7,210	-	7,210	-	-	10/14	-%	-	129,908	-	-	-
Malaria PPT (ACT)	34,689	852	34,896	-	110,766		(68)%	256,333	3,223,792	31,406	-	4,896
AL 1	382	39	402	-	1,106	7/12	(64)%	3,413	17,404	362	-	56
AL 2	384	43	389	-	1,068	7/12	(64)%	3,390	18,142	350	-	55
AL 3	365	72	433	-	1,123	1/11	(61)%	3,470	52,827	390	-	61
AL 4	571	1,103	773	-	1,850	1/11	(58)%	13,664	277,195	696	-	108
Arte+1	3	-	3	-	-	8/14	-%	-	22,282	3	-	-
Arte+2	3	-	3	-	-	8/14	-%	-	23,181	3	-	-
Arte+3	3	-	3	-	-	8/14	-%	-	26,545	3	-	-
Arte+4	21,600	-	21,600	-	64,987	8/14	(67)%	114,680	602,968	19,440	-	3,030
(b)PSI QAACTs Distributed Provided after Diagnosis	(134)	(404)	(222)	-	(528)		-%	(4,786)	(19,861)	(200)	-	(31)
Supa Arte 1	503	-	503	-	-	9/12	-%	-	121,214	453	-	71
Supa Arte 2	503	-	503	-	-	9/12	-%	-	117,055	453	-	71
Supa Arte 3	503	-	503	-	-	9/12	-%	-	196,962	453	-	71
Supa Arte 4	10,003	-	10,003	-	41,160	9/12	(76)%	122,502	1,767,878	9,003	-	1,403
Malaria PPT (Non-ACT)	(147)	(229)	(195)	-	(145)		0%	(1,900)	104,131	(176)	-	(27)
(b)PSI Vivax Tx Distributed Provided after Diagnosis	(147)	(244)	(204)	-	(257)		-%	(3,244)	(9,410)	(184)	-	(29)
Vivax Treatment Kit	-	15	9	-	112	6/11	(92)%	1,344	113,541	8	-	1
Malaria RDK	41,025	46,067	70,035	-	63,650		10%	743,410	4,802,009	63,032	-	-
Malaria RDT (Diagnosis)	41,025	46,067	70,035	-	63,650	3/11	10%	743,410	4,802,009	63,032	-	-

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

**Period: 2**

**Year: 2019**

	DISTRIBUTION 2/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
Micronutrient Powder	-	528,193	-	-	-		0%	2,000,000	9,499,690	-	-	-
Happy Kid (Micronutrient powder)	-	528,193	-	-	-	9/16	-%	2,000,000	9,499,690	-	-	-
Multivitamin	-	-	-	-	67,730		(100)%	450,010	883,520	-	-	-
May May Vita Plus	-	-	-	-	67,730	6/17	(100)%	450,010	883,520	-	-	-
OCs	640,462	456,227	804,653	-	454,561		77%	5,856,883	27,958,235	48,279	48,279	6,369
OK Pills	638,955	455,073	802,260	-	451,542	9/01	78%	5,831,882	27,919,220	48,136	48,136	6,350
OK Pills (Zinnia F)	1,507	1,155	2,393	-	3,019	11/16	(21)%	25,001	39,015	144	144	19
ORS	23,125	39,403	41,145	-	59,889		(31)%	514,198	1,271,999	18,515	-	1,079
ORS	23,125	39,403	41,145	-	59,889	1/08	(31)%	514,198	1,271,999	18,515	-	1,079
Positive RDTs	335	746	525	-	859		(39)%	9,712	35,996	525	-	-
Positive RDTs	335	746	525	-	859		(39)%	9,712	35,996	525	-	-
Positive RDTs Given First Line Treatment	328	711	500	-	818		(39)%	8,937	31,503	500	-	-
Positive RDTs Given First Line Treatment	328	711	500	-	818		(39)%	8,937	31,503	500	-	-
PUR	-	-	-	-	13,773		(100)%	633,309	15,857,790	-	-	-
Purifier of Water	-	-	-	-	13,773	4/14	(100)%	633,309	15,857,790	-	-	-
QAACs Provided after Confirmatory Diagnosis	134	404	222	-	528		(58)%	4,786	19,861	222	-	41
PSI QAACs Provided after Confirmed Diagnosis	134	404	222	-	528		(58)%	4,786	19,861	222	-	41
Referral to TB DOTS (completion confirmed)	72	130	130	-	-		0%	1,214	1,637	130	-	403
Referral to TB DOTS (completion confirmed)	72	130	130	-	-		-%	1,214	1,637	130	-	403
Referral to TB DOTS (completion unknown)	66	206	133	-	-		0%	1,575	1,708	133	-	371
Referral to TB DOTS (completion unknown)	66	206	133	-	-		-%	1,575	1,708	133	-	371
STI Screening	2,157	1,985	3,926	-	4,722		(17)%	27,221	64,435	3,926	-	-
STI Screening	2,157	1,985	3,926	-	4,722		(17)%	27,221	64,435	3,926	-	-
TB Diagnosis	824	1,098	1,165	-	1,287		(9)%	14,259	60,098	1,165	-	-
TB Diagnosis	824	1,098	1,165	-	1,287		(9)%	14,259	60,098	1,165	-	-

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

Period: 2

Year: 2019

	DISTRIBUTION 2/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
TB DOTS	931	1,005	1,887	-	1,763		7%	12,891	219,338	1,887	-	11,705
TB DOTS	931	1,005	1,887	-	1,763	12/04	7%	12,891	219,338	1,887	-	11,705
TB Screening	6,186	7,652	8,250	-	7,650		8%	97,611	300,079	8,250	-	-
TB Screening	6,186	7,652	8,250	-	7,650		8%	97,611	300,079	8,250	-	-
Vivax Treatment after Confirmatory Diagnosis	147	244	204	-	257		(21)%	3,244	9,410	204	-	37
PSI Vivax Treatment after Confirmed Diagnosis	147	244	204	-	257		(21)%	3,244	9,410	204	-	37
<b>Nigeria</b>											<b>6,120</b>	<b>6,776</b>
Emergency Contraception Provided	-	14	5	-	24		(79)%	60	65	-	-	-
Non-PSI Emergency Contraception Provided	-	14	5	-	24		(79)%	60	65	-	-	-
HIV Testing Services	-	-	-	-	572,004		(100)%	609,489	2,485,606	-	-	-
VCT Individual (HIV-Negative)	-	-	-	-	568,035	12/09	(100)%	604,543	2,342,815	-	-	-
VCT Individual (HIV-Positive)	-	-	-	-	3,969	12/09	(100)%	4,946	142,791	-	-	-
Implant 3 Insertion	-	1,484	692	-	-		0%	4,133	4,825	692	1,730	1,986
Non-PSI Implant 3 Inserted	-	1,484	692	-	-		-%	4,133	4,825	692	1,730	1,986
Implant 4 Insertion	-	-	-	-	288		(100)%	288	288	-	-	-
Non-PSI Implant 4 Inserted	-	-	-	-	288		(100)%	288	288	-	-	-
Implant 5 Insertion	-	725	695	-	-		0%	2,833	94,397	695	2,641	2,985
Non-PSI Implant 5 Inserted	-	725	695	-	-	3/16	-%	2,833	94,397	695	2,641	2,985
Injectable 1 Provided	-	14	5	-	-		0%	37	42	-	-	-
Non-PSI Injectable 1 Provided	-	14	5	-	-		-%	37	42	-	-	-
Injectable 2 Provided	-	2,250	876	-	-		0%	5,875	6,751	146	146	123
Non-PSI Injectable 2 Provided	-	2,250	876	-	-		-%	5,875	6,751	146	146	123
Injectable 3-IM Provided	-	2,142	734	-	426		72%	6,118	6,852	184	184	155
Non-PSI Injectable 3 IM Provided	-	2,142	734	-	426		72%	6,118	6,852	184	184	155
Injectable 3-SC Provided	-	296	887	-	-		0%	-	887	222	222	187

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**  
**Monthly Distribution by Country**  
**Period: 2**  
**Year: 2019**

	DISTRIBUTION 2/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
Non-PSI Injectable 3 SC Provided	-	296	887	-	-		-%	-	887	222	222	187
IUD 10 Insertion	-	28	85	-	-		0%	-	275,137	85	391	423
Non-PSI IUD 10 Inserted	-	28	85	-	-	3/16	-%	-	275,137	85	391	423
IUD 5 Insertion	-	144	-	-	3		(100)%	479	479	-	-	-
Non-PSI IUD 5 Inserted	-	144	-	-	3		(100)%	479	479	-	-	-
IUS 5 Insertion	130	92	232	-	-		0%	716	1,574	232	766	880
Non-PSI IUS 5 Inserted	130	92	232	-	-		-%	716	1,574	232	766	880
OCs Provided	-	1,984	614	-	248		148%	5,586	6,200	41	41	36
Non-PSI OCs Provided	-	1,984	614	-	248		148%	5,586	6,200	41	41	36
SDM (Cycle Beads) Provided	-	1	-	-	-		0%	3	3	-	-	-
Non-PSI SDM (Cycle Beads) Provided	-	1	-	-	-		-%	3	3	-	-	-
<b>PSI Nigeria</b>											<b>70,939</b>	<b>90,107</b>
Implant 5 Insertion	2,598	2,532	5,166	-	3,965		30%	29,200	34,366	5,166	19,631	22,184
Non-PSI Implant 5 Inserted	2,598	2,532	5,166	-	3,965		30%	29,200	34,366	5,166	19,631	22,184
Injectable 3-IM Provided	27	-	27	-	-		0%	2,423	2,450	7	7	6
Non-PSI Injectable 3 IM Provided	27	-	27	-	-		-%	2,423	2,450	7	7	6
IUD 10 Insertion	5,586	5,673	11,139	-	11,401		(2)%	72,696	83,835	11,139	51,239	55,459
Non-PSI IUD 10 Inserted	5,586	5,673	11,139	-	11,401		(2)%	72,696	83,835	11,139	51,239	55,459
IUD 5 Insertion	-	-	-	-	-		0%	58	58	-	-	-
Non-PSI IUD 5 Inserted	-	-	-	-	-		-%	58	58	-	-	-
IUS 5 Insertion	-	-	-	-	59		(100)%	59	59	-	-	-
Non-PSI IUS 5 Inserted	-	-	-	-	59		(100)%	59	59	-	-	-
Manual Vacuum Aspiration for PAC	1,576	443	1,576	-	-		0%	19,176	20,752	1,576	-	1,262
MVA for PAC	1,576	443	1,576	-	-		-%	19,176	20,752	1,576	-	1,262
Misoprostol for PAC Provided	1,578	418	1,578	-	-		0%	14,855	16,433	1,578	-	1,496

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

**Period: 2**

**Year: 2019**

	DISTRIBUTION 2/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
PSI Misoprostol for PAC Provided	1,578	418	1,578	-	-		-%	14,855	16,433	1,578	-	1,496
Misoprostol for Safe Abortion	196,428	195,213	218,558	-	-		0%	2,321,200	2,539,758	11,474	-	9,635
Mistol	202,740	196,883	224,870	-	-	3/18	-%	2,380,620	2,605,490	11,806	-	9,913
(b)PSI Misoprostol for Safe Abortion Dist Provided	(6,312)	(1,671)	(6,312)	-	-		-%	(59,420)	(65,732)	(331)	-	(278)
OCs Provided	475	-	475	-	-		0%	1,376	1,851	32	32	28
Non-PSI OCs Provided	475	-	475	-	-		-%	1,376	1,851	32	32	28
SDM (Cycle Beads) Provided	20	-	20	-	-		0%	-	20	20	30	36
Non-PSI SDM (Cycle Beads) Provided	20	-	20	-	-		-%	-	20	20	30	36
<b>South Africa</b>												<b>54,886</b>
Free Condom	-	5,302,000	-	-	6,685,200		(100)%	39,319,200	1,084,659,760	-	-	-
(b)Public Distribution	-	5,302,000	-	-	6,685,200	1/04	(100)%	39,319,200	1,084,659,760	-	-	-
Free Female Condom	-	260,300	-	-	57,600		(100)%	1,108,500	5,030,600	-	-	-
Female Condom GOSA	-	260,300	-	-	57,600	10/13	(100)%	1,108,500	5,030,600	-	-	-
HIV Self-Testing Kit	-	433,566	12,448	-	-		0%	1,288,251	1,300,699	11,203	-	-
ORAQUICK HIV Self-Testing Kit (Pouch)	-	433,566	12,448	-	-		-%	1,288,251	1,300,699	11,203	-	-
HIV Testing Services	4,054	2,707	7,361	-	73,604		(90)%	219,862	1,997,362	7,361	-	522
VCT Individual (HIV-Negative)	3,364	2,431	6,301	-	69,664	12/09	(91)%	206,993	1,836,481	6,301	-	447
VCT Individual (HIV-Positive)	690	276	1,060	-	3,940	12/09	(73)%	12,869	160,881	1,060	-	75
Voluntary Medical Male Circumcision	6,256	2,930	7,718	-	6,478		19%	78,885	159,945	7,718	-	54,364
Voluntary Medical Male Circumcision	6,256	2,930	7,718	-	6,478		19%	78,885	159,945	7,718	-	54,364

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

# Anglophone Africa Market Group



**POPULATION SERVICES INTERNATIONAL**  
**CYPs, Cases, and Deaths by Country**  
**1/2019 - 2/2019**

	New HIV Infections	STI Deaths	PWID Deaths	TB Deaths	CYP*	Maternal Deaths	Unintended Pregnancies	Malaria Deaths	Diarrhea Deaths	Pneumonia Deaths	Cervical Cancer Death	Sum of All Deaths
Anglophone Africa Market Group	14,942	9	-	1	495,685	495	200,999	13	19	-	1	4,728
Ethiopia	635	7	-	-	25,489	11	7,178	-	11	-	-	173
Ghana	-	-	-	-	16,858	13	6,215	-	-	-	-	86
Lesotho	159	-	-	1	2,145	2	698	-	-	-	-	12
Malawi	1,960	-	-	-	86,415	143	32,304	5	1	-	-	778
PSI Uganda	88	-	-	-	185,913	187	85,846	-	1	-	-	2,221
Rwanda	1,124	-	-	-	30,951	14	9,049	-	1	-	-	202
Swaziland	2,676	1	-	-	19,024	12	5,355	-	-	-	-	93
Tanzania	1	-	-	-	63,538	61	29,354	8	1	-	-	650
Uganda	105	-	-	-	76	-	21	-	-	-	-	1
Zambia	1,423	-	-	-	31,113	17	13,447	-	5	-	-	345
Zimbabwe	6,770	1	-	-	34,163	36	11,530	-	-	-	1	168

\* Using USAID CYP conversion factors

POPULATION SERVICES INTERNATIONAL  
Monthly Distribution by Market Group and Product  
Period: 2  
Year: 2019

	DISTRIBUTION 2/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE SALES	YTD USERS REACHED <sup>(a)</sup> 2019	YTD CYP 2019	YTD DALY 2019
<b>Anglophone Africa Market Group</b>										<b>495,685</b>	<b>979,759</b>
Antiretroviral Treatment (Currently Enrolled)	12,727	13,240	25,661	-	18,012	42%	148,026	292,920	2,138	-	4,542
Antiretroviral Treatment (Newly Enrolled)	436	396	824	-	944	(13)%	6,634	23,689	824	-	-
Basic Care Package	-	-	-	-	-	-%	1	1	-	-	-
CD4 Tests Provided to HIV+ Clients	-	-	-	-	544	(100)%	544	9,414	-	-	-
Cervical Cancer-HPV DNA and Cryotherapy	-	-	-	-	3	(100)%	3	3	-	-	-
Cervical Cancer-VIA and Conization	19	17	30	-	8	275%	126	334	30	-	11
Cervical Cancer-VIA and Cryotherapy	39	38	74	-	121	(39)%	639	6,554	74	-	26
Cervical Cancer-VIA and Refer to any Treatment	8	1	9	-	4	125%	25	320	9	-	2
Cervical Cancer-VIA and Refer to Conization	4	8	6	-	-	-%	98	2,040	6	-	1
Cervical Cancer-VIA and Refer to Cryotherapy	-	-	-	-	-	-%	10	459	-	-	-
Cervical Cancer-VIA/VILI Screening	4,145	3,510	6,798	-	15,973	(57)%	95,922	347,883	6,798	-	-
Chlorhexidine	443	1,060	773	-	431	79%	23,622	37,438	696	-	54
Clean Delivery Kit	-	-	-	-	1,277	(100)%	3,449	181,765	-	-	-
Condom	3,554,416	5,929,273	8,805,352	-	9,033,061	(3)%	65,266,786	1,324,118,681	66,040	66,040	173,830
Emergency Contraception	2,873	13,120	8,305	-	9,400	(12)%	180,947	1,071,475	374	374	121
Emergency Contraception Provided	338	302	656	-	678	(3)%	6,887	8,708	33	33	16
Expanded Clean Delivery Kit	-	-	-	-	-	-%	13,160	13,160	-	-	-
Expanded Clean Delivery Kit (+CHX)	193	925	464	-	694	(33)%	14,531	15,612	418	-	68
Female Condom	14,396	20,225	44,376	-	91,001	(51)%	469,229	28,428,702	333	333	1,280
Free Condom	6,688,529	4,690,665	8,599,417	-	13,163,026	(35)%	77,319,731	392,163,951	64,496	64,496	202,478
Free Female Condom	10,160	35,974	16,160	-	27,234	(41)%	623,007	4,387,920	121	121	380

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

**POPULATION SERVICES INTERNATIONAL**  
**Monthly Distribution by Market Group and Product**  
**Period: 2**  
**Year: 2019**

	DISTRIBUTION 2/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE SALES	YTD USERS REACHED <sup>(a)</sup> 2019	YTD CYP 2019	YTD DALY 2019
HIV Self-Testing Kit	19,922	177,514	85,094	-	67,428	26%	996,954	1,451,595	76,585	-	-
HIV Testing Services	24,706	25,255	49,969	-	66,313	(25)%	541,424	5,743,262	49,969	-	4,109
Hypertension Diagnosis	25	21	56	-	61	(8)%	278	614	56	-	-
Hypertension Screening	14,333	13,191	26,093	-	24,280	7%	147,793	524,546	26,093	-	-
Hypertension_Controlled Condition	7	4	12	-	21	(43)%	91	169	5	-	-
Implant 3	6,222	2,787	6,865	-	(1,323)	-%	12,798	160,391	6,179	15,446	15,997
Implant 3 Insertion	20,598	13,287	35,396	-	31,726	12%	240,316	745,595	35,396	88,490	83,555
Implant 4	(1)	(798)	(28)	-	-	-%	(3,883)	(3,911)	(25)	(81)	(72)
Implant 4 Insertion	1	1,714	28	-	-	-%	33,884	34,028	28	90	80
Implant 5	3,933	9,754	3,910	-	752	420%	22,810	207,929	3,519	13,372	15,666
Implant 5 Insertion	12,754	11,756	27,794	-	20,258	37%	154,215	622,054	27,794	105,617	96,077
Injectable 1 Provided	3	7	10	-	78	(87)%	537	1,769	1	1	-
Injectable 2 Provided	1,546	1,883	3,587	-	3,598	-%	22,699	37,930	598	598	443
Injectable 3-IM	28,561	53,318	46,281	-	66,961	(31)%	1,798,175	8,223,390	10,413	10,413	6,993
Injectable 3-IM Provided	34,112	36,487	68,615	-	46,505	48%	342,639	760,838	17,154	17,154	11,364
Injectable 3-SC	6,180	8,249	12,630	-	-	-%	224,675	237,305	2,842	2,842	2,115
IUD 10	1,743	10,089	(115)	-	(3,890)	-%	85,439	322,473	(104)	(476)	1,390
IUD 10 Insertion	9,072	7,168	16,649	-	28,965	(43)%	220,262	1,138,090	16,649	76,585	66,596
IUD 5	(15)	(7)	(25)	-	-	-%	(134)	(159)	(23)	(74)	(75)
IUD 5 Insertion	26	42	80	-	88	(9)%	345	28,645	80	264	182
IUS 5	(18)	(7)	(28)	-	(11)	-%	926	1,852	(25)	(83)	(45)

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

**POPULATION SERVICES INTERNATIONAL**  
**Monthly Distribution by Market Group and Product**  
**Period: 2**  
**Year: 2019**

	DISTRIBUTION 2/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE SALES	YTD USERS REACHED <sup>(a)</sup> 2019	YTD CYP 2019	YTD DALY 2019
IUS 5 Insertion	99	64	167	-	134	25%	739	1,272	167	551	472
LLIN	14,333	236,476	16,912	-	416,205	(96)%	4,545,198	12,400,826	27,397	-	917
Lubricant	289,745	173,690	436,586	-	292,976	49%	2,574,286	6,144,881	-	-	-
Manual Vacuum Aspiration for PAC	492	565	1,104	-	100	1,004%	7,531	11,625	1,104	-	181
Manual Vacuum Aspiration for SA	76	39	143	-	26	450%	411	1,752	143	-	52
Medical Abortion	548	318	854	-	-	-%	16,535	17,389	769	-	269
Medical Abortion (Misoprostol) Provided	109	75	225	-	34	562%	531	756	225	-	70
Medical Abortion Provided	75	44	140	-	175	(20)%	747	1,508	140	-	49
Misoprostol for PAC Provided	281	308	701	-	135	419%	3,631	5,537	701	-	155
Misoprostol for Safe Abortion	81,748	131,372	113,556	-	202,720	(44)%	1,659,272	6,727,628	5,962	-	1,557
OCs	126,585	203,370	317,797	-	375,888	(15)%	2,600,349	16,524,315	19,068	19,068	8,767
OCs Provided	35,602	35,915	64,927	-	41,344	57%	321,499	1,409,161	4,328	4,328	2,500
PrEP	3,521	3,479	7,097	-	3,443	106%	34,437	44,650	591	-	235
PUR	3,065,000	1,034,230	3,865,000	-	2,063,365	87%	33,931,875	201,952,547	31,767	-	105
Referral to Advanced Cervical Cancer Treatment	3	4	10	-	4	150%	17	427	10	-	-
Referral to Diabetes Management (gestational)	-	14	-	-	26	(100)%	67	67	-	-	-
Referral to Emergency Contraception	-	-	-	-	-	-%	1	134	-	-	-
Referral to HIV Testing Services	2,611	8,933	5,352	-	4	133,700%	24,714	111,357	5,352	-	166
Referral to Hypertension Management	37	38	43	-	37	16%	567	1,173	43	-	-
Referral to Implant 3 Insertion	-	-	-	-	2	(100)%	2	11	-	-	-
Referral to Implant 5 Insertion	-	-	-	-	2	(100)%	2	992	-	-	-

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

POPULATION SERVICES INTERNATIONAL  
 Monthly Distribution by Market Group and Product  
 Period: 2  
 Year: 2019

	DISTRIBUTION 2/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE SALES	YTD USERS REACHED <sup>(a)</sup> 2019	YTD CYP 2019	YTD DALY 2019
Referral to Injectable 1	-	-	-	-	12	(100)%	36	384	-	-	-
Referral to Injectable 3	-	-	-	-	63	(100)%	75	1,416	-	-	-
Referral to IUD 10 Insertion	-	-	-	-	4	(100)%	5	209	-	-	-
Referral to Linkage to HIV Care	4,186	5,335	8,934	-	3,636	146%	24,186	55,578	8,934	-	6,885
Referral to OCs	-	-	-	-	57	(100)%	93	1,415	-	-	-
Referral to Pre-Exposure Prophylaxis (PrEP)	-	-	-	-	-	-%	20	250	-	-	-
Referral to STI Screening (syndromic)	-	-	-	-	7	(100)%	7	14,416	-	-	-
Referral to STI Treatment (unknown)	-	-	-	-	16	(100)%	119	2,584	-	-	-
Referral to TB Diagnosis	-	-	-	-	11	(100)%	11	255	-	-	-
Referral to TB DOTS (completion confirmed)	-	-	-	-	-	-%	2	19	-	-	-
Referral to TB DOTS (completion unknown)	-	-	-	-	43	(100)%	74	2,704	-	-	-
Referral to TB Screening	-	-	-	-	308	(100)%	308	29,857	-	-	-
Referral to Treatment for Cervicitis	-	-	-	-	29	(100)%	47	116	-	-	-
Referral to Treatment for Genital Herpes	-	-	-	-	-	-%	3	6	-	-	-
Referral to Treatment for Inguinal Bubo	-	-	-	-	-	-%	2	2	-	-	-
Referral to Treatment for Lower Abdominal Pain	-	-	-	-	-	-%	1	28	-	-	-
Referral to Treatment for Urethral Discharge (Mer	-	-	-	-	1	(100)%	53	113	-	-	-
Referral to Tubal Ligation	-	-	-	-	-	-%	2	3	-	-	-
Referral to Tx for Nonherpetic Genital Ulcer	1	-	1	-	3	(67)%	25	73	1	-	-
Referral to Tx for Urethral Discharge (Women)	2	1	4	-	18	(78)%	48	551	4	-	-
Referral to Voluntary Medical Male Circumcision	-	-	-	-	79	(100)%	139	15,552	-	-	-

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

**POPULATION SERVICES INTERNATIONAL**  
**Monthly Distribution by Market Group and Product**  
**Period: 2**  
**Year: 2019**

	DISTRIBUTION 2/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE SALES	YTD USERS REACHED <sup>(a)</sup> 2019	YTD CYP 2019	YTD DALY 2019
Safe Water Solution	101,092	154,755	287,578	-	642,966	(55)%	2,248,493	71,044,128	198,922	-	701
STI Kit (Non-Ulcerative)	2,067	633	2,067	-	-	-%	6,655	833,598	1,860	-	135
STI Kit (Ulcerative)	1,115	-	1,115	-	-	-%	-	73,343	1,004	-	214
STI Screening	13,024	6,799	26,777	-	14,285	87%	75,388	589,693	26,777	-	-
TB Diagnosis	21	15	35	-	56	(38)%	283	1,512	35	-	-
TB DOTS	3	2	4	-	12	(67)%	35	105	4	-	33
TB Screening	23,023	16,817	40,423	-	39,595	2%	225,880	1,491,448	40,423	-	-
Toilets Sold	917	939	1,468	-	-	-%	5,651	7,118	6,688	-	258
Treatment for Cervicitis	4	11	16	-	5	220%	73	379	16	-	1
Treatment for Genital Herpes	5	1	6	-	7	(14)%	28	86	6	-	-
Treatment for Inguinal Bubo	-	-	-	-	-	-%	3	17	-	-	-
Treatment for Lower Abdominal Pain	8	5	22	-	16	38%	78	235	22	-	-
Treatment for Nonherpetic Genital Ulcer	50	37	95	-	73	30%	546	1,241	95	-	33
Treatment for Urethral Discharge (Men)	47	19	77	-	39	97%	292	979	154	-	9
Treatment for Urethral Discharge (Women)	53	42	90	-	96	(6)%	507	1,613	90	-	17
Treatment for Vaginitis	73	23	131	-	102	28%	506	2,343	131	-	22
Tubal Ligation	655	735	1,018	-	1,807	(44)%	16,391	36,832	1,018	10,180	8,013
Type 2 Diabetes Diagnosis	-	-	-	-	-	-%	3	8	-	-	-
Type 2 Diabetes Screening	370	426	525	-	1,379	(62)%	6,711	17,115	525	-	-
Type 2 Diabetes_Controlled Condition	-	-	-	-	1	(100)%	6	12	-	-	-
Voluntary Medical Male Circumcision	21,395	18,358	37,323	-	47,035	(21)%	345,985	751,345	37,323	-	260,691

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

**POPULATION SERVICES INTERNATIONAL**  
**Monthly Distribution by Market Group and Product**  
**Period: 2**  
**Year: 2019**

	DISTRIBUTION 2/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE SALES	YTD USERS REACHED <sup>(a)</sup> 2019	YTD CYP 2019	YTD DALY 2019
<b>Water Treatment Tablets</b>	<b>507,100</b>	<b>513,967</b>	<b>919,400</b>	-	<b>1,876,042</b>	<b>(51)%</b>	<b>6,957,142</b>	<b>53,509,902</b>	<b>15,113</b>	-	<b>59</b>
<b>Woman Condom</b>	<b>480</b>	<b>4,048</b>	<b>480</b>	-	<b>8,496</b>	<b>(94)%</b>	<b>97,728</b>	<b>140,040</b>	<b>4</b>	<b>4</b>	<b>10</b>

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

Period: 2

Year: 2019

	DISTRIBUTION 2/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
<b>Anglophone Africa Market Group</b>											<b>495,685</b>	<b>979,759</b>
<b>Ethiopia</b>											<b>25,489</b>	<b>38,503</b>
Antiretroviral Treatment (Currently Enrolled)	1,113	1,129	2,227	-	1,004		122%	16,938	29,477	186	-	356
Antiretroviral Treatment (Currently Enrolled)	1,113	1,129	2,227	-	1,004		122%	16,938	29,477	186	-	356
Antiretroviral Treatment (Newly Enrolled)	34	26	53	-	32		66%	1,115	2,623	53	-	-
Antiretroviral Treatment (Newly Enrolled)	34	26	53	-	32		66%	1,115	2,623	53	-	-
Free Condom	3,398,500	1,103,000	3,398,500	-	8,028,000		(58)%	23,871,707	167,961,945	25,489	25,489	37,147
No Logo Condom	2,298,000	833,333	2,298,000	-	-	8/09	-%	5,869,000	12,283,000	17,235	17,235	25,118
Protector Plus	1,100,500	269,667	1,100,500	-	8,028,000	12/12	(86)%	18,002,707	155,678,945	8,254	8,254	12,029
Free Female Condom	-	8,000	-	-	-		0%	138,000	899,089	-	-	-
Free Female Condoms	-	8,000	-	-	-	10/13	-%	138,000	899,089	-	-	-
HIV Self-Testing Kit	-	1,339	-	-	-		0%	14,958	14,958	-	-	-
ORAQUICK HIV Self-Testing Kit (Pouch)	-	1,339	-	-	-		-%	14,958	14,958	-	-	-
HIV Testing Services	4,331	3,265	6,759	-	2,544		166%	219,864	1,195,973	6,759	-	36
VCT Individual (HIV-Negative)	4,210	3,173	6,582	-	2,452	3/13	168%	213,839	1,167,668	6,582	-	35
VCT Individual (HIV-Positive)	121	92	177	-	92	3/13	92%	6,025	28,305	177	-	1
Lubricant	-	8,100	-	-	-		0%	62,647	62,647	-	-	-
Lubricant gel 4.5 g	-	8,100	-	-	-		-%	62,647	62,647	-	-	-
PUR	-	682,006	-	-	564,947		(100)%	20,446,684	84,712,405	-	-	-
P&G Purifier of Water	-	682,006	-	-	564,947	11/15	(100)%	20,446,684	84,712,405	-	-	-
Referral to Emergency Contraception	-	-	-	-	-		0%	1	134	-	-	-
Referral to Emergency Contraception	-	-	-	-	-	2/15	-%	1	134	-	-	-
Referral to HIV Testing Services	-	-	-	-	4		(100)%	9	56,137	-	-	-
Referral to HIV Testing Services	-	-	-	-	4		(100)%	9	56,137	-	-	-
Referral to Linkage to HIV Care	-	-	-	-	23		(100)%	33	2,833	-	-	-

(a) The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.



**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

**Period: 2**

**Year: 2019**

	DISTRIBUTION 2/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
Referral to Linkage to HIV Care	-	-	-	-	23		(100)%	33	2,833	-	-	-
Referral to STI Screening (syndromic)	-	-	-	-	4		(100)%	4	14,311	-	-	-
Referrals to STI Screening (syndromic)	-	-	-	-	4		(100)%	4	14,311	-	-	-
Referral to TB Screening	-	-	-	-	4		(100)%	4	13,488	-	-	-
Referrals to TB Screening	-	-	-	-	4		(100)%	4	13,488	-	-	-
Safe Water Solution	10,000	62,710	122,314	-	92,554		32%	791,708	24,696,205	100,532	-	361
Wuha Agar	10,000	62,710	122,314	-	92,554	2/06	32%	791,708	24,696,205	100,532	-	361
STI Kit (Non-Ulcerative)	2,067	633	2,067	-	-		0%	6,655	833,598	1,860	-	135
STI kit for Urethral Discharge	1,015	200	1,015	-	-	11/10	-%	2,397	451,114	914	-	56
STI Kit for Vaginal Discharge	1,052	433	1,052	-	-	11/10	-%	4,258	382,484	947	-	79
STI Kit (Ulcerative)	1,115	-	1,115	-	-		0%	-	73,343	1,004	-	214
STI Kit for Genital Ulcer	1,115	-	1,115	-	-	11/10	-%	-	73,343	1,004	-	214
STI Screening	3,985	807	6,405	-	2,918		119%	33,336	446,455	6,405	-	-
STI Screening	3,985	807	6,405	-	2,918		119%	33,336	446,455	6,405	-	-
TB Screening	4,318	807	6,738	-	2,990		125%	31,664	425,480	6,738	-	-
TB Screening	4,318	807	6,738	-	2,990		125%	31,664	425,480	6,738	-	-
Toilets Sold	861	914	1,405	-	-		0%	5,471	6,876	6,463	-	252
Toilets Sold	861	914	1,405	-	-		-%	5,471	6,876	6,463	-	252
Treatment for Lower Abdominal Pain	-	-	-	-	1		(100)%	4	67	-	-	-
Treatment for Lower Abdominal Pain	-	-	-	-	1		(100)%	4	67	-	-	-
Treatment for Nonherpetic Genital Ulcer	1	2	7	-	3		133%	16	78	7	-	1
Treatment for Nonherpetic Genital Ulcer	1	2	7	-	3		133%	16	78	7	-	1
Treatment for Urethral Discharge (Men)	7	1	9	-	3		200%	5	154	18	-	-
Treatment for Urethral Discharge (Men)	7	1	9	-	3		200%	5	154	18	-	-
Treatment for Urethral Discharge (Women)	-	-	-	-	11		(100)%	12	76	-	-	-

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**  
**Monthly Distribution by Country**  
**Period: 2**  
**Year: 2019**

	DISTRIBUTION 2/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
Treatment for Urethral Discharge (Women)	-	-	-	-	11		(100)%	12	76	-	-	-
Treatment for Vaginitis	39	5	53	-	47		13%	116	1,288	53	-	1
Treatment for Vaginitis	39	5	53	-	47		13%	116	1,288	53	-	1
<b>Ghana</b>											<b>16,858</b>	<b>6,966</b>
Condom	-	-	-	-	-		0%	14,700	799,268	-	-	-
Protector	-	-	-	-	-		-%	14,700	799,268	-	-	-
Injectable 3-IM	-	35,492	2,125	-	54,757		(96)%	1,376,081	3,142,768	478	478	187
Famplan	-	35,492	2,125	-	54,757		(96)%	1,376,481	3,143,168	478	478	187
(b)PSI Injectable 3 IM Distributed Provided	-	-	-	-	-		-%	(400)	(400)	-	-	-
Injectable 3-IM Provided	-	-	-	-	-		0%	400	400	-	-	-
PSI Injectable 3 IM Provided	-	-	-	-	-		-%	400	400	-	-	-
OCs	91,920	168,580	273,000	-	107,400		154%	1,969,134	4,665,359	16,380	16,380	6,769
(b)PSI OCs Distributed Provided	-	-	-	-	-		-%	(66)	(66)	-	-	-
Secure	91,920	168,580	273,000	-	107,400		154%	1,969,200	4,665,425	16,380	16,380	6,769
OCs Provided	-	-	-	-	-		0%	66	66	-	-	-
PSI OCs Provided	-	-	-	-	-		-%	66	66	-	-	-
Toilets Sold	56	25	63	-	-		0%	180	242	225	-	6
Toilets Sold	56	25	63	-	-		-%	180	242	225	-	6
Water Treatment Tablets	91,600	43,467	100,400	-	111,500		(10)%	844,900	1,038,700	1,650	-	4
Aquatabs 67 mg (20 L)	91,600	43,467	100,400	-	111,500	7/17	(10)%	844,900	1,038,700	1,650	-	4
<b>Lesotho</b>											<b>2,145</b>	<b>7,563</b>
Antiretroviral Treatment (Currently Enrolled)	1,328	1,604	2,635	-	1,681		57%	18,922	41,114	220	-	499
Antiretroviral Treatment (Currently Enrolled)	1,328	1,604	2,635	-	1,681		57%	18,922	41,114	220	-	499
Antiretroviral Treatment (Newly Enrolled)	2	6	10	-	22		(55)%	110	238	10	-	-

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

**Period: 2**

**Year: 2019**

	DISTRIBUTION 2/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
Antiretroviral Treatment (Newly Enrolled)	2	6	10	-	22		(55)%	110	238	10	-	-
Emergency Contraception Provided	-	2	2	-	3		(33)%	20	173	-	-	-
Non-PSI Emergency Contraception Provided	-	2	2	-	3		(33)%	20	173	-	-	-
Female Condom	20	47	120	-	12,121		(99)%	96,546	2,511,202	1	1	3
Generic	20	47	120	-	12,121	1/08	(99)%	96,546	2,511,202	1	1	3
Free Condom	76,870	146,000	122,570	-	915,895		(87)%	13,845,256	32,330,952	919	919	3,567
Camouflage Free	18,000	92,033	24,000	-	171,686	1/16	(86)%	747,700	2,982,100	180	180	698
Vibe Condom	58,870	53,967	98,570	-	744,209	9/14	(87)%	13,097,556	29,348,852	739	739	2,868
HIV Self-Testing Kit	3,922	20,707	9,769	-	-		0%	56,275	66,044	8,792	-	-
ORAQUICK HIV Self-Testing Kit (Pouch)	3,922	20,707	9,769	-	-		-%	56,275	66,044	8,792	-	-
HIV Testing Services	10,292	11,126	21,671	-	33,890		(36)%	158,712	1,124,432	21,671	-	2,270
VCT Individual (HIV-Negative)	9,810	10,613	20,606	-	32,763	12/09	(37)%	153,406	1,057,788	20,606	-	2,159
VCT Individual (HIV-Positive)	482	513	1,065	-	1,127	12/09	(6)%	5,306	66,644	1,065	-	112
Hypertension Screening	74	77	141	-	1,085		(87)%	2,494	13,837	141	-	-
Hypertension Screening	74	77	141	-	1,085		(87)%	2,494	13,837	141	-	-
Implant 3 Insertion	-	2	4	-	-		0%	6	844	4	10	6
Non-PSI Implant 3 Inserted	-	2	4	-	-		-%	6	844	4	10	6
Implant 5 Insertion	-	1	1	-	8		(88)%	12	128	1	4	2
Non-PSI Implant 5 Inserted	-	1	1	-	8		(88)%	12	128	1	4	2
Injectable 2 Provided	-	1	1	-	290		(100)%	2,864	4,923	-	-	-
Non-PSI Injectable 2 Provided	-	1	1	-	290		(100)%	2,864	4,923	-	-	-
Injectable 3-IM Provided	1,677	1,284	3,106	-	1,831		70%	12,574	27,815	777	777	351
Non-PSI Injectable 3 IM Provided	1,677	1,284	3,106	-	1,831		70%	12,574	27,815	777	777	351
OCs Provided	2,871	2,769	6,513	-	2,228		192%	17,197	50,768	434	434	207
Non-PSI OCs Provided	2,871	2,769	6,513	-	2,228		192%	17,197	50,768	434	434	207

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

Period: 2

Year: 2019

	DISTRIBUTION 2/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
PrEP	36	12	69	-	-		0%	14	83	6	-	6
PrEP	36	12	69	-	-		-%	14	83	6	-	6
Referral to HIV Testing Services	-	217	-	-	-		0%	1,299	26,462	-	-	-
Referral to HIV Testing Services	-	217	-	-	-		-%	1,299	26,462	-	-	-
Referral to Linkage to HIV Care	384	143	813	-	952		(15)%	3,328	11,561	813	-	489
Referral to Linkage to HIV Care	384	143	813	-	952		(15)%	3,328	11,561	813	-	489
TB Diagnosis	5	4	9	-	5		80%	41	95	9	-	-
TB Diagnosis	5	4	9	-	5		80%	41	95	9	-	-
TB DOTS	3	2	4	-	10		(60)%	31	51	4	-	33
TB DOTS	3	2	4	-	10		(60)%	31	51	4	-	33
TB Screening	1,842	2,047	3,766	-	2,029		86%	21,329	31,794	3,766	-	-
TB Screening	1,842	2,047	3,766	-	2,029		86%	21,329	31,794	3,766	-	-
Type 2 Diabetes Screening	-	-	-	-	304		(100)%	395	3,939	-	-	-
Type 2 Diabetes Screening	-	-	-	-	304		(100)%	395	3,939	-	-	-
Voluntary Medical Male Circumcision	2	74	10	-	47		(79)%	2,962	3,641	10	-	131
Voluntary Medical Male Circumcision	2	74	10	-	47		(79)%	2,962	3,641	10	-	131
<b>Malawi</b>											<b>86,415</b>	<b>139,585</b>
Cervical Cancer-VIA/VILI Screening	1,379	731	1,379	-	-		0%	19,630	21,009	1,379	-	-
Cervical Cancer-VIA/VILI Screening	1,379	731	1,379	-	-		-%	19,630	21,009	1,379	-	-
Condom	1,038,528	958,180	2,103,004	-	2,601,520		(19)%	17,252,824	227,567,930	15,773	15,773	43,228
Chishango	1,038,528	958,180	2,103,004	-	2,601,520	10/94	(19)%	17,252,824	227,567,930	15,773	15,773	43,228
Emergency Contraception	745	561	1,066	-	1,439		(26)%	11,120	109,406	48	48	24
Levonorgestrel Tablet 0.75 mg x 2's	850	702	1,410	-	-		-%	1,545	2,955	63	63	32
NORLEVO (Norlevo 1.5mg)	-	-	-	-	2,003	2/14	(100)%	13,994	111,455	-	-	-
(b)PSI Emergency Contraception Distributed Provided	(105)	(141)	(344)	-	(564)		-%	(4,419)	(5,004)	(15)	(15)	(8)

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

**Period: 2**

**Year: 2019**

	DISTRIBUTION 2/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
Emergency Contraception Provided	105	141	344	-	564		(39)%	4,419	5,004	17	17	9
PSI Emergency Contraception Provided	105	141	344	-	564		(39)%	4,419	5,004	17	17	9
Female Condom	12,376	10,678	27,256	-	5,080		437%	86,203	819,739	204	204	546
Care	12,376	10,678	27,256	-	5,080	1/08	437%	86,203	819,739	204	204	546
Free Condom	2,532,159	450,305	2,551,267	-	3,363,326		(24)%	10,466,262	29,924,525	19,135	19,135	52,442
Blue Gold Condoms	-	-	-	-	455,724	8/17	(100)%	590,724	1,856,634	-	-	-
Key Population Male Condom	2,532,159	450,305	2,551,267	-	2,907,602	7/16	(12)%	9,131,741	22,820,140	19,135	19,135	52,442
One Community Male Condom	-	-	-	-	-	7/16	-%	743,797	5,247,751	-	-	-
Free Female Condom	-	597	-	-	27,234		(100)%	151,992	407,841	-	-	-
Free Female Condoms	-	597	-	-	12,127	2/14	(100)%	68,719	307,906	-	-	-
Key Population Female Condom	-	-	-	-	15,107	12/17	(100)%	83,273	99,935	-	-	-
HIV Self-Testing Kit	16,000	23,450	35,325	-	36,128		(2)%	258,868	383,190	31,793	-	-
ORAQUICK HIV Self-Testing Kit (Pouch)	16,000	23,333	34,975	-	36,128	8/17	(3)%	258,868	382,840	31,478	-	-
Sure Check HIV Self-Test	-	117	350	-	-		-%	-	350	315	-	-
HIV Testing Services	3,263	3,168	7,060	-	9,955		(29)%	76,101	249,009	7,060	-	300
VCT Individual (HIV-Negative)	3,085	3,001	6,692	-	9,508	12/14	(30)%	72,736	242,232	6,692	-	285
VCT Individual (HIV-Positive)	178	167	368	-	447	12/14	(18)%	3,365	6,777	368	-	16
Implant 3	100	64	242	-	(518)		0%	(11,432)	6,924	218	545	495
Implanon	-	-	-	-	5,757	10/12	(100)%	18,883	84,144	-	-	-
Implanon NXT	4,380	1,870	7,089	-	-		-%	2,901	9,990	6,380	15,950	14,490
(b)PSI Implant 3 Distributed Inserted	(4,280)	(1,806)	(6,847)	-	(6,275)		-%	(33,216)	(87,210)	(6,162)	(15,406)	(13,995)
Implant 3 Insertion	4,310	1,806	6,877	-	6,275		10%	33,272	87,296	6,877	17,193	15,618
Non-PSI Implant 3 Inserted	30	-	30	-	-		-%	56	86	30	75	68
PSI Implant 3 Inserted	4,280	1,806	6,847	-	6,275		9%	33,216	87,210	6,847	17,118	15,550

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

**Period: 2**

**Year: 2019**

	DISTRIBUTION 2/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
Implant 4	(1)	(798)	(28)	-	-		0%	(3,883)	(3,911)	(25)	(81)	(72)
Levoplant	-	917	-	-	-		-%	30,000	30,000	-	-	-
(b)PSI Implant 4 Distributed Inserted	(1)	(1,714)	(28)	-	-		-%	(33,883)	(33,911)	(25)	(81)	(72)
Implant 4 Insertion	1	1,714	28	-	-		0%	33,883	33,911	28	90	80
PSI Implant 4 Inserted	1	1,714	28	-	-		-%	33,883	33,911	28	90	80
Implant 5	(1,440)	(422)	(2,711)	-	1,381		(296)%	(9,003)	7,860	(2,440)	(9,272)	(8,301)
Jadelle	351	1,521	1,801	-	8,698	10/12	(79)%	27,995	123,191	1,621	6,159	5,515
(b)PSI Implant 5 Distributed Inserted	(1,791)	(1,943)	(4,512)	-	(7,317)	3/16	-%	(36,998)	(115,331)	(4,061)	(15,431)	(13,816)
Implant 5 Insertion	1,991	1,943	4,712	-	7,317		(36)%	37,102	115,635	4,712	17,906	16,032
Non-PSI Implant 5 Inserted	200	-	200	-	-		-%	104	304	200	760	680
PSI Implant 5 Inserted	1,791	1,943	4,512	-	7,317	3/16	(38)%	36,998	115,331	4,512	17,146	15,351
Injectable 3-IM	13,756	3,999	21,027	-	1,055		1893%	60,576	1,849,864	4,731	4,731	3,150
Depo-Provera	20,690	7,769	34,275	-	-		-%	9,721	43,996	7,712	7,712	5,135
(b)PSI Injectable 3 IM Distributed Provided	(6,934)	(3,770)	(13,248)	-	(10,285)		-%	(66,440)	(87,028)	(2,981)	(2,981)	(1,985)
SafePlan Inj3	-	-	-	-	11,340	1/08	(100)%	117,295	1,892,896	-	-	-
Injectable 3-IM Provided	6,964	3,878	13,278	-	10,285		29%	67,465	88,083	3,320	3,320	2,210
Non-PSI Injectable 3 IM Provided	30	108	30	-	-		-%	1,025	1,055	8	8	5
PSI Injectable 3 IM Provided	6,934	3,770	13,248	-	10,285		29%	66,440	87,028	3,312	3,312	2,205
IUD 10	(63)	(82)	46	-	355		(87)%	(818)	5,298	41	190	164
IUD Copper T 380A	530	372	1,080	-	973	10/12	11%	5,154	18,229	972	4,471	3,841
(b)PSI IUD 10 Distributed Inserted	(593)	(454)	(1,034)	-	(618)	3/16	-%	(5,972)	(12,931)	(931)	(4,281)	(3,678)
IUD 10 Insertion	593	454	1,034	-	618		67%	5,972	12,931	1,034	4,756	4,086
PSI IUD 10 Inserted	593	454	1,034	-	618	3/16	67%	5,972	12,931	1,034	4,756	4,086
LLIN	2,839	2,488	5,418	-	6,773		(20)%	34,209	437,461	8,777	-	339

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

Period: 2

Year: 2019

	DISTRIBUTION 2/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
Super Chitetezo Net	2,839	2,488	5,418	-	6,773	2/11	(20)%	34,209	437,461	8,777	-	339
Lubricant	235,945	54,673	248,786	-	196,976		26%	1,071,889	3,327,134	-	-	-
Personal Lubricant Water 4.5 g	235,945	54,673	248,786	-	196,976	12/12	26%	1,071,889	3,327,134	-	-	-
OCs	10,024	18,413	18,714	-	30,145		(38)%	164,930	835,672	1,123	1,123	789
Microgynon	4,020	2,322	6,786	-	42,454	11/11	(84)%	150,604	812,526	407	407	286
Microgynon combination 3	11,780	7,170	19,650	-	-		-%	13,640	33,290	1,179	1,179	828
Microlut	-	10,301	-	-	600	8/17	(100)%	47,803	58,879	-	-	-
(b)PSI OCs Distributed Provided	(5,776)	(1,380)	(7,722)	-	(12,909)		-%	(47,117)	(69,023)	(463)	(463)	(325)
OCs Provided	6,487	2,774	11,220	-	14,512		(23)%	58,051	83,455	748	748	525
Non-PSI OCs Provided	711	1,394	3,498	-	1,603		118%	10,934	14,432	233	233	164
PSI OCs Provided	5,776	1,380	7,722	-	12,909		(40)%	47,117	69,023	515	515	362
PUR	2,000,000	266,667	2,800,000	-	1,240,338		126%	5,781,185	62,908,440	23,014	-	70
PuR WaterGuard Waufa	2,000,000	266,667	2,800,000	-	1,240,338	3/06	126%	5,781,185	62,908,440	23,014	-	70
Safe Water Solution	-	144	432	-	57,292		(99)%	143,085	8,495,987	355	-	1
WaterGuard	-	144	432	-	57,292	12/02	(99)%	143,085	8,495,987	355	-	1
STI Screening	154	96	154	-	7		2100%	2,620	2,774	154	-	-
STI Screening	154	96	154	-	7		2,100%	2,620	2,774	154	-	-
Tubal Ligation	646	713	999	-	1,781		(44)%	16,027	36,165	999	9,990	7,849
Tubal Ligation	646	713	999	-	1,781	1/15	(44)%	16,027	36,165	999	9,990	7,849
Voluntary Medical Male Circumcision	-	1,298	-	-	8,950		(100)%	53,033	93,460	-	-	-
Voluntary Medical Male Circumcision	-	1,298	-	-	8,950		(100)%	53,033	93,460	-	-	-
<b>PSI Uganda</b>											<b>185,913</b>	<b>187,393</b>
Basic Care Package	-	-	-	-	-		0%	1	1	-	-	-
PLP Kit - NFB (with WaterGuard Tab)	-	-	-	-	-		-%	1	1	-	-	-
Cervical Cancer-VIA and Cryotherapy	1	6	4	-	-		0%	150	154	4	-	2

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

**Period: 2**

**Year: 2019**

	DISTRIBUTION 2/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
Cervical Cancer-VIA and Cryotherapy	1	6	4	-	-		-%	150	154	4	-	2
Cervical Cancer-VIA/VILI Screening	1,177	1,214	2,445	-	-		0%	38,866	41,311	2,445	-	-
Cervical Cancer-VIA/VILI Screening	1,177	1,214	2,445	-	-		-%	38,866	41,311	2,445	-	-
Chlorhexidine	443	1,060	773	-	-		0%	23,211	23,984	696	-	54
Chlorhexidine Gel, 5 g tube	443	1,060	773	-	-		-%	23,211	23,984	696	-	54
Clean Delivery Kit	-	-	-	-	-		0%	2,840	2,840	-	-	-
Maama Kit	-	-	-	-	-		-%	572	572	-	-	-
Maama Kit Extra Clean Delivery	-	-	-	-	-		-%	2,268	2,268	-	-	-
Condom	266,400	70,872	285,696	-	-		0%	1,604,736	1,890,432	2,143	2,143	4,993
Trust	79,848	29,520	84,384	-	-		-%	630,504	714,888	633	633	1,475
Trust Ribbed	69,408	1,152	72,360	-	-		-%	87,408	159,768	543	543	1,265
Trust Scented	68,904	16,344	74,448	-	-		-%	349,272	423,720	558	558	1,301
Trust Studded	48,240	23,856	54,504	-	-		-%	537,552	592,056	409	409	952
Emergency Contraception	(12)	(37)	(17)	-	-		0%	(107)	(124)	(1)	(1)	-
(b)PSI Emergency Contraception Distributed Provided	(12)	(37)	(17)	-	-		-%	(107)	(124)	(1)	(1)	-
Emergency Contraception Provided	12	38	17	-	-		0%	109	126	1	1	-
Non-PSI Emergency Contraception Provided	-	1	-	-	-		-%	2	2	-	-	-
PSI Emergency Contraception Provided	12	37	17	-	-		-%	107	124	1	1	-
Expanded Clean Delivery Kit	-	-	-	-	-		0%	13,160	13,160	-	-	-
Mama Kit Expanded(Chlorhexidine 400gm&Misoprostol)	-	-	-	-	-		-%	13,160	13,160	-	-	-
Expanded Clean Delivery Kit (+CHX)	193	925	464	-	-		0%	13,837	14,301	418	-	68
Mama Kit with Chlorhexidine	193	925	464	-	-		-%	13,837	14,301	418	-	68
Free Condom	-	-	-	-	-		0%	576,000	576,000	-	-	-
Generic Male Condom	-	-	-	-	-		-%	576,000	576,000	-	-	-
Implant 3	6,439	2,996	7,332	-	-		0%	34,268	41,600	6,599	16,497	16,704

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.



**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

**Period: 2**

**Year: 2019**

	DISTRIBUTION 2/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
Implanon	8,022	4,402	10,778	-	-		-%	55,110	65,888	9,700	24,251	24,555
(b)PSI Implanon 3 Distributed Inserted	(1,583)	(1,406)	(3,446)	-	-		-%	(20,842)	(24,288)	(3,101)	(7,754)	(7,851)
Implanon 3 Insertion	10,591	7,625	18,108	-	-		0%	99,913	118,021	18,108	45,270	45,838
Non-PSI Implanon 3 Inserted	9,008	6,219	14,662	-	-		-%	79,071	93,733	14,662	36,655	37,115
PSI Implanon 3 Inserted	1,583	1,406	3,446	-	-		-%	20,842	24,288	3,446	8,615	8,723
Implanon 5	5,915	9,542	7,887	-	-		0%	41,363	49,250	7,098	26,974	26,845
Jadelle	6,660	10,127	9,360	-	-		-%	53,160	62,520	8,424	32,011	31,858
(b)PSI Implanon 5 Distributed Inserted	(745)	(585)	(1,473)	-	-		-%	(11,797)	(13,270)	(1,326)	(5,038)	(5,014)
Implanon 5 Insertion	4,206	4,987	11,490	-	-		0%	33,335	44,825	11,490	43,662	43,454
Non-PSI Implanon 5 Inserted	3,461	4,402	10,017	-	-		-%	21,538	31,555	10,017	38,065	37,883
PSI Implanon 5 Inserted	745	585	1,473	-	-		-%	11,797	13,270	1,473	5,597	5,571
Injectable 3-IM	5,566	5,849	9,788	-	-		0%	59,649	69,437	2,202	2,202	1,639
Depo-Provera	7,500	14,108	13,975	-	-		-%	82,175	96,150	3,144	3,144	2,341
(b)PSI Injectable 3 IM Distributed Provided	(1,934)	(8,260)	(4,187)	-	-		-%	(22,526)	(26,713)	(942)	(942)	(701)
Injectable 3-IM Provided	2,047	8,866	4,347	-	-		0%	24,298	28,645	1,087	1,087	809
Non-PSI Injectable 3 IM Provided	113	606	160	-	-		-%	1,772	1,932	40	40	30
PSI Injectable 3 IM Provided	1,934	8,260	4,187	-	-		-%	22,526	26,713	1,047	1,047	779
Injectable 3-SC	6,180	8,249	12,630	-	-		0%	55,900	68,530	2,842	2,842	2,115
Sayana Press	6,180	8,249	12,630	-	-		-%	55,900	68,530	2,842	2,842	2,115
IUD 10	2,682	11,132	2,015	-	-		0%	112,806	114,821	1,814	8,342	7,939
Copper T 380	3,250	9,708	3,650	-	-		-%	110,545	114,195	3,285	15,111	14,381
IUD PACK CU T380A	780	2,448	1,550	-	-		-%	43,587	45,137	1,395	6,417	6,107
PPIUD Cu T380A	310	500	350	-	-		-%	2,675	3,025	315	1,449	1,379
(b)PSI IUD 10 Distributed Inserted	(1,658)	(1,524)	(3,535)	-	-		-%	(44,001)	(47,536)	(3,182)	(14,635)	(13,928)

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

**Period: 2**

**Year: 2019**

	DISTRIBUTION 2/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
IUD 10 Insertion	4,532	3,499	7,816	-	-		0%	89,907	97,723	7,816	35,954	34,217
Non-PSI IUD 10 Inserted	2,874	1,975	4,281	-	-		-%	45,906	50,187	4,281	19,693	18,741
PSI IUD 10 Inserted	1,658	1,524	3,535	-	-		-%	44,001	47,536	3,535	16,261	15,475
IUD 5	(15)	(7)	(25)	-	-		0%	(134)	(159)	(23)	(74)	(75)
(b)PSI IUD 5 Distributed Inserted	(15)	(7)	(25)	-	-		-%	(134)	(159)	(23)	(74)	(75)
IUD 5 Insertion	15	7	25	-	-		0%	135	160	25	82	84
Non-PSI IUD 5 Inserted	-	-	-	-	-		-%	1	1	-	-	-
PSI IUD 5 Inserted	15	7	25	-	-		-%	134	159	25	82	84
Manual Vacuum Aspiration for PAC	125	67	248	-	-		0%	469	717	248	-	73
MVA for PAC	125	67	248	-	-		-%	469	717	248	-	73
Manual Vacuum Aspiration for SA	76	39	143	-	-		0%	261	404	143	-	52
Manual Vacuum Aspiration for SA	76	39	143	-	-		-%	261	404	143	-	52
Medical Abortion	548	318	854	-	-		0%	16,535	17,389	769	-	269
Divabo - Combipack (1+4's)	623	362	994	-	-		-%	16,804	17,798	895	-	313
(b)PSI Medical Abortion Distributed Provided	(75)	(44)	(140)	-	-		-%	(269)	(409)	(126)	-	(44)
Medical Abortion (Misoprostol) Provided	109	75	225	-	-		0%	344	569	225	-	70
PSI Medical Abortion (Misoprostol) Provided	109	75	225	-	-		-%	344	569	225	-	70
Medical Abortion Provided	75	44	140	-	-		0%	269	409	140	-	49
PSI Medical Abortion Provided	75	44	140	-	-		-%	269	409	140	-	49
Misoprostol for PAC Provided	103	85	263	-	-		0%	586	849	263	-	90
PSI Misoprostol for PAC Provided	103	85	263	-	-		-%	586	849	263	-	90
Misoprostol for Safe Abortion	54,380	58,104	80,748	-	-		0%	452,048	532,796	4,239	-	1,324
Misoprostol for Safe Abortion	56,100	59,340	84,500	-	-		-%	458,520	543,020	4,436	-	1,386
(b)PSI Misoprostol for Safe Abortion Dist Provided	(1,720)	(1,236)	(3,752)	-	-		-%	(6,472)	(10,224)	(197)	-	(62)
OCs	8,063	4,666	12,079	-	-		0%	43,581	55,660	725	725	569

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

Period: 2

Year: 2019

	DISTRIBUTION 2/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
Combination 3	460	2,270	1,360	-	-		-%	7,900	9,260	82	82	64
Family Planning Pills	-	-	-	-	-		-%	28,590	28,590	-	-	-
Microlut - Oral Contraceptive	1,212	383	1,662	-	-		-%	699	2,361	100	100	78
(b)PSI OCs Distributed Provided	(188)	(1,034)	(399)	-	-		-%	(2,890)	(3,289)	(24)	(24)	(19)
Zinnia	6,579	3,047	9,456	-	-		-%	9,282	18,738	567	567	446
OCs Provided	207	1,095	426	-	-		0%	3,066	3,492	28	28	22
Non-PSI OCs Provided	19	61	27	-	-		-%	176	203	2	2	1
PSI OCs Provided	188	1,034	399	-	-		-%	2,890	3,289	27	27	21
PUR	1,065,000	80	1,065,000	-	-		0%	6,413,745	7,478,745	8,753	-	35
PuR	1,065,000	80	1,065,000	-	-		-%	6,413,745	7,478,745	8,753	-	35
Referral to HIV Testing Services	-	3,901	-	-	-		0%	11,703	11,703	-	-	-
Referral to HIV Testing Services	-	3,901	-	-	-		-%	11,703	11,703	-	-	-
Referral to Linkage to HIV Care	-	1,538	-	-	-		0%	4,614	4,614	-	-	-
Referral to Linkage to HIV Care	-	1,538	-	-	-		-%	4,614	4,614	-	-	-
Tubal Ligation	8	6	18	-	-		0%	46	64	18	180	155
Tubal Ligation	8	6	18	-	-		-%	46	64	18	180	155
<b>Rwanda</b>											<b>30,951</b>	<b>59,672</b>
Condom	760,992	3,196,355	3,522,164	-	1,629,696		116%	13,673,659	77,888,564	26,416	26,416	56,669
Plaisir	240,540	345,533	561,480	-	256,800	2/13	119%	1,688,521	11,063,434	4,211	4,211	9,034
Prudence Plus	520,452	2,850,821	2,960,684	-	1,372,896	2/13	116%	11,985,138	66,825,130	22,205	22,205	47,635
Free Condom	-	320	-	-	21,600		(100)%	22,662	2,390,408	-	-	-
Military Condom	-	320	-	-	21,600	4/14	(100)%	22,662	2,390,408	-	-	-
Injectable 3-IM	10,080	9,104	15,082	-	5,280		186%	42,020	96,694	3,393	3,393	2,184
Confiance Depo-Provera	10,080	9,104	15,082	-	5,280	2/13	186%	42,020	96,694	3,393	3,393	2,184

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

**Period: 2**

**Year: 2019**

	DISTRIBUTION 2/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
OCs	18,720	19,335	19,027	-	28,800		(34)%	170,171	385,830	1,142	1,142	775
Microgynon	18,720	19,335	19,027	-	28,800	6/15	(34)%	170,171	385,830	1,142	1,142	775
PUR	-	85,478	-	-	254,240		(100)%	1,286,421	6,289,177	-	-	-
PuR	-	85,478	-	-	254,240	2/13	(100)%	1,286,421	6,289,177	-	-	-
Safe Water Solution	26,784	30,261	26,784	-	84,100		(68)%	250,823	1,137,794	22,014	-	44
Sur Eau	26,784	30,261	26,784	-	84,100	2/13	(68)%	250,823	1,137,794	22,014	-	44
<b>Swaziland</b>											19,024	116,238
Antiretroviral Treatment (Currently Enrolled)	1,000	1,020	1,981	-	480		313%	9,037	12,891	165	-	407
Antiretroviral Treatment (Currently Enrolled)	1,000	1,020	1,981	-	480		313%	9,037	12,891	165	-	407
Antiretroviral Treatment (Newly Enrolled)	30	38	69	-	98		(30)%	593	1,231	69	-	-
Antiretroviral Treatment (Newly Enrolled)	30	38	69	-	98		(30)%	593	1,231	69	-	-
CD4 Tests Provided to HIV+ Clients	-	-	-	-	101		(100)%	101	1,499	-	-	-
CD4 Tests Provided to HIV+ Clients	-	-	-	-	101		(100)%	101	1,499	-	-	-
Condom	-	-	-	-	2,273,445		(100)%	5,072,763	24,040,979	-	-	-
Lovers Plus	-	-	-	-	288	2/01	(100)%	288	1,271,986	-	-	-
Lovers Plus C&F	-	-	-	-	15	1/05	(100)%	253	188,237	-	-	-
Lovers Plus R&S	-	-	-	-	-	5/10	-%	80	111,824	-	-	-
Trust Regular BGF	-	-	-	-	234	7/08	(100)%	234	74,421	-	-	-
Trust Studded	-	-	-	-	1,908	1/05	(100)%	1,908	5,550,730	-	-	-
Trust Workplace	-	-	-	-	2,271,000	2/06	(100)%	5,070,000	16,843,781	-	-	-
Emergency Contraception Provided	-	1	-	-	-		0%	2	7	-	-	-
Non-PSI Emergency Contraception Provided	-	1	-	-	-		-%	2	7	-	-	-
Female Condom	2,000	9,500	17,000	-	23,000		(26)%	116,500	1,049,727	127	127	731
Female Condom	2,000	9,500	17,000	-	23,000	7/06	(26)%	116,500	1,049,727	127	127	731
Free Condom	681,000	1,360,000	2,517,000	-	834,205		202%	11,994,690	75,758,108	18,877	18,877	109,146

(a) The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

**Period: 2**

**Year: 2019**

	DISTRIBUTION 2/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
Generic	300,000	811,000	1,200,000	-	834,000	4/05	44%	11,283,000	63,338,544	9,000	9,000	52,036
Vanilla & Strawberry	381,000	549,000	1,317,000	-	-		-%	711,000	2,028,000	9,877	9,877	57,110
Workplace	-	-	-	-	205	10/01	(100)%	690	10,391,564	-	-	-
HIV Self-Testing Kit	-	12,192	-	-	-		0%	36,575	36,575	-	-	-
ORAQUICK HIV Self-Testing Kit (Pouch)	-	12,192	-	-	-		-%	36,575	36,575	-	-	-
HIV Testing Services	3,997	3,292	7,785	-	11,157		(30)%	37,788	627,756	7,785	-	1,058
VCT Individual (HIV-Negative)	3,584	2,990	7,016	-	10,158	12/09	(31)%	32,716	574,813	7,016	-	954
VCT Individual (HIV-Positive)	413	301	769	-	999	12/09	(23)%	5,072	52,943	769	-	105
Hypertension Screening	520	346	917	-	501		83%	3,270	9,421	917	-	-
Hypertension Screening	520	346	917	-	501		83%	3,270	9,421	917	-	-
Implant 3 Insertion	-	3	3	-	34		(91)%	170	175	3	8	5
Non-PSI Implant 3 Inserted	-	3	3	-	34		(91)%	170	175	3	8	5
Injectable 1 Provided	3	7	10	-	78		(87)%	537	1,769	1	1	-
Non-PSI Injectable 1 Provided	3	7	10	-	78		(87)%	537	1,769	1	1	-
Injectable 3-IM Provided	1	35	39	-	142		(73)%	1,194	2,872	10	10	5
Non-PSI Injectable 3 IM Provided	1	35	39	-	142		(73)%	1,194	2,872	10	10	5
Lubricant	18,000	80,333	113,000	-	80,000		41%	1,342,000	2,128,000	-	-	-
Lifestyles Liquid Personal Lubricant (4.5 g)	18,000	80,333	113,000	-	80,000	8/11	41%	1,342,000	2,128,000	-	-	-
OCs Provided	5	16	17	-	116		(85)%	692	2,228	1	1	1
Non-PSI OCs Provided	5	16	17	-	116		(85)%	692	2,228	1	1	1
PrEP	7	12	19	-	-		0%	78	97	2	-	1
PrEP	7	12	19	-	-		-%	78	97	2	-	1
Referral to Hypertension Management	1	-	1	-	2		(50)%	3	46	1	-	-
Referral to Hypertension Management	1	-	1	-	2		(50)%	3	46	1	-	-
Referral to Injectable 1	-	-	-	-	12		(100)%	36	384	-	-	-

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

**Period: 2**

**Year: 2019**

	DISTRIBUTION 2/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
Referral to Injectable 1	-	-	-	-	12		(100)%	36	384	-	-	-
Referral to Injectable 3	-	-	-	-	46		(100)%	55	646	-	-	-
Referral to Injectable 3	-	-	-	-	46		(100)%	55	646	-	-	-
Referral to Linkage to HIV Care	248	190	539	-	693		(22)%	2,541	7,142	539	-	352
Referral to Linkage to HIV Care	248	190	539	-	693		(22)%	2,541	7,142	539	-	352
Referral to OCs	-	-	-	-	40		(100)%	76	547	-	-	-
Referral to OCs	-	-	-	-	40		(100)%	76	547	-	-	-
Referral to STI Treatment (unknown)	-	-	-	-	14		(100)%	26	247	-	-	-
Referral to STI Treatment (unknown)	-	-	-	-	14	12/14	(100)%	26	247	-	-	-
Referral to TB Screening	-	-	-	-	303		(100)%	303	4,032	-	-	-
Referrals to TB Screening	-	-	-	-	303		(100)%	303	4,032	-	-	-
Referral to Voluntary Medical Male Circumcision	-	-	-	-	-		0%	19	4,737	-	-	-
Referral to Voluntary Medical Male Circumcision	-	-	-	-	-	12/14	-%	19	4,737	-	-	-
STI Screening	4,031	3,314	7,858	-	11,157		(30)%	37,972	117,306	7,858	-	-
STI Screening	4,031	3,314	7,858	-	11,157		(30)%	37,972	117,306	7,858	-	-
TB Screening	3,997	3,292	7,785	-	11,157		(30)%	37,910	108,082	7,785	-	-
TB Screening	3,997	3,292	7,785	-	11,157		(30)%	37,910	108,082	7,785	-	-
Treatment for Genital Herpes	5	1	6	-	7		(14)%	17	50	6	-	-
Treatment for Genital Herpes	5	1	6	-	7		(14)%	17	50	6	-	-
Treatment for Inguinal Bubo	-	-	-	-	-		0%	1	5	-	-	-
Treatment for Inguinal Bubo	-	-	-	-	-		-%	1	5	-	-	-
Treatment for Lower Abdominal Pain	8	5	20	-	8		150%	54	129	20	-	-
Treatment for Lower Abdominal Pain	8	5	20	-	8		150%	54	129	20	-	-
Treatment for Nonherpetic Genital Ulcer	7	5	19	-	23		(17)%	94	258	19	-	7
Treatment for Nonherpetic Genital Ulcer	7	5	19	-	23		(17)%	94	258	19	-	7

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**  
**Monthly Distribution by Country**  
**Period: 2**  
**Year: 2019**

	DISTRIBUTION 2/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
Treatment for Urethral Discharge (Men)	29	9	51	-	17		200%	195	465	102	-	7
Treatment for Urethral Discharge (Men)	29	9	51	-	17		200%	195	465	102	-	7
Treatment for Urethral Discharge (Women)	3	-	3	-	-		0%	2	7	3	-	1
Treatment for Urethral Discharge (Women)	3	-	3	-	-		-%	2	7	3	-	1
Treatment for Vaginitis	32	16	72	-	52		38%	380	1,038	72	-	19
Treatment for Vaginitis	32	16	72	-	52		38%	380	1,038	72	-	19
Type 2 Diabetes Screening	324	105	437	-	67		552%	658	1,354	437	-	-
Type 2 Diabetes Screening	324	105	437	-	67		552%	658	1,354	437	-	-
Voluntary Medical Male Circumcision	233	104	322	-	355		(9)%	2,766	7,189	322	-	4,497
Voluntary Medical Male Circumcision	233	104	322	-	355		(9)%	2,766	7,189	322	-	4,497
<b>Tanzania</b>											<b>63,538</b>	<b>53,278</b>
Cervical Cancer-VIA/VILI Screening	-	-	-	-	22		(100)%	39	19,810	-	-	-
Cervical Cancer-VIA/VILI Screening	-	-	-	-	22		(100)%	39	19,810	-	-	-
Condom	1,296	2,160	6,048	-	1,296		367%	9,719,136	614,744,060	45	45	69
Salama Halisi	-	144	-	-	432	2/11	(100)%	4,191,696	345,728,504	-	-	-
Salama Scented	-	288	-	-	432	8/06	(100)%	4,398,624	136,918,956	-	-	-
Salama Studded	1,296	1,728	6,048	-	432	6/04	1,300%	1,128,816	132,096,600	45	45	69
Emergency Contraception	(124)	(52)	(168)	-	(74)		0%	(779)	(996)	(8)	(8)	(4)
(b)PSI Emergency Contraception Distributed Provided	(124)	(52)	(168)	-	(74)		-%	(779)	(996)	(8)	(8)	(4)
Emergency Contraception Provided	202	112	272	-	99		175%	2,258	2,670	14	14	7
Non-PSI Emergency Contraception Provided	78	60	104	-	25		316%	1,479	1,674	5	5	2
PSI Emergency Contraception Provided	124	52	168	-	74		127%	779	996	8	8	4
Implant 3	(185)	(166)	(482)	-	(1,724)		0%	(10,487)	(77,716)	(434)	(1,085)	(925)
(b)PSI Implant 3 Distributed Inserted	(185)	(166)	(482)	-	(1,724)		-%	(10,487)	(77,716)	(434)	(1,085)	(925)
Implant 3 Insertion	4,789	3,182	8,735	-	7,026		24%	73,748	229,895	8,735	21,838	18,631

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

**Period: 2**

**Year: 2019**

	DISTRIBUTION 2/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
Non-PSI Implant 3 Inserted	4,604	3,015	8,253	-	5,302		56%	63,261	152,179	8,253	20,633	17,603
PSI Implant 3 Inserted	185	166	482	-	1,724		(72)%	10,487	77,716	482	1,205	1,028
Implant 5	(212)	(251)	(548)	-	(2,211)		0%	(12,107)	(108,364)	(493)	(1,874)	(1,569)
(b)PSI Implant 5 Distributed Inserted	(212)	(251)	(548)	-	(2,211)		-%	(12,107)	(108,364)	(493)	(1,874)	(1,569)
Implant 5 Insertion	2,724	1,544	4,748	-	4,520		5%	45,509	201,887	4,748	18,042	15,104
Non-PSI Implant 5 Inserted	2,512	1,293	4,200	-	2,309		82%	33,402	93,523	4,200	15,960	13,361
PSI Implant 5 Inserted	212	251	548	-	2,211		(75)%	12,107	108,364	548	2,082	1,743
Injectable 3-IM	(137)	(175)	(248)	-	(514)		0%	241,911	1,900,590	(56)	(56)	(35)
Familia Injectable 3 Kit	-	-	-	-	-	1/10	-%	246,600	1,913,951	-	-	-
(b)PSI Injectable 3 IM Distributed Provided	(137)	(175)	(248)	-	(514)		-%	(4,689)	(13,361)	(56)	(56)	(35)
Injectable 3-IM Provided	3,123	2,590	5,785	-	5,871		(1)%	37,606	112,222	1,446	1,446	909
Non-PSI Injectable 3 IM Provided	2,986	2,415	5,537	-	5,357		3%	32,917	98,861	1,384	1,384	870
PSI Injectable 3 IM Provided	137	175	248	-	514		(52)%	4,689	13,361	62	62	39
IUD 10	(616)	(891)	(1,770)	-	(5,296)		0%	(26,670)	(120,312)	(1,593)	(7,328)	(5,854)
Familia IUD Kit	800	533	1,100	-	2,100	11/09	(48)%	12,820	254,729	990	4,554	3,638
(b)PSI IUD 10 Distributed Inserted	(1,416)	(1,424)	(2,870)	-	(7,396)		-%	(39,490)	(375,041)	(2,583)	(11,882)	(9,492)
IUD 10 Insertion	3,447	2,825	6,973	-	13,441		(48)%	96,804	586,577	6,973	32,076	25,623
Non-PSI IUD 10 Inserted	2,031	1,401	4,103	-	6,045		(32)%	57,314	211,536	4,103	18,874	15,077
PSI IUD 10 Inserted	1,416	1,424	2,870	-	7,396		(61)%	39,490	375,041	2,870	13,202	10,546
LLIN	11,494	233,988	11,494	-	409,432		(97)%	4,510,989	11,963,365	18,620	-	577
"New Brand" (School Net Program)	-	-	-	-	97,352		(100)%	97,352	1,255,210	-	-	-
Olyset Nets Health Facility	-	64,093	-	-	-		-%	486,680	486,680	-	-	-
Permanet (180x160x180 CM) SI	-	-	-	-	312,080	2/16	(100)%	978,840	7,261,864	-	-	-
Permanet Health Facility	11,120	4,907	11,120	-	-		-%	91,648	102,768	18,014	-	559

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.



**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

Period: 2

Year: 2019

	DISTRIBUTION 2/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
Permanet Nets School	374	164,988	374	-	-		-%	2,856,469	2,856,843	606	-	19
Manual Vacuum Aspiration for PAC	367	498	856	-	-		0%	6,674	8,604	856	-	108
MVA for PAC	367	498	856	-	-		-%	6,674	8,604	856	-	108
Misoprostol for PAC Provided	178	223	438	-	-		0%	2,547	3,036	438	-	65
PSI Misoprostol for PAC Provided	178	223	438	-	-		-%	2,547	3,036	438	-	65
Misoprostol for Safe Abortion	27,368	73,268	32,808	-	202,720		(84)%	1,207,224	6,194,832	1,722	-	233
Misoprostol Cipla 200 mcg	28,080	74,160	34,560	-	-		-%	776,776	811,336	1,814	-	245
Misoprostol for Safe Abortion	-	-	-	-	202,720	3/18	(100)%	440,636	5,395,640	-	-	-
(b)PSI Misoprostol for Safe Abortion Dist Provided	(712)	(892)	(1,752)	-	-		-%	(10,188)	(12,144)	(92)	-	(12)
OCs	(246)	(327)	(630)	-	212,412		(100)%	287,100	10,206,559	(38)	(38)	(25)
Familia [OC]	-	-	-	-	213,120	2/08	(100)%	295,056	10,228,009	-	-	-
(b)PSI OCs Distributed Provided	(246)	(327)	(630)	-	(708)		-%	(7,956)	(21,450)	(38)	(38)	(25)
OCs Provided	4,512	6,767	6,975	-	4,299		62%	75,344	127,240	465	465	308
Non-PSI OCs Provided	4,266	6,440	6,345	-	3,591		77%	67,388	105,790	423	423	280
PSI OCs Provided	246	327	630	-	708		(11)%	7,956	21,450	42	42	28
Water Treatment Tablets	415,500	470,500	819,000	-	1,764,542		(54)%	6,112,242	52,471,202	13,463	-	55
Aquatab Tubs 8.68g	-	-	-	-	960	3/16	(100)%	960	446,520	-	-	-
WaterGuard Tablet ENF	415,500	470,500	819,000	-	1,763,582	7/12	(54)%	6,111,282	52,024,682	13,463	-	55
<b>Uganda</b>											<b>76</b>	<b>5,604</b>
Cervical Cancer-VIA and Cryotherapy	-	-	-	-	53		(100)%	74	2,360	-	-	-
Cervical Cancer-VIA and Cryotherapy	-	-	-	-	53	11/13	(100)%	74	2,360	-	-	-
Cervical Cancer-VIA/VILI Screening	-	-	-	-	13,128		(100)%	18,884	176,960	-	-	-
Cervical Cancer-VIA/VILI Screening	-	-	-	-	13,128		(100)%	18,884	176,960	-	-	-
Chlorhexidine	-	-	-	-	431		(100)%	411	13,454	-	-	-

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

Period: 2

Year: 2019

	DISTRIBUTION 2/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
Chlorhexidine Gel, 5 g tube	-	-	-	-	431	11/16	(100)%	411	13,454	-	-	-
Clean Delivery Kit	-	-	-	-	1,277		(100)%	609	178,925	-	-	-
Maama Kit Extra Clean Delivery	-	-	-	-	1,277	8/10	(100)%	609	178,925	-	-	-
Condom	-	-	-	-	184,464		(100)%	180,648	46,911,638	-	-	-
Trust	-	-	-	-	50,688	6/06	(100)%	49,392	44,987,870	-	-	-
Trust Ribbed	-	-	-	-	39,528	11/15	(100)%	39,528	610,632	-	-	-
Trust Scented	-	-	-	-	43,632	11/15	(100)%	42,408	649,224	-	-	-
Trust Studded	-	-	-	-	50,616	11/15	(100)%	49,320	663,912	-	-	-
Expanded Clean Delivery Kit (+CHX)	-	-	-	-	694		(100)%	694	1,311	-	-	-
Mama Kit with Chlorhexidine	-	-	-	-	694	11/17	(100)%	694	1,311	-	-	-
Free Condom	-	1,631,039	10,080	-	-		0%	16,543,154	83,222,013	76	76	176
Generic	-	799,200	-	-	-	1/99	-%	13,304,596	79,973,375	-	-	-
Ulinzi Condoms	-	831,839	10,080	-	-		-%	3,238,558	3,248,638	76	76	176
Free Female Condom	-	13,332	-	-	-		0%	105,995	2,310,630	-	-	-
Female Condom Free	-	13,332	-	-	-	11/09	-%	105,995	2,310,630	-	-	-
Implant 3	-	-	-	-	(3,332)		0%	(5,778)	105,174	-	-	-
Implanon	-	-	-	-	932	12/08	(100)%	932	192,634	-	-	-
(b)PSI Implant 3 Distributed Inserted	-	-	-	-	(4,264)		-%	(6,710)	(87,460)	-	-	-
Implant 3 Insertion	-	-	-	-	17,478		(100)%	27,489	292,024	-	-	-
Non-PSI Implant 3 Inserted	-	-	-	-	13,214		(100)%	20,779	204,564	-	-	-
PSI Implant 3 Inserted	-	-	-	-	4,264		(100)%	6,710	87,460	-	-	-
Implant 5	-	-	-	-	(2,772)		0%	(4,540)	95,981	-	-	-
Jadelle	-	-	-	-	760	12/08	(100)%	760	181,319	-	-	-
(b)PSI Implant 5 Distributed Inserted	-	-	-	-	(3,532)		-%	(5,300)	(85,338)	-	-	-

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

**Period: 2**

**Year: 2019**

	DISTRIBUTION 2/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
Implant 5 Insertion	-	-	-	-	3,603		(100)%	5,464	114,325	-	-	-
Non-PSI Implant 5 Inserted	-	-	-	-	71		(100)%	164	28,987	-	-	-
PSI Implant 5 Inserted	-	-	-	-	3,532		(100)%	5,300	85,338	-	-	-
Injectable 3-IM	-	-	-	-	4,200		(100)%	3,950	263,573	-	-	-
Depo-Provera	-	-	-	-	4,200	11/11	(100)%	3,950	263,573	-	-	-
IUD 10	-	-	-	-	(10,036)		0%	(16,307)	1,791	-	-	-
IUD PACK CU T380A	-	-	-	-	1,130	4/11	(100)%	890	238,341	-	-	-
(b)PSI IUD 10 Distributed Inserted	-	-	-	-	(11,166)		-%	(17,197)	(236,550)	-	-	-
IUD 10 Insertion	-	-	-	-	14,365		(100)%	23,549	426,314	-	-	-
Non-PSI IUD 10 Inserted	-	-	-	-	3,199		(100)%	6,352	189,765	-	-	-
PSI IUD 10 Inserted	-	-	-	-	11,166		(100)%	17,197	236,550	-	-	-
IUD 5	-	-	-	-	(88)		0%	(129)	(17,342)	-	-	-
(b)PSI IUD 5 Distributed Inserted	-	-	-	-	(88)		-%	(129)	(17,342)	-	-	-
IUD 5 Insertion	-	-	-	-	88		(100)%	130	28,350	-	-	-
Non-PSI IUD 5 Inserted	-	-	-	-	-		-%	1	11,007	-	-	-
PSI IUD 5 Inserted	-	-	-	-	88		(100)%	129	17,342	-	-	-
Manual Vacuum Aspiration for PAC	-	-	-	-	100		(100)%	388	2,304	-	-	-
MVA for PAC	-	-	-	-	100	3/16	(100)%	388	2,304	-	-	-
Manual Vacuum Aspiration for SA	-	-	-	-	26		(100)%	150	1,348	-	-	-
Manual Vacuum Aspiration for SA	-	-	-	-	26		(100)%	150	1,348	-	-	-
Medical Abortion	-	-	-	-	478		(100)%	(2,536)	8,475	-	-	-
Divabo - Combipack (1+4's)	-	-	-	-	653	5/17	(100)%	(2,058)	9,574	-	-	-
(b)PSI Medical Abortion Distributed Provided	-	-	-	-	(175)		-%	(478)	(1,099)	-	-	-
Medical Abortion (Misoprostol) Provided	-	-	-	-	34		(100)%	187	187	-	-	-
Non-PSI Medical Abortion (Misoprostol) Provided	-	-	-	-	-		-%	26	26	-	-	-

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

Period: 2

Year: 2019

	DISTRIBUTION 2/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
PSI Medical Abortion (Misoprostol) Provided	-	-	-	-	34		(100)%	161	161	-	-	-
Medical Abortion Provided	-	-	-	-	175		(100)%	478	1,099	-	-	-
PSI Medical Abortion Provided	-	-	-	-	175		(100)%	478	1,099	-	-	-
Misoprostol for PAC Provided	-	-	-	-	135		(100)%	498	1,652	-	-	-
Non-PSI Misoprostol for PAC Provided	-	-	-	-	-		-%	18	36	-	-	-
PSI Misoprostol for PAC Provided	-	-	-	-	135		(100)%	480	1,616	-	-	-
Misoprostol for Safe Abortion	-	-	-	-	(948)		0%	(3,852)	(8,396)	-	-	-
(b)PSI Misoprostol for Safe Abortion Dist Provided	-	-	-	-	(948)		-%	(3,852)	(8,396)	-	-	-
OCs	-	-	-	-	1,425		(100)%	1,425	394,086	-	-	-
Family Planning Pills	-	-	-	-	1,425	11/11	(100)%	1,425	394,086	-	-	-
PUR	-	-	-	-	3,840		(100)%	3,840	40,563,780	-	-	-
PuR	-	-	-	-	3,840	10/04	(100)%	3,840	40,563,780	-	-	-
Referral to HIV Testing Services	2,611	4,815	5,352	-	-		0%	11,703	17,055	5,352	-	166
Referral to HIV Testing Services	2,611	4,815	5,352	-	-		-%	11,703	17,055	5,352	-	166
Referral to Linkage to HIV Care	2,807	2,658	6,168	-	-		0%	4,614	10,782	6,168	-	5,261
Referral to Linkage to HIV Care	2,807	2,658	6,168	-	-		-%	4,614	10,782	6,168	-	5,261
Tubal Ligation	-	-	-	-	3		(100)%	10	123	-	-	-
Tubal Ligation	-	-	-	-	3		(100)%	10	123	-	-	-
<b>Zambia</b>											31,113	87,811
Emergency Contraception Provided	-	-	-	-	-		0%	1	1	-	-	-
Non-PSI Emergency Contraception Provided	-	-	-	-	-		-%	1	1	-	-	-
Free Female Condom	-	-	-	-	-		0%	3,020	192,200	-	-	-
Free Female Condoms	-	-	-	-	-	1/12	-%	3,020	192,200	-	-	-
HIV Self-Testing Kit	-	41,150	40,000	-	31,300		28%	394,250	714,800	36,000	-	-
ORAQUICK HIV Self-Testing Kit (Pouch)	-	41,150	40,000	-	31,300	5/16	28%	394,250	714,800	36,000	-	-

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

**Period: 2**

**Year: 2019**

	DISTRIBUTION 2/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
Implant 3 Insertion	504	393	1,024	-	896		14%	4,567	6,488	1,024	2,560	2,584
Non-PSI Implant 3 Inserted	504	393	1,024	-	896		14%	4,567	6,488	1,024	2,560	2,584
Implant 4 Insertion	-	-	-	-	-		0%	1	117	-	-	-
Non-PSI Implant 4 Inserted	-	-	-	-	-		-%	1	117	-	-	-
Implant 5 Insertion	2,348	2,264	4,359	-	3,529		24%	24,703	52,202	4,359	16,564	16,456
Non-PSI Implant 5 Inserted	2,348	2,264	4,359	-	3,529		24%	24,703	52,202	4,359	16,564	16,456
Injectable 2 Provided	1,546	1,882	3,586	-	3,308		8%	19,835	33,007	598	598	443
Non-PSI Injectable 2 Provided	1,546	1,882	3,586	-	3,308		8%	19,835	33,007	598	598	443
Injectable 3-IM Provided	16,022	15,478	33,817	-	22,100		53%	157,477	274,728	8,454	8,454	6,263
Non-PSI Injectable 3 IM Provided	16,022	15,478	33,817	-	22,100		53%	157,477	274,728	8,454	8,454	6,263
Injectable 3-SC	-	-	-	-	-		0%	168,775	168,775	-	-	-
Sayana Press	-	-	-	-	-		-%	168,775	168,775	-	-	-
IUD 10	-	-	-	-	-		0%	165	83,219	-	-	-
MyChoice IUD-10	-	-	-	-	-	11/08	-%	165	83,219	-	-	-
IUD 10 Insertion	203	177	359	-	262		37%	2,175	4,477	359	1,651	1,572
Non-PSI IUD 10 Inserted	203	177	359	-	262		37%	2,175	4,477	359	1,651	1,572
IUS 5	-	-	-	-	-		0%	800	1,600	-	-	-
LNG-IUS	-	-	-	-	-		-%	800	1,600	-	-	-
IUS 5 Insertion	55	44	112	-	123		(9)%	595	885	112	370	374
Non-PSI IUS 5 Inserted	55	44	112	-	123		(9)%	595	885	112	370	374
OCs Provided	6,639	6,190	13,532	-	8,891		52%	64,379	111,325	902	902	705
Non-PSI OCs Provided	6,639	6,190	13,532	-	8,891		52%	64,379	111,325	902	902	705
Safe Water Solution	64,308	61,640	138,048	-	409,020		(66)%	930,072	35,933,483	76,021	-	295
Clorin	64,308	61,640	138,048	-	409,020	11/98	(66)%	930,072	35,933,483	76,021	-	295
Tubal Ligation	1	16	1	-	23		(96)%	308	480	1	10	9

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

Period: 2

Year: 2019

	DISTRIBUTION 2/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
Tubal Ligation	1	16	1	-	23		(96)%	308	480	1	10	9
Voluntary Medical Male Circumcision	3,730	4,894	7,923	-	2,845		178%	43,253	155,322	7,923	-	59,102
Voluntary Medical Male Circumcision	3,730	4,894	7,923	-	2,845		178%	43,253	155,322	7,923	-	59,102
Woman Condom	480	4,048	480	-	8,496		(94)%	97,728	140,040	4	4	10
MAXIMUM DIVA	480	4,048	480	-	8,496	4/16	(94)%	97,728	140,040	4	4	10
<b>Zimbabwe</b>											<b>34,163</b>	<b>277,144</b>
Antiretroviral Treatment (Currently Enrolled)	9,286	9,486	18,818	-	14,847		27%	103,129	209,438	1,568	-	3,279
Antiretroviral Treatment (Currently Enrolled)	9,286	9,486	18,818	-	14,847		27%	103,129	209,438	1,568	-	3,279
Antiretroviral Treatment (Newly Enrolled)	370	326	692	-	792		(13)%	4,816	19,597	692	-	-
Antiretroviral Treatment (Newly Enrolled)	370	326	692	-	792		(13)%	4,816	19,597	692	-	-
CD4 Tests Provided to HIV+ Clients	-	-	-	-	443		(100)%	443	7,915	-	-	-
CD4 Tests Provided to HIV+ Clients	-	-	-	-	443		(100)%	443	7,915	-	-	-
Cervical Cancer-HPV DNA and Cryotherapy	-	-	-	-	3		(100)%	3	3	-	-	-
Cervical Cancer-HPV DNA and Cryotherapy	-	-	-	-	3		(100)%	3	3	-	-	-
Cervical Cancer-VIA and Conization	19	17	30	-	8		275%	126	334	30	-	11
Cervical Cancer-VIA and Conization	19	17	30	-	8		275%	126	334	30	-	11
Cervical Cancer-VIA and Cryotherapy	38	33	70	-	68		3%	415	4,040	70	-	24
Cervical Cancer-VIA and Cryotherapy	38	33	70	-	68	11/13	3%	415	4,040	70	-	24
Cervical Cancer-VIA and Refer to any Treatment	8	1	9	-	4		125%	25	320	9	-	2
Cervical Cancer-VIA and Refer to any Treatment	8	1	9	-	4	1/15	125%	25	320	9	-	2
Cervical Cancer-VIA and Refer to Conization	4	8	6	-	-		0%	98	2,040	6	-	1
Cervical Cancer-VIA and Refer to Conization	4	8	6	-	-	12/14	-%	98	2,040	6	-	1
Cervical Cancer-VIA and Refer to Cryotherapy	-	-	-	-	-		0%	10	459	-	-	-
Cervical Cancer-VIA and Refer to Cryotherapy	-	-	-	-	-	12/14	-%	10	459	-	-	-
Cervical Cancer-VIA/VILI Screening	1,589	1,565	2,974	-	2,823		5%	18,503	88,793	2,974	-	-

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

**Period: 2**

**Year: 2019**

	DISTRIBUTION 2/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
Cervical Cancer-VIA/VILI Screening	1,589	1,565	2,974	-	2,823		5%	18,503	88,793	2,974	-	-
Condom	1,487,200	1,701,707	2,888,440	-	2,342,640		23%	17,748,320	330,275,810	21,663	21,663	68,871
Protector Plus	259,720	394,467	541,000	-	535,080	1/08	1%	3,626,960	277,236,850	4,057	4,057	12,899
Protector Plus Flavors	1,227,480	1,307,240	2,347,440	-	1,807,560	3/14	30%	14,121,360	53,038,960	17,606	17,606	55,972
Emergency Contraception	2,264	12,649	7,424	-	8,035		(8)%	170,713	963,189	334	334	101
Pregnon	2,280	12,052	7,440	-	-	9/10	-%	160,767	870,402	335	335	101
(b)PSI Emergency Contraception Distributed Provided	(16)	(4)	(16)	-	(5)		-%	(54)	(513)	(1)	(1)	-
Revoke-72	-	600	-	-	8,040	12/15	(100)%	10,000	93,300	-	-	-
Emergency Contraception Provided	19	8	21	-	12		75%	78	727	1	1	-
Non-PSI Emergency Contraception Provided	3	5	5	-	7		(29)%	24	214	-	-	-
PSI Emergency Contraception Provided	16	4	16	-	5		220%	54	513	1	1	-
Female Condom	-	-	-	-	50,800		(100)%	169,980	24,048,034	-	-	-
Care	-	-	-	-	50,800	6/97	(100)%	169,980	24,048,034	-	-	-
Free Female Condom	10,160	14,045	16,160	-	-		0%	224,000	578,160	121	121	380
(b)Care (Free Distribution)	10,160	14,045	16,160	-	-	12/11	-%	224,000	578,160	121	121	380
HIV Self-Testing Kit	-	78,676	-	-	-		0%	236,028	236,028	-	-	-
ORAQUICK HIV Self-Testing Kit (Pouch)	-	78,676	-	-	-		-%	236,028	236,028	-	-	-
HIV Testing Services	2,823	4,404	6,694	-	8,767		(24)%	48,959	2,546,092	6,694	-	444
VCT Individual (HIV-Negative)	1,704	3,143	4,489	-	5,231	12/09	(14)%	31,915	2,251,659	4,489	-	298
VCT Individual (HIV-Positive)	1,119	1,261	2,205	-	3,536	12/09	(38)%	17,044	294,433	2,205	-	146
Hypertension Diagnosis	25	21	56	-	61		(8)%	278	614	56	-	-
Hypertension Diagnosis	25	21	56	-	61		(8)%	278	614	56	-	-
Hypertension Screening	13,739	12,767	25,035	-	22,694		10%	142,029	501,288	25,035	-	-
Hypertension Screening	13,739	12,767	25,035	-	22,694		10%	142,029	501,288	25,035	-	-
Hypertension_Controlled Condition	7	4	12	-	21		(43)%	91	169	5	-	-

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

**Period: 2**

**Year: 2019**

	DISTRIBUTION 2/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
Hypertension_Controlled Condition	7	4	12	-	21		(43)%	91	169	5	-	-
Implant 3	(132)	(107)	(227)	-	(13)		0%	(483)	(3,051)	(204)	(511)	(276)
(b)PSI Implant 3 Distributed Inserted	(132)	(107)	(227)	-	(13)		-%	(483)	(3,051)	(204)	(511)	(276)
Implant 3 Insertion	404	276	645	-	17		3694%	1,151	10,852	645	1,613	872
Non-PSI Implant 3 Inserted	272	170	418	-	4	3/16	10,350%	668	7,801	418	1,045	565
PSI Implant 3 Inserted	132	107	227	-	13		1,646%	483	3,051	227	568	307
Implant 5	(330)	885	(718)	-	822		(187)%	1,797	77,864	(646)	(2,456)	(1,308)
Jadelle	500	1,333	500	-	1,600	9/09	(69)%	6,500	113,208	450	1,710	911
(b)PSI Implant 5 Distributed Inserted	(830)	(448)	(1,218)	-	(778)		-%	(4,703)	(35,344)	(1,096)	(4,166)	(2,219)
Implant 5 Insertion	1,485	1,018	2,484	-	1,281		94%	8,090	93,052	2,484	9,439	5,029
Non-PSI Implant 5 Inserted	655	570	1,266	-	503	1/14	152%	3,387	57,708	1,266	4,811	2,563
PSI Implant 5 Inserted	830	448	1,218	-	778		57%	4,703	35,344	1,218	4,628	2,466
Injectable 3-IM	(704)	(951)	(1,493)	-	2,183		(168)%	13,588	900,064	(336)	(336)	(133)
Depo-Provera	-	-	-	-	3,062	9/00	(100)%	26,562	724,283	-	-	-
Petogen	-	-	-	-	700	9/09	(100)%	700	230,835	-	-	-
(b)PSI Injectable 3 IM Distributed Provided	(704)	(951)	(1,493)	-	(1,579)		-%	(13,674)	(55,054)	(336)	(336)	(133)
Injectable 3-IM Provided	4,278	4,356	8,243	-	6,276		31%	41,625	226,073	2,061	2,061	817
Non-PSI Injectable 3 IM Provided	3,574	3,406	6,750	-	4,697		44%	27,951	171,019	1,688	1,688	669
PSI Injectable 3 IM Provided	704	951	1,493	-	1,579		(5)%	13,674	55,054	373	373	148
IUD 10	(260)	(70)	(406)	-	(79)		0%	(934)	1,106	(365)	(1,681)	(859)
(b)PSI IUD 10 Distributed Inserted	(260)	(170)	(406)	-	(279)	3/16	-%	(1,684)	(9,635)	(365)	(1,681)	(859)
TCU 380A IUCD Copper T	-	100	-	-	200	4/12	(100)%	750	10,741	-	-	-
IUD 10 Insertion	297	212	467	-	279		67%	1,855	10,068	467	2,148	1,098
Non-PSI IUD 10 Inserted	37	42	61	-	-		-%	171	433	61	281	143

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.



**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

**Period: 2**

**Year: 2019**

	DISTRIBUTION 2/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
PSI IUD 10 Inserted	260	170	406	-	279	3/16	46%	1,684	9,635	406	1,868	954
IUD 5 Insertion	11	34	55	-	-		0%	80	135	55	181	98
Non-PSI IUD 5 Inserted	11	34	55	-	-		-%	80	135	55	181	98
IUS 5	(18)	(7)	(28)	-	(11)		0%	126	252	(25)	(83)	(45)
LNG-IUS	20	13	20	-	-		-%	270	615	18	59	32
(b)PSI IUS 5 Distributed Inserted	(38)	(20)	(48)	-	(11)		-%	(144)	(363)	(43)	(143)	(77)
IUS 5 Insertion	44	20	55	-	11		400%	144	387	55	181	98
Non-PSI IUS 5 Inserted	6	-	7	-	-		-%	-	24	7	23	13
PSI IUS 5 Inserted	38	20	48	-	11		336%	144	363	48	158	86
Lubricant	35,800	30,583	74,800	-	16,000		368%	97,750	627,100	-	-	-
Personal lubricants water based 4.5 g	35,800	30,583	74,800	-	16,000	2/17	368%	97,750	627,100	-	-	-
OCs	(1,896)	(7,298)	(4,393)	-	(4,294)		0%	(36,058)	(18,917)	(264)	(264)	(110)
(b)PSI OCs Distributed Provided	(1,896)	(7,298)	(4,393)	-	(4,294)		-%	(43,258)	(280,066)	(264)	(264)	(110)
Secure POP	-	-	-	-	-	4/12	-%	7,200	261,149	-	-	-
OCs Provided	14,881	16,305	26,244	-	11,298		132%	102,704	1,030,587	1,750	1,750	732
Non-PSI OCs Provided	12,985	9,007	21,851	-	7,004		212%	59,446	750,521	1,457	1,457	609
PSI OCs Provided	1,896	7,298	4,393	-	4,294		2%	43,258	280,066	293	293	122
PrEP	3,478	3,455	7,009	-	3,443		104%	34,345	44,470	584	-	228
PrEP	3,478	3,455	7,009	-	3,443		104%	34,345	44,470	584	-	228
Referral to Advanced Cervical Cancer Treatment	3	4	10	-	4		150%	17	427	10	-	-
Referral to Advanced Cervical Cancer Treatment	3	4	10	-	4	12/14	150%	17	427	10	-	-
Referral to Diabetes Management (gestational)	-	14	-	-	26		(100)%	67	67	-	-	-
Referral to Diabetes Management (gestational)	-	14	-	-	26		(100)%	67	67	-	-	-
Referral to Hypertension Management	36	38	42	-	35		20%	564	1,127	42	-	-
Referral to Hypertension Management	36	38	42	-	35		20%	564	1,127	42	-	-

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

**Period: 2**

**Year: 2019**

	DISTRIBUTION 2/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
Referral to Implant 3 Insertion	-	-	-	-	2		(100)%	2	11	-	-	-
Referral to Implant 3 Insertion	-	-	-	-	2		(100)%	2	11	-	-	-
Referral to Implant 5 Insertion	-	-	-	-	2		(100)%	2	992	-	-	-
Referral to Implant 5 Insertion	-	-	-	-	2	12/13	(100)%	2	992	-	-	-
Referral to Injectable 3	-	-	-	-	17		(100)%	20	770	-	-	-
Referral to Injectable 3	-	-	-	-	17		(100)%	20	770	-	-	-
Referral to IUD 10 Insertion	-	-	-	-	4		(100)%	5	209	-	-	-
Referral to IUD 10 Insertion	-	-	-	-	4	12/13	(100)%	5	209	-	-	-
Referral to Linkage to HIV Care	747	806	1,414	-	1,968		(28)%	9,056	18,646	1,414	-	783
Referral to Linkage to HIV Care	747	806	1,414	-	1,968		(28)%	9,056	18,646	1,414	-	783
Referral to OCs	-	-	-	-	17		(100)%	17	868	-	-	-
Referral to OCs	-	-	-	-	17	1/15	(100)%	17	868	-	-	-
Referral to Pre-Exposure Prophylaxis (PrEP)	-	-	-	-	-		0%	20	250	-	-	-
Referral to Pre-Exposure Prophylaxis (PrEP)	-	-	-	-	-		-%	20	250	-	-	-
Referral to STI Screening (syndromic)	-	-	-	-	3		(100)%	3	105	-	-	-
Referrals to STI Screening (syndromic)	-	-	-	-	3		(100)%	3	105	-	-	-
Referral to STI Treatment (unknown)	-	-	-	-	2		(100)%	93	2,337	-	-	-
Referral to STI Treatment (unknown)	-	-	-	-	2	1/15	(100)%	93	2,337	-	-	-
Referral to TB Diagnosis	-	-	-	-	11		(100)%	11	255	-	-	-
Referral to TB Diagnosis	-	-	-	-	11		(100)%	11	255	-	-	-
Referral to TB DOTS (completion confirmed)	-	-	-	-	-		0%	2	19	-	-	-
Referral to TB DOTS (completion confirmed)	-	-	-	-	-		-%	2	19	-	-	-
Referral to TB DOTS (completion unknown)	-	-	-	-	43		(100)%	74	2,704	-	-	-
Referral to TB DOTS (completion unknown)	-	-	-	-	43	12/13	(100)%	74	2,704	-	-	-
Referral to TB Screening	-	-	-	-	1		(100)%	1	12,337	-	-	-

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

**Period: 2**

**Year: 2019**

	DISTRIBUTION 2/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
Referrals to TB Screening	-	-	-	-	1		(100)%	1	12,337	-	-	-
Referral to Treatment for Cervicitis	-	-	-	-	29		(100)%	47	116	-	-	-
Referral to Treatment for Cervicitis	-	-	-	-	29	1/15	(100)%	47	116	-	-	-
Referral to Treatment for Genital Herpes	-	-	-	-	-		0%	3	6	-	-	-
Referral to Treatment for Genital Herpes	-	-	-	-	-		-%	3	6	-	-	-
Referral to Treatment for Inguinal Bubo	-	-	-	-	-		0%	2	2	-	-	-
Referral to Treatment for Inguinal Bubo	-	-	-	-	-		-%	2	2	-	-	-
Referral to Treatment for Lower Abdominal Pain	-	-	-	-	-		0%	1	28	-	-	-
Referral to Treatment for Lower Abdominal Pain	-	-	-	-	-		-%	1	28	-	-	-
Referral to Treatment for Urethral Discharge (Men)	-	-	-	-	1		(100)%	53	113	-	-	-
Referral to Treatment for Urethral Discharge (Men)	-	-	-	-	1		(100)%	53	113	-	-	-
Referral to Tubal Ligation	-	-	-	-	-		0%	2	3	-	-	-
Referral to Tubal Ligation	-	-	-	-	-		-%	2	3	-	-	-
Referral to Tx for Nonherpetic Genital Ulcer	1	-	1	-	3		(67)%	25	73	1	-	-
Referral to Tx for Nonherpetic Genital Ulcer	1	-	1	-	3		(67)%	25	73	1	-	-
Referral to Tx for Urethral Discharge (Women)	2	1	4	-	18		(78)%	48	551	4	-	-
Referral to Tx for Urethral Discharge (Women)	2	1	4	-	18		(78)%	48	551	4	-	-
Referral to Voluntary Medical Male Circumcision	-	-	-	-	79		(100)%	120	10,815	-	-	-
Referral to Voluntary Medical Male Circumcision	-	-	-	-	79	12/14	(100)%	120	10,815	-	-	-
Safe Water Solution	-	-	-	-	-		0%	132,805	780,659	-	-	-
WaterGuard Solution 150mL SI	-	-	-	-	-	4/14	-%	132,805	780,659	-	-	-
STI Screening	4,854	2,582	12,360	-	203		5989%	1,460	23,158	12,360	-	-
STI Screening	4,854	2,582	12,360	-	203		5,989%	1,460	23,158	12,360	-	-
TB Diagnosis	16	11	26	-	51		(49)%	242	1,417	26	-	-
TB Diagnosis	16	11	26	-	51		(49)%	242	1,417	26	-	-

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

**Period: 2**

**Year: 2019**

	DISTRIBUTION 2/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
TB DOTS	-	-	-	-	2		(100)%	4	54	-	-	-
TB DOTS	-	-	-	-	2	7/14	(100)%	4	54	-	-	-
TB Screening	12,866	10,671	22,134	-	23,419		(5)%	134,977	926,092	22,134	-	-
TB Screening	12,866	10,671	22,134	-	23,419		(5)%	134,977	926,092	22,134	-	-
Treatment for Cervicitis	4	11	16	-	5		220%	73	379	16	-	1
Treatment for Cervicitis	4	11	16	-	5		220%	73	379	16	-	1
Treatment for Genital Herpes	-	-	-	-	-		0%	11	36	-	-	-
Treatment for Genital Herpes	-	-	-	-	-		-%	11	36	-	-	-
Treatment for Inguinal Bubo	-	-	-	-	-		0%	2	12	-	-	-
Treatment for Inguinal Bubo	-	-	-	-	-		-%	2	12	-	-	-
Treatment for Lower Abdominal Pain	-	1	2	-	7		(71)%	20	39	2	-	-
Treatment for Lower Abdominal Pain	-	1	2	-	7		(71)%	20	39	2	-	-
Treatment for Nonherpetic Genital Ulcer	42	30	69	-	47		47%	436	905	69	-	25
Treatment for Nonherpetic Genital Ulcer	42	30	69	-	47		47%	436	905	69	-	25
Treatment for Urethral Discharge (Men)	11	9	17	-	19		(11)%	92	360	34	-	2
Treatment for Urethral Discharge (Men)	11	9	17	-	19		(11)%	92	360	34	-	2
Treatment for Urethral Discharge (Women)	50	42	87	-	85		2%	493	1,530	87	-	16
Treatment for Urethral Discharge (Women)	50	42	87	-	85		2%	493	1,530	87	-	16
Treatment for Vaginitis	2	2	6	-	3		100%	10	17	6	-	1
Treatment for Vaginitis	2	2	6	-	3		100%	10	17	6	-	1
Type 2 Diabetes Diagnosis	-	-	-	-	-		0%	3	8	-	-	-
Type 2 Diabetes Diagnosis	-	-	-	-	-		-%	3	8	-	-	-
Type 2 Diabetes Screening	46	321	88	-	1,008		(91)%	5,658	11,822	88	-	-
Type 2 Diabetes Screening	46	321	88	-	1,008		(91)%	5,658	11,822	88	-	-
Type 2 Diabetes_Controlled Condition	-	-	-	-	1		(100)%	6	12	-	-	-

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

**Period: 2**

**Year: 2019**

	DISTRIBUTION 2/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	<sup>(a)</sup> YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
Type 2 Diabetes_Controlled Condition	-	-	-	-	1		(100)%	6	12	-	-	-
Voluntary Medical Male Circumcision	17,430	11,988	29,068	-	34,838		(17)%	243,971	491,733	29,068	-	196,962
Voluntary Medical Male Circumcision	17,430	11,988	29,068	-	34,838		(17)%	243,971	491,733	29,068	-	196,962

(a) The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

# Franco/Lusophone Africa Africa Market Group

**POPULATION SERVICES INTERNATIONAL**  
**CYPs, Cases, and Deaths by Country**  
**1/2019 - 2/2019**

	New HIV Infections	STI Deaths	PWID Deaths	TB Deaths	CYP*	Maternal Deaths	Unintended Pregnancies	Malaria Deaths	Diarrhea Deaths	Pneumonia Deaths	Cervical Cancer Death	Sum of All Deaths
Franco/Lusophone Africa Market Gro	1,837	1	-	-	208,135	282	79,317	556	41	-	-	2,620
Angola	54	-	-	-	14,795	17	5,155	409	4	-	-	561
Benin	45	-	-	-	12,502	15	4,761	-	19	-	-	115
Burundi	272	1	-	-	12,932	18	3,977	143	-	-	-	261
Cameroon	742	-	-	-	82,439	121	30,777	4	8	-	-	770
Cote d'Ivoire	-	-	-	-	13,875	25	6,436	-	3	-	-	135
Mozambique	660	-	-	-	48,689	47	19,074	-	5	-	-	557
Niger	4	-	-	-	9,621	14	4,141	-	-	-	-	121
PSI Benin	-	-	-	-	3,519	18	1,589	-	-	-	-	44
Senegal	60	-	-	-	9,762	6	3,408	1	2	-	-	56

\* Using USAID CYP conversion factors

POPULATION SERVICES INTERNATIONAL  
Monthly Distribution by Market Group and Product  
Period: 2  
Year: 2019

	DISTRIBUTION 2/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE SALES	YTD USERS REACHED <sup>(a)</sup> 2019	YTD CYP 2019	YTD DALY 2019
<b>Franco/Lusophone Africa Market Group</b>										<b>208,135</b>	<b>282,827</b>
Acute Malnutrition Screening_CU5	-	-	-	-	324	(100)%	518	1,895	-	-	-
Antiretroviral Treatment (Currently Enrolled)	2,940	2,884	5,843	-	1,255	366%	19,016	31,489	487	-	1,101
Antiretroviral Treatment (Newly Enrolled)	27	50	68	-	130	(48)%	1,807	2,289	68	-	-
CD4 Tests Provided to HIV+ Clients	-	-	-	-	122	(100)%	122	1,327	-	-	-
Cervical Cancer-VIA and Cryotherapy	1	2	1	-	7	(86)%	48	375	1	-	-
Cervical Cancer-VIA/VILI Screening	1,173	4,094	2,528	-	4,673	(46)%	50,592	154,003	2,528	-	-
Condom	3,442,340	4,831,098	8,416,546	-	6,877,003	22%	51,030,685	328,342,023	63,124	63,124	105,594
Diarrhea Treatment Kit	18,249	16,838	31,297	-	20,937	49%	431,332	4,166,826	28,167	-	1,791
Emergency Contraception	7,609	5,955	14,615	-	54,289	(73)%	135,874	185,558	658	658	389
Emergency Contraception Provided	371	422	739	-	226	227%	2,877	4,142	37	37	23
Fecal Sludge Management (Households)	36	171	64	-	48	33%	1,374	1,438	326	-	-
Fecal Sludge Management (Liters)	768,000	527,333	1,232,000	-	518,000	138%	5,110,000	6,342,000	-	-	131
Female Condom	132,560	365,350	594,790	-	125,149	375%	1,160,677	6,007,721	4,461	4,461	6,348
Fever Cases Attended	-	-	-	-	-	-%	14,143	26,907	-	-	-
Fever Cases Tested with RDTs	-	-	-	-	-	-%	14,143	42,041	-	-	-
Free Condom	30,600	35,719	31,100	-	141,648	(78)%	3,201,731	21,602,461	233	233	193
Free Female Condom	-	7,916	-	-	2,900	(100)%	49,536	260,329	-	-	-
HIV Testing Services	5,618	7,984	15,243	-	22,288	(32)%	106,415	996,372	15,243	-	127
Implant 3	2,796	(3,436)	1,081	-	3,564	(70)%	7,414	27,525	973	2,432	2,268
Implant 3 Insertion	1,413	7,511	6,927	-	1,120	518%	24,546	50,801	6,927	17,318	16,184
Implant 4 Insertion	-	1	3	-	-	-%	2	23	3	10	6

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.



**POPULATION SERVICES INTERNATIONAL**  
**Monthly Distribution by Market Group and Product**  
**Period: 2**  
**Year: 2019**

	DISTRIBUTION 2/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE SALES	YTD USERS REACHED <sup>(a)</sup> 2019	YTD CYP 2019	YTD DALY 2019
Implant 5	385	1,910	(321)	-	(15)	-%	27,721	(6,018)	(289)	(1,098)	(867)
Implant 5 Insertion	4,181	6,212	9,106	-	7,413	23%	76,301	311,323	9,106	34,603	33,181
Injectable 2	(31)	3,347	195	-	7,145	(97)%	54,602	294,539	29	29	16
Injectable 2 Provided	888	1,358	2,356	-	2,230	6%	15,848	41,106	393	393	211
Injectable 3-IM	20,943	54,015	7,248	-	15,918	(54)%	272,940	293,513	1,631	1,631	1,150
Injectable 3-IM Provided	14,048	35,300	51,561	-	37,967	36%	272,082	663,563	12,890	12,890	9,841
Injectable 3-SC	6,530	4,107	10,055	-	470	2,039%	26,328	38,998	2,262	2,262	1,431
Injectable 3-SC Provided	3,926	3,211	7,830	-	-	-%	5,729	13,559	1,958	1,958	1,616
IUD 10	2,351	(403)	2,727	-	4,008	(32)%	29,864	215,134	2,454	11,290	9,663
IUD 10 Insertion	2,003	7,333	6,709	-	8,541	(21)%	73,738	261,351	6,709	30,861	27,806
LLIN	134,944	362,695	248,932	-	137,234	81%	4,602,963	24,484,094	403,270	-	29,802
Lubricant	385	4,761	855	-	8,032	(89)%	45,024	614,212	-	-	-
Malaria PPT (ACT)	18,960	12,883	43,412	-	123,036	(65)%	297,174	528,353	39,071	-	12,059
Malaria RDK	15,025	21,020	24,575	-	-	-%	177,919	1,117,196	22,118	-	-
Manual Vacuum Aspiration for PAC	181	352	410	-	185	122%	2,579	4,570	410	-	147
Manual Vacuum Aspiration for SA	36	83	86	-	12	617%	562	1,269	86	-	34
Medical Abortion	460	143	675	-	-	-%	215	890	608	-	248
Medical Abortion (Misoprostol) Provided	80	48	111	-	2	5,450%	309	420	111	-	40
Medical Abortion Provided	-	-	-	-	51	(100)%	51	136	-	-	-
Micronutrient Powder	77,730	2,971	78,120	-	550,612	(86)%	948,572	2,414,712	193	-	-
Misoprostol for PAC Provided	88	314	316	-	169	87%	2,304	3,694	316	-	160

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

**POPULATION SERVICES INTERNATIONAL**  
**Monthly Distribution by Market Group and Product**  
**Period: 2**  
**Year: 2019**

	DISTRIBUTION 2/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE SALES	YTD USERS REACHED <sup>(a)</sup> 2019	YTD CYP 2019	YTD DALY 2019
Misoprostol for Safe Abortion	47,937	87,596	76,943	-	76,185	1%	745,045	1,621,237	4,040	-	1,477
OCs	277,976	56,030	350,199	-	86,883	303%	1,347,096	6,020,908	21,012	21,012	15,713
OCs Provided	27,439	37,205	60,044	-	50,594	19%	367,827	1,007,065	4,003	4,003	3,469
Pneumonia PPT	-	(28)	-	-	-	-%	30,316	477,424	-	-	-
Positive RDTs	-	-	-	-	-	-%	13,716	40,358	-	-	-
Positive RDTs Given First Line Treatment	-	-	-	-	-	-%	13,647	39,926	-	-	-
QAACTs Provided after Confirmatory Diagnosis	-	-	-	-	-	-%	13,647	13,647	-	-	-
Safe Water Solution	-	90,000	81,360	-	518,413	(84)%	870,831	6,187,090	66,871	-	349
SDM (Cycle Beads)	13	48	9	-	44	(80)%	1,533	48,038	8	12	9
SDM (Cycle Beads) Provided	7	10	11	-	5	120%	96	274	11	17	13
Seasonal Malaria Chemoprevention	-	-	-	-	-	-%	344,748	344,748	-	-	-
Skilled Birth Attendance	140	147	255	-	-	-%	9,160	26,590	255	-	323
STI Screening	866	884	1,726	-	1,289	34%	8,747	32,712	1,726	-	-
Toilets Sold	722	597	1,094	-	15	7,110%	4,017	5,111	7,565	-	179
Treatment for Cervicitis	1	2	6	-	-	-%	-	6	6	-	-
Treatment for Genital Herpes	124	8	124	-	1	12,300%	42	188	124	-	3
Treatment for Inguinal Bubo	-	5	6	-	4	50%	33	73	6	-	-
Treatment for Lower Abdominal Pain	66	98	174	-	84	107%	693	1,241	174	-	-
Treatment for Nonherpetic Genital Ulcer	23	138	167	-	136	23%	1,027	1,956	167	-	18
Treatment for Urethral Discharge (Men)	246	189	433	-	236	83%	1,631	3,389	866	-	5
Treatment for Urethral Discharge (Women)	349	299	734	-	298	146%	2,054	4,259	734	-	17

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

**POPULATION SERVICES INTERNATIONAL**  
**Monthly Distribution by Market Group and Product**  
**Period: 2**  
**Year: 2019**

	DISTRIBUTION 2/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE SALES	YTD USERS REACHED <sup>(a)</sup> 2019	YTD CYP 2019	YTD DALY 2019
Treatment for Vaginitis	-	-	-	-	1	(100)%	2	7	-	-	-
Tubal Ligation	-	68	-	-	-	-%	204	204	-	-	-
Vasectomy	-	35	-	-	-	-%	104	104	-	-	-
Water Treatment Tablets	3,728,300	1,166,430	4,314,620	-	1,546,900	179%	20,217,570	158,171,700	70,925	-	564

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

**POPULATION SERVICES INTERNATIONAL**  
**Monthly Distribution by Country**  
**Period: 2**  
**Year: 2019**

	DISTRIBUTION 2/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
<b>Franco/Lusophone Africa Market Group</b>											<b>208,135</b>	<b>282,827</b>
<b>Angola</b>											<b>14,795</b>	<b>45,790</b>
Condom	316,080	349,743	474,084	-	496,188		(4)%	3,793,904	15,494,595	3,556	3,556	4,289
Sensual Champagne	6,084	7,620	12,888	-	78,588		(84)%	314,100	697,608	97	97	117
Sensual Chocolate	119,448	121,908	179,568	-	97,596	12/12	84%	804,168	3,854,652	1,347	1,347	1,624
Sensual Maracuja	46,116	57,720	71,712	-	63,720		13%	631,476	1,341,432	538	538	649
Sensual Menta	-	48,339	-	-	133,380	12/12	(100)%	1,138,688	4,819,068	-	-	-
Sensual Morango	144,432	114,156	209,916	-	122,904	12/12	71%	905,472	4,781,835	1,574	1,574	1,899
Emergency Contraception	7,356	3,570	10,329	-	-		0%	45,514	55,843	465	465	288
Pronta	7,356	3,570	10,329	-	-		-%	45,514	55,843	465	465	288
Implant 5	4	15	5	-	542		(99)%	1,334	1,839	5	17	19
Jadelle	4	15	5	-	542	12/17	(99)%	1,334	1,839	5	17	19
IUD 10	-	195	(852)	-	(389)		0%	981	7,418	(767)	(3,527)	(3,669)
Copper T 380 A – ENOVA	-	1,440	46	-	1,224		(96)%	20,092	29,823	41	190	198
(b)PSI IUD 10 Distributed Inserted	-	(1,245)	(898)	-	(1,613)		-%	(19,111)	(22,405)	(808)	(3,718)	(3,867)
IUD 10 Insertion	-	1,245	898	-	1,613		(44)%	19,111	22,405	898	4,131	4,297
PSI IUD 10 Inserted	-	1,245	898	-	1,613		(44)%	19,111	22,405	898	4,131	4,297
LLIN	79,515	282,881	145,078	-	495		29209%	3,520,905	13,172,672	235,026	-	19,416
Generic LLINs	78,754	282,381	143,875	-	-	4/11	-%	3,409,889	12,303,308	233,078	-	19,255
Joia	761	(32,833)	1,203	-	495	11/04	143%	11,016	347,162	1,949	-	161
PermaNet	-	33,333	-	-	-	10/12	-%	100,000	522,202	-	-	-
Malaria PPT (ACT)	18,960	12,860	43,412	-	122,836		(65)%	281,787	425,345	39,071	-	12,059
ALU 20mg/120mg, 12's, 3-8Yrs (15-24Kg)	4,578	4,676	16,135	-	15,866	6/17	2%	59,156	104,718	14,522	-	4,482
ALU 20mg/120mg, 18's, 9-14Yrs (25-34Kg)	7,285	2,268	9,780	-	20,499	6/17	(52)%	89,660	114,285	8,802	-	2,717

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**  
**Monthly Distribution by Country**  
**Period: 2**  
**Year: 2019**

	DISTRIBUTION 2/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
ALU 20mg/120mg, 24's, >14Yrs (>34Kg)	4,414	1,629	6,169	-	56,779	6/17	(89)%	85,439	118,854	5,552	-	1,714
ALU 20mg/120mg, 6's, >3Yrs (5-14Kg)	2,683	4,286	11,328	-	29,692	6/17	(62)%	47,532	87,488	10,195	-	3,147
Malaria RDK	15,025	20,825	24,575	-	-		0%	161,350	900,350	22,118	-	-
Bioline (RDT)	15,025	20,825	24,575	-	-	2/14	-%	161,350	900,350	22,118	-	-
Misoprostol for Safe Abortion	2,452	22,744	5,864	-	856		585%	195,208	448,000	308	-	150
ACE Miso (Misoprostol 200mcg tablet)	2,452	22,744	5,864	-	856	3/18	585%	195,208	448,000	308	-	150
OCs	160,696	4,016	169,237	-	2,118		7890%	123,041	313,929	10,154	10,154	8,707
MEURI	160,696	4,016	169,237	-	2,118		7,890%	123,041	313,929	10,154	10,154	8,707
Water Treatment Tablets	1,235,600	266,300	1,432,200	-	1,039,300		38%	7,883,400	69,546,662	23,543	-	235
Certeza Water Tabs	1,235,600	266,300	1,432,200	-	1,039,300	4/11	38%	7,883,400	69,546,662	23,543	-	235
<b>Benin</b>											12,502	10,994
Cervical Cancer-VIA and Cryotherapy	1	2	1	-	7		(86)%	48	375	1	-	-
Cervical Cancer-VIA and Cryotherapy	1	2	1	-	7	2/13	(86)%	48	375	1	-	-
Cervical Cancer-VIA/VILI Screening	1,173	4,094	2,528	-	4,673		(46)%	50,592	154,003	2,528	-	-
Cervical Cancer-VIA/VILI Screening	1,173	4,094	2,528	-	4,673		(46)%	50,592	154,003	2,528	-	-
Condom	473,832	301,845	708,888	-	712,392		0%	4,658,955	77,432,825	5,317	5,317	3,984
Kool	-	-	-	-	115,332	2/10	(100)%	176,099	16,803,302	-	-	-
Kool Banane	52,140	32,483	85,740	-	-	4/18	-%	360,744	446,484	643	643	482
Kool Fraise	52,500	32,803	84,900	-	-	4/18	-%	352,122	437,022	637	637	477
Kool Menthe	60,240	34,863	96,240	-	-	4/18	-%	407,334	503,574	722	722	541
Prudence Plus	308,952	201,696	442,008	-	597,060	1/08	(26)%	3,362,656	59,242,443	3,315	3,315	2,484
Diarrhea Treatment Kit	10,034	10,779	17,650	-	15,680		13%	399,297	3,373,125	15,885	-	1,106
Orasel Zinc DTK	10,034	10,779	17,650	-	15,680	4/08	13%	399,297	3,373,125	15,885	-	1,106
Fecal Sludge Management (Households)	-	151	-	-	-		0%	1,059	1,059	-	-	-

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

**Period: 2**

**Year: 2019**

	DISTRIBUTION 2/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
Fecal Sludge Management (Households)	-	151	-	-	-		-%	1,059	1,059	-	-	-
Fecal Sludge Management (Liters)	228,000	256,000	228,000	-	-		0%	1,743,000	1,971,000	-	-	33
Fecal Sludge Management (Liters)	228,000	256,000	228,000	-	-		-%	1,743,000	1,971,000	-	-	33
Female Condom	-	-	-	-	460		(100)%	9,985	33,646	-	-	-
Cupid	-	-	-	-	460	3/14	(100)%	9,985	33,646	-	-	-
Free Condom	27,300	14,739	27,800	-	-		0%	683,616	2,964,895	208	208	156
No Logo	27,300	14,739	27,800	-	-	1/12	-%	683,616	2,964,895	208	208	156
HIV Testing Services	3,351	3,065	7,956	-	10,497		(24)%	47,885	632,707	7,956	-	42
VCT Individual (HIV-Negative)	3,347	3,056	7,944	-	10,377	1/10	(23)%	47,316	625,583	7,944	-	42
VCT Individual (HIV-Positive)	4	9	12	-	120	1/10	(90)%	569	7,124	12	-	-
Implant 5	431	2,039	(186)	-	(587)		0%	28,303	(3,396)	(167)	(636)	(455)
Implant 5 (insertion)	940	2,698	940	-	800	12/09	18%	37,266	130,577	846	3,215	2,298
(b)PSI Implant 5 Distributed Inserted	(509)	(659)	(1,126)	-	(1,387)		-%	(8,963)	(133,973)	(1,013)	(3,851)	(2,752)
Implant 5 Insertion	653	2,591	1,504	-	2,502		(40)%	38,442	194,124	1,504	5,715	4,084
Non-PSI Implant 5 Inserted	144	1,931	378	-	1,115		(66)%	29,479	60,151	378	1,436	1,027
PSI Implant 5 Inserted	509	659	1,126	-	1,387		(19)%	8,963	133,973	1,126	4,279	3,058
Injectable 2	(31)	3,347	195	-	7,145		(97)%	54,602	294,539	29	29	16
Noristerat	656	4,071	1,856	-	8,590	1/12	(78)%	62,728	320,637	278	278	149
(b)PSI Injectable 2 Distributed Provided	(687)	(724)	(1,661)	-	(1,445)		-%	(8,126)	(26,098)	(249)	(249)	(133)
Injectable 2 Provided	868	1,102	2,131	-	2,230		(4)%	14,475	39,508	355	355	189
Non-PSI Injectable 2 Provided	181	378	470	-	785		(40)%	6,349	13,410	78	78	42
PSI Injectable 2 Provided	687	724	1,661	-	1,445		15%	8,126	26,098	277	277	148
Injectable 3-SC	150	-	150	-	-		0%	-	150	34	34	18
Sayana Press	150	-	150	-	-		-%	-	150	34	34	18
IUD 10	(504)	(481)	(1,189)	-	(2,288)		0%	(6,402)	44,137	(1,070)	(4,922)	(3,368)

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

**Period: 2**

**Year: 2019**

	DISTRIBUTION 2/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
IUD (insertion)	-	-	-	-	-	12/09	-%	1,109	13,420	-	-	-
IUD Copper-T TCU 380A	120	644	120	-	50	9/09	140%	7,435	139,128	108	497	340
(b)PSI IUD 10 Distributed Inserted	(624)	(1,125)	(1,309)	-	(2,338)		-%	(14,946)	(108,411)	(1,178)	(5,419)	(3,708)
IUD 10 Insertion	653	1,458	1,383	-	2,494		(45)%	20,070	119,718	1,383	6,362	4,353
Non-PSI IUD 10 Inserted	29	333	74	-	156		(53)%	5,124	11,307	74	340	233
PSI IUD 10 Inserted	624	1,125	1,309	-	2,338		(44)%	14,946	108,411	1,309	6,021	4,120
LLIN	-	-	-	-	69		(100)%	5,018	734,451	-	-	-
Super Moustiquaire Longue Durée	-	-	-	-	-	5/06	-%	4,808	730,601	-	-	-
SuperMoustiquaire (blanche 1 place)	-	-	-	-	69	9/15	(100)%	210	3,850	-	-	-
Lubricant	-	3,307	-	-	-		0%	9,920	485,348	-	-	-
Gel Lubricant 5 mL	-	3,307	-	-	-	12/16	-%	9,920	485,348	-	-	-
Manual Vacuum Aspiration for PAC	102	109	226	-	-		0%	803	2,196	226	-	72
MVA for PAC	102	109	226	-	-	10/16	-%	803	2,196	226	-	72
Manual Vacuum Aspiration for SA	34	25	70	-	-		0%	211	902	70	-	27
Manual Vacuum Aspiration for SA	34	25	70	-	-		-%	211	902	70	-	27
Medical Abortion (Misoprostol) Provided	25	12	41	-	-		0%	93	134	41	-	14
PSI Medical Abortion (Misoprostol) Provided	25	12	41	-	-		-%	93	134	41	-	14
Misoprostol for PAC Provided	59	59	130	-	-		0%	459	866	130	-	49
PSI Misoprostol for PAC Provided	59	59	130	-	-		-%	459	866	130	-	49
Misoprostol for Safe Abortion	(536)	(384)	(1,012)	-	-		0%	(2,952)	(5,072)	(53)	-	(18)
(b)PSI Misoprostol for Safe Abortion Dist Provided	(536)	(384)	(1,012)	-	-		-%	(2,952)	(5,072)	(53)	-	(18)
OCs	(306)	425	(637)	-	35,971		(102)%	215,192	1,296,488	(38)	(38)	(22)
Laafia Pilule	-	707	-	-	36,375	6/12	(100)%	218,541	1,325,594	-	-	-
(b)PSI OCs Distributed Provided	(306)	(282)	(637)	-	(404)		-%	(3,349)	(29,106)	(38)	(38)	(22)
OCs Provided	345	370	740	-	498		49%	5,041	32,316	49	49	28

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

**Period: 2**

**Year: 2019**

	DISTRIBUTION 2/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
Non-PSI OCs Provided	39	88	103	-	94		10%	1,692	3,210	7	7	4
PSI OCs Provided	306	282	637	-	404		58%	3,349	29,106	42	42	24
SDM (Cycle Beads)	13	48	9	-	44		(80)%	1,520	37,331	8	12	9
CycleBeads	20	58	20	-	49	12/04	(59)%	1,612	37,590	18	27	21
(b)PSI SDM (Cycle Beads) Distributed Provided	(7)	(10)	(11)	-	(5)		-%	(92)	(259)	(10)	(15)	(11)
SDM (Cycle Beads) Provided	7	10	11	-	5		120%	96	274	11	17	13
Non-PSI SDM (Cycle Beads) Provided	-	-	-	-	-		-%	4	15	-	-	-
PSI SDM (Cycle Beads) Provided	7	10	11	-	5		120%	92	259	11	17	13
Skilled Birth Attendance	140	147	255	-	-		0%	9,160	26,590	255	-	323
Skilled Birth Attendance	140	147	255	-	-		-%	9,160	26,590	255	-	323
STI Screening	352	225	618	-	529		17%	3,265	19,400	618	-	-
STI Screening	352	225	618	-	529		17%	3,265	19,400	618	-	-
Toilets Sold	113	207	196	-	15		1194%	2,776	2,972	982	-	49
Toilets Sold	113	207	196	-	15		1,194%	2,776	2,972	982	-	49
Treatment for Cervicitis	1	2	6	-	-		0%	-	6	6	-	-
Treatment for Cervicitis	1	2	6	-	-		-%	-	6	6	-	-
Treatment for Genital Herpes	21	-	21	-	-		0%	-	21	21	-	-
Treatment for Genital Herpes	21	-	21	-	-		-%	-	21	21	-	-
Treatment for Lower Abdominal Pain	13	2	20	-	-		0%	-	20	20	-	-
Treatment for Lower Abdominal Pain	13	2	20	-	-		-%	-	20	20	-	-
Treatment for Nonherpetic Genital Ulcer	23	8	48	-	-		0%	-	48	48	-	-
Treatment for Nonherpetic Genital Ulcer	23	8	48	-	-		-%	-	48	48	-	-
Treatment for Urethral Discharge (Men)	56	16	105	-	-		0%	-	221	210	-	1
Treatment for Urethral Discharge (Men)	56	16	105	-	-		-%	-	221	210	-	1
Treatment for Urethral Discharge (Women)	181	52	336	-	-		0%	-	474	336	-	4

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.



**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

Period: 2

Year: 2019

	DISTRIBUTION 2/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
Treatment for Urethral Discharge (Women)	181	52	336	-	-		-%	-	474	336	-	4
Water Treatment Tablets	1,872,300	634,153	2,190,300	-	441,400		396%	8,283,060	76,241,830	36,005	-	286
Aquatab	1,872,300	634,153	2,190,300	-	441,400	1/08	396%	8,283,060	76,241,830	36,005	-	286
<b>Burundi</b>											<b>12,932</b>	<b>30,350</b>
Antiretroviral Treatment (Currently Enrolled)	2,314	2,123	4,592	-	717		540%	10,802	22,024	383	-	863
Antiretroviral Treatment (Currently Enrolled)	2,314	2,123	4,592	-	717		540%	10,802	22,024	383	-	863
Antiretroviral Treatment (Newly Enrolled)	26	42	66	-	30		120%	1,346	1,826	66	-	-
Antiretroviral Treatment (Newly Enrolled)	26	42	66	-	30		120%	1,346	1,826	66	-	-
CD4 Tests Provided to HIV+ Clients	-	-	-	-	56		(100)%	56	539	-	-	-
CD4 Tests Provided to HIV+ Clients	-	-	-	-	56		(100)%	56	539	-	-	-
Condom	543,330	817,740	1,358,640	-	288,720		371%	5,134,060	30,521,353	10,190	10,190	16,698
Prudence Class	543,330	817,740	1,358,640	-	288,720	12/09	371%	5,134,060	30,521,353	10,190	10,190	16,698
Emergency Contraception	213	176	88	-	89		(1)%	3,720	4,108	4	4	2
Nowill	490	444	671	-	228	9/17	194%	5,699	6,829	30	30	19
(b)PSI Emergency Contraception Distributed Provided	(277)	(268)	(583)	-	(139)		-%	(1,979)	(2,721)	(26)	(26)	(16)
Emergency Contraception Provided	277	268	583	-	139		319%	1,979	2,721	29	29	18
PSI Emergency Contraception Provided	277	268	583	-	139		319%	1,979	2,721	29	29	18
Free Condom	-	-	-	-	-		0%	1,000,800	10,271,216	-	-	-
Free Male Condoms	-	-	-	-	-	5/11	-%	1,000,800	10,271,216	-	-	-
Free Female Condom	-	-	-	-	-		0%	16,000	160,930	-	-	-
Free Female Condoms	-	-	-	-	-	5/11	-%	16,000	160,930	-	-	-
HIV Testing Services	1,973	2,520	4,406	-	3,704		19%	24,249	135,439	4,406	-	29
VCT Individual (HIV-Negative)	1,931	2,464	4,318	-	3,633	12/09	19%	23,617	133,366	4,318	-	29
VCT Individual (HIV-Positive)	42	56	88	-	71	12/09	24%	632	2,073	88	-	1
Implant 5	37	(28)	17	-	27		(37)%	88	1,100	15	58	64

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

**Period: 2**

**Year: 2019**

	DISTRIBUTION 2/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
Jadelle	123	67	209	-	226	2/14	(8)%	1,413	5,967	188	715	788
(b)PSI Implant 5 Distributed Inserted	(86)	(95)	(192)	-	(199)		-%	(1,325)	(4,867)	(173)	(657)	(724)
Implant 5 Insertion	86	95	192	-	199		(4)%	1,325	4,867	192	730	804
PSI Implant 5 Inserted	86	95	192	-	199		(4)%	1,325	4,867	192	730	804
Injectable 3-IM	606	129	1,012	-	288		251%	2,296	12,678	228	228	188
DMPA 3-month Injectable	2,460	2,127	4,981	-	3,296	2/14	51%	23,387	70,870	1,121	1,121	924
(b)PSI Injectable 3 IM Distributed Provided	(1,854)	(1,998)	(3,969)	-	(3,008)		-%	(21,091)	(58,192)	(893)	(893)	(736)
Injectable 3-IM Provided	1,854	1,998	3,969	-	3,008		32%	21,091	58,192	992	992	818
PSI Injectable 3 IM Provided	1,854	1,998	3,969	-	3,008		32%	21,091	58,192	992	992	818
IUD 10	29	(2)	28	-	23		22%	126	1,308	25	116	122
Copper-T 380-A IUD	65	35	112	-	111	2/14	1%	670	3,066	101	464	489
(b)PSI IUD 10 Distributed Inserted	(36)	(37)	(84)	-	(88)		-%	(544)	(1,758)	(76)	(348)	(366)
IUD 10 Insertion	36	37	84	-	88		(5)%	544	1,758	84	386	407
PSI IUD 10 Inserted	36	37	84	-	88		(5)%	544	1,758	84	386	407
LLIN	52,450	75,862	100,150	-	130,050		(23)%	790,442	1,372,379	162,243	-	10,069
MIILDA - DAWA PLUS 2.0	52,450	75,862	100,150	-	130,050	5/17	(23)%	790,442	1,372,379	162,243	-	10,069
Manual Vacuum Aspiration for PAC	10	11	26	-	13		100%	66	179	26	-	16
MVA for PAC	10	11	26	-	13	6/16	100%	66	179	26	-	16
Misoprostol for PAC Provided	27	26	59	-	16		269%	179	401	59	-	43
PSI Misoprostol for PAC Provided	27	26	59	-	16		269%	179	401	59	-	43
Misoprostol for Safe Abortion	(68)	59	(76)	-	41		(285)%	779	1,791	(4)	-	(3)
Misoprostol for Safe Abortion	40	163	160	-	105	3/18	52%	1,495	3,395	8	-	6
(b)PSI Misoprostol for Safe Abortion Dist Provided	(108)	(104)	(236)	-	(64)		-%	(716)	(1,604)	(12)	-	(8)
OCs	534	90	912	-	1,161		(21)%	4,428	19,903	55	55	48
Confiance OC	1,530	1,230	3,081	-	2,985	2/14	3%	16,422	54,666	185	185	161

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**  
**Monthly Distribution by Country**  
**Period: 2**  
**Year: 2019**

	DISTRIBUTION 2/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
(b)PSI OCs Distributed Provided	(996)	(1,140)	(2,169)	-	(1,824)		-%	(11,994)	(34,763)	(130)	(130)	(113)
OCs Provided	996	1,140	2,169	-	1,824		19%	11,994	34,763	145	145	126
PSI OCs Provided	996	1,140	2,169	-	1,824		19%	11,994	34,763	145	145	126
STI Screening	514	659	1,108	-	760		46%	5,482	13,312	1,108	-	-
STI Screening	514	659	1,108	-	760		46%	5,482	13,312	1,108	-	-
Treatment for Genital Herpes	103	8	103	-	1		10200%	42	167	103	-	3
Treatment for Genital Herpes	103	8	103	-	1		10,200%	42	167	103	-	3
Treatment for Inguinal Bubo	-	5	6	-	4		50%	33	73	6	-	-
Treatment for Inguinal Bubo	-	5	6	-	4		50%	33	73	6	-	-
Treatment for Lower Abdominal Pain	53	96	154	-	84		83%	693	1,221	154	-	-
Treatment for Lower Abdominal Pain	53	96	154	-	84		83%	693	1,221	154	-	-
Treatment for Nonherpetic Genital Ulcer	-	130	119	-	136		(13)%	1,027	1,908	119	-	18
Treatment for Nonherpetic Genital Ulcer	-	130	119	-	136		(13)%	1,027	1,908	119	-	18
Treatment for Urethral Discharge (Men)	190	172	328	-	236		39%	1,631	3,168	656	-	4
Treatment for Urethral Discharge (Men)	190	172	328	-	236		39%	1,631	3,168	656	-	4
Treatment for Urethral Discharge (Women)	168	247	398	-	298		34%	2,054	3,785	398	-	13
Treatment for Urethral Discharge (Women)	168	247	398	-	298		34%	2,054	3,785	398	-	13
Treatment for Vaginitis	-	-	-	-	1		(100)%	2	7	-	-	-
Treatment for Vaginitis	-	-	-	-	1		(100)%	2	7	-	-	-
<b>Cameroon</b>											<b>82,439</b>	<b>93,231</b>
Condom	1,849,930	1,914,181	3,831,422	-	3,379,831		13%	18,305,203	75,264,129	28,736	28,736	42,962
Lovers Plus	-	(1,476)	-	-	-	1/15	-%	(15,109)	3,215,171	-	-	-
Préservatif Masculin Aromatisé UNFPA	-	-	-	-	-	12/15	-%	7,200	9,274	-	-	-
Préservatif Masculin UNFPA	58,696	629,394	1,014,588	-	-	12/15	-%	932,290	2,067,718	7,609	7,609	11,377
Prudence Plus Nouveau	1,791,234	1,286,263	2,816,834	-	3,379,831	1/15	(17)%	17,380,822	69,971,966	21,126	21,126	31,585

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

**Period: 2**

**Year: 2019**

	DISTRIBUTION 2/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
Diarrhea Treatment Kit	8,215	6,059	13,647	-	5,257		160%	32,035	793,701	12,282	-	685
Orasel Zinc	8,215	6,059	13,647	-	5,257	10/09	160%	32,035	793,701	12,282	-	685
Emergency Contraception	40	2,209	4,198	-	54,200		(92)%	86,640	125,607	189	189	99
Norlevo	40	2,307	4,207	-	54,203	11/15	(92)%	86,934	126,120	189	189	99
(b)PSI Emergency Contraception Distributed Provided	-	(98)	(9)	-	(3)		-%	(294)	(513)	-	-	-
Emergency Contraception Provided	-	98	9	-	7		29%	307	531	-	-	-
Non-PSI Emergency Contraception Provided	-	-	-	-	4		(100)%	13	18	-	-	-
PSI Emergency Contraception Provided	-	98	9	-	3		200%	294	513	-	-	-
Female Condom	132,560	365,350	594,790	-	124,689		377%	1,150,692	5,974,075	4,461	4,461	6,348
Préservatif Féminin CUPID	-	-	-	-	114,484	7/14	(100)%	160,327	1,125,022	-	-	-
Préservatif Féminins UNFPA	3,360	3,557	3,960	-	5,045	3/15	(22)%	26,300	834,379	30	30	42
Protectiv Plus	111,200	6,000	129,200	-	-	4/14	-%	-	1,087,357	969	969	1,379
Securite Plus Female Condom	18,000	355,793	461,630	-	5,160	11/13	8,846%	964,065	2,927,317	3,462	3,462	4,927
Fever Cases Attended	-	-	-	-	-		0%	14,143	26,907	-	-	-
Fever Cases Attended	-	-	-	-	-		-%	14,143	26,907	-	-	-
Fever Cases Tested with RDTs	-	-	-	-	-		0%	14,143	42,041	-	-	-
Fever Cases Tested with RDTs	-	-	-	-	-		-%	14,143	42,041	-	-	-
Free Condom	3,300	20,981	3,300	-	24,980		(87)%	419,155	1,350,160	25	25	37
Generic MC	3,300	20,981	3,300	-	24,980	11/16	(87)%	419,155	1,350,160	25	25	37
Free Female Condom	-	6,667	-	-	-		0%	23,300	26,400	-	-	-
Generic FC	-	6,667	-	-	-	1/08	-%	23,300	26,400	-	-	-
HIV Testing Services	-	1,890	2,117	-	-		0%	5,827	69,160	2,117	-	49
VCT Individual (HIV-Negative)	-	1,862	2,049	-	-	1/10	-%	5,742	65,309	2,049	-	48
VCT Individual (HIV-Positive)	-	28	68	-	-	1/10	-%	85	3,851	68	-	2
Implant 3	2,796	(3,436)	1,081	-	3,564		(70)%	7,414	27,525	973	2,432	2,268

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

**Period: 2**

**Year: 2019**

	DISTRIBUTION 2/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
Implanon NXT	2,796	2,730	4,919	-	3,567	12/15	38%	22,089	59,195	4,427	11,068	10,318
(b)PSI Implant 3 Distributed Inserted	-	(6,166)	(3,838)	-	(3)	3/16	-%	(14,675)	(31,670)	(3,454)	(8,636)	(8,051)
Implant 3 Insertion	-	6,167	3,838	-	6		63867%	14,684	31,682	3,838	9,595	8,945
Non-PSI Implant 3 Inserted	-	2	-	-	3		(100)%	9	12	-	-	-
PSI Implant 3 Inserted	-	6,166	3,838	-	3	3/16	127,833%	14,675	31,670	3,838	9,595	8,945
Implant 5	(86)	(81)	(153)	-	3		(5200)%	(1,373)	2,832	(138)	(523)	(480)
Jadelle UNFPA	-	-	-	-	550	3/15	(100)%	550	34,416	-	-	-
(b)PSI Implant 5 Distributed Inserted	(86)	(81)	(153)	-	(547)		-%	(1,923)	(31,584)	(138)	(523)	(480)
Implant 5 Insertion	92	112	171	-	1,094		(84)%	3,201	34,041	171	650	595
Non-PSI Implant 5 Inserted	6	31	18	-	547		(97)%	1,278	2,457	18	68	63
PSI Implant 5 Inserted	86	81	153	-	547		(72)%	1,923	31,584	153	581	533
Injectable 3-IM	20,352	2,185	6,251	-	17,855		(65)%	130,960	163,462	1,406	1,406	964
Equilibre	20,450	21,562	26,197	-	18,106	5/16	45%	170,812	250,611	5,894	5,894	4,040
(b)PSI Injectable 3 IM Distributed Provided	(98)	(19,377)	(19,946)	-	(251)		-%	(39,852)	(87,149)	(4,488)	(4,488)	(3,076)
Injectable 3-IM Provided	129	19,435	19,977	-	413		4737%	40,845	88,648	4,994	4,994	3,423
Non-PSI Injectable 3 IM Provided	31	58	31	-	162		(81)%	993	1,499	8	8	5
PSI Injectable 3 IM Provided	98	19,377	19,946	-	251		7,847%	39,852	87,149	4,987	4,987	3,417
Injectable 3-SC	400	442	1,050	-	-		0%	3,476	4,526	236	236	162
Sayana Press	400	442	1,050	-	-	3/18	-%	3,476	4,526	236	236	162
IUD 10	2,224	(938)	3,818	-	5,112		(25)%	20,481	124,933	3,436	15,807	13,851
DIU UNFPA	-	-	-	-	1,800	3/15	(100)%	2,077	24,810	-	-	-
IUD	2,400	1,900	4,450	-	3,300	9/09	35%	25,200	157,672	4,005	18,423	16,144
IUD Copper T 380A	233	688	1,785	-	1,559	2/16	14%	12,066	31,761	1,607	7,390	6,476
(b)PSI IUD 10 Distributed Inserted	(409)	(3,527)	(2,417)	-	(1,547)		-%	(18,862)	(89,310)	(2,175)	(10,006)	(8,769)

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

**Period: 2**

**Year: 2019**

	DISTRIBUTION 2/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
IUD 10 Insertion	422	3,619	2,487	-	3,094		(20)%	21,794	93,541	2,487	11,440	10,025
Non-PSI IUD 10 Inserted	13	92	70	-	1,547		(95)%	2,932	4,231	70	322	282
PSI IUD 10 Inserted	409	3,527	2,417	-	1,547		56%	18,862	89,310	2,417	11,118	9,743
LLIN	954	813	1,679	-	5,472		(69)%	15,521	8,017,606	2,720	-	260
Super Moustiquaire	954	554	1,679	-	4,157	1/09	(60)%	9,665	8,011,706	2,720	-	260
Super Moustiquaire Interceptor	-	260	-	-	1,315	10/15	(100)%	5,856	5,900	-	-	-
Lubricant	385	982	855	-	1,848		(54)%	16,186	37,415	-	-	-
Lubricant 60 mL bottle	385	907	855	-	748	12/15	14%	6,061	16,415	-	-	-
Water-based Lubricant, 4 mL sachet	-	75	-	-	1,100	12/16	(100)%	10,125	21,000	-	-	-
Malaria PPT (ACT)	-	(3)	-	-	200		(100)%	15,227	109,448	-	-	-
ACT 1 (ASAQ 25 / 67.5 mg, 3 tablets)_2 -11 months	-	(26)	-	-	-	2/15	-%	(160)	6,440	-	-	-
ACT 2 (ASAQ 50 / 135.5 mg, 3 tablets)_1 - 5 years	-	(61)	-	-	100	2/15	(100)%	11,449	67,905	-	-	-
ACT 3 (ASAQ 100 / 270 mg, 3 tablets)_6 - 13 years	-	41	-	-	100	2/15	(100)%	1,685	17,250	-	-	-
ACT 4 (ASAQ 100 / 270 mg, 6 tablets)_14 years & up	-	43	-	-	-	2/15	-%	2,253	17,853	-	-	-
Malaria RDK	-	195	-	-	-		0%	16,569	216,846	-	-	-
Malaria Ag Pf/Pan_PA	-	195	-	-	-	12/12	-%	16,569	216,846	-	-	-
Manual Vacuum Aspiration for PAC	69	219	145	-	172		(16)%	1,309	1,781	145	-	51
MVA for PAC	69	219	145	-	172		(16)%	1,309	1,781	145	-	51
Manual Vacuum Aspiration for SA	2	58	16	-	12		33%	351	367	16	-	7
Manual Vacuum Aspiration for SA	2	58	16	-	12		33%	351	367	16	-	7
Medical Abortion	400	133	585	-	(43)		0%	172	697	527	-	218
Mifepack	400	133	585	-	-		-%	215	800	527	-	218
(b)PSI Medical Abortion Distributed Provided	-	-	-	-	(43)		-%	(43)	(103)	-	-	-
Medical Abortion (Misoprostol) Provided	55	36	70	-	2		3400%	216	286	70	-	26

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

**Period: 2**

**Year: 2019**

	DISTRIBUTION 2/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
Non-PSI Medical Abortion (Misoprostol) Provided	5	6	14	-	-		-%	24	38	14	-	5
PSI Medical Abortion (Misoprostol) Provided	50	30	56	-	2		2,700%	192	248	56	-	21
Medical Abortion Provided	-	-	-	-	51		(100)%	51	136	-	-	-
Non-PSI Medical Abortion Provided	-	-	-	-	8		(100)%	8	33	-	-	-
PSI Medical Abortion Provided	-	-	-	-	43		(100)%	43	103	-	-	-
Micronutrient Powder	77,730	2,971	78,120	-	550,612		(86)%	948,572	2,414,712	193	-	-
Super Bebe	77,730	2,971	78,120	-	550,612	9/16	(86)%	948,572	2,414,712	193	-	-
Misoprostol for PAC Provided	2	203	70	-	153		(54)%	1,105	1,809	70	-	29
Non-PSI Misoprostol for PAC Provided	-	14	7	-	42		(83)%	183	190	7	-	3
PSI Misoprostol for PAC Provided	2	189	63	-	111		(43)%	922	1,619	63	-	26
Misoprostol for Safe Abortion	12,113	19,704	26,811	-	45,444		(41)%	243,174	769,346	1,408	-	521
Misoprostol for Safe Abortion	12,721	20,820	27,735	-	45,912	3/18	(40)%	249,166	778,798	1,456	-	539
(b)PSI Misoprostol for Safe Abortion Dist Provided	(608)	(1,116)	(924)	-	(468)		-%	(5,992)	(9,452)	(49)	-	(18)
OCs	29,176	(1,630)	47,411	-	20,847		127%	341,853	1,057,331	2,845	2,845	2,057
Microgynon Ed Fe	-	-	-	-	8,745	7/14	(100)%	19,981	478,173	-	-	-
Microlut	-	-	-	-	-	12/17	-%	5,001	5,001	-	-	-
Novelle Duo	29,176	6,807	49,598	-	12,152	1/08	308%	340,259	619,966	2,976	2,976	2,152
(b)PSI OCs Distributed Provided	-	(8,437)	(2,187)	-	(50)		-%	(23,388)	(45,809)	(131)	(131)	(95)
OCs Provided	-	8,446	2,187	-	119		1738%	23,718	46,334	146	146	105
Non-PSI OCs Provided	-	8	-	-	69		(100)%	330	525	-	-	-
PSI OCs Provided	-	8,437	2,187	-	50		4,274%	23,388	45,809	146	146	105
Pneumonia PPT	-	(28)	-	-	-		0%	30,316	477,424	-	-	-
Amoxicillin 500mg x 15's -- Children 1-5 years	-	-	-	-	-	1/13	-%	28,750	326,142	-	-	-
Amoxicillin 500mg x 7's - Children 2-11 months	-	(28)	-	-	-	1/13	-%	1,566	151,282	-	-	-

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

Period: 2

Year: 2019

	DISTRIBUTION 2/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
Positive RDTs	-	-	-	-	-		0%	13,716	40,358	-	-	-
Positive RDTs	-	-	-	-	-		-%	13,716	40,358	-	-	-
Positive RDTs Given First Line Treatment	-	-	-	-	-		0%	13,647	39,926	-	-	-
Positive RDTs Given First Line Treatment	-	-	-	-	-		-%	13,647	39,926	-	-	-
QAACTs Provided after Confirmatory Diagnosis	-	-	-	-	-		0%	13,647	13,647	-	-	-
Non-PSI QAACTs Provided after Confirmed Diagnosis	-	-	-	-	-		-%	13,647	13,647	-	-	-
Tubal Ligation	-	68	-	-	-		0%	204	204	-	-	-
Tubal Ligation	-	68	-	-	-		-%	204	204	-	-	-
Vasectomy	-	35	-	-	-		0%	104	104	-	-	-
Vasectomy	-	35	-	-	-		-%	104	104	-	-	-
Water Treatment Tablets	148,700	162,110	215,220	-	2,200		9683%	2,071,710	2,440,642	3,538	-	22
Aquatabs 67 mg (20 L)	148,700	162,110	215,220	-	2,200	12/15	9,683%	2,071,710	2,440,642	3,538	-	22
<b>Cote d'Ivoire</b>											13,875	10,589
Antiretroviral Treatment (Currently Enrolled)	-	344	-	-	538		(100)%	7,589	7,589	-	-	-
Antiretroviral Treatment (Currently Enrolled)	-	344	-	-	538		(100)%	7,589	7,589	-	-	-
Antiretroviral Treatment (Newly Enrolled)	-	7	-	-	100		(100)%	460	460	-	-	-
Antiretroviral Treatment (Newly Enrolled)	-	7	-	-	100		(100)%	460	460	-	-	-
CD4 Tests Provided to HIV+ Clients	-	-	-	-	66		(100)%	66	788	-	-	-
CD4 Tests Provided to HIV+ Clients	-	-	-	-	66		(100)%	66	788	-	-	-
Emergency Contraception Provided	-	2	-	-	-		0%	16	16	-	-	-
Non-PSI Emergency Contraception Provided	-	2	-	-	-		-%	16	16	-	-	-
Fecal Sludge Management (Households)	36	19	64	-	48		33%	315	379	326	-	-
Fecal Sludge Management (Households)	36	19	64	-	48		33%	315	379	326	-	-
Fecal Sludge Management (Liters)	540,000	271,333	1,004,000	-	518,000		94%	3,367,000	4,371,000	-	-	98
Fecal Sludge Management (Liters)	540,000	271,333	1,004,000	-	518,000		94%	3,367,000	4,371,000	-	-	98

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.



**POPULATION SERVICES INTERNATIONAL**  
**Monthly Distribution by Country**  
**Period: 2**  
**Year: 2019**

	DISTRIBUTION 2/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
Free Condom	-	-	-	-	110,044		(100)%	1,091,536	6,318,813	-	-	-
(b)Free Distribution	-	-	-	-	110,044	1/08	(100)%	1,091,536	6,318,813	-	-	-
Free Female Condom	-	1,249	-	-	2,900		(100)%	10,236	72,999	-	-	-
Female Condom Free	-	1,249	-	-	2,900	8/12	(100)%	10,236	72,999	-	-	-
HIV Testing Services	-	111	-	-	4,829		(100)%	13,282	126,485	-	-	-
VCT Individual (HIV-Negative)	-	106	-	-	4,493	1/10	(100)%	12,419	120,213	-	-	-
VCT Individual (HIV-Positive)	-	5	-	-	336	1/10	(100)%	863	6,272	-	-	-
Implant 3 Insertion	730	633	1,560	-	-		0%	2,070	3,630	1,560	3,900	3,028
Non-PSI Implant 3 Inserted	730	633	1,560	-	-		-%	2,070	3,630	1,560	3,900	3,028
Implant 5 Insertion	1,005	633	2,124	-	233		812%	2,823	4,947	2,124	8,071	6,158
Non-PSI Implant 5 Inserted	1,005	633	2,124	-	233		812%	2,823	4,947	2,124	8,071	6,158
Injectable 2 Provided	20	255	225	-	-		0%	1,373	1,598	38	38	21
Non-PSI Injectable 2 Provided	20	255	225	-	-		-%	1,373	1,598	38	38	21
Injectable 3-IM Provided	1,122	786	2,570	-	78		3195%	7,836	10,406	643	643	367
Non-PSI Injectable 3 IM Provided	1,122	786	2,570	-	78		3,195%	7,836	10,406	643	643	367
Injectable 3-SC Provided	264	474	428	-	-		0%	1,258	1,686	107	107	61
Non-PSI Injectable 3 SC Provided	264	474	428	-	-		-%	1,258	1,686	107	107	61
IUD 10 Insertion	115	91	229	-	11		1982%	390	619	229	1,053	768
Non-PSI IUD 10 Inserted	115	91	229	-	11		1,982%	390	619	229	1,053	768
Lubricant	-	473	-	-	6,184		(100)%	18,918	91,449	-	-	-
Gel Lubricant 4.5 g	-	473	-	-	6,184	9/12	(100)%	18,918	91,449	-	-	-
OCs Provided	509	570	957	-	89		975%	4,743	5,700	64	64	38
Non-PSI OCs Provided	509	570	957	-	89		975%	4,743	5,700	64	64	38
Toilets Sold	234	103	272	-	-		0%	282	555	1,388	-	50
Toilets Sold	234	103	272	-	-		-%	282	555	1,388	-	50

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**  
**Monthly Distribution by Country**  
**Period: 2**  
**Year: 2019**

	DISTRIBUTION 2/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
<b>Mozambique</b>											<b>48,689</b>	<b>71,847</b>
Condom	-	1,129,488	1,668,744	-	1,898,688		(12)%	13,175,544	101,525,364	12,516	12,516	34,428
J0.1	-	284,640	853,920	-	144	10/17	592,900%	144	2,582,064	6,404	6,404	17,617
J1	-	559,608	814,824	-	922,080	10/12	(12)%	4,752,480	48,572,136	6,111	6,111	16,811
J18	-	-	-	-	-	4/18	-%	1,728,000	1,728,000	-	-	-
J2	-	-	-	-	75,528	10/12	(100)%	1,469,880	17,399,520	-	-	-
J24	-	-	-	-	864,000	10/17	(100)%	1,728,000	3,456,000	-	-	-
J3	-	285,240	-	-	1,368	10/12	(100)%	3,449,088	22,948,560	-	-	-
Jeito 4	-	-	-	-	35,496	11/13	(100)%	44,568	3,487,464	-	-	-
Jeito 5	-	-	-	-	72	1/14	(100)%	3,384	1,351,620	-	-	-
Emergency Contraception Provided	94	54	147	-	80		84%	575	874	7	7	5
Non-PSI Emergency Contraception Provided	94	54	147	-	80		84%	575	874	7	7	5
Free Condom	-	-	-	-	6,624		(100)%	6,624	697,377	-	-	-
No Logo Condom Lubricant Combo	-	-	-	-	6,624	5/15	(100)%	6,624	697,377	-	-	-
Implant 3 Insertion	-	-	-	-	-		0%	40	40	-	-	-
Non-PSI Implant 3 Inserted	-	-	-	-	-		-%	40	40	-	-	-
Implant 5	(1)	(34)	(4)	-	-		0%	(631)	(8,393)	(4)	(14)	(15)
Jadelle	255	332	589	-	316	12/15	86%	3,427	11,723	530	2,014	2,257
(b)PSI Implant 5 Distributed Inserted	(256)	(367)	(593)	-	(316)		-%	(4,058)	(20,116)	(534)	(2,028)	(2,272)
Implant 5 Insertion	2,129	2,635	4,723	-	3,133		51%	28,867	69,593	4,723	17,947	20,109
Non-PSI Implant 5 Inserted	1,873	2,268	4,130	-	2,817		47%	24,809	49,477	4,130	15,694	17,584
PSI Implant 5 Inserted	256	367	593	-	316		88%	4,058	20,116	593	2,253	2,525
Injectable 3-IM	-	51,701	-	-	(2,225)		0%	139,684	117,388	-	-	-
Enaf Injectable	399	52,633	911	-	846	6/13	8%	162,512	239,104	205	205	172

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**  
**Monthly Distribution by Country**  
**Period: 2**  
**Year: 2019**

	DISTRIBUTION 2/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
(b)PSI Injectable 3 IM Distributed Provided	(399)	(932)	(911)	-	(3,071)		-%	(22,828)	(121,716)	(205)	(205)	(172)
Injectable 3-IM Provided	7,360	9,815	17,138	-	29,064		(41)%	161,823	437,048	4,285	4,285	3,599
Non-PSI Injectable 3 IM Provided	6,961	8,883	16,227	-	25,993		(38)%	138,995	315,332	4,057	4,057	3,408
PSI Injectable 3 IM Provided	399	932	911	-	3,071		(70)%	22,828	121,716	228	228	191
Injectable 3-SC	3,604	641	4,103	-	-		0%	8,364	12,467	923	923	776
(b)PSI Injectable 3 SC Distributed Provided	(1,146)	(805)	(2,523)	-	-		-%	(1,038)	(3,561)	(568)	(568)	(477)
Sayana Press	4,750	1,446	6,626	-	-		-%	9,402	16,028	1,491	1,491	1,252
Injectable 3-SC Provided	3,662	2,737	7,402	-	-		0%	4,471	11,873	1,851	1,851	1,555
Non-PSI Injectable 3 SC Provided	2,516	1,932	4,879	-	-		-%	3,433	8,312	1,220	1,220	1,025
PSI Injectable 3 SC Provided	1,146	805	2,523	-	-		-%	1,038	3,561	631	631	530
IUD 10	52	7	72	-	-		0%	-	21,810	65	298	319
DIU Copper T 380A	52	7	72	-	-	1/15	-%	-	21,810	65	298	319
IUD 10 Insertion	560	757	1,283	-	803		60%	8,354	17,877	1,283	5,902	6,314
Non-PSI IUD 10 Inserted	560	757	1,283	-	803	3/16	60%	8,354	17,877	1,283	5,902	6,314
LLIN	-	-	-	-	695		(100)%	695	199,832	-	-	-
Serena	-	-	-	-	695	4/14	(100)%	695	199,832	-	-	-
OCs	46,836	(151)	46,876	-	-		0%	(1,935)	44,589	2,813	2,813	2,493
Microginon Mobiz	-	-	-	-	-	5/15	-%	1,682	7,430	-	-	-
Microlenyn 30 Combined OC	5,019	3,146	8,210	-	5,603	6/13	47%	38,163	210,476	493	493	437
Progestyn OC	47,066	839	47,969	-	1,433	6/13	3,247%	10,218	137,675	2,878	2,878	2,551
(b)PSI OCs Distributed Provided	(5,249)	(4,136)	(9,303)	-	(7,036)		-%	(51,998)	(310,992)	(558)	(558)	(495)
OCs Provided	14,582	16,490	32,431	-	36,155		(10)%	223,704	696,131	2,162	2,162	1,916
Non-PSI OCs Provided	9,333	12,354	23,128	-	29,119		(21)%	171,706	385,139	1,542	1,542	1,366
PSI OCs Provided	5,249	4,136	9,303	-	7,036		32%	51,998	310,992	620	620	550

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

**Period: 2**

**Year: 2019**

	DISTRIBUTION 2/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
Safe Water Solution	-	90,000	81,360	-	518,413		(84)%	870,831	6,187,090	66,871	-	349
Certeza Commercial ISM	-	13,888	15,360	-	219,828	9/12	(93)%	323,748	3,003,375	12,625	-	66
Certeza Free ISM	-	76,112	66,000	-	298,585	9/12	(78)%	547,083	3,183,715	54,247	-	283
SDM (Cycle Beads)	-	-	-	-	-		0%	13	10,707	-	-	-
Missangas Ciclo	-	-	-	-	-	2/11	-%	13	10,707	-	-	-
<b>Niger</b>											9,621	10,110
Antiretroviral Treatment (Currently Enrolled)	626	417	1,251	-	-		0%	625	1,876	104	-	239
Antiretroviral Treatment (Currently Enrolled)	626	417	1,251	-	-		-%	625	1,876	104	-	239
Antiretroviral Treatment (Newly Enrolled)	1	1	2	-	-		0%	1	3	2	-	-
Antiretroviral Treatment (Newly Enrolled)	1	1	2	-	-		-%	1	3	2	-	-
HIV Testing Services	294	399	764	-	3,012		(75)%	14,858	31,678	764	-	6
VCT Individual (HIV-Negative)	293	391	745	-	3,007		(75)%	14,820	31,011	745	-	6
VCT Individual (HIV-Positive)	1	8	19	-	5		280%	38	667	19	-	-
Implant 3	-	-	-	-	-		0%	(91)	(91)	-	-	-
(b)PSI Implant 3 Distributed Inserted	-	-	-	-	-		-%	(91)	(91)	-	-	-
Implant 3 Insertion	624	700	1,457	-	1,089		34%	7,625	15,183	1,457	3,643	4,102
Non-PSI Implant 3 Inserted	624	700	1,457	-	1,089		34%	7,534	15,092	1,457	3,643	4,102
PSI Implant 3 Inserted	-	-	-	-	-		-%	91	91	-	-	-
Implant 5	-	-	-	-	-		0%	(1)	(1)	-	-	-
(b)PSI Implant 5 Distributed Inserted	-	-	-	-	-		-%	(1)	(1)	-	-	-
Implant 5 Insertion	110	134	280	-	187		50%	1,486	3,403	280	1,064	1,178
Non-PSI Implant 5 Inserted	110	134	280	-	187		50%	1,485	3,402	280	1,064	1,178
PSI Implant 5 Inserted	-	-	-	-	-		-%	1	1	-	-	-
Injectable 3-IM Provided	3,568	3,251	7,875	-	5,361		47%	40,305	68,954	1,969	1,969	1,630
Non-PSI Injectable 3 IM Provided	3,568	3,251	7,875	-	5,361		47%	40,305	68,954	1,969	1,969	1,630

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

**Period: 2**

**Year: 2019**

	DISTRIBUTION 2/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
IUD 10	-	-	-	-	-		0%	(60)	(60)	-	-	-
(b)PSI IUD 10 Distributed Inserted	-	-	-	-	-		-%	(60)	(60)	-	-	-
IUD 10 Insertion	200	126	328	-	432		(24)%	3,448	5,370	328	1,509	1,597
Non-PSI IUD 10 Inserted	200	126	328	-	432		(24)%	3,388	5,310	328	1,509	1,597
PSI IUD 10 Inserted	-	-	-	-	-		-%	60	60	-	-	-
Manual Vacuum Aspiration for PAC	-	12	13	-	-		0%	401	414	13	-	7
MVA for PAC	-	12	13	-	-	1/16	-%	401	414	13	-	7
Misoprostol for PAC Provided	-	26	57	-	-		0%	561	618	57	-	37
Non-PSI Misoprostol for PAC Provided	-	26	57	-	-		-%	561	618	57	-	37
Misoprostol for Safe Abortion	1,096	31,693	1,916	-	1,424		35%	99,856	154,752	101	-	58
Misoprostol for Safe Abortion	1,096	31,693	1,916	-	1,424	3/18	35%	99,856	154,752	101	-	58
OCs Provided	11,007	10,188	21,559	-	11,901		81%	98,610	191,797	1,437	1,437	1,255
Non-PSI OCs Provided	11,007	10,188	21,559	-	11,901		81%	98,610	191,797	1,437	1,437	1,255
Seasonal Malaria Chemoprevention	-	-	-	-	-		0%	344,748	344,748	-	-	-
SMC for Children ages 12-59 months	-	-	-	-	-		-%	291,064	291,064	-	-	-
SMC for Infants ages 3-11 months	-	-	-	-	-		-%	53,684	53,684	-	-	-
<b>PSI Benin</b>											3,519	3,206
IUD 10	550	817	850	-	1,550		(45)%	14,678	15,528	765	3,519	2,408
IUD Copper T 380A	550	817	850	-	1,550	1/18	(45)%	14,678	15,528	765	3,519	2,408
Medical Abortion	60	10	90	-	-		0%	-	90	81	-	30
Mifeso	60	10	90	-	-		-%	-	90	81	-	30
Misoprostol for Safe Abortion	32,880	13,780	43,440	-	28,420		53%	208,980	252,420	2,281	-	768
Misoprostol for Safe Abortion	32,880	13,780	43,440	-	28,420	3/18	53%	208,980	252,420	2,281	-	768
<b>Senegal</b>											9,762	6,711
Acute Malnutrition Screening_CU5	-	-	-	-	324		(100)%	518	1,895	-	-	-

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

**Period: 2**

**Year: 2019**

	DISTRIBUTION 2/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
Acute Malnutrition Screening_CU5	-	-	-	-	324		(100)%	518	1,895	-	-	-
Condom	259,168	316,625	374,768	-	101,184		270%	5,947,910	31,318,928	2,811	2,811	3,234
Fagaru	30,880	73,893	79,040	-	5,760	11/12	1,272%	2,751,835	11,898,225	593	593	682
Protec Fraise	79,344	54,384	88,512	-	85,920	1/13	3%	822,288	4,244,116	664	664	764
Protec Naturel	148,944	188,348	207,216	-	9,504	1/13	2,080%	2,373,787	15,176,587	1,554	1,554	1,788
HIV Testing Services	-	-	-	-	246		(100)%	314	903	-	-	-
VCT Individual (HIV-Negative)	-	-	-	-	245		(100)%	313	888	-	-	-
VCT Individual (HIV-Positive)	-	-	-	-	1		(100)%	1	15	-	-	-
Implant 3 Insertion	59	11	72	-	25		188%	127	266	72	180	109
Non-PSI Implant 3 Inserted	59	11	72	-	25		188%	127	266	72	180	109
Implant 4 Insertion	-	1	3	-	-		0%	2	23	3	10	6
Non-PSI Implant 4 Inserted	-	1	3	-	-		-%	2	23	3	10	6
Implant 5 Insertion	106	13	112	-	65		72%	157	348	112	426	253
Non-PSI Implant 5 Inserted	106	13	112	-	65		72%	157	348	112	426	253
Injectable 3-IM	(15)	-	(15)	-	-		0%	-	(15)	(3)	(3)	(1)
(b)PSI Injectable 3 IM Distributed Provided	(15)	-	(15)	-	-		-%	-	(15)	(3)	(3)	(1)
Injectable 3-IM Provided	15	14	32	-	43		(26)%	182	315	8	8	4
Non-PSI Injectable 3 IM Provided	-	14	17	-	43		(60)%	182	300	4	4	2
PSI Injectable 3 IM Provided	15	-	15	-	-		-%	-	15	4	4	2
Injectable 3-SC	2,376	3,024	4,752	-	470		911%	14,488	21,855	1,069	1,069	475
Securil Press	2,376	3,024	4,752	-	470		911%	14,488	21,855	1,069	1,069	475
IUD 10 Insertion	17	1	17	-	6		183%	27	63	17	78	44
Non-PSI IUD 10 Inserted	17	1	17	-	6		183%	27	63	17	78	44
LLIN	2,025	3,138	2,025	-	453		347%	270,382	987,154	3,281	-	57
MILDA	2,025	3,138	2,025	-	453	8/13	347%	270,382	987,154	3,281	-	57

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

**Period: 2**

**Year: 2019**

	DISTRIBUTION 2/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
OCs	41,040	53,280	86,400	-	26,786		223%	664,517	3,288,668	5,184	5,184	2,430
Securil	41,040	53,280	86,400	-	26,786	11/12	223%	664,517	3,288,668	5,184	5,184	2,430
OCs Provided	-	1	1	-	8		(88)%	17	24	-	-	-
Non-PSI OCs Provided	-	1	1	-	8		(88)%	17	24	-	-	-
Toilets Sold	375	287	626	-	-		0%	958	1,584	5,196	-	80
Toilets Sold	375	287	626	-	-		-%	958	1,584	5,196	-	80
Water Treatment Tablets	471,700	103,867	476,900	-	64,000		645%	1,979,400	9,942,566	7,839	-	21
Aquatabs 67 mg (20 L)	471,700	103,867	476,900	-	64,000	11/12	645%	1,979,400	9,942,566	7,839	-	21

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

# Latin America & Asia Market Group



**POPULATION SERVICES INTERNATIONAL**  
**CYPs, Cases, and Deaths by Country**  
**1/2019 - 2/2019**

	New HIV Infections	STI Deaths	PWID Deaths	TB Deaths	CYP*	Maternal Deaths	Unintended Pregnancies	Malaria Deaths	Diarrhea Deaths	Pneumonia Deaths	Cervical Cancer Death	Sum of All Deaths
Latin America & Asia Market Group	809	-	-	349	639,797	351	246,362	1	12	-	-	2,308
Cambodia	384	-	-	-	100,049	112	35,985	-	12	-	-	322
Costa Rica	9	-	-	-	2,311	-	651	-	-	-	-	1
Dominican Republic	77	-	-	-	16,753	2	4,718	-	-	-	-	15
El Salvador	19	-	-	-	3,920	-	1,142	-	-	-	-	3
El Salvador SA	-	-	-	-	3,243	-	1,470	-	-	-	-	4
Guatemala	58	-	-	-	14,565	2	4,183	-	-	-	-	22
Guatemala SA	-	-	-	-	18,481	4	7,922	-	-	-	-	43
Honduras	82	-	-	-	7,472	1	2,242	-	-	-	-	8
Kazakhstan	2	-	-	-	-	-	-	-	-	-	-	-
Kyrgyzstan	2	-	-	-	-	-	-	-	-	-	-	-
Laos	21	-	-	6	18,799	7	7,502	1	-	-	-	58
Nepal	-	-	-	-	986	26	447	-	-	-	-	28
Nicaragua	26	-	-	-	10,760	3	3,889	-	-	-	-	17
Pakistan	97	-	-	343	375,236	173	149,083	-	-	-	-	1,582
Panama	23	-	-	-	4,480	1	1,262	-	-	-	-	3
Papua New Guinea	-	-	-	-	-	-	-	-	-	-	-	-
PSI Pakistan	5	-	-	-	61,959	19	25,536	-	-	-	-	202
Tajikistan	4	-	-	-	180	-	51	-	-	-	-	-
Viet Nam	-	-	-	-	601	-	278	-	-	-	-	1

\* Using USAID CYP conversion factors

POPULATION SERVICES INTERNATIONAL  
Monthly Distribution by Market Group and Product  
Period: 2  
Year: 2019

	DISTRIBUTION 2/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE SALES	YTD USERS REACHED <sup>(a)</sup> 2019	YTD CYP 2019	YTD DALY 2019
<b>Latin America &amp; Asia Market Group</b>										<b>639,797</b>	<b>210,758</b>
Antiretroviral Treatment (Currently Enrolled)	-	-	-	-	-	-%	233	233	-	-	-
Antiretroviral Treatment (Newly Enrolled)	-	-	-	-	-	-%	92	92	-	-	-
Cervical Cancer-Pap Smear Screening	11	32	106	-	-	-%	92	434	106	-	-
Condom	13,244,266	18,494,727	26,441,144	-	29,171,185	(9)%	187,077,716	3,510,384,120	198,309	198,309	63,399
Diarrhea Treatment Kit	10,580	1,717	14,940	-	11,750	27%	57,190	945,380	13,446	-	294
Emergency Contraception	250,851	268,421	436,526	-	314,574	39%	2,139,292	9,644,545	19,644	19,644	3,404
Emergency Contraception Provided	2,072	2,596	5,387	-	2,773	94%	15,372	49,237	269	269	47
Female Condom	-	-	-	-	20	(100)%	100	338,539	-	-	-
Fever Cases Attended	4,648	5,767	10,030	-	38,203	(74)%	118,263	289,955	10,030	-	-
Fever Cases Tested with RDTs	5,869	8,110	13,496	-	38,200	(65)%	134,061	309,183	13,496	-	-
Free Condom	90,000	453,037	564,000	-	397,244	42%	3,430,359	11,158,733	4,230	4,230	1,116
Free Female Condom	-	-	-	-	16,245	(100)%	21,200	45,770	-	-	-
HIV Testing Services	5,011	4,897	10,254	-	13,491	(24)%	98,169	364,054	10,254	-	22
Hypertension Diagnosis	1,930	765	2,942	-	7,569	(61)%	26,102	55,377	2,942	-	-
Hypertension Screening	34,453	31,493	64,734	-	87,740	(26)%	413,477	680,428	64,734	-	-
Hypertension_Controlled Condition	2,589	2,071	4,255	-	5,693	(25)%	30,443	54,806	1,702	-	-
Implant 3	926	(25)	944	-	141	570%	1,681	3,487	850	2,124	327
Implant 3 Insertion	952	800	2,114	-	1,515	40%	12,809	28,874	2,114	5,285	1,264
Implant 5	(291)	(8)	(840)	-	12,909	(107)%	22,460	59,123	(756)	(2,873)	(631)
Implant 5 Insertion	521	1,789	1,977	-	1,953	1%	21,679	89,709	1,977	7,513	1,570
Injectable 1	17,336	13,578	30,430	-	15,958	91%	131,181	1,998,944	2,107	2,107	490

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

**POPULATION SERVICES INTERNATIONAL**  
**Monthly Distribution by Market Group and Product**  
**Period: 2**  
**Year: 2019**

	DISTRIBUTION 2/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE SALES	YTD USERS REACHED <sup>(a)</sup> 2019	YTD CYP 2019	YTD DALY 2019
Injectable 1 Provided	4,338	4,868	10,321	-	15,347	(33)%	88,483	235,237	794	794	178
Injectable 2	3,772	17,402	24,792	-	56,703	(56)%	134,028	7,108,875	3,719	3,719	854
Injectable 2 Provided	212	1,914	3,502	-	12,554	(72)%	58,184	150,078	584	584	97
Injectable 3-IM	43,553	45,725	59,629	-	97,552	(39)%	688,678	8,496,852	13,417	13,417	2,655
Injectable 3-IM Provided	23,371	48,097	78,699	-	140,634	(44)%	705,711	1,234,249	19,675	19,675	3,895
IUD 10	907	834	93	-	18,785	(100)%	67,041	129,041	84	385	1,297
IUD 10 Insertion	9,282	9,706	16,887	-	15,538	9%	148,352	775,324	16,887	77,680	19,191
IUD 5	9,439	11,730	25,281	-	(4,014)	-%	22,736	3,044,454	22,753	75,085	23,427
IUD 5 Insertion	10,608	9,291	38,466	-	21,657	78%	63,576	977,751	38,466	126,938	39,635
IUS 5 Insertion	-	1	3	-	-	-%	2	6	3	10	2
LLIN (Hammock net)	-	138	400	-	15	2,567%	1,259	1,704	360	-	-
Lubricant	174,634	95,980	306,471	-	225,148	36%	1,423,274	16,819,286	-	-	-
Malaria PPT (ACT)	(56)	(40)	(70)	-	2,855	(102)%	357	860,625	(63)	-	(8)
Malaria RDK	2,100	1,870	5,340	-	131,394	(96)%	305,189	3,287,816	4,806	-	-
Manual Vacuum Aspiration for PAC	5,234	6,809	19,711	-	9,645	104%	34,966	125,675	19,711	-	991
Manual Vacuum Aspiration for SA	8	23	8	-	-	-%	251	259	8	-	1
Medical Abortion	32,715	40,590	76,958	-	78,134	(2)%	457,337	2,188,118	69,262	-	6,612
Medical Abortion Provided	862	794	1,224	-	1,554	(21)%	12,104	21,298	1,224	-	113
Misoprostol for PAC Provided	7,544	6,030	15,470	-	663	2,233%	53,383	72,503	15,470	-	923
Misoprostol for Safe Abortion	61,708	247,913	414,184	-	243,036	70%	1,285,943	2,400,321	21,745	-	1,678
Naloxone	-	23	-	-	-	-%	2,570	16,713	-	-	-

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

POPULATION SERVICES INTERNATIONAL  
Monthly Distribution by Market Group and Product  
Period: 2  
Year: 2019

	DISTRIBUTION 2/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE SALES	YTD USERS REACHED <sup>(a)</sup> 2019	YTD CYP 2019	YTD DALY 2019
Needle & Syringe	58,200	572,733	225,000	-	502,100	(55)%	5,815,215	25,734,068	785	-	1,583
OCs	542,268	587,822	1,103,646	-	1,158,862	(5)%	6,487,754	65,657,782	66,219	66,219	12,220
OCs Provided	99,915	113,013	208,574	-	47,768	337%	921,067	1,831,928	13,905	13,905	3,341
ORS	66,225	171,084	79,477	-	-	-%	500,000	608,711	35,765	-	751
Positive RDTs	266	324	611	-	6,471	(91)%	11,799	39,184	611	-	-
Positive RDTs Given First Line Treatment	250	263	523	-	6,098	(91)%	10,103	36,071	523	-	-
QAACTs Provided after Confirmatory Diagnosis	166	176	324	-	6,103	(95)%	9,977	35,774	324	-	58
Referral to Emergency Contraception	-	-	-	-	-	-%	31	107	-	-	-
Referral to HIV Testing Services	3	1	3	-	-	-%	10	11,180	3	-	-
Referral to Implant 3 Insertion	146	540	311	-	-	-%	1,455	1,766	311	389	53
Referral to Implant 5 Insertion	46	30	77	-	29	166%	221	1,104	77	146	33
Referral to Injectable 1	1	3	1	-	-	-%	11	12	1	-	-
Referral to Injectable 3	73	37	105	-	40	163%	396	1,740	105	13	2
Referral to IUD 10 Insertion	168	96	297	-	118	152%	729	58,541	297	683	121
Referral to Linkage to HIV Care	227	225	421	-	539	(22)%	2,800	6,553	421	-	356
Referral to OCs	58	47	83	-	30	177%	391	1,025	83	3	1
Referral to Opioid Treatment	2	11	10	-	39	(74)%	135	482	10	-	-
Referral to TB DOTS (completion confirmed)	35	-	35	-	57	(39)%	148	426	35	-	12
Referral to TB DOTS (completion unknown)	4	-	4	-	1	300%	43	248	4	-	1
Referral to TB Screening	-	-	-	-	21	(100)%	21	50	-	-	-
Referral to Vasectomy	1	-	1	-	-	-%	-	1	1	5	1

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

POPULATION SERVICES INTERNATIONAL  
Monthly Distribution by Market Group and Product  
Period: 2  
Year: 2019

	DISTRIBUTION 2/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE SALES	YTD USERS REACHED <sup>(a)</sup> 2019	YTD CYP 2019	YTD DALY 2019
SDM (Cycle Beads) Provided	1	-	1	-	1	-%	7	123	1	2	-
STI Screening	12	2	19	-	39	(51)%	99	3,912	19	-	-
TB Diagnosis	2,117	2,213	4,116	-	4,810	(14)%	29,853	89,734	4,116	-	-
TB DOTS	2,048	2,109	4,047	-	3,372	20%	26,012	117,522	4,047	-	18,521
TB Screening	4,781	4,876	9,349	-	13,980	(33)%	72,433	150,865	9,349	-	-
Toilets Sold	199	483	410	-	695	(41)%	4,405	6,713	1,722	-	14
Treatment for Cervicitis	7	4	20	-	-	-%	28	63	20	-	-
Treatment for Genital Herpes	-	-	1	-	-	-%	-	9	1	-	-
Treatment for Lower Abdominal Pain	-	-	1	-	-	-%	-	1	1	-	-
Treatment for Urethral Discharge (Women)	-	-	-	-	-	-%	1	8	-	-	-
Treatment for Vaginitis	5	16	54	-	-	-%	25	82	54	-	-
Tubal Ligation	2	321	344	-	1,353	(75)%	11,913	27,765	344	3,440	821
Type 2 Diabetes Diagnosis	-	-	-	-	-	-%	1	1	-	-	-
Type 2 Diabetes Screening	-	-	-	-	-	-%	1	3	-	-	-
Type 2 Diabetes_Controlled Condition	-	-	1	-	-	-%	-	1	-	-	-
Vasectomy	-	17	10	-	52	(81)%	318	911	10	100	24
Vivax Treatment after Confirmatory Diagnosis	-	28	-	-	-	-%	156	165	-	-	-
Water Treatment Tablets	-	22,833	50,500	-	800	6,213%	91,160	1,029,283	830	-	2
Zika Prevention Kit	-	4	-	-	105	(100)%	725	2,621	-	-	-
Zinc	2	-	2	-	-	-%	-	32,846	2	-	-

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

Period: 2

Year: 2019

	DISTRIBUTION 2/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
<b>Latin America &amp; Asia Market Group</b>											<b>639,797</b>	<b>210,758</b>
<b>Cambodia</b>											<b>100,049</b>	<b>39,419</b>
Condom	1,293,360	820,388	2,407,854	-	2,064,960		17%	10,667,766	388,472,405	18,059	18,059	17,843
Number One	235,800	262,008	336,024	-	964,800	12/94	(65)%	4,440,816	269,608,093	2,520	2,520	2,490
OK Condom	1,057,560	558,380	2,071,830	-	1,100,160	2/04	88%	6,226,950	118,864,312	15,539	15,539	15,353
Diarrhea Treatment Kit	10,580	1,717	14,940	-	11,750		27%	57,190	945,380	13,446	-	294
Orasel Kit	10,580	1,717	14,940	-	11,750	3/09	27%	57,190	945,380	13,446	-	294
Emergency Contraception	8,514	5,556	16,283	-	14,472		13%	73,948	318,818	733	733	97
NEXT 72 EC	8,520	5,556	16,290	-	14,480	8/13	13%	73,979	318,889	733	733	97
(b)PSI Emergency Contraception Distributed Provided	(6)	(1)	(7)	-	(8)		-%	(31)	(71)	-	-	-
Emergency Contraception Provided	6	1	7	-	8		(13)%	31	71	-	-	-
PSI Emergency Contraception Provided	6	1	7	-	8		(13)%	31	71	-	-	-
Fever Cases Attended	728	1,386	1,689	-	34,046		(95)%	75,172	227,462	1,689	-	-
Fever Cases Attended	728	1,386	1,689	-	34,046		(95)%	75,172	227,462	1,689	-	-
Fever Cases Tested with RDTs	549	1,344	1,384	-	34,044		(96)%	75,088	227,051	1,384	-	-
Fever Cases Tested with RDTs	549	1,344	1,384	-	34,044		(96)%	75,088	227,051	1,384	-	-
Implant 3 Insertion	7	13	15	-	-		0%	112	127	15	38	9
Non-PSI Implant 3 Inserted	7	13	15	-	-		-%	112	127	15	38	9
Implant 5	(212)	103	(246)	-	1,238		(120)%	8,131	21,782	(221)	(841)	(195)
Implant 5	-	272	54	-	1,601	5/09	(97)%	10,570	53,380	49	185	43
(b)PSI Implant 5 Distributed Inserted	(212)	(169)	(300)	-	(363)		-%	(2,439)	(31,598)	(270)	(1,026)	(238)
Implant 5 Insertion	212	169	300	-	363		(17)%	2,439	31,598	300	1,140	264
PSI Implant 5 Inserted	212	169	300	-	363		(17)%	2,439	31,598	300	1,140	264
Injectable 3-IM	30,067	16,457	33,781	-	59,872		(44)%	290,704	5,588,010	7,601	7,601	1,320
OK Injection-3	30,500	16,717	34,350	-	60,475	2/02	(43)%	294,200	5,602,909	7,729	7,729	1,343

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

**Period: 2**

**Year: 2019**

	DISTRIBUTION 2/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
(b)PSI Injectable 3 IM Distributed Provided	(433)	(260)	(569)	-	(603)		-%	(3,496)	(14,899)	(128)	(128)	(22)
Injectable 3-IM Provided	433	260	569	-	603		(6)%	3,496	14,899	142	142	25
PSI Injectable 3 IM Provided	433	260	569	-	603		(6)%	3,496	14,899	142	142	25
IUD 10	(1,000)	601	(389)	-	2,214		(118)%	20,787	92,145	(350)	(1,610)	(357)
IUD Copper T	685	1,863	2,005	-	5,440	1/10	(63)%	40,515	238,330	1,805	8,301	1,840
(b)PSI IUD 10 Distributed Inserted	(1,685)	(1,263)	(2,394)	-	(3,226)		-%	(19,728)	(146,185)	(2,155)	(9,911)	(2,197)
IUD 10 Insertion	1,685	1,263	2,394	-	3,226		(26)%	19,728	146,185	2,394	11,012	2,441
PSI IUD 10 Inserted	1,685	1,263	2,394	-	3,226		(26)%	19,728	146,185	2,394	11,012	2,441
Lubricant	73,320	31,920	133,500	-	119,340		12%	521,340	9,311,600	-	-	-
OK Plus Lubricant	73,320	31,920	133,500	-	119,340	6/09	12%	521,340	9,311,600	-	-	-
Malaria PPT (ACT)	(56)	(40)	(70)	-	(4,927)		0%	(7,425)	15,148	(63)	-	(8)
ASMQ for Adult	-	-	-	-	776	5/16	(100)%	776	46,378	-	-	-
ASMQ for Children	-	-	-	-	175	10/16	(100)%	175	2,033	-	-	-
(b)PSI QAACTs Distributed Provided after Diagnosis	(56)	(40)	(70)	-	(5,878)		-%	(8,376)	(33,263)	(63)	-	(8)
Malaria RDK	-	-	-	-	126,925		(100)%	276,500	1,896,300	-	-	-
Malaria RDT (Diagnosis)	-	-	-	-	126,925	6/15	(100)%	276,500	1,896,300	-	-	-
Medical Abortion	32,827	28,055	64,980	-	55,527		17%	334,762	1,811,097	58,482	-	5,120
Medabon	22,106	11,609	37,738	-	57,081	11/09	(34)%	240,656	1,697,719	33,964	-	2,974
Mifeso	11,471	17,070	28,354	-	-		-%	104,939	133,293	25,519	-	2,234
(b)PSI Medical Abortion Distributed Provided	(750)	(623)	(1,112)	-	(1,554)		-%	(10,833)	(19,915)	(1,001)	-	(88)
Medical Abortion Provided	750	623	1,112	-	1,554		(28)%	10,833	19,915	1,112	-	97
PSI Medical Abortion Provided	750	623	1,112	-	1,554		(28)%	10,833	19,915	1,112	-	97
OCs	540,966	552,782	1,054,568	-	880,485		20%	5,456,565	61,245,401	63,274	63,274	11,596
Marvelon	100,842	83,965	196,311	-	139,785	12/12	40%	908,657	2,560,523	11,779	11,779	2,159

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

**Period: 2**

**Year: 2019**

	DISTRIBUTION 2/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
OK Pills	440,316	468,912	858,480	-	741,384	9/97	16%	4,551,732	58,697,660	51,509	51,509	9,439
(b)PSI OCs Distributed Provided	(192)	(95)	(223)	-	(684)		-%	(3,824)	(12,782)	(13)	(13)	(2)
OCs Provided	192	95	223	-	684		(67)%	3,825	12,784	15	15	3
Non-PSI OCs Provided	-	-	-	-	-		-%	1	2	-	-	-
PSI OCs Provided	192	95	223	-	684		(67)%	3,824	12,782	15	15	3
ORS	66,225	171,083	79,475	-	-		0%	500,000	579,475	35,764	-	751
Orasel ORS Sachet	66,225	171,083	79,475	-	-		-%	500,000	579,475	35,764	-	751
Positive RDTs	57	79	135	-	6,184		(98)%	9,841	36,009	135	-	-
Positive RDTs	57	79	135	-	6,184		(98)%	9,841	36,009	135	-	-
Positive RDTs Given First Line Treatment	56	40	70	-	5,878		(99)%	8,376	33,263	70	-	-
Positive RDTs Given First Line Treatment	56	40	70	-	5,878		(99)%	8,376	33,263	70	-	-
QAACTs Provided after Confirmatory Diagnosis	56	40	70	-	5,883		(99)%	8,400	33,318	70	-	10
Non-PSI QAACTs Provided after Confirmed Diagnosis	-	-	-	-	5		(100)%	24	55	-	-	-
PSI QAACTs Provided after Confirmed Diagnosis	56	40	70	-	5,878		(99)%	8,376	33,263	70	-	10
Referral to Emergency Contraception	-	-	-	-	-		0%	31	107	-	-	-
Referral to Emergency Contraception	-	-	-	-	-		-%	31	107	-	-	-
Referral to Implant 5 Insertion	39	20	64	-	29		121%	190	1,035	64	122	28
Referral to Implant 5 Insertion	39	20	64	-	29		121%	190	1,035	64	122	28
Referral to Injectable 3	73	37	105	-	40		163%	396	1,740	105	13	2
Referral to Injectable 3	73	37	105	-	40		163%	396	1,740	105	13	2
Referral to IUD 10 Insertion	85	68	152	-	118		29%	677	9,631	152	350	77
Referral to IUD 10 Insertion	85	68	152	-	118	12/11	29%	677	9,631	152	350	77
Referral to OCs	58	47	83	-	30		177%	389	1,023	83	3	1
Referral to OCs	58	47	83	-	30		177%	389	1,023	83	3	1
<b>Costa Rica</b>											<b>2,311</b>	<b>377</b>

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.



**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

**Period: 2**

**Year: 2019**

	DISTRIBUTION 2/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
Condom	189,348	175,831	308,090	-	283,490		9%	1,937,134	19,054,153	2,311	2,311	377
Combo-Pack Lub Fresa	2,064	1,515	2,528	-	1,694	10/10	49%	29,308	88,359	19	19	3
Vive	109,524	105,199	185,475	-	40,854	12/97	354%	504,093	5,348,983	1,391	1,391	227
Vive Amor	-	-	-	-	117,936	6/04	(100)%	602,928	8,042,921	-	-	-
Vive Colors/Mas Colors	46,536	43,468	71,529	-	71,679	5/03	-%	489,846	3,747,246	536	536	87
Vive Mas Fuerte /Retardante	12,876	10,882	19,230	-	18,933	6/04	2%	133,953	796,818	144	144	24
Vive Mas Natural /Sensitivo	18,348	14,767	29,328	-	32,394	6/04	(9)%	177,006	1,029,826	220	220	36
Lubricant	3,796	2,091	6,186	-	4,167		48%	22,294	167,987	-	-	-
Vive Lub Natural (sachet)	1,050	450	1,600	-	1,004	5/11	59%	5,532	56,114	-	-	-
Vive Lub Natural (tube)	958	559	1,528	-	950	5/11	61%	5,433	24,883	-	-	-
Vive Lub Sachet Fresa 5 mL	800	525	1,350	-	429	5/12	215%	3,809	59,538	-	-	-
Vive Lub Tubo Fresa 120 mL	988	557	1,708	-	1,784	1/12	(4)%	7,520	27,452	-	-	-
<b>Dominican Republic</b>											16,753	4,200
Antiretroviral Treatment (Currently Enrolled)	-	-	-	-	-		0%	233	233	-	-	-
Antiretroviral Treatment (Currently Enrolled)	-	-	-	-	-		-%	233	233	-	-	-
Antiretroviral Treatment (Newly Enrolled)	-	-	-	-	-		0%	92	92	-	-	-
Antiretroviral Treatment (Newly Enrolled)	-	-	-	-	-		-%	92	92	-	-	-
Condom	1,491,344	930,605	1,693,744	-	1,250,792		35%	7,560,134	44,260,322	12,703	12,703	3,185
Pante	1,445,888	928,549	1,647,688	-	1,250,792	6/14	32%	7,554,566	44,208,698	12,358	12,358	3,098
Vive Colors/Mas Colors	22,176	1,024	22,464	-	-		-%	2,784	25,248	168	168	42
VIVE Mas/Sensitivo	12,240	520	12,408	-	-		-%	1,392	13,800	93	93	23
Vive Mas/Texturizado	11,040	512	11,184	-	-		-%	1,392	12,576	84	84	21
Free Condom	78,000	232,000	540,000	-	324,000		67%	2,214,000	8,397,423	4,050	4,050	1,015
No Logo	78,000	232,000	540,000	-	324,000	6/14	67%	2,214,000	8,397,423	4,050	4,050	1,015

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

**Period: 2**

**Year: 2019**

	DISTRIBUTION 2/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
HIV Testing Services	-	-	-	-	3,536		(100)%	31,033	107,865	-	-	-
VCT Individual (HIV-Negative)	-	-	-	-	3,438	9/13	(100)%	30,230	105,214	-	-	-
VCT Individual (HIV-Positive)	-	-	-	-	98	9/13	(100)%	803	2,651	-	-	-
Lubricant	26,000	21,667	37,000	-	27,000		37%	278,000	1,825,992	-	-	-
No Logo Lubricant (4.5 gram sachet)	26,000	21,667	37,000	-	27,000	6/14	37%	278,000	1,825,992	-	-	-
Referral to Linkage to HIV Care	-	-	-	-	328		(100)%	371	412	-	-	-
Referral to Linkage to HIV Care	-	-	-	-	328		(100)%	371	412	-	-	-
<b>EI Salvador</b>											<b>3,920</b>	<b>925</b>
Cervical Cancer-Pap Smear Screening	11	32	106	-	-		0%	92	434	106	-	-
Cervical Cancer-Pap Smear Screening	11	32	106	-	-		-%	92	434	106	-	-
Condom	257,307	286,148	470,451	-	482,104		(2)%	3,210,525	40,672,187	3,528	3,528	890
Combo-Mix Lub Natural	-	-	-	-	-	10/10	-%	48	19,432	-	-	-
Combo-Pack Lub Fresa	-	-	-	-	16	5/12	(100)%	4,896	10,224	-	-	-
Vive	53,712	68,880	133,968	-	109,056	4/98	23%	739,008	15,338,812	1,005	1,005	253
Vive Amor	106,560	133,888	141,888	-	258,576	7/04	(45)%	1,534,176	14,600,305	1,064	1,064	268
Vive Colors/Mas Colors	66,624	57,602	139,464	-	67,776	10/03	106%	597,348	7,443,078	1,046	1,046	264
Vive Mas Fuerte /Retardante	20,547	17,592	32,139	-	30,792	7/04	4%	206,016	1,586,567	241	241	61
Vive Mas Natural /Sensitivo	9,864	8,162	22,992	-	11,376	7/04	102%	87,849	823,697	172	172	43
Vive Mas/Texturizado	-	24	-	-	4,512	7/04	(100)%	41,184	850,072	-	-	-
HIV Testing Services	317	278	630	-	566		11%	2,945	45,434	630	-	1
VCT Individual (HIV-Negative)	304	268	604	-	542	12/09	11%	2,823	44,756	604	-	1
VCT Individual (HIV-Positive)	13	10	26	-	24	12/09	8%	122	678	26	-	-
Hypertension Screening	-	-	1	-	-		0%	2	6	1	-	-
Hypertension Screening	-	-	1	-	-		-%	2	6	1	-	-

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

**Period: 2**

**Year: 2019**

	DISTRIBUTION 2/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
Implant 5	-	(17)	-	-	26		(100)%	(25)	4,363	-	-	-
Jadelle	2	6	7	-	42	12/08	(83)%	336	5,623	6	24	2
(b)PSI Implant 5 Distributed Inserted	(2)	(23)	(7)	-	(16)		-%	(361)	(1,260)	(6)	(24)	(2)
Implant 5 Insertion	2	23	7	-	16		(56)%	361	1,260	7	27	2
PSI Implant 5 Inserted	2	23	7	-	16		(56)%	361	1,260	7	27	2
Injectable 1	(1)	(2)	(6)	-	-		0%	(2)	(18)	-	-	-
(b)PSI Injectable 1 Distributed Provided	(1)	(2)	(6)	-	-		-%	(2)	(18)	-	-	-
Injectable 1 Provided	1	2	6	-	7		(14)%	19	86	-	-	-
Non-PSI Injectable 1 Provided	-	-	-	-	7		(100)%	17	68	-	-	-
PSI Injectable 1 Provided	1	2	6	-	-		-%	2	18	-	-	-
IUD 10	(8)	(27)	(17)	-	(421)		0%	(761)	(25,198)	(15)	(70)	(6)
(b)PSI IUD 10 Distributed Inserted	(8)	(27)	(17)	-	(421)		-%	(761)	(25,198)	(15)	(70)	(6)
IUD 10 Insertion	8	27	17	-	606		(97)%	1,118	36,433	17	78	7
Non-PSI IUD 10 Inserted	-	-	-	-	185	11/13	(100)%	357	11,235	-	-	-
PSI IUD 10 Inserted	8	27	17	-	421		(96)%	761	25,198	17	78	7
Lubricant	6,287	21,150	46,525	-	14,477		221%	175,111	1,474,104	-	-	-
Vive Lub (sachet)	1,250	10,033	20,900	-	11,450	12/06	83%	94,900	823,290	-	-	-
Vive Lub (tube)	2,277	723	3,185	-	1,041	12/06	206%	8,084	66,244	-	-	-
Vive Lub Natural (sachet)	2,350	9,633	20,700	-	1,250	1/10	1,556%	65,700	553,552	-	-	-
Vive Lub Natural (tube)	410	761	1,740	-	736	1/10	136%	6,427	31,018	-	-	-
Manual Vacuum Aspiration for PAC	-	-	-	-	109		(100)%	109	2,666	-	-	-
MVA for PAC	-	-	-	-	109	8/16	(100)%	109	2,666	-	-	-
OCs	2,829	2,273	5,914	-	2,180		171%	22,861	177,855	355	355	26
(b)PSI OCs Distributed Provided	(1)	(3)	(1)	-	(4)		-%	(17)	(27)	-	-	-

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

**Period: 2**

**Year: 2019**

	DISTRIBUTION 2/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
Segura Plus	2,830	2,276	5,915	-	2,184	2/12	171%	22,878	177,882	355	355	26
OCs Provided	1	3	1	-	4		(75)%	51	67	-	-	-
Non-PSI OCs Provided	-	-	-	-	-		-%	34	40	-	-	-
PSI OCs Provided	1	3	1	-	4		(75)%	17	27	-	-	-
Referral to HIV Testing Services	-	1	-	-	-		0%	2	406	-	-	-
Referral to HIV Testing Services	-	1	-	-	-		-%	2	406	-	-	-
Referral to Implant 5 Insertion	-	1	-	-	-		0%	4	6	-	-	-
Referral to Implant 5 Insertion	-	1	-	-	-	12/11	-%	4	6	-	-	-
Referral to Injectable 1	1	2	1	-	-		0%	6	7	1	-	-
Referral to Injectable 1	1	2	1	-	-		-%	6	7	1	-	-
Referral to IUD 10 Insertion	-	2	1	-	-		0%	4	18,939	1	2	-
Referral to IUD 10 Insertion	-	2	1	-	-	12/11	-%	4	18,939	1	2	-
Referral to Linkage to HIV Care	6	4	10	-	-		0%	41	200	10	-	5
Referral to Linkage to HIV Care	6	4	10	-	-		-%	41	200	10	-	5
STI Screening	12	2	19	-	-		0%	60	2,714	19	-	-
STI Screening	12	2	19	-	-		-%	60	2,714	19	-	-
Treatment for Cervicitis	7	4	20	-	-		0%	28	63	20	-	-
Treatment for Cervicitis	7	4	20	-	-		-%	28	63	20	-	-
Treatment for Genital Herpes	-	-	1	-	-		0%	-	9	1	-	-
Treatment for Genital Herpes	-	-	1	-	-		-%	-	9	1	-	-
Treatment for Lower Abdominal Pain	-	-	1	-	-		0%	-	1	1	-	-
Treatment for Lower Abdominal Pain	-	-	1	-	-		-%	-	1	1	-	-
Treatment for Urethral Discharge (Women)	-	-	-	-	-		0%	1	8	-	-	-
Treatment for Urethral Discharge (Women)	-	-	-	-	-		-%	1	8	-	-	-
Treatment for Vaginitis	5	16	54	-	-		0%	25	82	54	-	-

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

**Period: 2**

**Year: 2019**

	DISTRIBUTION 2/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
Treatment for Vaginitis	5	16	54	-	-		-%	25	82	54	-	-
Type 2 Diabetes Diagnosis	-	-	-	-	-		0%	1	1	-	-	-
Type 2 Diabetes Diagnosis	-	-	-	-	-		-%	1	1	-	-	-
Type 2 Diabetes Screening	-	-	-	-	-		0%	1	3	-	-	-
Type 2 Diabetes Screening	-	-	-	-	-		-%	1	3	-	-	-
Type 2 Diabetes_Controlled Condition	-	-	1	-	-		0%	-	1	-	-	-
Type 2 Diabetes_Controlled Condition	-	-	1	-	-		-%	-	1	-	-	-
Zika Prevention Kit	-	4	-	-	105		(100)%	725	2,621	-	-	-
Zika Prevention Kit	-	4	-	-	105	7/16	(100)%	725	2,621	-	-	-
<b>EI Salvador SA</b>											<b>3,243</b>	<b>304</b>
Condom	5,760	1,136	5,760	-	4,320		33%	30,048	35,808	43	43	11
Vive Amor	5,760	1,136	5,760	-	4,320	10/17	33%	30,048	35,808	43	43	11
Implant 3 Insertion	55	6	72	-	-		0%	-	72	72	180	17
Non-PSI Implant 3 Inserted	55	6	72	-	-		-%	-	72	72	180	17
Implant 5	96	47	89	-	67		33%	911	1,000	80	304	29
Jadelle	100	54	100	-	67	10/17	49%	976	1,076	90	342	32
(b)PSI Implant 5 Distributed Inserted	(4)	(7)	(11)	-	-		-%	(65)	(76)	(10)	(38)	(4)
Implant 5 Insertion	4	8	11	-	-		0%	69	80	11	42	4
Non-PSI Implant 5 Inserted	-	1	-	-	-		-%	4	4	-	-	-
PSI Implant 5 Inserted	4	7	11	-	-		-%	65	76	11	42	4
Injectable 1 Provided	-	1	-	-	-		0%	4	4	-	-	-
Non-PSI Injectable 1 Provided	-	1	-	-	-		-%	4	4	-	-	-
IUD 10	313	87	80	-	600		(87)%	2,576	2,656	72	331	30
Copper T 380	429	235	429	-	600	10/17	(29)%	4,021	4,450	386	1,776	159
(b)PSI IUD 10 Distributed Inserted	(116)	(149)	(349)	-	-		-%	(1,445)	(1,794)	(314)	(1,445)	(130)

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

**Period: 2**

**Year: 2019**

	DISTRIBUTION 2/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
IUD 10 Insertion	274	247	507	-	-		0%	2,956	3,463	507	2,332	209
Non-PSI IUD 10 Inserted	158	99	158	-	-		-%	1,511	1,669	158	727	65
PSI IUD 10 Inserted	116	149	349	-	-		-%	1,445	1,794	349	1,605	144
Lubricant	-	-	-	-	12		(100)%	12	12	-	-	-
Vive Lub Natural (tube)	-	-	-	-	12	10/17	(100)%	12	12	-	-	-
Manual Vacuum Aspiration for PAC	-	343	65	-	-		0%	965	1,030	65	-	1
MVA for PAC	-	343	65	-	-		-%	965	1,030	65	-	1
Medical Abortion	-	(1)	-	-	-		0%	(3)	(3)	-	-	-
(b)PSI Medical Abortion Distributed Provided	-	(1)	-	-	-		-%	(3)	(3)	-	-	-
Medical Abortion Provided	-	3	-	-	-		0%	8	8	-	-	-
Non-PSI Medical Abortion Provided	-	2	-	-	-		-%	5	5	-	-	-
PSI Medical Abortion Provided	-	1	-	-	-		-%	3	3	-	-	-
Misoprostol for PAC Provided	-	112	46	-	-		0%	291	337	46	-	1
Non-PSI Misoprostol for PAC Provided	-	97	41	-	-		-%	250	291	41	-	1
PSI Misoprostol for PAC Provided	-	15	5	-	-		-%	41	46	5	-	-
Misoprostol for Safe Abortion	1,704	229	1,684	-	96		1654%	5,928	7,612	88	-	2
Misoprostol for Safe Abortion	1,704	291	1,704	-	96	3/18	1,675%	6,092	7,796	89	-	2
(b)PSI Misoprostol for Safe Abortion Dist Provided	-	(61)	(20)	-	-		-%	(164)	(184)	(1)	-	-
OCs	-	-	-	-	44		(100)%	100	100	-	-	-
Segura Plus	-	-	-	-	44	10/17	(100)%	100	100	-	-	-
Tubal Ligation	-	-	1	-	-		0%	1	2	1	10	1
Tubal Ligation	-	-	1	-	-		-%	1	2	1	10	1
<b>Guatemala</b>											<b>14,565</b>	<b>4,232</b>
Condom	804,400	1,073,245	1,832,296	-	1,926,488		(5)%	11,280,624	146,622,837	13,742	13,742	4,085
Combo Pack	5,200	2,645	8,416	-	4,592	4/05	83%	28,752	455,672	63	63	19

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

Period: 2

Year: 2019

	DISTRIBUTION 2/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
Vive	180,000	352,544	634,896	-	647,424	4/98	(2)%	3,743,136	58,339,773	4,762	4,762	1,415
Vive Amor	500,304	584,576	913,824	-	1,033,440	7/04	(12)%	6,293,856	68,041,743	6,854	6,854	2,037
Vive Colors/Mas Colors	61,656	83,224	174,360	-	152,640	4/02	14%	725,880	14,480,134	1,308	1,308	389
Vive Mas Fuerte /Retardante	38,232	40,536	72,816	-	80,304	7/04	(9)%	393,648	3,234,992	546	546	162
Vive Mas Natural /Sensitivo	15,120	7,848	24,096	-	8,088	7/04	198%	86,712	1,106,965	181	181	54
Vive Mas/Texturizado	3,888	1,872	3,888	-	-	7/04	-%	8,640	963,558	29	29	9
Emergency Contraception	-	-	-	-	(1)		0%	(1)	(1)	-	-	-
(b)PSI Emergency Contraception Distributed Provided	-	-	-	-	(1)		-%	(1)	(1)	-	-	-
Emergency Contraception Provided	-	-	-	-	1		(100)%	1	1	-	-	-
PSI Emergency Contraception Provided	-	-	-	-	1		(100)%	1	1	-	-	-
HIV Testing Services	311	263	586	-	388		51%	2,755	52,484	586	-	2
VCT Individual (HIV-Negative)	306	255	574	-	377	12/09	52%	2,647	51,685	574	-	1
VCT Individual (HIV-Positive)	5	8	12	-	11	12/09	9%	108	799	12	-	-
Implant 5	-	-	-	-	(498)		0%	(867)	(14,210)	-	-	-
(b)PSI Implant 5 Distributed Inserted	-	-	-	-	(498)		-%	(867)	(14,210)	-	-	-
Implant 5 Insertion	-	-	-	-	1,274		(100)%	2,308	34,014	-	-	-
Non-PSI Implant 5 Inserted	-	-	-	-	776		(100)%	1,441	19,804	-	-	-
PSI Implant 5 Inserted	-	-	-	-	498		(100)%	867	14,210	-	-	-
Injectable 1	3,870	2,077	5,945	-	4,906		21%	29,950	263,625	412	412	69
Cyclofem	3,870	2,077	5,945	-	5,628	5/11	6%	30,961	270,839	412	412	69
(b)PSI Injectable 1 Distributed Provided	-	-	-	-	(722)		-%	(1,011)	(7,214)	-	-	-
Injectable 1 Provided	-	-	-	-	10,534		(100)%	14,790	62,320	-	-	-
Non-PSI Injectable 1 Provided	-	-	-	-	9,812		(100)%	13,779	55,106	-	-	-
PSI Injectable 1 Provided	-	-	-	-	722		(100)%	1,011	7,214	-	-	-

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

**Period: 2**

**Year: 2019**

	DISTRIBUTION 2/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
Injectable 2 Provided	-	-	-	-	8,515		(100)%	13,271	34,974	-	-	-
Non-PSI Injectable 2 Provided	-	-	-	-	8,515		(100)%	13,271	34,974	-	-	-
Injectable 3-IM Provided	-	-	-	-	124,744		(100)%	130,743	266,096	-	-	-
Non-PSI Injectable 3 IM Provided	-	-	-	-	124,744		(100)%	130,743	266,096	-	-	-
IUD 10	-	-	-	-	(1,316)		0%	(2,251)	(88,649)	-	-	-
(b)PSI IUD 10 Distributed Inserted	-	-	-	-	(1,316)		-%	(2,251)	(88,649)	-	-	-
IUD 10 Insertion	-	-	-	-	1,865		(100)%	2,939	111,458	-	-	-
Non-PSI IUD 10 Inserted	-	-	-	-	549		(100)%	688	22,809	-	-	-
PSI IUD 10 Inserted	-	-	-	-	1,316		(100)%	2,251	88,649	-	-	-
Lubricant	39,978	5,822	48,430	-	6,720		621%	115,766	1,599,424	-	-	-
Vive Lub (sachet)	31,016	1,167	32,466	-	600	4/05	5,311%	54,903	1,032,107	-	-	-
Vive Lub (tube)	1,112	1,817	4,238	-	2,625	4/05	61%	14,996	152,004	-	-	-
Vive Lub Natural (sachet)	6,300	1,117	7,650	-	950	1/10	705%	29,200	309,427	-	-	-
Vive Lub Natural (tube)	1,550	1,722	4,076	-	2,545	1/10	60%	16,667	105,886	-	-	-
Manual Vacuum Aspiration for PAC	-	-	-	-	714		(100)%	1,431	9,176	-	-	-
MVA for PAC	-	-	-	-	714	5/16	(100)%	1,431	9,176	-	-	-
Misoprostol for PAC Provided	-	-	-	-	662		(100)%	2,281	5,883	-	-	-
Non-PSI Misoprostol for PAC Provided	-	-	-	-	478		(100)%	1,452	3,049	-	-	-
PSI Misoprostol for PAC Provided	-	-	-	-	184		(100)%	829	2,834	-	-	-
Misoprostol for Safe Abortion	-	-	-	-	(736)		0%	(3,316)	(11,336)	-	-	-
(b)PSI Misoprostol for Safe Abortion Dist Provided	-	-	-	-	(736)		-%	(3,316)	(11,336)	-	-	-
OCs	2,970	4,822	6,020	-	16,724		(64)%	63,764	195,681	361	361	59
(b)PSI OCs Distributed Provided	-	-	-	-	(583)		-%	(699)	(4,667)	-	-	-
Segura Plus	2,970	4,822	6,020	-	17,307	5/14	(65)%	64,463	200,348	361	361	59
OCs Provided	-	-	-	-	28,674		(100)%	31,295	85,031	-	-	-

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.



**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

Period: 2

Year: 2019

	DISTRIBUTION 2/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
Non-PSI OCs Provided	-	-	-	-	28,091		(100)%	30,596	80,364	-	-	-
PSI OCs Provided	-	-	-	-	583		(100)%	699	4,667	-	-	-
Referral to Implant 5 Insertion	7	8	13	-	-		0%	27	63	13	25	5
Referral to Implant 5 Insertion	7	8	13	-	-	12/11	-%	27	63	13	25	5
Referral to Injectable 1	-	1	-	-	-		0%	5	5	-	-	-
Referral to Injectable 1	-	1	-	-	-		-%	5	5	-	-	-
Referral to IUD 10 Insertion	2	9	9	-	-		0%	48	29,836	9	21	4
Referral to IUD 10 Insertion	2	9	9	-	-	12/11	-%	48	29,836	9	21	4
Referral to Linkage to HIV Care	7	4	12	-	5		140%	55	233	12	-	8
Referral to Linkage to HIV Care	7	4	12	-	5		140%	55	233	12	-	8
Referral to OCs	-	-	-	-	-		0%	2	2	-	-	-
Referral to OCs	-	-	-	-	-		-%	2	2	-	-	-
Referral to Vasectomy	1	-	1	-	-		0%	-	1	1	5	1
Referral to Vasectomy	1	-	1	-	-		-%	-	1	1	5	1
SDM (Cycle Beads) Provided	-	-	-	-	1		(100)%	1	116	-	-	-
Non-PSI SDM (Cycle Beads) Provided	-	-	-	-	1		(100)%	1	116	-	-	-
Tubal Ligation	-	-	-	-	1,341		(100)%	1,807	17,292	-	-	-
Tubal Ligation	-	-	-	-	1,341	7/12	(100)%	1,807	17,292	-	-	-
Vasectomy	-	-	-	-	52		(100)%	77	660	-	-	-
Vasectomy	-	-	-	-	52	7/12	(100)%	77	660	-	-	-
<b>Guatemala SA</b>											<b>18,481</b>	<b>3,539</b>
Condom	5,328	5,232	5,328	-	17,424		(69)%	95,328	100,656	40	40	12
Vive	-	48	-	-	10,944	7/17	(100)%	50,832	50,832	-	-	-
Vive Amor	5,328	5,184	5,328	-	6,480	7/17	(18)%	44,496	49,824	40	40	12
Emergency Contraception	-	-	-	-	-		0%	(4)	(4)	-	-	-

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

**Period: 2**

**Year: 2019**

	DISTRIBUTION 2/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
(b)PSI Emergency Contraception Distributed Provided	-	-	-	-	-		-%	(4)	(4)	-	-	-
Emergency Contraception Provided	3	-	3	-	-		0%	6	9	-	-	-
Non-PSI Emergency Contraception Provided	3	-	3	-	-		-%	2	5	-	-	-
PSI Emergency Contraception Provided	-	-	-	-	-		-%	4	4	-	-	-
Implant 5	(226)	(150)	(734)	-	645		(214)%	1,602	868	(661)	(2,510)	(518)
Jadelle	10	132	10	-	645	7/17	(98)%	3,672	3,682	9	34	7
(b)PSI Implant 5 Distributed Inserted	(236)	(282)	(744)	-	-		-%	(2,070)	(2,814)	(670)	(2,544)	(525)
Implant 5 Insertion	285	1,581	1,635	-	-		0%	15,706	17,341	1,635	6,213	1,282
Non-PSI Implant 5 Inserted	49	1,299	891	-	-		-%	13,636	14,527	891	3,386	699
PSI Implant 5 Inserted	236	282	744	-	-		-%	2,070	2,814	744	2,827	583
Injectable 1	87	(97)	7	-	798		(99)%	417	424	-	-	-
Cyclofem	154	71	154	-	798	7/17	(81)%	2,127	2,281	11	11	2
(b)PSI Injectable 1 Distributed Provided	(67)	(168)	(147)	-	-		-%	(1,710)	(1,857)	(10)	(10)	(2)
Injectable 1 Provided	417	1,594	3,043	-	-		0%	50,852	53,895	234	234	39
Non-PSI Injectable 1 Provided	350	1,426	2,896	-	-		-%	49,142	52,038	223	223	37
PSI Injectable 1 Provided	67	168	147	-	-		-%	1,710	1,857	11	11	2
Injectable 2 Provided	206	1,236	2,916	-	-		0%	34,427	37,343	486	486	75
Non-PSI Injectable 2 Provided	206	1,236	2,916	-	-		-%	34,427	37,343	486	486	75
Injectable 3-IM Provided	703	13,274	30,329	-	-		0%	224,719	255,048	7,582	7,582	1,170
Non-PSI Injectable 3 IM Provided	703	13,274	30,329	-	-		-%	224,719	255,048	7,582	7,582	1,170
IUD 10	(270)	374	(1,030)	-	1,079		(195)%	4,388	3,358	(927)	(4,264)	(841)
Copper T 380	324	927	324	-	1,057	7/17	(69)%	11,187	11,511	292	1,341	265
Copper T 380 Postpartum	6	10	6	-	22	7/17	(73)%	1,084	1,090	5	25	5
(b)PSI IUD 10 Distributed Inserted	(600)	(563)	(1,360)	-	-		-%	(7,883)	(9,243)	(1,224)	(5,630)	(1,111)

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

**Period: 2**

**Year: 2019**

	DISTRIBUTION 2/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
IUD 10 Insertion	615	631	1,541	-	-		0%	11,810	13,351	1,541	7,089	1,399
Non-PSI IUD 10 Inserted	15	67	181	-	-		-%	3,927	4,108	181	833	164
PSI IUD 10 Inserted	600	563	1,360	-	-		-%	7,883	9,243	1,360	6,256	1,235
IUD 5	-	-	-	-	1,000		(100)%	1,002	1,002	-	-	-
IUD Slek	-	-	-	-	1,000	7/17	(100)%	1,002	1,002	-	-	-
Lubricant	8	8	8	-	26		(69)%	136	144	-	-	-
Vive Lub (tube)	-	4	-	-	22	7/17	(100)%	74	74	-	-	-
Vive Lub Natural (tube)	8	4	8	-	4	7/17	100%	62	70	-	-	-
Manual Vacuum Aspiration for PAC	179	1,768	583	-	-		0%	4,901	5,484	583	-	16
MVA for PAC	179	1,768	583	-	-		-%	4,901	5,484	583	-	16
Misoprostol for PAC Provided	322	1,555	899	-	-		0%	4,088	4,987	899	-	30
Non-PSI Misoprostol for PAC Provided	-	748	4	-	-		-%	2,240	2,244	4	-	-
PSI Misoprostol for PAC Provided	322	807	895	-	-		-%	1,848	2,743	895	-	30
Misoprostol for Safe Abortion	15,480	(2,921)	13,188	-	5,260		151%	56,728	69,916	692	-	20
Misoprostol for Safe Abortion	16,768	307	16,768	-	5,260	3/18	219%	64,120	80,888	880	-	26
(b)PSI Misoprostol for Safe Abortion Dist Provided	(1,288)	(3,228)	(3,580)	-	-		-%	(7,392)	(10,972)	(188)	-	(5)
OCs	142	162	125	-	-		0%	(1,020)	(895)	8	8	1
(b)PSI OCs Distributed Provided	(12)	(45)	(29)	-	-		-%	(2,320)	(2,349)	(2)	(2)	-
Segura Plus	154	207	154	-	-	7/17	-%	1,300	1,454	9	9	2
OCs Provided	307	1,060	1,675	-	-		0%	40,905	42,580	112	112	18
Non-PSI OCs Provided	295	1,015	1,646	-	-		-%	38,585	40,231	110	110	18
PSI OCs Provided	12	45	29	-	-		-%	2,320	2,349	2	2	-
SDM (Cycle Beads) Provided	1	-	1	-	-		0%	6	7	1	2	-
Non-PSI SDM (Cycle Beads) Provided	1	-	1	-	-		-%	6	7	1	2	-
Tubal Ligation	2	318	339	-	-		0%	9,992	10,331	339	3,390	812

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

Period: 2

Year: 2019

	DISTRIBUTION 2/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
Tubal Ligation	2	318	339	-	-		-%	9,992	10,331	339	3,390	812
Vasectomy	-	17	10	-	-		0%	241	251	10	100	24
Vasectomy	-	17	10	-	-		-%	241	251	10	100	24
<b>Honduras</b>											<b>7,472</b>	<b>4,100</b>
Condom	413,384	312,333	896,120	-	688,568		30%	4,116,704	51,240,888	6,721	6,721	3,995
Combo-Pack Lub Fresa	1,088	581	1,616	-	512	2/16	216%	6,880	17,664	12	12	7
Combo-Pack Lub Natural	-	-	-	-	480	10/10	(100)%	688	27,648	-	-	-
Vive	63,216	84,880	188,496	-	145,584	9/00	29%	1,088,832	15,609,427	1,414	1,414	840
Vive Amor	244,656	154,016	511,824	-	443,088	8/04	16%	2,348,928	24,650,696	3,839	3,839	2,282
Vive Colors/Mas Colors	83,808	48,056	142,200	-	66,552	4/02	114%	455,400	8,756,038	1,066	1,066	634
Vive Mas Fuerte /Retardante	15,096	18,776	39,600	-	14,832	8/04	167%	145,680	1,160,856	297	297	177
Vive Mas Natural /Sensitivo	5,232	5,496	11,880	-	6,408	8/04	85%	45,096	501,698	89	89	53
Vive Mas/Texturizado	288	528	504	-	11,112	8/04	(95)%	25,200	516,861	4	4	2
HIV Testing Services	336	274	602	-	510		18%	3,254	15,719	602	-	1
VCT Individual (HIV-Negative)	312	266	567	-	492	4/12	15%	3,156	15,410	567	-	1
VCT Individual (HIV-Positive)	24	8	35	-	18	4/14	94%	98	309	35	-	-
Implant 3 Insertion	-	(421)	2	-	11		(82)%	22	63	2	5	1
Non-PSI Implant 3 Inserted	-	(421)	2	-	11		(82)%	22	63	2	5	1
Injectable 1 Provided	-	2	2	-	4		(50)%	9	60	-	-	-
Non-PSI Injectable 1 Provided	-	2	2	-	4		(50)%	9	60	-	-	-
Injectable 3-IM Provided	2	1	2	-	11		(82)%	21	80	1	1	-
Non-PSI Injectable 3 IM Provided	2	1	2	-	11		(82)%	21	80	1	1	-
IUD 10	(39)	(31)	(91)	-	-		0%	(570)	(664)	(82)	(377)	(48)
(b)PSI IUD 10 Distributed Inserted	(39)	(31)	(91)	-	-		-%	(570)	(664)	(82)	(377)	(48)

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

Period: 2

Year: 2019

	DISTRIBUTION 2/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
IUD 10 Insertion	39	49	92	-	11		736%	977	1,100	92	423	54
Non-PSI IUD 10 Inserted	-	19	1	-	11		(91)%	407	436	1	5	1
PSI IUD 10 Inserted	39	31	91	-	-		-%	570	664	91	419	53
Lubricant	8,140	6,688	12,460	-	10,149		23%	113,476	919,207	-	-	-
Vive Lub (sachet)	4,150	283	4,650	-	3,050	3/05	52%	49,802	584,329	-	-	-
Vive Lub (tube)	2,735	1,555	4,722	-	2,639	3/05	79%	14,051	99,522	-	-	-
Vive Lub Natural (sachet)	-	3,533	-	-	2,990	1/10	(100)%	37,832	174,548	-	-	-
Vive Lub Natural (tube)	1,255	1,317	3,088	-	1,470	1/10	110%	11,791	60,808	-	-	-
OCs Provided	-	-	-	-	2		(100)%	2	15	-	-	-
Non-PSI OCs Provided	-	-	-	-	2		(100)%	2	15	-	-	-
Referral to Implant 3 Insertion	146	540	311	-	-		0%	1,455	1,766	311	389	53
Referral to Implant 3 Insertion	146	540	311	-	-		-%	1,455	1,766	311	389	53
Referral to IUD 10 Insertion	81	18	135	-	-		0%	-	135	135	310	39
Referral to IUD 10 Insertion	81	18	135	-	-		-%	-	135	135	310	39
Referral to Linkage to HIV Care	1	5	8	-	19		(58)%	75	179	8	-	5
Referral to Linkage to HIV Care	1	5	8	-	19		(58)%	75	179	8	-	5
<b>Kazakhstan</b>												109
Free Condom	-	-	-	-	14,900		(100)%	46,385	673,550	-	-	-
Generic Male Condom	-	-	-	-	14,900	8/16	(100)%	46,385	673,550	-	-	-
Free Female Condom	-	-	-	-	3,245		(100)%	8,200	32,770	-	-	-
Generic Female Condom	-	-	-	-	3,245	8/16	(100)%	8,200	32,770	-	-	-
HIV Testing Services	319	188	492	-	379		30%	2,373	6,395	492	-	1
VCT Individual (HIV-Negative)	304	173	468	-	365		28%	2,219	6,160	468	-	1
VCT Individual (HIV-Positive)	15	16	24	-	14		71%	154	235	24	-	-
Referral to HIV Testing Services	-	-	-	-	-		0%	4	3,160	-	-	-

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

**Period: 2**

**Year: 2019**

	DISTRIBUTION 2/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
Referral to HIV Testing Services	-	-	-	-	-		-%	4	3,160	-	-	-
Referral to Linkage to HIV Care	65	95	120	-	46		161%	997	1,836	120	-	109
Referral to Linkage to HIV Care	65	95	120	-	46		161%	997	1,836	120	-	109
Referral to Opioid Treatment	-	5	5	-	5		0%	26	98	5	-	-
Referral to Opioid Treatment	-	5	5	-	5		-%	26	98	5	-	-
Referral to TB Screening	-	-	-	-	7		(100)%	7	17	-	-	-
Referrals to TB Screening	-	-	-	-	7		(100)%	7	17	-	-	-
TB Diagnosis	-	-	-	-	3		(100)%	11	44	-	-	-
TB Diagnosis	-	-	-	-	3		(100)%	11	44	-	-	-
TB Screening	151	327	374	-	458		(18)%	2,591	6,003	374	-	-
TB Screening	151	327	374	-	458		(18)%	2,591	6,003	374	-	-
<b>Kyrgyzstan</b>											-	91
Free Condom	-	-	-	-	27,144		(100)%	30,144	30,144	-	-	-
Generic Male Condom	-	-	-	-	27,144	11/17	(100)%	30,144	30,144	-	-	-
Free Female Condom	-	-	-	-	13,000		(100)%	13,000	13,000	-	-	-
Generic Female Condom	-	-	-	-	13,000	11/17	(100)%	13,000	13,000	-	-	-
HIV Testing Services	1,555	1,845	3,161	-	3,576		(12)%	25,008	41,637	3,161	-	6
VCT Individual (HIV-Negative)	1,523	1,812	3,087	-	3,511		(12)%	24,608	40,927	3,087	-	6
VCT Individual (HIV-Positive)	32	33	74	-	65		14%	400	710	74	-	-
Referral to Linkage to HIV Care	45	36	81	-	52		56%	456	1,599	81	-	85
Referral to Linkage to HIV Care	45	36	81	-	52		56%	456	1,599	81	-	85
Referral to Opioid Treatment	2	3	3	-	19		(84)%	44	193	3	-	-
Referral to Opioid Treatment	2	3	3	-	19		(84)%	44	193	3	-	-
Referral to TB Screening	-	-	-	-	13		(100)%	13	25	-	-	-
Referrals to TB Screening	-	-	-	-	13		(100)%	13	25	-	-	-

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

Period: 2

Year: 2019

	DISTRIBUTION 2/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
TB Diagnosis	1	1	2	-	-		0%	8	40	2	-	-
TB Diagnosis	1	1	2	-	-		-%	8	40	2	-	-
TB Screening	114	107	191	-	295		(35)%	1,418	6,782	191	-	-
TB Screening	114	107	191	-	295		(35)%	1,418	6,782	191	-	-
<b>Laos</b>											18,799	5,035
Condom	86,400	463,412	779,040	-	881,841		(12)%	3,760,689	32,000,511	5,843	5,843	1,665
No 1 Condom Grp	51,840	52,649	122,400	-	157,248	11/10	(22)%	628,416	5,031,268	918	918	262
No 1 Condom Strw	-	260,955	345,600	-	327,024	8/08	6%	1,901,232	16,412,712	2,592	2,592	739
Number One Rose	34,560	149,808	311,040	-	397,569	4/08	(22)%	1,231,041	10,556,531	2,333	2,333	665
Fever Cases Attended	3,920	4,381	8,341	-	4,157		101%	43,091	62,493	8,341	-	-
Fever Cases Attended	3,920	4,381	8,341	-	4,157		101%	43,091	62,493	8,341	-	-
Fever Cases Tested with RDTs	3,920	4,381	8,341	-	4,156		101%	43,075	62,463	8,341	-	-
Fever Cases Tested with RDTs	3,920	4,381	8,341	-	4,156		101%	43,075	62,463	8,341	-	-
HIV Testing Services	485	414	894	-	433		106%	5,345	20,291	894	-	1
VCT Individual (HIV-Negative)	483	412	892	-	430	2/10	107%	5,309	20,116	892	-	1
VCT Individual (HIV-Positive)	2	2	2	-	3	4/10	(33)%	36	175	2	-	-
Implant 3 Insertion	876	1,077	1,919	-	1,464		31%	11,434	26,216	1,919	4,798	1,204
Non-PSI Implant 3 Inserted	876	1,077	1,919	-	1,464	3/16	31%	11,434	26,216	1,919	4,798	1,204
Injectable 3-IM	-	-	-	-	-		0%	(1,586)	(1,586)	-	-	-
(b)PSI Injectable 3 IM Distributed Provided	-	-	-	-	-		-%	(1,586)	(1,586)	-	-	-
Injectable 3-IM Provided	1,479	1,873	3,575	-	2,102		70%	19,748	41,032	894	894	166
Non-PSI Injectable 3 IM Provided	1,479	1,873	3,575	-	2,102	3/16	70%	18,162	39,446	894	894	166
PSI Injectable 3 IM Provided	-	-	-	-	-		-%	1,586	1,586	-	-	-
IUD 10	(54)	(68)	(123)	-	-		0%	(260)	(383)	(111)	(509)	(119)
(b)PSI IUD 10 Distributed Inserted	(54)	(68)	(123)	-	-		-%	(260)	(383)	(111)	(509)	(119)

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

**Period: 2**

**Year: 2019**

	DISTRIBUTION 2/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
IUD 10 Insertion	705	968	1,616	-	1,812		(11)%	11,005	47,305	1,616	7,434	1,738
Non-PSI IUD 10 Inserted	651	900	1,493	-	1,812		(18)%	10,745	46,922	1,493	6,868	1,606
PSI IUD 10 Inserted	54	68	123	-	-		-%	260	383	123	566	132
IUD 5	-	-	-	-	-		0%	800	2,610	-	-	-
IUD Cu375	-	-	-	-	-	7/12	-%	800	2,610	-	-	-
Manual Vacuum Aspiration for SA	-	-	-	-	-		0%	81	81	-	-	-
Manual Vacuum Aspiration for SA	-	-	-	-	-		-%	81	81	-	-	-
Misoprostol for PAC Provided	-	-	-	-	-		0%	70	70	-	-	-
Non-PSI Misoprostol for PAC Provided	-	-	-	-	-		-%	52	52	-	-	-
PSI Misoprostol for PAC Provided	-	-	-	-	-		-%	18	18	-	-	-
Misoprostol for Safe Abortion	30,000	17,333	53,000	-	24,000		121%	202,928	649,398	2,782	-	253
Misoprostol for Safe Abortion	30,000	17,333	53,000	-	24,000	3/18	121%	203,000	649,470	2,782	-	253
(b)PSI Misoprostol for Safe Abortion Dist Provided	-	-	-	-	-		-%	(72)	(72)	-	-	-
OCs	-	-	-	-	-		0%	(2,241)	(2,241)	-	-	-
(b)PSI OCs Distributed Provided	-	-	-	-	-		-%	(2,241)	(2,241)	-	-	-
OCs Provided	2,178	2,810	5,111	-	3,201		60%	29,665	58,823	341	341	67
Non-PSI OCs Provided	2,178	2,810	5,111	-	3,201	3/16	60%	27,424	56,582	341	341	67
PSI OCs Provided	-	-	-	-	-		-%	2,241	2,241	-	-	-
Positive RDTs	110	118	253	-	208		22%	1,324	2,140	253	-	-
Positive RDTs	110	118	253	-	208		22%	1,324	2,140	253	-	-
Positive RDTs Given First Line Treatment	110	118	253	-	208		22%	1,324	2,140	253	-	-
Positive RDTs Given First Line Treatment	110	118	253	-	208		22%	1,324	2,140	253	-	-
QAACts Provided after Confirmatory Diagnosis	110	118	253	-	208		22%	1,324	2,140	253	-	48
Non-PSI QAACts Provided after Confirmed Diagnosis	110	118	253	-	208		22%	1,324	2,140	253	-	48
Referral to TB DOTS (completion confirmed)	35	-	35	-	57		(39)%	148	426	35	-	12

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.



**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

Period: 2

Year: 2019

	DISTRIBUTION 2/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
Referral to TB DOTS (completion confirmed)	35	-	35	-	57	3/16	(39)%	148	426	35	-	12
Referral to TB DOTS (completion unknown)	4	-	4	-	1		300%	43	248	4	-	1
Referral to TB DOTS (completion unknown)	4	-	4	-	1	12/13	300%	43	248	4	-	1
TB Diagnosis	47	-	47	-	52		(10)%	185	836	47	-	-
TB Diagnosis	47	-	47	-	52		(10)%	185	836	47	-	-
TB Screening	209	-	209	-	176		19%	755	3,226	209	-	-
TB Screening	209	-	209	-	176		19%	755	3,226	209	-	-
<b>Nepal</b>											<b>986</b>	<b>1,683</b>
Emergency Contraception	-	-	-	-	-		0%	221	221	-	-	-
i-pill	-	-	-	-	-	7/17	-%	221	221	-	-	-
Free Condom	-	-	-	-	-		0%	2,148	574,282	-	-	-
Generic Condom	-	-	-	-	-	1/16	-%	2,148	574,282	-	-	-
Implant 5	-	-	-	-	-		0%	(34)	(1,377)	-	-	-
(b)PSI Implant 5 Distributed Inserted	-	-	-	-	-		-%	(34)	(1,377)	-	-	-
Implant 5 Insertion	18	5	24	-	5		380%	75	1,709	24	91	17
Non-PSI Implant 5 Inserted	18	5	24	-	5		380%	41	332	24	91	17
PSI Implant 5 Inserted	-	-	-	-	-		-%	34	1,377	-	-	-
IUD 10	(1,600)	(394)	(1,725)	-	1,270		(236)%	(9,464)	(181,880)	(1,553)	(7,141)	(1,258)
OK IUD	-	833	-	-	6,550	5/04	(100)%	23,060	41,310	-	-	-
Pregna T Cu 380A	-	-	-	-	-	7/17	-%	20	40	-	-	-
(b)PSI IUD 10 Distributed Inserted	(1,600)	(1,227)	(1,725)	-	(5,280)		-%	(32,544)	(223,230)	(1,553)	(7,141)	(1,258)
IUD 10 Insertion	1,622	1,269	1,747	-	5,519		(68)%	33,521	234,672	1,747	8,036	1,415
Non-PSI IUD 10 Inserted	22	42	22	-	239		(91)%	977	11,441	22	101	18
PSI IUD 10 Inserted	1,600	1,227	1,725	-	5,280		(67)%	32,544	223,230	1,725	7,935	1,398
Manual Vacuum Aspiration for PAC	-	2	-	-	-		0%	12	12	-	-	-

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

Period: 2

Year: 2019

	DISTRIBUTION 2/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
MVA for PAC	-	2	-	-	-		-%	12	12	-	-	-
Manual Vacuum Aspiration for SA	8	23	8	-	-		0%	170	178	8	-	1
Manual Vacuum Aspiration for SA	8	23	8	-	-		-%	170	178	8	-	1
Medical Abortion	(112)	12,534	11,978	-	22,607		(47)%	122,575	377,021	10,780	-	1,491
Medabon	-	12,699	12,090	-	22,607	12/08	(47)%	123,798	378,356	10,881	-	1,505
(b)PSI Medical Abortion Distributed Provided	(112)	(165)	(112)	-	-		-%	(1,223)	(1,335)	(101)	-	(14)
Medical Abortion Provided	112	168	112	-	-		0%	1,263	1,375	112	-	15
Non-PSI Medical Abortion Provided	-	3	-	-	-		-%	40	40	-	-	-
PSI Medical Abortion Provided	112	165	112	-	-		-%	1,223	1,335	112	-	15
OCs	-	-	-	-	-		0%	15,134	158,306	-	-	-
Zinnia	-	-	-	-	-	8/15	-%	554	143,726	-	-	-
Zinnia - F	-	-	-	-	-	7/17	-%	14,580	14,580	-	-	-
STI Screening	-	-	-	-	39		(100)%	39	1,198	-	-	-
STI Screening	-	-	-	-	39		(100)%	39	1,198	-	-	-
<b>Nicaragua</b>											<b>10,760</b>	<b>2,534</b>
Condom	420,360	304,648	808,872	-	860,856		(6)%	3,880,941	75,606,101	6,067	6,067	1,756
Bodyguard	-	-	-	-	-	2/04	-%	(1,613)	11,095,477	-	-	-
Combo-Pack Lub Fresa	432	288	864	-	3,024	5/11	(71)%	14,866	70,282	6	6	2
Combo-Pack Lub Natural	-	-	-	-	(432)	10/10	-%	(3,374)	23,618	-	-	-
Vive	292,896	186,640	525,456	-	518,016	4/98	1%	2,580,363	48,636,299	3,941	3,941	1,141
Vive Colors/Mas Colors	95,184	78,624	202,104	-	229,944	4/02	(12)%	864,750	11,806,610	1,516	1,516	439
Vive Mas Fuerte /Retardante	26,016	30,456	66,840	-	86,568	6/04	(23)%	325,560	2,221,454	501	501	145
Vive Mas Natural /Sensitivo	5,832	8,640	13,608	-	20,424	6/04	(33)%	88,989	1,002,368	102	102	30
Vive Mas/Texturizado	-	-	-	-	3,312	6/04	(100)%	11,400	749,993	-	-	-

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

**Period: 2**

**Year: 2019**

	DISTRIBUTION 2/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
HIV Testing Services	76	92	165	-	56		195%	687	7,883	165	-	-
VCT Individual (HIV-Negative)	67	87	148	-	54	12/09	174%	648	7,735	148	-	-
VCT Individual (HIV-Positive)	9	5	17	-	2	12/09	750%	39	148	17	-	-
Implant 3	880	(83)	844	-	(1)		0%	789	2,194	760	1,899	318
Implanon	880	-	880	-	-	7/15	-%	1,506	3,895	792	1,980	332
(b)PSI Implant 3 Distributed Inserted	-	(83)	(36)	-	(1)	3/16	-%	(717)	(1,701)	(32)	(81)	(14)
Implant 3 Insertion	-	115	69	-	12		475%	974	2,012	69	173	29
Non-PSI Implant 3 Inserted	-	31	33	-	11		200%	257	311	33	83	14
PSI Implant 3 Inserted	-	83	36	-	1	3/16	3,500%	717	1,701	36	90	15
Implant 5	-	(3)	-	-	554		(100)%	474	2,373	-	-	-
Jadelle	-	-	-	-	849	12/08	(100)%	1,195	6,080	-	-	-
(b)PSI Implant 5 Distributed Inserted	-	(3)	-	-	(295)		-%	(721)	(3,707)	-	-	-
Implant 5 Insertion	-	3	-	-	295		(100)%	721	3,707	-	-	-
PSI Implant 5 Inserted	-	3	-	-	295		(100)%	721	3,707	-	-	-
Injectable 1 Provided	-	36	54	-	32		69%	312	654	4	4	1
Non-PSI Injectable 1 Provided	-	36	54	-	32		69%	312	654	4	4	1
Injectable 3-IM Provided	-	8	15	-	-		0%	62	126	4	4	-
Non-PSI Injectable 3 IM Provided	-	8	15	-	-		-%	62	126	4	4	-
IUD 10	565	139	388	-	773		(50)%	2,979	40,598	349	1,606	253
Copper T 380	545	321	545	-	1,150	12/08	(53)%	5,325	85,420	491	2,256	356
Copper-T 380-A IUD	20	13	20	-	-	3/16	-%	84	166	18	83	13
(b)PSI IUD 10 Distributed Inserted	-	(195)	(177)	-	(377)		-%	(2,430)	(44,988)	(159)	(733)	(115)
IUD 10 Insertion	-	195	177	-	377		(53)%	2,430	44,988	177	814	128
PSI IUD 10 Inserted	-	195	177	-	377		(53)%	2,430	44,988	177	814	128
IUD 5	47	(4)	43	-	97		(56)%	659	1,030	39	128	21

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

**Period: 2**

**Year: 2019**

	DISTRIBUTION 2/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
Copper T375 Sleek	47	3	47	-	106	3/16	(56)%	732	1,119	42	140	23
(b)PSI IUD 5 Distributed Inserted	-	(7)	(4)	-	(9)		-%	(73)	(89)	(4)	(12)	(2)
IUD 5 Insertion	-	7	4	-	9		(56)%	73	89	4	13	2
PSI IUD 5 Inserted	-	7	4	-	9		(56)%	73	89	4	13	2
IUS 5 Insertion	-	1	3	-	-		0%	2	6	3	10	2
Non-PSI IUS 5 Inserted	-	1	3	-	-		-%	2	6	3	10	2
Lubricant	20,007	10,938	32,265	-	28,107		15%	175,397	1,063,533	-	-	-
Vive Lub (sachet)	6,750	4,200	10,800	-	13,230	3/05	(18)%	74,450	477,193	-	-	-
Vive Lub (tube)	2,727	1,233	4,590	-	3,564	3/05	29%	18,659	131,574	-	-	-
Vive Lub Natural (sachet)	8,100	4,083	12,150	-	6,696	1/10	81%	63,538	364,333	-	-	-
Vive Lub Natural (tube)	2,430	1,422	4,725	-	4,617	1/10	2%	18,750	90,433	-	-	-
Manual Vacuum Aspiration for PAC	-	66	121	-	26		365%	496	1,529	121	-	5
MVA for PAC	-	66	121	-	26	5/16	365%	496	1,529	121	-	5
Misoprostol for PAC Provided	-	13	29	-	1		2800%	82	159	29	-	1
PSI Misoprostol for PAC Provided	-	13	29	-	1		2,800%	82	159	29	-	1
Misoprostol for Safe Abortion	4,112	(251)	3,996	-	540		640%	37,641	49,561	210	-	8
Misoprostol for Safe Abortion	4,112	(197)	4,112	-	544	3/18	656%	37,969	50,197	216	-	9
(b)PSI Misoprostol for Safe Abortion Dist Provided	-	(53)	(116)	-	(4)		-%	(328)	(636)	(6)	-	-
OCs Provided	-	40	42	-	19		121%	300	514	3	3	-
Non-PSI OCs Provided	-	40	42	-	19		121%	300	514	3	3	-
Referral to Linkage to HIV Care	-	-	-	-	1		(100)%	2	39	-	-	-
Referral to Linkage to HIV Care	-	-	-	-	1		(100)%	2	39	-	-	-
Tubal Ligation	-	3	4	-	12		(67)%	113	140	4	40	8
Tubal Ligation	-	3	4	-	12		(67)%	113	140	4	40	8

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**  
**Monthly Distribution by Country**  
**Period: 2**  
**Year: 2019**

	DISTRIBUTION 2/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
<b>Pakistan</b>											<b>375,236</b>	<b>124,261</b>
Condom	7,672,896	13,396,948	15,817,704	-	19,900,697		(21)%	133,792,588	2,663,925,483	118,633	118,633	27,009
Do	173,520	212,448	373,320	-	176,400	8/17	112%	1,581,084	3,123,324	2,800	2,800	637
Sathi	6,064,656	11,457,760	12,439,824	-	16,632,576	1/87	(25)%	116,349,078	2,401,167,337	93,299	93,299	21,242
Sathi Plus	390,720	381,120	865,440	-	432,000	8/17	100%	2,133,120	4,114,560	6,491	6,491	1,478
Touch	920,160	1,241,820	1,885,680	-	2,556,041	4/96	(26)%	13,002,106	253,665,182	14,143	14,143	3,220
Touch Delay	123,840	103,800	253,440	-	103,680	8/17	144%	727,200	1,855,080	1,901	1,901	433
Emergency Contraception	242,337	262,866	420,243	-	300,102		40%	2,065,123	9,325,506	18,911	18,911	3,307
ECP	244,400	265,460	425,620	-	302,783	9/14	41%	2,080,232	9,373,776	19,153	19,153	3,350
(b)PSI Emergency Contraception Distributed Provided	(2,063)	(2,594)	(5,377)	-	(2,681)		-%	(15,109)	(48,270)	(242)	(242)	(42)
Emergency Contraception Provided	2,063	2,594	5,377	-	2,681		101%	15,109	48,270	269	269	47
PSI Emergency Contraception Provided	2,063	2,594	5,377	-	2,681		101%	15,109	48,270	269	269	47
Implant 5	51	8	51	-	10,084		(99)%	10,646	25,030	46	174	54
Jadelle	51	8	51	-	10,084	12/11	(99)%	10,646	25,030	46	174	54
Injectable 1	13,380	11,601	24,484	-	9,532		157%	99,805	1,727,699	1,695	1,695	422
Femi-ject	17,300	14,833	31,700	-	14,300	6/03	122%	122,300	1,845,913	2,195	2,195	546
(b)PSI Injectable 1 Distributed Provided	(3,920)	(3,232)	(7,216)	-	(4,768)		-%	(22,495)	(118,214)	(500)	(500)	(124)
Injectable 1 Provided	3,920	3,232	7,216	-	4,768		51%	22,495	118,214	555	555	138
PSI Injectable 1 Provided	3,920	3,232	7,216	-	4,768		51%	22,495	118,214	555	555	138
Injectable 2	3,772	17,402	24,792	-	56,703		(56)%	134,028	7,108,875	3,719	3,719	854
Novaject	3,778	18,080	25,378	-	60,742	12/96	(58)%	144,514	7,186,636	3,807	3,807	874
(b)PSI Injectable 2 Distributed Provided	(6)	(678)	(586)	-	(4,039)		-%	(10,486)	(77,761)	(88)	(88)	(20)
Injectable 2 Provided	6	678	586	-	4,039		(85)%	10,486	77,761	98	98	22
PSI Injectable 2 Provided	6	678	586	-	4,039		(85)%	10,486	77,761	98	98	22

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

**Period: 2**

**Year: 2019**

	DISTRIBUTION 2/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
Injectable 3-IM	23,931	29,254	36,268	-	37,682		(4)%	406,105	2,927,160	8,160	8,160	1,873
Depo-Provera	28,241	35,467	47,441	-	45,414	7/11	4%	451,716	3,043,624	10,674	10,674	2,450
(b)PSI Injctable 3 IM Distributed Provided	(4,310)	(6,212)	(11,173)	-	(7,732)		-%	(45,611)	(116,464)	(2,514)	(2,514)	(577)
Injectable 3-IM Provided	4,310	6,212	11,173	-	7,732		45%	45,611	116,464	2,793	2,793	641
PSI Injctable 3 IM Provided	4,310	6,212	11,173	-	7,732		45%	45,611	116,464	2,793	2,793	641
IUD 10	3,000	154	3,000	-	13,270		(77)%	47,316	198,259	2,700	12,420	3,643
Safeload	3,000	154	3,000	-	13,270	8/14	(77)%	47,316	198,259	2,700	12,420	3,643
IUD 5	9,392	11,734	25,238	-	(5,111)		0%	20,275	3,039,812	22,714	74,957	23,406
Multiload	20,000	21,019	63,700	-	15,821	12/95	303%	81,850	4,010,226	57,330	189,189	59,075
(b)PSI IUD 5 Distributed Inserted	(10,608)	(9,285)	(38,462)	-	(20,932)		-%	(61,575)	(970,414)	(34,616)	(114,232)	(35,670)
IUD 5 Insertion	10,608	9,285	38,462	-	20,932		84%	61,575	970,414	38,462	126,925	39,633
PSI IUD 5 Inserted	10,608	9,285	38,462	-	20,932		84%	61,575	970,414	38,462	126,925	39,633
Manual Vacuum Aspiration for PAC	5,055	4,629	18,942	-	8,796		115%	27,052	105,778	18,942	-	970
MVA for PAC	5,055	4,629	18,942	-	8,796		115%	27,052	105,778	18,942	-	970
Misoprostol for PAC Provided	7,222	4,349	14,496	-	-		0%	46,571	61,067	14,496	-	891
PSI Misoprostol for PAC Provided	7,222	4,349	14,496	-	-		-%	46,571	61,067	14,496	-	891
Misoprostol for Safe Abortion	10,412	233,523	342,316	-	213,140		61%	982,646	1,623,762	17,972	-	1,395
Misoprostol for Safe Abortion	39,300	250,920	400,300	-	213,140	3/18	88%	1,168,930	1,868,030	21,016	-	1,631
(b)PSI Misoprostol for Safe Abortion Dist Provided	(28,888)	(17,397)	(57,984)	-	-		-%	(186,284)	(244,268)	(3,044)	-	(236)
OCs	55,590	27,783	97,248	-	258,846		(62)%	963,276	3,970,521	5,835	5,835	1,413
Novadol	56,160	30,792	98,640	-	267,912	1/08	(63)%	1,004,634	4,180,020	5,918	5,918	1,433
(b)PSI OCs Distributed Provided	(570)	(3,009)	(1,392)	-	(9,066)		-%	(41,358)	(209,499)	(84)	(84)	(20)
OCs Provided	570	3,009	1,392	-	9,066		(85)%	41,358	209,499	93	93	22
PSI OCs Provided	570	3,009	1,392	-	9,066		(85)%	41,358	209,499	93	93	22
TB Diagnosis	2,069	2,211	4,067	-	4,665		(13)%	29,215	83,443	4,067	-	-

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

Period: 2

Year: 2019

	DISTRIBUTION 2/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
TB Diagnosis	2,069	2,211	4,067	-	4,665		(13)%	29,215	83,443	4,067	-	-
TB DOTS	2,048	2,109	4,047	-	3,372		20%	26,012	117,522	4,047	-	18,521
TB DOTS	2,048	2,109	4,047	-	3,372	4/05	20%	26,012	117,522	4,047	-	18,521
TB Screening	4,219	4,128	8,395	-	12,899		(35)%	65,777	127,693	8,395	-	-
TB Screening	4,219	4,128	8,395	-	12,899		(35)%	65,777	127,693	8,395	-	-
<b>Panama</b>											4,480	1,184
Condom	173,088	344,696	597,384	-	671,064		(11)%	3,308,400	43,784,742	4,480	4,480	1,173
Vive	120,432	293,904	501,120	-	515,520	7/00	(3)%	2,656,128	36,330,449	3,758	3,758	984
Vive Colors/Mas Colors	30,168	22,088	46,464	-	75,648	3/05	(39)%	263,112	4,083,396	348	348	91
Vive Mas Fuerte /Retardante	15,624	13,200	18,024	-	51,384	3/05	(65)%	240,288	1,781,311	135	135	35
Vive Mas Natural /Sensitivo	1,248	10,304	20,160	-	21,072	3/05	(4)%	92,832	879,953	151	151	40
Vive Mas/Texturizado	5,616	5,200	11,616	-	7,440	3/05	56%	56,040	709,633	87	87	23
HIV Testing Services	193	79	272	-	158		72%	1,395	19,049	272	-	1
VCT Individual (HIV-Negative)	179	68	243	-	142	12/11	71%	1,259	18,343	243	-	-
VCT Individual (HIV-Positive)	14	12	29	-	16	12/11	81%	136	706	29	-	-
Lubricant	(2,902)	(4,305)	(9,903)	-	15,150		(165)%	21,742	457,283	-	-	-
Vive Lub (sachet)	(50)	(50)	(200)	-	9,200	2/09	(102)%	9,200	268,026	-	-	-
Vive Lub (tube)	-	(4)	-	-	2,350	2/09	(100)%	10,843	76,283	-	-	-
Vive Lub Natural (sachet)	(2,850)	(4,250)	(9,700)	-	1,050	5/11	(1,024)%	(850)	49,705	-	-	-
Vive Lub Natural (tube)	(2)	-	(3)	-	2,550	5/11	(100)%	2,549	63,269	-	-	-
Referral to Linkage to HIV Care	23	6	23	-	10		130%	112	285	23	-	11
Referral to Linkage to HIV Care	23	6	23	-	10		130%	112	285	23	-	11
<b>Papua New Guinea</b>											-	2
Condom	-	-	-	-	58,119		(100)%	62,259	8,050,159	-	-	-

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

**Period: 2**

**Year: 2019**

	DISTRIBUTION 2/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
Seif Raida	-	-	-	-	57,408	1/08	(100)%	59,552	6,969,005	-	-	-
Seif Raida Orange Plus	-	-	-	-	711	8/13	(100)%	2,707	1,081,154	-	-	-
Female Condom	-	-	-	-	20		(100)%	100	338,539	-	-	-
Stap Seif	-	-	-	-	20	2/09	(100)%	100	338,539	-	-	-
Malaria PPT (ACT)	-	-	-	-	7,782		(100)%	7,782	845,477	-	-	-
Coartem 1x12's for 1-5 years old	-	-	-	-	95	8/15	(100)%	95	125,793	-	-	-
Coartem 1x18's for 6-13 years old	-	-	-	-	4,535	8/15	(100)%	4,535	275,970	-	-	-
Coartem 1x24's for 14+ years old	-	-	-	-	1,490	8/15	(100)%	1,490	259,952	-	-	-
Coartem 1x6's for 2-11 months	-	-	-	-	1,662	8/15	(100)%	1,662	183,762	-	-	-
Malaria RDK	-	-	-	-	4,469		(100)%	4,469	1,361,956	-	-	-
Carestart Malaria HRP2/pLDH (pf/PAN)	-	-	-	-	4,469	10/13	(100)%	4,469	1,361,956	-	-	-
ORS	-	1	2	-	-		0%	-	29,236	1	-	-
ORS	-	1	2	-	-	12/11	-%	-	29,236	1	-	-
Water Treatment Tablets	-	22,833	50,500	-	800		6213%	91,160	1,029,283	830	-	2
Aquatab	-	22,833	50,500	-	800	12/11	6,213%	91,160	1,029,283	830	-	2
Zinc	2	-	2	-	-		0%	-	32,846	2	-	-
Zinc 20 mg	2	-	2	-	-	12/11	-%	-	32,846	2	-	-
<b>PSI Pakistan</b>											<b>61,959</b>	<b>16,897</b>
Condom	431,291	380,105	818,501	-	80,030		923%	3,369,589	7,676,963	6,139	6,139	1,398
Generic Male Condom	431,291	380,105	818,501	-	80,030	4/16	923%	3,369,589	7,676,963	6,139	6,139	1,398
Injectable 3-IM	(10,437)	-	(10,437)	-	-		0%	(8,571)	(19,008)	(2,348)	(2,348)	(539)
(b)PSI Injectable 3 IM Distributed Provided	(10,437)	-	(10,437)	-	-		-%	(8,571)	(19,008)	(2,348)	(2,348)	(539)
Injectable 3-IM Provided	16,431	26,439	32,983	-	5,390		512%	280,576	538,894	8,246	8,246	1,893
Non-PSI Injectable 3 IM Provided	5,994	26,439	22,546	-	5,390		318%	272,005	519,886	5,637	5,637	1,294

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.



**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

**Period: 2**

**Year: 2019**

	DISTRIBUTION 2/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
PSI Injectable 3 IM Provided	10,437	-	10,437	-	-		-%	8,571	19,008	2,609	2,609	599
IUD 10 Insertion	4,323	5,008	8,738	-	2,081		320%	61,472	135,720	8,738	40,195	11,790
Non-PSI IUD 10 Inserted	4,323	5,008	8,738	-	2,081		320%	61,472	135,720	8,738	40,195	11,790
IUD 5 Insertion	-	-	-	-	716		(100)%	1,928	7,248	-	-	-
Non-PSI IUD 5 Inserted	-	-	-	-	716		(100)%	1,928	7,248	-	-	-
OCs	(60,229)	-	(60,229)	-	-		0%	(33,625)	(93,854)	(3,614)	(3,614)	(875)
(b)PSI OCs Distributed Provided	(60,229)	-	(60,229)	-	-		-%	(33,625)	(93,854)	(3,614)	(3,614)	(875)
OCs Provided	96,667	105,995	200,130	-	6,016		3227%	773,098	1,421,097	13,342	13,342	3,231
Non-PSI OCs Provided	36,438	105,995	139,901	-	6,016		2,225%	739,473	1,327,243	9,327	9,327	2,258
PSI OCs Provided	60,229	-	60,229	-	-		-%	33,625	93,854	4,015	4,015	972
<b>Tajikistan</b>											<b>180</b>	<b>243</b>
Free Condom	12,000	221,037	24,000	-	31,200		(23)%	1,137,682	1,483,334	180	180	101
Generic Male Condom	12,000	221,037	24,000	-	31,200	8/16	(23)%	1,137,682	1,483,334	180	180	101
HIV Testing Services	1,419	1,245	2,938	-	3,325		(12)%	16,547	34,732	2,938	-	9
VCT Individual (HIV-Negative)	1,385	1,209	2,863	-	3,217		(11)%	16,076	33,807	2,863	-	9
VCT Individual (HIV-Positive)	34	37	75	-	108		(31)%	471	925	75	-	-
Naloxone	-	23	-	-	-		0%	2,570	16,713	-	-	-
Naloxone	-	23	-	-	-	1/11	-%	2,570	16,713	-	-	-
Needle & Syringe	-	6,567	-	-	76,800		(100)%	689,065	2,858,018	-	-	-
Needle/Syringe	-	6,567	-	-	76,800	1/11	(100)%	689,065	2,858,018	-	-	-
Referral to HIV Testing Services	3	-	3	-	-		0%	4	7,614	3	-	-
Referral to HIV Testing Services	3	-	3	-	-		-%	4	7,614	3	-	-
Referral to Linkage to HIV Care	80	74	167	-	78		114%	691	1,770	167	-	133
Referral to Linkage to HIV Care	80	74	167	-	78		114%	691	1,770	167	-	133
Referral to Opioid Treatment	-	3	2	-	15		(87)%	65	191	2	-	-

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

**Period: 2**

**Year: 2019**

	DISTRIBUTION 2/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
Referral to Opioid Treatment	-	3	2	-	15		(87)%	65	191	2	-	-
Referral to TB Screening	-	-	-	-	1		(100)%	1	8	-	-	-
Referrals to TB Screening	-	-	-	-	1		(100)%	1	8	-	-	-
TB Screening	88	315	180	-	152		18%	1,892	7,161	180	-	-
TB Screening	88	315	180	-	152		18%	1,892	7,161	180	-	-
<b>Viet Nam</b>											601	1,621
Emergency Contraception	-	-	-	-	(52)		0%	(52)	(104)	-	-	-
(b)PSI Emergency Contraception Distributed Provided	-	-	-	-	(52)		-%	(52)	(104)	-	-	-
Emergency Contraception Provided	-	1	-	-	83		(100)%	225	886	-	-	-
Non-PSI Emergency Contraception Provided	-	1	-	-	31		(100)%	173	782	-	-	-
PSI Emergency Contraception Provided	-	-	-	-	52		(100)%	52	104	-	-	-
Fever Cases Tested with RDTs	1,400	2,386	3,771	-	-		0%	15,898	19,669	3,771	-	-
Fever Cases Tested with RDTs	1,400	2,386	3,771	-	-		-%	15,898	19,669	3,771	-	-
HIV Testing Services	-	218	514	-	564		(9)%	6,827	12,565	514	-	1
VCT Individual (HIV-Negative)	-	209	491	-	535		(8)%	6,402	11,717	491	-	1
VCT Individual (HIV-Positive)	-	9	23	-	29		(21)%	425	848	23	-	-
Hypertension Diagnosis	1,930	765	2,942	-	7,569		(61)%	26,102	55,377	2,942	-	-
Hypertension Diagnosis	1,930	765	2,942	-	7,569		(61)%	26,102	55,377	2,942	-	-
Hypertension Screening	34,453	31,493	64,733	-	87,740		(26)%	413,475	680,422	64,733	-	-
Hypertension Screening	34,453	31,493	64,733	-	87,740		(26)%	413,475	680,422	64,733	-	-
Hypertension_Controlled Condition	2,589	2,071	4,255	-	5,693		(25)%	30,443	54,806	1,702	-	-
Hypertension_Controlled Condition	2,589	2,071	4,255	-	5,693		(25)%	30,443	54,806	1,702	-	-
Implant 3	46	58	100	-	142		(30)%	892	1,293	90	225	9
Implanon NXT	60	69	137	-	164	2/17	(16)%	1,147	1,620	123	308	12
(b)PSI Implant 3 Distributed Inserted	(14)	(11)	(37)	-	(22)		-%	(255)	(327)	(33)	(83)	(3)

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

**Period: 2**

**Year: 2019**

	DISTRIBUTION 2/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
Implant 3 Insertion	14	11	37	-	28		32%	267	384	37	93	4
Non-PSI Implant 3 Inserted	-	-	-	-	6		(100)%	12	57	-	-	-
PSI Implant 3 Inserted	14	11	37	-	22		68%	255	327	37	93	4
Injectable 1	-	-	-	-	(2)		0%	(2)	(4)	-	-	-
(b)PSI Injectable 1 Distributed Provided	-	-	-	-	(2)		-%	(2)	(4)	-	-	-
Injectable 1 Provided	-	-	-	-	2		(100)%	2	4	-	-	-
PSI Injectable 1 Provided	-	-	-	-	2		(100)%	2	4	-	-	-
Injectable 3-IM	(8)	14	17	-	(2)		0%	440	690	4	4	-
Depoteron	-	27	50	-	-	2/17	-%	712	1,233	11	11	-
(b)PSI Injectable 3 IM Distributed Provided	(8)	(12)	(33)	-	(2)		-%	(272)	(543)	(7)	(7)	-
Injectable 3-IM Provided	13	29	53	-	52		2%	735	1,610	13	13	-
Non-PSI Injectable 3 IM Provided	5	17	20	-	50		(60)%	463	1,067	5	5	-
PSI Injectable 3 IM Provided	8	12	33	-	2		1,550%	272	543	8	8	-
IUD 10	-	-	-	-	-		0%	50	150	-	-	-
Copper-T 380-A IUD	-	-	-	-	-	9/16	-%	50	150	-	-	-
IUD 10 Insertion	11	48	58	-	41		41%	396	649	58	267	10
Non-PSI IUD 10 Inserted	11	48	58	-	41		41%	396	649	58	267	10
LLIN (Hammock net)	-	138	400	-	15		2567%	1,259	1,704	360	-	-
Tana Nets	-	138	400	-	15		2,567%	1,259	1,704	360	-	-
Malaria PPT (ACT)	-	(18)	-	-	-		0%	(210)	(210)	-	-	-
(b)PSI QAACTs Distributed Provided after Diagnosis	-	(18)	-	-	-		-%	(210)	(210)	-	-	-
Malaria PPT (Non-ACT)	-	(28)	-	-	-		0%	(141)	(141)	-	-	-
(b)PSI Vivax Tx Distributed Provided after Diagnosis	-	(28)	-	-	-		-%	(141)	(141)	-	-	-
Malaria RDK	2,100	1,870	5,340	-	-		0%	24,220	29,560	4,806	-	-
On-site Malaria Pf/Pv Ag Rapid Test	-	820	90	-	-	10/17	-%	24,220	24,310	81	-	-

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

**Period: 2**

**Year: 2019**

	DISTRIBUTION 2/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
SD Bioline Malaria Ag Pf/Pv Rapid Test	2,100	1,050	5,250	-	-		-%	-	5,250	4,725	-	-
Needle & Syringe	58,200	566,167	225,000	-	425,300		(47)%	5,126,150	22,876,050	785	-	1,583
B-braun Omnican 40 (U-40 Insulin/40I.U.)	58,200	400,833	225,000	-	425,300	9/13	(47)%	4,610,150	22,360,050	785	-	1,583
Co-pack LDS	-	165,333	-	-	-		-%	516,000	516,000	-	-	-
OCs	-	-	-	-	(70)		0%	(70)	(187)	-	-	-
(b)PSI OCs Distributed Provided	-	-	-	-	(70)		-%	(70)	(187)	-	-	-
OCs Provided	-	1	-	-	102		(100)%	568	1,518	-	-	-
Non-PSI OCs Provided	-	1	-	-	32		(100)%	498	1,331	-	-	-
PSI OCs Provided	-	-	-	-	70		(100)%	70	187	-	-	-
Positive RDTs	99	127	223	-	79		182%	634	1,035	223	-	-
Positive RDTs	99	127	223	-	79		182%	634	1,035	223	-	-
Positive RDTs Given First Line Treatment	84	105	200	-	12		1567%	403	668	200	-	-
Positive RDTs Given First Line Treatment	84	105	200	-	12		1,567%	403	668	200	-	-
QAACTs Provided after Confirmatory Diagnosis	-	18	1	-	12		(92)%	253	316	1	-	-
Non-PSI QAACTs Provided after Confirmed Diagnosis	-	-	1	-	12		(92)%	43	106	1	-	-
PSI QAACTs Provided after Confirmed Diagnosis	-	18	-	-	-		-%	210	210	-	-	-
TB Diagnosis	-	-	-	-	90		(100)%	434	5,371	-	-	-
TB Diagnosis	-	-	-	-	90		(100)%	434	5,371	-	-	-
Toilets Sold	199	483	410	-	695		(41)%	4,405	6,713	1,722	-	14
Toilet Type 1, Direct Sales	199	483	410	-	695		(41)%	4,405	6,713	1,722	-	14
Vivax Treatment after Confirmatory Diagnosis	-	28	-	-	-		0%	156	165	-	-	-
Non-PSI Vivax Treatment after Confirmed Diagnosis	-	-	-	-	-		-%	15	24	-	-	-
PSI Vivax Treatment after Confirmed Diagnosis	-	28	-	-	-		-%	141	141	-	-	-

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

# Foundation Market Group

**POPULATION SERVICES INTERNATIONAL**  
**CYPs, Cases, and Deaths by Country**  
**1/2019 - 2/2019**

	<u>New HIV Infections</u>	<u>STI Deaths</u>	<u>PWID Deaths</u>	<u>TB Deaths</u>	<u>CYP*</u>	<u>Maternal Deaths</u>	<u>Unintended Pregnancies</u>	<u>Malaria Deaths</u>	<u>Diarrhea Deaths</u>	<u>Pneumonia Deaths</u>	<u>Cervical Cancer Death</u>	<u>Sum of All Deaths</u>
Foundation Market Group	115	-	-	238	129,805	157	52,285	5,637	59	36	-	7,118
Haiti	66	-	-	238	8,025	4	2,252	-	-	-	-	266
Liberia	12	-	-	-	1,103	1	311	-	-	-	-	7
Madagascar	37	-	-	-	80,969	73	31,273	1,292	6	-	-	1,800
Mali	-	-	-	-	39,247	73	18,243	3,760	-	-	-	4,307
Somaliland	1	-	-	-	462	7	205	2	53	36	-	156
South Sudan	-	-	-	-	-	-	-	583	-	-	-	583

\* Using USAID CYP conversion factors

POPULATION SERVICES INTERNATIONAL  
 Monthly Distribution by Market Group and Product  
 Period: 2  
 Year: 2019

	DISTRIBUTION 2/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE SALES	YTD USERS REACHED <sup>(a)</sup> 2019	YTD CYP 2019	YTD DALY 2019
<b>Foundation Market Group</b>										<b>129,805</b>	<b>547,233</b>
Acute Malnutrition Screening_CU5	-	206,481	389	-	-	-%	619,055	619,444	389	-	-
Antiretroviral Treatment (Currently Enrolled)	-	-	-	-	-	-%	216,577	486,575	-	-	-
Antiretroviral Treatment (Newly Enrolled)	-	87	-	-	-	-%	3,898	8,199	-	-	-
Cervical Cancer-Pap and Cryotherapy	-	-	-	-	-	-%	4	4	-	-	-
Cervical Cancer-VIA and Cryotherapy	5	10	6	-	28	(79)%	189	1,348	6	-	2
Cervical Cancer-VIA/VILI Screening	66	714	103	-	2,265	(95)%	13,295	73,803	103	-	-
Chlorhexidine	-	-	-	-	60,950	(100)%	107,120	432,844	-	-	-
Condom	98,136	242,392	263,016	-	269,532	(2)%	3,347,338	69,561,028	1,973	1,973	2,144
Counseling & Tx for Moderate Acute Malnutrition	1,169	5,178	1,962	-	-	-%	20,332	22,294	1,962	-	-
Diarrhea Treatment Kit	20,300	23,284	41,240	-	50,754	(19)%	179,738	2,159,143	37,116	-	3,955
Diarrhea Treatment Kit Provided	-	-	-	-	406	(100)%	1,812	12,274	-	-	-
Emergency Contraception	(29)	14,945	44,847	-	15,252	194%	40,018	83,808	2,018	2,018	549
Emergency Contraception Provided	29	15	33	-	48	(31)%	282	1,372	2	2	1
Fever Cases Attended	14,159	8,167	23,449	-	16,277	44%	86,150	489,608	23,449	-	-
Fever Cases Tested with Microscopy	4,379	2,009	4,381	-	10,057	(56)%	56,797	188,623	4,381	-	-
Fever Cases Tested with RDTs	35,152	17,066	42,060	-	45,469	(7)%	274,829	1,178,899	42,060	-	-
Free Condom	151,920	1,108,141	956,862	-	336,600	184%	28,342,179	36,667,990	7,176	7,176	5,855
Free Female Condom	-	-	-	-	-	-%	253	21,253	-	-	-
HIV Testing Services	3,304	25,368	19,807	-	840	2,258%	395,037	1,435,493	19,807	-	83
Implant 3	3,791	304	5,455	-	616	786%	8,075	15,936	4,910	12,274	9,885
Implant 3 Insertion	3,349	4,419	5,133	-	3,452	49%	48,078	104,471	5,133	12,833	8,994

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

**POPULATION SERVICES INTERNATIONAL**  
**Monthly Distribution by Market Group and Product**  
**Period: 2**  
**Year: 2019**

	DISTRIBUTION 2/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE SALES	YTD USERS REACHED <sup>(a)</sup> 2019	YTD CYP 2019	YTD DALY 2019
Implant 4 Insertion	-	1	-	-	3	(100)%	14	2,528	-	-	-
Implant 5	4,493	1,264	4,492	-	(90)	-%	5,334	118,751	4,043	15,363	17,449
Implant 5 Insertion	7	3,135	1,687	-	4,310	(61)%	38,472	108,373	1,687	6,411	7,259
Injectable 3-IM	104,688	95,491	194,568	-	119,652	63%	1,669,487	20,070,824	43,778	43,778	19,678
Injectable 3-IM Provided	4,135	5,556	6,666	-	8,162	(18)%	77,146	251,948	1,667	1,667	915
Injectable 3-SC	14,530	27,007	21,291	-	67,145	(68)%	535,592	1,438,085	4,790	4,790	2,141
Injectable 3-SC Provided	44	65	63	-	-	-%	175	238	16	16	6
IPTp2	399	503	753	-	21	3,486%	81,911	286,105	753	-	84
IUD 10	984	656	943	-	231	308%	7,568	46,156	849	3,904	4,987
IUD 10 Insertion	1,499	2,826	2,763	-	4,619	(40)%	40,411	270,807	2,763	12,710	9,764
IUD 5 Insertion	36	43	56	-	-	-%	299	355	56	185	188
IUS 3	12	7	24	-	-	-%	98	122	22	54	31
IUS 3 Insertion	52	13	58	-	-	-%	135	193	58	145	83
LLIN	257,300	5,677,003	1,274,895	-	1,000,260	27%	19,624,561	71,147,544	2,065,330	-	312,071
Lubricant	33,864	448,850	1,110,864	-	87,550	1,169%	1,223,813	3,053,518	-	-	-
Malaria PPT (ACT)	306,349	308,355	430,578	-	625,432	(31)%	6,990,357	25,823,507	387,520	-	115,601
Malaria RDK	122,250	1,418,231	122,250	-	53,300	129%	10,954,467	25,714,008	110,025	-	-
Manual Vacuum Aspiration for PAC	217	443	414	-	839	(51)%	6,247	14,300	414	-	172
Micronutrient Powder	-	-	-	-	10,500	(100)%	5,797,980	16,505,640	-	-	-
Misoprostol for PAC Provided	764	899	1,210	-	1,682	(28)%	12,741	26,770	1,210	-	570
Misoprostol for PPH	1,000	4,167	2,500	-	7,800	(68)%	30,800	197,208	750	-	16

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.



**POPULATION SERVICES INTERNATIONAL**  
**Monthly Distribution by Market Group and Product**  
**Period: 2**  
**Year: 2019**

	DISTRIBUTION 2/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE SALES	YTD USERS REACHED <sup>(a)</sup> 2019	YTD CYP 2019	YTD DALY 2019
Misoprostol for Safe Abortion	16,444	14,279	16,200	-	(2,064)	-%	81,047	77,607	850	-	288
OCs	34,459	103,672	73,238	-	251,450	(71)%	2,094,239	41,064,221	4,394	4,394	2,072
OCs Provided	927	1,071	1,435	-	2,128	(33)%	16,628	100,014	96	96	57
ORS	560	3	570	-	56,859	(99)%	1,249,743	15,607,912	257	-	13
ORS Provided	2,227	1,595	4,445	-	-	-%	13,509	17,954	4,445	-	232
Pneumonia PPT	-	381	-	-	41,354	(100)%	738,319	2,839,112	-	-	-
Pneumonia PPT Provided	1,565	918	2,689	-	-	-%	11,575	14,264	2,689	-	3,107
Positive RDTs	2,413	1,104	3,254	-	3,770	(14)%	17,054	156,447	3,254	-	-
QAACTs Provided after Confirmatory Diagnosis	109	477	295	-	-	-%	1,872	2,167	295	-	66
Referral to HIV Testing Services	-	-	-	-	-	-%	5	606	-	-	-
Safe Water Solution	32,760	56,687	99,248	-	484,294	(80)%	1,345,883	23,657,423	114,715	-	389
SDM (Cycle Beads)	(34)	(17)	(39)	-	365	(111)%	5,121	143,478	(35)	(53)	(34)
SDM (Cycle Beads) Provided	34	23	41	-	56	(27)%	503	5,198	41	62	41
Seasonal Malaria Chemoprevention	-	-	-	-	1,665,225	(100)%	1,665,225	4,076,234	-	-	-
Skilled Birth Attendance	1,357	2,252	2,239	-	-	-%	16,695	18,934	2,239	-	3,190
STI Screening	1,042	1,515	1,361	-	1,956	(30)%	142,852	615,443	1,361	-	-
TB Diagnosis	-	1,057	3,172	-	3,856	(18)%	18,240	42,302	3,172	-	-
TB DOTS	-	1,300	3,901	-	5,038	(23)%	22,400	46,935	3,901	-	13,352
TB Screening	-	4,978	14,933	-	16,226	(8)%	76,668	115,134	14,933	-	-
Toilets Sold	-	4	6	-	-	-%	27	6,303	34	-	1
Treatment for Inguinal Bubo	3	5	6	-	5	20%	53	142	6	-	-

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

**POPULATION SERVICES INTERNATIONAL**  
**Monthly Distribution by Market Group and Product**  
**Period: 2**  
**Year: 2019**

	DISTRIBUTION 2/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE SALES	YTD USERS REACHED <sup>(a)</sup> 2019	YTD CYP 2019	YTD DALY 2019
Treatment for Lower Abdominal Pain	44	65	66	-	105	(37)%	800	2,163	66	-	-
Treatment for Nonherpetic Genital Ulcer	77	66	112	-	173	(35)%	5,172	13,702	112	-	13
Treatment for Pre-Eclampsia (with MgSO4)	23	44	38	-	-	-%	343	381	38	-	132
Treatment for Severe Acute Malnutrition	389	1,713	389	-	-	-%	12,893	54,928	389	-	1,483
Treatment for Urethral Discharge (Men)	420	345	563	-	853	(34)%	5,596	13,780	1,126	-	3
Treatment for Urethral Discharge (Women)	-	5	-	-	-	-%	15	15	-	-	-
Treatment for Vaginitis	358	280	468	-	796	(41)%	4,978	12,501	468	-	4
Tubal Ligation	1	3	1	-	4	(75)%	42	117	1	10	5
Water Treatment Tablets	533,200	988,053	1,123,360	-	1,608,600	(30)%	10,958,880	147,648,402	18,466	-	224
Zinc	40	60	40	-	17,770	(100)%	512,836	1,906,276	36	-	-
Zinc Provided	2,181	1,578	4,376	-	-	-%	11,834	16,210	4,376	-	115

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

**POPULATION SERVICES INTERNATIONAL**  
**Monthly Distribution by Country**  
**Period: 2**  
**Year: 2019**

	DISTRIBUTION 2/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
<b>Foundation Market Group</b>											<b>129,805</b>	<b>547,233</b>
<b>Haiti</b>											<b>8,025</b>	<b>18,279</b>
Antiretroviral Treatment (Currently Enrolled)	-	-	-	-	-		0%	216,577	486,575	-	-	-
Antiretroviral Treatment (Currently Enrolled)	-	-	-	-	-		-%	216,577	486,575	-	-	-
Antiretroviral Treatment (Newly Enrolled)	-	-	-	-	-		0%	3,561	7,862	-	-	-
Antiretroviral Treatment (Newly Enrolled)	-	-	-	-	-		-%	3,561	7,862	-	-	-
Cervical Cancer-VIA and Cryotherapy	-	-	-	-	-		0%	5	123	-	-	-
Cervical Cancer-VIA and Cryotherapy	-	-	-	-	-		-%	5	123	-	-	-
Cervical Cancer-VIA/VILI Screening	-	1	1	-	5		(80)%	31	814	1	-	-
Cervical Cancer-VIA/VILI Screening	-	1	1	-	5		(80)%	31	814	1	-	-
Emergency Contraception	-	14,960	44,880	-	15,300		193%	40,300	85,180	2,020	2,020	549
Levonorgestrel 1.5 mg Tablet	-	14,960	44,880	-	15,300	9/17	193%	40,300	85,180	2,020	2,020	549
Fever Cases Attended	795	412	795	-	2,925		(73)%	9,014	47,364	795	-	-
Fever Cases Attended	795	412	795	-	2,925		(73)%	9,014	47,364	795	-	-
Fever Cases Tested with Microscopy	4,252	1,956	4,252	-	9,697		(56)%	54,725	179,487	4,252	-	-
Fever Cases Tested with Microscopy	4,252	1,956	4,252	-	9,697		(56)%	54,725	179,487	4,252	-	-
Fever Cases Tested with RDTs	25,901	11,199	25,901	-	36,949		(30)%	221,408	793,741	25,901	-	-
Fever Cases Tested with RDTs	25,901	11,199	25,901	-	36,949		(30)%	221,408	793,741	25,901	-	-
Free Condom	-	870,234	781,902	-	-		0%	8,256,538	9,038,440	5,864	5,864	4,299
Generic Condom	-	870,234	781,902	-	-	3/17	-%	8,256,538	9,038,440	5,864	5,864	4,299
HIV Testing Services	-	-	-	-	-		0%	127,117	666,958	-	-	-
VCT Individual (HIV-Negative)	-	-	-	-	-	4/10	-%	122,702	633,641	-	-	-
VCT Individual (HIV-Positive)	-	-	-	-	-	4/10	-%	4,415	33,317	-	-	-
Implant 3	-	-	-	-	-		0%	2,016	4,032	-	-	-
Implanon NXT	-	-	-	-	-	7/17	-%	2,016	4,032	-	-	-

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

**Period: 2**

**Year: 2019**

	DISTRIBUTION 2/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
Implant 3 Insertion	11	9	21	-	50		(58)%	465	708	21	53	26
Non-PSI Implant 3 Inserted	11	9	21	-	50		(58)%	465	708	21	53	26
Injectable 3-IM Provided	-	-	-	-	120		(100)%	949	1,137	-	-	-
Non-PSI Injectable 3 IM Provided	-	-	-	-	120		(100)%	949	1,137	-	-	-
Injectable 3-SC	-	4,167	-	-	-		0%	12,500	12,500	-	-	-
Sayana Press	-	4,167	-	-	-	3/17	-%	12,500	12,500	-	-	-
Injectable 3-SC Provided	44	65	63	-	-		0%	175	238	16	16	6
Non-PSI Injectable 3 SC Provided	44	65	63	-	-		-%	175	238	16	16	6
IUD 10	-	17	-	-	-		0%	50	2,297	-	-	-
Confiance Plus IUD	-	17	-	-	-	12/13	-%	50	2,297	-	-	-
IUD 10 Insertion	4	6	13	-	12		8%	125	337	13	60	27
Non-PSI IUD 10 Inserted	4	6	13	-	12		8%	125	337	13	60	27
LLIN	-	1,033	50	-	3,933		(99)%	36,486	3,705,376	81	-	3
LLIN Free	-	1,033	50	-	3,933	1/08	(99)%	36,486	3,705,376	81	-	3
Lubricant	-	430,667	1,077,000	-	-		0%	223,000	1,300,000	-	-	-
Lube Sachet Free	-	430,667	1,077,000	-	-	3/17	-%	223,000	1,300,000	-	-	-
OCs	-	-	-	-	76,322		(100)%	76,322	76,322	-	-	-
MEURI	-	-	-	-	76,322	3/17	(100)%	76,322	76,322	-	-	-
OCs Provided	6	150	189	-	234		(19)%	1,413	1,944	13	13	5
Non-PSI OCs Provided	6	150	189	-	234		(19)%	1,413	1,944	13	13	5
ORS	480	3	490	-	-		0%	-	10,047,828	221	-	12
Sel Lavi	480	3	490	-	-	10/99	-%	-	10,047,828	221	-	12
Positive RDTs	1,099	384	1,099	-	2,710		(59)%	8,354	40,783	1,099	-	-
Positive RDTs	1,099	384	1,099	-	2,710		(59)%	8,354	40,783	1,099	-	-
STI Screening	-	-	-	-	-		0%	127,773	535,770	-	-	-

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

Period: 2

Year: 2019

	DISTRIBUTION 2/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
STI Screening	-	-	-	-	-		-%	127,773	535,770	-	-	-
TB Diagnosis	-	1,057	3,172	-	3,856		(18)%	18,240	42,302	3,172	-	-
TB Diagnosis	-	1,057	3,172	-	3,856		(18)%	18,240	42,302	3,172	-	-
TB DOTS	-	1,300	3,901	-	5,038		(23)%	22,400	46,935	3,901	-	13,352
TB DOTS	-	1,300	3,901	-	5,038		(23)%	22,400	46,935	3,901	-	13,352
TB Screening	-	4,978	14,933	-	16,226		(8)%	76,668	115,134	14,933	-	-
TB Screening	-	4,978	14,933	-	16,226		(8)%	76,668	115,134	14,933	-	-
Treatment for Nonherpetic Genital Ulcer	-	-	-	-	-		0%	4,007	10,724	-	-	-
Treatment for Nonherpetic Genital Ulcer	-	-	-	-	-		-%	4,007	10,724	-	-	-
<b>Liberia</b>											1,103	1,083
Antiretroviral Treatment (Newly Enrolled)	-	87	-	-	-		0%	337	337	-	-	-
Antiretroviral Treatment (Newly Enrolled)	-	87	-	-	-		-%	337	337	-	-	-
Condom	23,040	76,828	129,024	-	202,752		(36)%	1,042,072	6,625,082	968	968	926
STAR	23,040	76,828	129,024	-	202,752	7/09	(36)%	1,042,072	6,625,082	968	968	926
Free Condom	18,000	72,432	18,000	-	21,600		(17)%	606,240	773,381	135	135	129
Generic Condom	18,000	72,432	18,000	-	21,600	5/17	(17)%	606,240	773,381	135	135	129
Free Female Condom	-	-	-	-	-		0%	253	21,253	-	-	-
Generic Female Condom	-	-	-	-	-	5/17	-%	253	21,253	-	-	-
HIV Testing Services	159	1,030	159	-	-		0%	12,049	14,464	159	-	1
VCT Individual (HIV-Negative)	154	987	154	-	-	5/14	-%	11,479	13,812	154	-	1
VCT Individual (HIV-Positive)	5	43	5	-	-	5/14	-%	570	652	5	-	-
Lubricant	33,000	18,183	33,000	-	21,600		53%	431,750	634,891	-	-	-
Lube Sachet Free	33,000	18,183	33,000	-	21,600	5/17	53%	431,750	634,891	-	-	-
Referral to HIV Testing Services	-	-	-	-	-		0%	5	606	-	-	-
Referral to HIV Testing Services	-	-	-	-	-		-%	5	606	-	-	-

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

Period: 2

Year: 2019

	DISTRIBUTION 2/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
Safe Water Solution	3,120	4,344	7,608	-	8,688		(12)%	37,800	780,297	6,253	-	27
WaterGuard	3,120	4,344	7,608	-	8,688	7/09	(12)%	37,800	780,297	6,253	-	27
STI Screening	-	21	-	-	-		0%	63	64	-	-	-
STI Screening	-	21	-	-	-		-%	63	64	-	-	-
Treatment for Lower Abdominal Pain	-	16	-	-	-		0%	48	48	-	-	-
Treatment for Lower Abdominal Pain	-	16	-	-	-		-%	48	48	-	-	-
Treatment for Urethral Discharge (Women)	-	5	-	-	-		0%	15	15	-	-	-
Treatment for Urethral Discharge (Women)	-	5	-	-	-		-%	15	15	-	-	-
<b>Madagascar</b>											<b>80,969</b>	<b>148,900</b>
Cervical Cancer-Pap and Cryotherapy	-	-	-	-	-		0%	4	4	-	-	-
Cervical Cancer-PAP and Cryotherapy	-	-	-	-	-		-%	4	4	-	-	-
Cervical Cancer-VIA and Cryotherapy	5	5	6	-	6		0%	63	186	6	-	2
Cervical Cancer-VIA and Cryotherapy	5	5	6	-	6		-%	63	186	6	-	2
Cervical Cancer-VIA/VILI Screening	66	50	85	-	183		(54)%	899	2,517	85	-	-
Cervical Cancer-VIA/VILI Screening	66	50	85	-	183		(54)%	899	2,517	85	-	-
Chlorhexidine	-	-	-	-	60,950		(100)%	107,120	432,844	-	-	-
Arofoitra	-	-	-	-	60,950	9/15	(100)%	107,120	432,844	-	-	-
Condom	75,096	165,564	133,992	-	66,780		101%	2,305,266	62,935,946	1,005	1,005	1,218
Protector Plus	33,696	40,464	63,792	-	66,720	1/08	(4)%	573,456	58,431,026	478	478	580
YES	41,400	125,100	70,200	-	60	9/14	116,900%	1,731,810	4,504,920	526	526	638
Diarrhea Treatment Kit	300	3,284	1,240	-	13,348		(91)%	49,568	1,156,434	1,116	-	26
Hydrazinc	-	-	-	-	13,754	1/10	(100)%	13,754	701,539	-	-	-
ORS-Zinc	300	3,284	1,240	-	-	8/14	-%	37,626	467,169	1,116	-	26
(b)PSI Diarrhea Treatment Kit Distributed Provided	-	-	-	-	(406)		-%	(1,812)	(12,274)	-	-	-
Diarrhea Treatment Kit Provided	-	-	-	-	406		(100)%	1,812	12,274	-	-	-

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

**Period: 2**

**Year: 2019**

	DISTRIBUTION 2/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
PSI Diarrhea Treatment Kit Provided	-	-	-	-	406		(100)%	1,812	12,274	-	-	-
Emergency Contraception	(29)	(15)	(33)	-	(48)		0%	(282)	(1,372)	(1)	(1)	(1)
(b)PSI Emergency Contraception Distributed Provided	(29)	(15)	(33)	-	(48)		-%	(282)	(1,372)	(1)	(1)	(1)
Emergency Contraception Provided	29	15	33	-	48		(31)%	282	1,372	2	2	1
PSI Emergency Contraception Provided	29	15	33	-	48		(31)%	282	1,372	2	2	1
Fever Cases Attended	13,364	7,755	22,654	-	13,352		70%	77,136	442,244	22,654	-	-
Fever Cases Attended	13,364	7,755	22,654	-	13,352		70%	77,136	442,244	22,654	-	-
Fever Cases Tested with Microscopy	127	53	129	-	360		(64)%	2,072	9,136	129	-	-
Fever Cases Tested with Microscopy	127	53	129	-	360		(64)%	2,072	9,136	129	-	-
Fever Cases Tested with RDTs	9,251	5,867	16,159	-	8,520		90%	53,421	385,158	16,159	-	-
Fever Cases Tested with RDTs	9,251	5,867	16,159	-	8,520		90%	53,421	385,158	16,159	-	-
Free Condom	133,920	165,408	156,960	-	315,000		(50)%	19,479,201	26,855,969	1,177	1,177	1,426
Generic Condom	-	-	-	-	9,000	10/16	(100)%	15,700	7,235,508	-	-	-
KPOTY	133,920	165,408	156,960	-	306,000	1/18	(49)%	19,463,501	19,620,461	1,177	1,177	1,426
HIV Testing Services	1,373	21,552	17,025	-	840		1927%	243,365	738,942	17,025	-	57
VCT Individual (HIV-Negative)	1,343	21,449	16,912	-	833	12/09	1,930%	242,688	737,125	16,912	-	57
VCT Individual (HIV-Positive)	30	103	113	-	7	12/09	1,514%	677	1,817	113	-	-
Implant 3	1,780	(153)	3,480	-	660		427%	4,681	8,084	3,132	7,830	4,750
Implanon	-	-	-	-	1,028	7/06	(100)%	2,007	35,127	-	-	-
Implanon NXT	5,081	2,915	7,678	-	577	5/17	1,231%	36,178	47,383	6,910	17,276	10,480
(b)PSI Implant 3 Distributed Inserted	(3,301)	(3,068)	(4,198)	-	(945)		-%	(33,504)	(74,426)	(3,778)	(9,446)	(5,730)
Implant 3 Insertion	3,301	3,068	4,198	-	945		344%	33,504	74,426	4,198	10,495	6,367
PSI Implant 3 Inserted	3,301	3,068	4,198	-	945		344%	33,504	74,426	4,198	10,495	6,367
Implant 4	-	(1)	-	-	(3)		0%	(14)	(2,528)	-	-	-
(b)PSI Implant 4 Distributed Inserted	-	(1)	-	-	(3)		-%	(14)	(2,528)	-	-	-

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

**Period: 2**

**Year: 2019**

	DISTRIBUTION 2/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
Implant 4 Insertion	-	1	-	-	3		(100)%	14	2,528	-	-	-
PSI Implant 4 Inserted	-	1	-	-	3		(100)%	14	2,528	-	-	-
Implant 5	(7)	(3)	(8)	-	(90)		0%	(265)	1,498	(7)	(27)	(16)
Jadelle	-	-	-	-	10	7/14	(100)%	20	3,703	-	-	-
(b)PSI Implant 5 Distributed Inserted	(7)	(3)	(8)	-	(100)		-%	(285)	(2,205)	(7)	(27)	(16)
Implant 5 Insertion	7	3	8	-	100		(92)%	285	2,205	8	30	18
PSI Implant 5 Inserted	7	3	8	-	100		(92)%	285	2,205	8	30	18
Injectable 3-IM	103,663	95,151	193,223	-	118,952		62%	1,664,193	20,041,226	43,475	43,475	19,429
Confiance Injectable	107,675	97,518	198,150	-	124,325	10/98	59%	1,702,545	20,249,646	44,584	44,584	19,924
(b)PSI Injectable 3 IM Distributed Provided	(4,012)	(2,367)	(4,927)	-	(5,373)		-%	(38,352)	(208,420)	(1,109)	(1,109)	(495)
Injectable 3-IM Provided	4,012	2,367	4,927	-	5,373		(8)%	38,352	208,420	1,232	1,232	550
PSI Injectable 3 IM Provided	4,012	2,367	4,927	-	5,373		(8)%	38,352	208,420	1,232	1,232	550
Injectable 3-SC	14,530	22,840	21,291	-	67,145		(68)%	523,092	1,425,585	4,790	4,790	2,141
Sayana Press	14,530	22,840	21,291	-	67,145	9/15	(68)%	523,092	1,425,585	4,790	4,790	2,141
IPTp2	-	-	-	-	21		(100)%	78,153	281,594	-	-	-
IPTp2	-	-	-	-	21		(100)%	78,153	281,594	-	-	-
IUD 10	(304)	54	(345)	-	231		(249)%	1,979	17,998	(311)	(1,428)	(811)
Copper T	336	108	361	-	50	5/06	622%	4,320	198,113	325	1,495	849
IUD 1 x 5	-	-	-	-	-	8/11	-%	25	5,285	-	-	-
Pregna T Cu 380A	855	1,123	975	-	1,499	7/17	(35)%	15,143	21,275	878	4,036	2,292
(b)PSI IUD 10 Distributed Inserted	(1,495)	(1,178)	(1,681)	-	(1,318)		-%	(17,509)	(206,675)	(1,513)	(6,959)	(3,951)
IUD 10 Insertion	1,495	1,178	1,681	-	1,318		28%	17,509	206,675	1,681	7,733	4,390
PSI IUD 10 Inserted	1,495	1,178	1,681	-	1,318		28%	17,509	206,675	1,681	7,733	4,390
IUS 3	12	7	24	-	-		0%	98	122	22	54	31
Avibela (52 mg levonorgestrel)	64	21	82	-	-	2/18	-%	233	315	74	185	105

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.



**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

**Period: 2**

**Year: 2019**

	DISTRIBUTION 2/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
(b)PSI IUS 3 Distributed Inserted	(52)	(13)	(58)	-	-		-%	(135)	(193)	(52)	(131)	(74)
IUS 3 Insertion	52	13	58	-	-		0%	135	193	58	145	83
PSI IUS 3 Inserted	52	13	58	-	-		-%	135	193	58	145	83
LLIN	214,800	4,529,890	575,250	-	300,600		91%	13,921,182	32,748,902	931,905	-	22,753
Dawa Plus Blue	-	387,271	-	-	-		-%	1,161,814	1,161,814	-	-	-
Dawa Plus White	-	2,340,933	131,050	-	-	4/18	-%	6,891,750	7,022,800	212,301	-	5,183
Generic net "PERMANET WHITE"	-	-	-	-	-	5/15	-%	1,760	9,216,036	-	-	-
PermaNet	-	747,986	38,000	-	2,250	3/07	1,589%	2,216,858	4,704,631	61,560	-	1,503
Safe Net Blue	-	580,417	8,650	-	-		-%	1,732,600	1,741,250	14,013	-	342
Safe Net White	214,000	215,017	363,400	-	-		-%	495,650	859,050	588,708	-	14,373
Super Moustiquaire	-	46,107	2,500	-	259,850	9/01	(99)%	482,572	3,663,104	4,050	-	99
Yorkool Blue (Generic Net)	-	83,167	-	-	18,250	7/15	(100)%	313,000	1,378,824	-	-	-
Yorkool White (Generic Net)	800	128,993	31,650	-	20,250	9/13	56%	625,178	3,001,393	51,273	-	1,252
Lubricant	864	-	864	-	65,950		(99)%	569,063	1,118,627	-	-	-
Gel Lubricant 5 mL	864	-	864	-	65,950	12/16	(99)%	569,063	1,118,627	-	-	-
Malaria PPT (ACT)	203,865	103,415	328,094	-	-		0%	3,507,514	7,006,813	295,285	-	83,297
ACT 100 mg (1x3's)	-	-	-	-	-	7/15	-%	331,575	574,532	-	-	-
ACT 100 mg (1x6's)	-	-	-	-	-	7/15	-%	318,325	560,050	-	-	-
ACT 25 mg (1x3's)	-	-	-	-	-	7/15	-%	280,575	520,199	-	-	-
ACT 50 mg (1x3's)	-	-	-	-	-	7/15	-%	773,650	1,454,575	-	-	-
AL for Adolescent, 20/120mg, 18's	-	-	-	-	-	7/16	-%	20,581	67,103	-	-	-
AL for Adult, 20/120mg, 24's	-	-	-	-	-	7/16	-%	28,330	98,705	-	-	-
AL for Infant, 20/120mg, 6's	-	-	-	-	-	7/16	-%	11,097	43,625	-	-	-
AL for Toddler, 20/120mg, 12's	-	16	-	-	-	7/16	-%	37,176	100,505	-	-	-

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

**Period: 2**

**Year: 2019**

	DISTRIBUTION 2/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
ASAQ for Adolescent, 100/270mg, 3's	93,445	8,320	109,995	-	-	7/16	-%	503,415	998,571	98,996	-	27,926
ASAQ for Adult, 100/270mg, 6's	110,420	64,081	153,475	-	-	7/16	-%	542,613	1,153,829	138,128	-	38,965
ASAQ for Infant, 25/67.5mg, 3's	-	5,781	9,859	-	-	7/16	-%	69,596	255,888	8,873	-	2,503
ASAQ for Toddler, 50/135mg, 3's	-	25,218	54,765	-	-	7/16	-%	590,581	1,179,231	49,289	-	13,904
Malaria RDK	70,950	1,299,633	70,950	-	-		0%	7,698,425	17,170,813	63,855	-	-
RDT Malaria	70,950	1,299,633	70,950	-	-	8/11	-%	7,698,425	17,170,813	63,855	-	-
Manual Vacuum Aspiration for PAC	217	196	269	-	296		(9)%	2,719	6,445	269	-	85
MVA for PAC	217	196	269	-	296	12/16	(9)%	2,719	6,445	269	-	85
Micronutrient Powder	-	-	-	-	10,500		(100)%	5,797,980	16,505,640	-	-	-
ZAZATOMADY (ZZT)	-	-	-	-	10,500	2/13	(100)%	5,797,980	16,505,640	-	-	-
Misoprostol for PAC Provided	764	472	825	-	516		60%	6,438	12,173	825	-	306
PSI Misoprostol for PAC Provided	764	472	825	-	516		60%	6,438	12,173	825	-	306
Misoprostol for Safe Abortion	16,444	14,279	16,200	-	(2,064)		0%	81,047	77,607	850	-	288
Misoprostol 200 mcg Tablet	19,500	16,167	19,500	-	-	3/18	-%	106,799	126,299	1,024	-	346
(b)PSI Misoprostol for Safe Abortion Dist Provided	(3,056)	(1,888)	(3,300)	-	(2,064)		-%	(25,752)	(48,692)	(173)	-	(59)
OCs	34,459	103,672	73,238	-	175,128		(58)%	1,994,828	40,837,859	4,394	4,394	2,072
Microgynon	9,960	23,470	27,960	-	32,990	2/18	(15)%	1,471,355	1,499,315	1,678	1,678	791
Pilplan	25,095	80,567	45,995	-	143,505	10/98	(68)%	531,113	39,427,322	2,760	2,760	1,301
(b)PSI OCs Distributed Provided	(596)	(365)	(717)	-	(1,367)		-%	(7,640)	(88,778)	(43)	(43)	(20)
OCs Provided	596	365	717	-	1,367		(48)%	7,640	88,778	48	48	23
PSI OCs Provided	596	365	717	-	1,367		(48)%	7,640	88,778	48	48	23
ORS	80	-	80	-	-		0%	39,368	39,448	36	-	1
SRO Generique	80	-	80	-	-	4/18	-%	39,368	39,448	36	-	1
Pneumonia PPT	-	381	-	-	7,870		(100)%	157,872	791,414	-	-	-

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

**Period: 2**

**Year: 2019**

	DISTRIBUTION 2/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
Pneumox 250 (10's) for Children under 12 months	-	381	-	-	7,870	7/16	(100)%	157,872	791,414	-	-	-
Positive RDTs	1,314	720	2,155	-	1,060		103%	8,700	115,664	2,155	-	-
Positive RDTs	1,314	720	2,155	-	1,060		103%	8,700	115,664	2,155	-	-
Safe Water Solution	29,640	52,343	91,640	-	475,606		(81)%	1,308,083	22,877,126	108,462	-	362
Sur Eau Vaovao	29,640	52,343	91,640	-	475,606	9/04	(81)%	1,308,083	22,877,126	108,462	-	362
SDM (Cycle Beads)	(34)	(17)	(39)	-	365		(111)%	5,121	143,478	(35)	(53)	(34)
(b)PSI SDM (Cycle Beads) Distributed Provided	(34)	(17)	(39)	-	(55)		-%	(467)	(5,150)	(35)	(53)	(34)
Rojo	-	-	-	-	420	3/12	(100)%	5,588	148,628	-	-	-
SDM (Cycle Beads) Provided	34	17	39	-	55		(29)%	467	5,150	39	59	37
PSI SDM (Cycle Beads) Provided	34	17	39	-	55		(29)%	467	5,150	39	59	37
STI Screening	923	759	1,239	-	1,956		(37)%	12,714	77,185	1,239	-	-
STI Screening	923	759	1,239	-	1,956		(37)%	12,714	77,185	1,239	-	-
Treatment for Inguinal Bubo	3	5	6	-	5		20%	53	142	6	-	-
Treatment for Inguinal Bubo	3	5	6	-	5		20%	53	142	6	-	-
Treatment for Lower Abdominal Pain	44	49	66	-	105		(37)%	752	2,115	66	-	-
Treatment for Lower Abdominal Pain	44	49	66	-	105		(37)%	752	2,115	66	-	-
Treatment for Nonherpetic Genital Ulcer	77	66	112	-	173		(35)%	1,165	2,978	112	-	13
Treatment for Nonherpetic Genital Ulcer	77	66	112	-	173		(35)%	1,165	2,978	112	-	13
Treatment for Severe Acute Malnutrition	-	-	-	-	-		0%	187	187	-	-	-
Treatment for Severe Acute Malnutrition	-	-	-	-	-		-%	187	187	-	-	-
Treatment for Urethral Discharge (Men)	420	345	563	-	853		(34)%	5,596	13,780	1,126	-	3
Treatment for Urethral Discharge (Men)	420	345	563	-	853		(34)%	5,596	13,780	1,126	-	3
Treatment for Vaginitis	358	280	468	-	796		(41)%	4,978	12,501	468	-	4
Treatment for Vaginitis	358	280	468	-	796		(41)%	4,978	12,501	468	-	4
Tubal Ligation	1	3	1	-	4		(75)%	42	117	1	10	5

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**  
**Monthly Distribution by Country**  
**Period: 2**  
**Year: 2019**

	DISTRIBUTION 2/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
Tubal Ligation	1	3	1	-	4		(75)%	42	117	1	10	5
Water Treatment Tablets	277,200	546,933	475,200	-	685,200		(31)%	6,183,000	28,764,830	7,812	-	26
SUR'EAU PILINA (67mg tablet)	277,200	546,933	475,200	-	685,200	10/14	(31)%	6,183,000	28,764,830	7,812	-	26
Zinc	40	60	40	-	-		0%	13,132	13,172	36	-	-
Zinc	40	60	40	-	-	1/08	-%	13,132	13,172	36	-	-
<b>Mali</b>											<b>39,247</b>	<b>319,581</b>
Cervical Cancer-VIA and Cryotherapy	-	5	-	-	22		(100)%	121	1,039	-	-	-
Cervical Cancer-VIA and Cryotherapy	-	5	-	-	22	12/13	(100)%	121	1,039	-	-	-
Cervical Cancer-VIA/VILI Screening	-	663	17	-	2,077		(99)%	12,365	70,472	17	-	-
Cervical Cancer-VIA/VILI Screening	-	663	17	-	2,077		(99)%	12,365	70,472	17	-	-
Free Condom	-	67	-	-	-		0%	200	200	-	-	-
Generic Condom	-	67	-	-	-		-%	200	200	-	-	-
Implant 3	2,016	445	2,016	-	-		0%	1,336	3,552	1,814	4,536	5,229
Implanon NXT	2,016	445	2,016	-	-	2/16	-%	1,336	3,552	1,814	4,536	5,229
Implant 3 Insertion	-	1,269	816	-	2,404		(66)%	13,564	28,343	816	2,040	2,352
Non-PSI Implant 3 Inserted	-	1,269	816	-	2,404		(66)%	13,564	28,343	816	2,040	2,352
Implant 5	4,500	1,267	4,500	-	-		0%	5,599	117,253	4,050	15,390	17,466
Jadelle	4,500	1,267	4,500	-	-	7/09	-%	5,599	117,253	4,050	15,390	17,466
Implant 5 Insertion	-	3,132	1,679	-	4,210		(60)%	38,187	106,168	1,679	6,380	7,241
Non-PSI Implant 5 Inserted	-	3,132	1,679	-	4,210		(60)%	38,187	106,168	1,679	6,380	7,241
Injectable 3-IM	1,025	-	1,025	-	-		0%	927	1,952	231	231	195
Depo-Provera	1,025	-	1,025	-	-	1/08	-%	927	1,952	231	231	195
Injectable 3-IM Provided	-	3,077	1,616	-	2,669		(39)%	36,909	41,332	404	404	342
Non-PSI Injectable 3 IM Provided	-	3,077	1,616	-	2,669		(39)%	36,909	41,332	404	404	342
IUD 10	1,288	586	1,288	-	-		0%	5,539	25,861	1,159	5,332	5,798

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

**Period: 2**

**Year: 2019**

	DISTRIBUTION 2/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
Copper-T 380-A with inserter	-	37	-	-	-		-%	112	112	-	-	-
IUD Copper T 380A	1,088	507	1,088	-	-	12/13	-%	5,302	25,424	979	4,504	4,898
PPIUD Cu T380A	200	42	200	-	-		-%	125	325	180	828	900
IUD 10 Insertion	-	1,642	1,069	-	3,289		(67)%	22,777	63,795	1,069	4,917	5,347
Non-PSI IUD 10 Inserted	-	1,642	1,069	-	3,289		(67)%	22,777	63,795	1,069	4,917	5,347
LLIN	-	951,635	657,095	-	665,434		(1)%	4,911,866	20,195,332	1,064,494	-	275,244
MILD - (G)	-	732,588	-	-	15,237	10/14	(100)%	3,685,706	11,198,152	-	-	-
MILD - (O)	-	15	-	-	-	9/16	-%	45	1,125,683	-	-	-
MILD - (U)	-	219,032	657,095	-	650,197	12/14	1%	1,226,115	7,871,497	1,064,494	-	275,244
Malaria PPT (ACT)	-	-	-	-	460,404		(100)%	460,404	4,646,729	-	-	-
Coartem 12 tabs	-	-	-	-	138,127	5/10	(100)%	138,127	1,694,442	-	-	-
Coartem 6 tabs	-	-	-	-	322,277	5/10	(100)%	322,277	2,952,287	-	-	-
Manual Vacuum Aspiration for PAC	-	247	145	-	543		(73)%	3,528	7,855	145	-	87
MVA for PAC	-	247	145	-	543	7/15	(73)%	3,528	7,855	145	-	87
Misoprostol for PAC Provided	-	427	385	-	1,166		(67)%	6,303	14,597	385	-	264
Non-PSI Misoprostol for PAC Provided	-	427	385	-	1,166		(67)%	6,303	14,597	385	-	264
OCs Provided	-	432	204	-	527		(61)%	5,695	7,087	14	14	12
Non-PSI OCs Provided	-	432	204	-	527		(61)%	5,695	7,087	14	14	12
SDM (Cycle Beads) Provided	-	6	2	-	1		100%	36	48	2	3	4
Non-PSI SDM (Cycle Beads) Provided	-	6	2	-	1		100%	36	48	2	3	4
Seasonal Malaria Chemoprevention	-	-	-	-	1,665,225		(100)%	1,665,225	4,076,234	-	-	-
SMC for Children ages 12-59 months	-	-	-	-	1,361,725		(100)%	1,361,725	3,333,317	-	-	-
SMC for Infants ages 3-11 months	-	-	-	-	303,500	3/17	(100)%	303,500	742,917	-	-	-
Toilets Sold	-	4	6	-	-		0%	27	6,303	34	-	1

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

Period: 2

Year: 2019

	DISTRIBUTION 2/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
Toilet Type 1, Direct Sales	-	4	6	-	-	12/16	-%	27	6,303	34	-	1
Water Treatment Tablets	-	70,400	-	-	-		0%	262,400	43,524,470	-	-	-
Aquatab	-	70,400	-	-	-	2/09	-%	262,400	43,524,470	-	-	-
<b>Somaliland</b>											<b>462</b>	<b>13,014</b>
Acute Malnutrition Screening_CU5	-	130	389	-	-		0%	-	389	389	-	-
Acute Malnutrition Screening_CU5	-	130	389	-	-		-%	-	389	389	-	-
Counseling & Tx for Moderate Acute MalnutritionCU!	1,169	5,178	1,962	-	-		0%	20,332	22,294	1,962	-	-
Counseling & Tx for Moderate Acute MalnutritionCU5	1,169	5,178	1,962	-	-		-%	20,332	22,294	1,962	-	-
Diarrhea Treatment Kit	20,000	20,000	40,000	-	37,000		8%	128,358	990,435	36,000	-	3,929
SD OFLV-DTK	20,000	20,000	40,000	-	37,000	9/11	8%	128,358	990,435	36,000	-	3,929
HIV Testing Services	1,772	2,786	2,623	-	-		0%	12,506	15,129	2,623	-	25
VCT Individual (HIV-Negative)	1,772	2,786	2,623	-	-		-%	12,506	15,129	2,623	-	25
Implant 3	(5)	11	(41)	-	(44)		0%	42	268	(37)	(92)	(94)
Nasiye Implant (Implanon)	5	37	5	-	-	12/15	-%	236	824	5	11	11
(b)PSI Implant 3 Distributed Inserted	(10)	(25)	(46)	-	(44)		-%	(194)	(556)	(41)	(104)	(105)
Implant 3 Insertion	37	73	98	-	53		85%	545	994	98	245	250
Non-PSI Implant 3 Inserted	27	48	52	-	9		478%	351	438	52	130	132
PSI Implant 3 Inserted	10	25	46	-	44		5%	194	556	46	115	117
Injectable 3-IM	-	340	320	-	700		(54)%	4,367	27,646	72	72	54
Nasiye - Inj 3	-	340	320	-	700	6/11	(54)%	4,367	27,646	72	72	54
Injectable 3-IM Provided	123	112	123	-	-		0%	936	1,059	31	31	23
Non-PSI Injectable 3 IM Provided	123	112	123	-	-		-%	936	1,059	31	31	23
IPTp2	399	503	753	-	-		0%	3,758	4,511	753	-	84
IPTp2	399	503	753	-	-		-%	3,758	4,511	753	-	84
IUD 5 Insertion	36	43	56	-	-		0%	299	355	56	185	188

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

**Period: 2**

**Year: 2019**

	DISTRIBUTION 2/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
Non-PSI IUD 5 Inserted	36	43	56	-	-		-%	299	355	56	185	188
Misoprostol for PPH	1,000	4,167	2,500	-	7,800		(68)%	30,800	197,208	750	-	16
Ummul-gargaar	1,000	4,167	2,500	-	7,800	3/10	(68)%	30,800	197,208	750	-	16
OCs	-	-	-	-	-		0%	23,089	150,040	-	-	-
Nasiye - OC	-	-	-	-	-	3/12	-%	23,089	150,040	-	-	-
OCs Provided	325	124	325	-	-		0%	1,880	2,205	22	22	17
Non-PSI OCs Provided	325	124	325	-	-		-%	1,880	2,205	22	22	17
ORS Provided	2,227	1,595	4,445	-	-		0%	13,509	17,954	4,445	-	232
Non-PSI ORS Provided	2,227	1,595	4,445	-	-		-%	13,509	17,954	4,445	-	232
Pneumonia PPT	-	-	-	-	3,097		(100)%	14,500	53,213	-	-	-
Pneumox 125mg tablet (Amoxicillin) x 20's	-	-	-	-	717	11/14	(100)%	2,900	10,716	-	-	-
Pneumox 250mg tablet (Amoxicillin) x 20's	-	-	-	-	2,380	11/14	(100)%	11,600	42,497	-	-	-
Pneumonia PPT Provided	1,565	918	2,689	-	-		0%	11,575	14,264	2,689	-	3,107
Non-PSI Pneumonia PPT Provided	1,565	918	2,689	-	-		-%	11,575	14,264	2,689	-	3,107
QAACTs Provided after Confirmatory Diagnosis	109	477	295	-	-		0%	1,872	2,167	295	-	66
Non-PSI QAACTs Provided after Confirmed Diagnosis	109	477	295	-	-		-%	1,872	2,167	295	-	66
Skilled Birth Attendance	1,357	2,252	2,239	-	-		0%	16,695	18,934	2,239	-	3,190
Skilled Birth Attendance	1,357	2,252	2,239	-	-		-%	16,695	18,934	2,239	-	3,190
STI Screening	119	735	122	-	-		0%	2,302	2,424	122	-	-
STI Screening	119	735	122	-	-		-%	2,302	2,424	122	-	-
Treatment for Pre-Eclampsia (with MgSO4)	23	44	38	-	-		0%	343	381	38	-	132
Treatment for Pre-Eclampsia (with MgSO4)	23	44	38	-	-		-%	343	381	38	-	132
Treatment for Severe Acute Malnutrition	389	677	389	-	-		0%	9,600	9,989	389	-	1,483
Treatment for Severe Acute Malnutrition	389	677	389	-	-		-%	9,600	9,989	389	-	1,483
Water Treatment Tablets	256,000	370,720	648,160	-	923,400		(30)%	4,513,480	75,359,102	10,655	-	198

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

Period: 2

Year: 2019

	DISTRIBUTION 2/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
Aquatab	256,000	-	256,000	-	-	9/10	-%	334,000	36,164,790	4,208	-	78
Biyosifeeye	-	370,720	392,160	-	923,400	7/08	(58)%	4,179,480	39,194,312	6,446	-	120
Zinc Provided	2,181	1,578	4,376	-	-		0%	11,834	16,210	4,376	-	115
Non-PSI Zinc Provided	2,181	1,578	4,376	-	-		-%	11,834	16,210	4,376	-	115
<b>South Sudan</b>												46,375
Acute Malnutrition Screening_CU5	-	206,352	-	-	-		0%	619,055	619,055	-	-	-
Acute Malnutrition Screening_CU5	-	206,352	-	-	-		-%	619,055	619,055	-	-	-
LLIN	42,500	194,445	42,500	-	30,293		40%	755,027	14,497,934	68,850	-	14,071
Free Permanet Mesh	42,500	194,445	42,500	-	-	4/08	-%	724,734	8,613,227	68,850	-	14,071
Mass LLIN - WES	-	-	-	-	30,293	6/14	(100)%	30,293	5,884,707	-	-	-
Malaria PPT (ACT)	102,484	204,940	102,484	-	165,028		(38)%	3,022,439	14,169,965	92,236	-	32,304
ACTs for Adult (14+ years)	45,700	82,100	45,700	-	47,930	2/13	(5)%	641,055	3,096,795	41,130	-	14,405
ACTs for Child (6-14 years)	34,200	62,767	34,200	-	2,300	2/13	1,387%	479,609	1,810,870	30,780	-	10,780
ACTs for Infant (2-12 months)	3,510	10,066	3,510	-	50,470	2/13	(93)%	692,193	3,490,894	3,159	-	1,106
ACTs for Toddler (1-5 years)	11,400	26,500	11,400	-	64,328	2/13	(82)%	1,139,058	5,693,208	10,260	-	3,593
Artemether Tabs – Adult	4,050	12,117	4,050	-	-		-%	36,350	40,400	3,645	-	1,277
Artemether Tabs - Child	2,700	8,759	2,700	-	-		-%	26,276	28,976	2,430	-	851
Artemether Tabs - Infant	264	674	264	-	-		-%	2,022	2,286	238	-	83
Artemether Tabs - Toddler	660	1,959	660	-	-		-%	5,876	6,536	594	-	208
Malaria RDK	51,300	118,598	51,300	-	53,300		(4)%	3,256,042	8,543,195	46,170	-	-
Malaria Rapid Diagnostic Kit	51,300	118,598	51,300	-	53,300	9/14	(4)%	3,256,042	8,543,195	46,170	-	-
ORS	-	-	-	-	56,859		(100)%	1,210,375	5,520,636	-	-	-
ORS	-	-	-	-	56,859	9/08	(100)%	1,210,375	5,520,636	-	-	-
Pneumonia PPT	-	-	-	-	30,387		(100)%	565,947	1,994,485	-	-	-

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.



**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

**Period: 2**

**Year: 2019**

	DISTRIBUTION 2/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
Amoxicillin for Children (1-5 years)	-	-	-	-	<b>25,998</b>	10/12	(100)%	<b>361,615</b>	<b>1,358,695</b>	-	-	-
Amoxicillin for Infant (2-12 months)	-	-	-	-	<b>4,389</b>	10/12	(100)%	<b>204,332</b>	<b>635,790</b>	-	-	-
Treatment for Severe Acute Malnutrition	-	<b>1,035</b>	-	-	-		<b>0%</b>	<b>3,106</b>	<b>44,752</b>	-	-	-
Treatment for Severe Acute Malnutrition	-	<b>1,035</b>	-	-	-		<b>-%</b>	<b>3,106</b>	<b>44,752</b>	-	-	-
Zinc	-	-	-	-	<b>17,770</b>		<b>(100)%</b>	<b>499,704</b>	<b>1,893,104</b>	-	-	-
Zinc	-	-	-	-	<b>17,770</b>	1/08	<b>(100)%</b>	<b>499,704</b>	<b>1,893,104</b>	-	-	-

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

# Social Enterprise Market Group

**POPULATION SERVICES INTERNATIONAL**  
**CYPs, Cases, and Deaths by Country**  
**1/2019 - 2/2019**

	<u>New HIV Infections</u>	<u>STI Deaths</u>	<u>PWID Deaths</u>	<u>TB Deaths</u>	<u>CYP*</u>	<u>Maternal Deaths</u>	<u>Unintended Pregnancies</u>	<u>Malaria Deaths</u>	<u>Diarrhea Deaths</u>	<u>Pneumonia Deaths</u>	<u>Cervical Cancer Death</u>	<u>Sum of All Deaths</u>
Social Enterprise	3,488	-	-	-	152,673	181	53,304	-	92	-	-	556
India LLC	273	-	-	-	94,705	168	36,333	-	92	-	-	445
Paraguay	54	-	-	-	13,575	3	4,469	-	-	-	-	15
PSI South Africa	3,161	-	-	-	44,392	10	12,502	-	-	-	-	95
<b>Total</b>	<b>26,479</b>	<b>10</b>	<b>-</b>	<b>1,020</b>	<b>2,044,051</b>	<b>2,060</b>	<b>820,828</b>	<b>6,328</b>	<b>294</b>	<b>53</b>	<b>2</b>	<b>20,709</b>

\* Using USAID CYP conversion factors

POPULATION SERVICES INTERNATIONAL  
 Monthly Distribution by Market Group and Product  
 Period: 2  
 Year: 2019

	DISTRIBUTION 2/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE SALES	YTD USERS REACHED <sup>(a)</sup> 2019	YTD CYP 2019	YTD DALY 2019
<b>Social Enterprise</b>										<b>152,673</b>	<b>176,323</b>
Condom	5,298,305	17,921,264	12,232,054	-	21,053,550	(42)%	159,709,190	721,044,153	91,740	91,740	147,811
Emergency Contraception	26,298	46,397	63,798	-	53,107	20%	553,951	3,129,901	2,871	2,871	237
Injectable 3-IM	2,304	10,635	7,285	-	11,808	(38)%	129,729	206,095	1,639	1,639	274
IUD 10	-	11,637	35	-	-	-%	65,510	65,545	32	145	31
IUD 3	(125)	42	(250)	-	1,053	(124)%	6,953	6,703	(225)	(563)	(120)
IUD 5	461	8,080	16,112	-	16,220	(1)%	79,621	196,447	14,501	47,853	10,848
IUS 5	9	85	264	-	-	-%	-	264	238	784	178
Lubricant	1,968	2,652	3,588	-	1,908	88%	37,944	127,956	-	-	-
Male Vasodilator	74,900	33,333	174,900	-	-	-%	-	174,900	1,312	-	-
Medical Abortion	57,881	111,223	88,281	-	123,570	(29)%	1,139,134	1,742,351	79,453	-	8,205
Multivitamin	119,430	156,330	215,610	-	311,010	(31)%	1,974,210	37,225,170	1,078	-	37
OCs	54,881	442,790	136,716	-	421,181	(68)%	4,758,355	16,220,116	8,203	8,203	835
ORS	310,269	45,317	398,019	-	84,600	370%	1,144,506	1,868,953	179,109	-	7,986
Pregnancy Test	34,970	80,792	58,716	-	-	-%	575,675	634,391	-	-	-
Vaginal Wash	1,920	-	1,920	-	-	-%	-	1,920	-	-	-

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

Period: 2

Year: 2019

	DISTRIBUTION 2/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
<b>Social Enterprise</b>											<b>152,673</b>	<b>176,323</b>
<b>India LLC</b>											<b>94,705</b>	<b>44,766</b>
Condom	2,095,320	14,164,548	5,838,078	-	14,437,200		(60)%	121,087,377	267,137,307	43,786	43,786	17,206
Masti Cherry 2's	183,600	-	183,600	-	-		-%	-	183,600	1,377	1,377	541
Masti Classic 10's	-	937,200	-	-	1,987,200	10/17	(100)%	12,641,730	17,074,530	-	-	-
Masti Classic 10's (Flavoured)	-	2,080,340	(180)	-	1,130,400	6/17	(100)%	12,638,400	21,847,860	(1)	(1)	(1)
Masti Classic 2's Orange	54,000	1,084,517	969,472	-	-	4/18	-%	7,334,310	8,303,782	7,271	7,271	2,857
Masti Classic 3's Cool Mint	-	(143)	(429)	-	-	4/18	-%	1,000,080	999,651	(3)	(3)	(1)
Masti Classic 3's	1,065,600	4,387,415	3,793,617	-	8,096,400	12/16	(53)%	43,947,594	112,907,038	28,452	28,452	11,181
Masti Classic 3's (Flavoured)	792,000	3,296,892	896,196	-	1,836,000		(51)%	22,653,043	37,635,599	6,721	6,721	2,641
Masti Classic 6's	-	-	-	-	-	12/16	-%	960	27,094,440	-	-	-
Masti Green Apple 2's	-	1,339,660	-	-	-		-%	4,018,980	4,018,980	-	-	-
Masti Long Innings 2's	120	-	120	-	-		-%	-	120	1	1	-
Masti Premium 10's (Flavoured)	-	1,019,047	(340)	-	374,400		(100)%	6,531,960	10,781,540	(3)	(3)	(1)
Masti Premium 2's Chocolate	-	-	-	-	-		-%	134,910	134,910	-	-	-
Masti Premium 2's Strawberry	-	-	-	-	-		-%	134,824	134,824	-	-	-
Masti Premium 3's	-	-	-	-	-	12/16	-%	23,656	8,984,681	-	-	-
Masti Premium 3's Cool Mint	-	-	-	-	-	4/18	-%	913,200	913,200	-	-	-
Masti Premium 3's (Flavoured)	-	19,619	(3,978)	-	1,012,800		(100)%	9,113,730	16,122,552	(30)	(30)	(12)
Emergency Contraception	2,460	14,342	13,660	-	890		1435%	212,227	225,887	615	615	78
Pronta	-	-	-	-	890		(100)%	18,500	18,500	-	-	-
Pronta1	(60)	6,536	2,797	-	-	4/18	-%	178,469	181,266	126	126	16
Pronta-72	2,520	7,807	10,863	-	-		-%	15,258	26,121	489	489	62
Injectable 3-IM	2,304	10,635	7,285	-	11,808		(38)%	129,729	206,095	1,639	1,639	274

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**  
**Monthly Distribution by Country**  
**Period: 2**  
**Year: 2019**

	DISTRIBUTION 2/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
Freedom Inject (3-month)	2,304	10,635	7,285	-	11,808	12/16	(38)%	129,729	206,095	1,639	1,639	274
IUD 10	-	11,637	35	-	-		0%	65,510	65,545	32	145	31
Freedom 10	-	11,637	35	-	-	12/16	-%	65,510	65,545	32	145	31
IUD 3	(125)	42	(250)	-	1,053		(124)%	6,953	6,703	(225)	(563)	(120)
Freedom 3	(125)	42	(250)	-	1,053	1/18	(124)%	6,953	6,703	(225)	(563)	(120)
IUD 5	461	8,080	16,112	-	16,220		(1)%	79,621	196,447	14,501	47,853	10,848
Freedom 5	500	7,975	16,220	-	15,370	12/16	6%	70,638	187,572	14,598	48,173	10,921
Freedom 5 – Sseek	-	58	(50)	-	850	1/18	(106)%	6,909	6,859	(45)	(148)	(34)
Freedom 5 (PPIUCD) Cu 375	(39)	47	(58)	-	-		-%	2,074	2,016	(52)	(172)	(39)
IUS 5	9	85	264	-	-		0%	-	264	238	784	178
Sabatica – LNG IUS	9	85	264	-	-		-%	-	264	238	784	178
Male Vasodilator	74,900	33,333	174,900	-	-		0%	-	174,900	1,312	-	-
Masti Super 100 - 100 mg Tab	74,900	33,333	174,900	-	-		-%	-	174,900	1,312	-	-
Medical Abortion	57,881	111,223	88,281	-	123,570		(29)%	1,139,134	1,742,351	79,453	-	8,205
Safe Abort kit	57,881	111,223	88,281	-	123,570	12/16	(29)%	1,139,134	1,742,351	79,453	-	8,205
OCs	(1,512)	371,223	7,448	-	300,900		(98)%	4,052,619	7,730,027	447	447	79
Freedom 28	(1,140)	820	(1,380)	-	-		-%	42,146	40,766	(83)	(83)	(15)
MEURI	708	2,043	1,718	-	-		-%	37,645	39,363	103	103	18
Pearl	(1,080)	368,360	7,110	-	300,900	12/16	(98)%	3,972,828	7,649,898	427	427	75
ORS	310,269	45,317	398,019	-	84,600		370%	1,144,506	1,868,953	179,109	-	7,986
Neotral Orange 1000ml	310,269	45,317	398,019	-	84,600	12/16	370%	1,144,506	1,868,953	179,109	-	7,986
Pregnancy Test	34,970	80,792	58,716	-	-		0%	575,675	634,391	-	-	-
Pronta (PTK)	34,970	80,792	58,716	-	-	4/18	-%	575,675	634,391	-	-	-
Vaginal Wash	1,920	-	1,920	-	-		0%	-	1,920	-	-	-
Pronta Intimate Wash – 100 ml bottle	1,920	-	1,920	-	-		-%	-	1,920	-	-	-

(a) The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

Period: 2

Year: 2019

	DISTRIBUTION 2/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
<b>Paraguay</b>											<b>13,575</b>	<b>3,680</b>
Condom	270,641	241,917	475,000	-	360,702		32%	3,450,963	43,863,027	3,562	3,562	2,728
Pantera	151,789	109,836	249,848	-	180,862	8/98	38%	1,641,868	37,031,003	1,874	1,874	1,435
Pantera Banana	10,788	13,180	21,101	-	16,945	9/16	25%	168,808	422,901	158	158	121
Pantera Chocolate	9,672	16,069	23,435	-	21,460	2/14	9%	231,222	1,047,357	176	176	135
Pantera Retardant	36,510	37,278	62,013	-	54,489	2/14	14%	562,869	2,323,682	465	465	356
Pantera Ribbed	10,870	14,202	22,224	-	17,635	2/14	26%	165,502	818,930	167	167	128
Pantera Strawberry	25,881	22,349	42,954	-	36,815	2/14	17%	313,950	1,323,475	322	322	247
Pantera Tachas	10,603	11,979	22,005	-	13,196	9/16	67%	147,059	378,645	165	165	126
Pantera Tutti Frutti	14,528	17,025	31,420	-	19,300	9/16	63%	219,685	517,034	236	236	180
Emergency Contraception	23,838	31,055	50,138	-	52,217		(4)%	338,724	2,901,014	2,256	2,256	159
Pronta	22,464	31,055	48,764	-	52,217	2/04	(7)%	338,634	2,899,550	2,194	2,194	155
Pronta1	1,374	-	1,374	-	-		-%	90	1,464	62	62	4
Multivitamin	119,430	156,330	215,610	-	311,010		(31)%	1,974,210	37,225,170	1,078	-	37
VitalDia	119,430	156,330	215,610	-	311,010	11/00	(31)%	1,974,210	37,225,170	1,078	-	37
OCs	56,393	71,567	129,268	-	120,281		7%	705,736	8,490,089	7,756	7,756	757
Segura	52,605	68,036	122,333	-	115,373	4/01	6%	667,753	8,239,705	7,340	7,340	716
Segura Plus	3,788	3,531	6,935	-	4,908	3/11	41%	37,983	250,384	416	416	41
<b>PSI South Africa</b>											<b>44,392</b>	<b>127,877</b>
Condom	2,932,344	3,514,800	5,918,976	-	6,255,648		(5)%	35,170,850	410,043,819	44,392	44,392	127,877
Lovers Plus	488,016	342,024	759,024	-	618,768	10/92	23%	3,350,719	48,492,784	5,693	5,693	16,261
Lovers Plus C&F	-	291,192	137,016	-	393,840	8/06	(65)%	3,238,511	38,586,190	1,028	1,028	2,938
Lovers Plus C&S	316,656	-	316,656	-	-		-%	-	316,656	2,375	2,375	6,789
Lovers Plus Climax Delay	82,368	-	82,368	-	-		-%	-	82,368	618	618	1,766

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

**Period: 2**

**Year: 2019**

	DISTRIBUTION 2/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
Lovers Plus Extra Play	-	64,272	63,072	-	75,312	3/16	(16)%	610,748	3,790,718	473	473	1,352
Lovers Plus R&S	214,560	235,776	338,040	-	300,816	4/07	12%	2,216,556	23,114,549	2,535	2,535	7,247
Lovers Plus UltraThin	46,872	58,944	95,760	-	-		-%	634,392	730,152	718	718	2,053
Trust	755,640	1,022,616	1,635,768	-	1,648,872	5/01	(1)%	9,253,073	141,999,600	12,268	12,268	35,114
Trust Extra C&S	73,944	151,392	113,256	-	-		-%	705,528	818,784	849	849	2,207
Trust Extra Thin	89,424	142,272	141,552	-	-		-%	692,496	834,048	1,062	1,062	2,951
Trust Studded	864,864	1,206,312	2,236,464	-	3,218,040	4/04	(31)%	14,468,827	151,277,970	16,773	16,773	49,199
Emergency Contraception	-	1,000	-	-	-		0%	3,000	3,000	-	-	-
Pronta1	-	1,000	-	-	-		-%	3,000	3,000	-	-	-
Lubricant	1,968	2,652	3,588	-	1,908		88%	37,944	127,956	-	-	-
Lovers Plus Lube Natural (100mL)	1,968	2,652	3,588	-	1,908	1/13	88%	37,944	127,956	-	-	-

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.